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Abstract
Colorectal cancer is a significant cause of mortality in the UK, being the third most 
common cancer type. Activating mutations within the Phosphoinositide 3-Kinase/Akt pathway 
have previously been reported in a significant proportion of sporadic colorectal cancers. 
Phosphatase and tensin homolog mutated on chromosome 10 (PTEN) is an antagonist of the 
PI3K/Akt pathway, and as such is a well characterised tumour suppressor. In this thesis I aimed to 
characterise the role of Pten within the murine intestine, with respect to homeostasis of 
otherwise normal epithelium, and also in the context of activated Wnt signalling and activation of 
the oncogene k-Ras. This has been achieved using a Cre-LoxP-based approach to conditionally 
delete Pten specifically from the adult murine intestinal epithelium.
Deletion of Pten alone is reported here to have little immediate effect on normal 
homeostasis of the intestinal epithelium or the intestinal stem cell. At extended timepoints after 
Pten loss, delayed formation of hamartomas and adenomas within the intestine is reported. In 
the context of activated Wnt signalling, additional loss of Pten is found to accelerate 
tumourigenesis, resulting in adenocarcinoma formation. These lesions are characterised by strong 
activation and membrane localisation of Akt.
Co-ordinate deletion of Pten and activation of k-Ras is reported here to show strong 
synergy in promoting the formation of both papillomatous lesions of biliary epithelia and 
widespread hyperplasia of the forestomach squamous epithelium. Lesions within the biliary 
epithelium are characterised by strong activation of Akt, with gall bladder lesions again showing 
membrane localisation of Akt. In the intestine, preliminary data reported here also indicates 
synergy between Pten loss and k-Ras activation in promoting hyperproliferation of the epithelium.
Together, these data therefore indicate that, in normal intestinal epithelium, PTEN is a 
weak tumour suppressor, but is critical for suppressing neoplasia in the context of other 
mutations.
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Chapter 1: General Introduction
1.1 Intestinal Tumourigenesis
1.1.1 Intestinal Cancer in Humans
1.1.1.1 Incidence
It is now estimated that one in three people will suffer from a form of cancer at some 
point in their lives. Colorectal cancer (CRC) is one of the most prevalent forms of cancer, with 
recent statistics placing it as the third most common cancer type across both genders, after lung 
and breast cancer (excluding non-melanoma skin cancer). Over 36000 new cases are diagnosed 
per year in the UK, and the incidence of colorectal cancer is increasing (Cancer Research UK, 
2007). Despite this fact, mortality rates for colorectal cancer are actually steadily decreasing 
within the UK (Cancer Research UK, 2007). This is probably largely attributed to enhanced 
awareness and detection of disease, and improved treatment methods.
1.1.1.2 Environmental risk factors
The observed increase in colorectal cancer incidence in the western world is often 
attributed to modern lifestyles (Cancer Research UK, 2007). The 'westernised' diet, typically 
comprising high consumption of red meats and processed foods coupled with low consumption of 
fresh vegetables and dietary fibre, is thought to be one of the biggest risk factors for colorectal 
cancers (Norat et al., 2005). Decreased physical activity is also known to contribute towards an 
increased risk of CRC (Slattery et al., 2003). Associated with these two factors, obesity is also 
known to be an important risk factor (Murphy et al., 2000), and it is estimated that up to 11% of 
cases within Europe are obesity-related (Bergstrom et al., 2001). Finally, smoking (Giovannucci et 
al., 1994, Chao et al., 2000) and high alcohol consumption (Bardou et al., 2002) have also been 
linked to increased risk of colorectal malignancy.
1.1.1.3 Genetic risk factors and predisposition
Recognised hereditary CRC predisposition syndromes are known to contribute 
significantly to the overall incidence of CRC. Two such syndromes are the most common and are 
well-characterised; Familial Adenomatous Polyposis (FAP), which is associated with mutations in 
the Adenomatous polyposis coli gene (Ape), and Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC; also known as Lynch Syndrome) which is associated with mutations in a number of
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mismatch repair (MMR) genes (OM IM , 2008, de la Chapelle, 2004). However, many cases of 
colorectal cancers show familial tendency, even without identification of an underlying inherited 
mutation. It has previously been shown that individuals who have a family history of CRC in first 
degree relatives show more than double the risk of developing CRC, compared to an individual 
with no family history of the disease (Johns and Houlston, 2001).
1.1.1.4 Treatment
As with any cancer, the course of treatment a patient undergoes is largely dependent 
upon the severity of disease at diagnosis. The vast majority of cases (approximately 80%) will 
undergo invasive surgical resection of the intestine to remove malignant tissue, which may 
involve a temporary or permanent stoma (NICE Guidelines, 2004). Pre-operative radiotherapy is 
given in a small number of cases, and has been shown to reduce rates of local recurrence of 
disease after surgery, though long-term toxicity of radiotherapy is a significant problem. Many 
patients with more advanced disease will also receive chemotherapy after surgery, providing they 
remain healthy enough to tolerate it. Traditionally, therapies involve the use of 5-Fluorouracil (5- 
FU)/Folinic acid (FUFA) as standard, which also carries a number of problems caused by off-target 
effects (NICE Guidelines, 2004). For therapies to improve, they need to become more specifically 
targeted towards cancer cells, both to reduce toxicity problems elsewhere in the body and to 
increase efficacy. In order to achieve this, modern therapeutic agents are becoming much more 
sophisticated, and the development of these has been largely facilitated by basic research into 
intestinal tumourigenesis. Generic examples of more recently developed chemotherapeutics 
include: therapeutic monoclonal antibodies targeting particular signalling pathways (such as 
Cetuximab, an epidermal growth factor receptor (EGFR) antagonist) (Rivera et al., 2008), 
Topoisomerase inhibitors (such as Irinotecan, a Topoisomerase II inhibitor) and small molecule 
tyrosine kinase inhibitors (such as Gefitinib, an EGFR inhibitor) (Van Cutsem and Geboes, 2007).
1.1.2 The mammalian small intestine
1.1.2.1 Gross structure and function of the small intestine
The mammalian small intestine is a highly specialised organ, adapted for the maximal 
absorption of nutrients from food. The intestine is comprised of three tissue layers; the external 
smooth muscle layer, the submucosal stroma and the inner mucosal surface (Crane, 1968)(See 
Figure 1.1). The main function of the smooth muscle layer is to facilitate the movement of food 
along the intestine by peristalsis. The submucosa functions largely as a supportive structure for 
the mucosal layer, and is comprised of blood vessels, enteric neurons, infiltrating immune cells 
and supportive stromal and mesenchymal cells. At regular intervals, the normal structure of the
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submucosa is interrupted by the presence of lymphoid follicles, known as Peyer's patches 
(MacDonald, 2003). The inner, mucosal surface of the intestine is in direct contact with food 
within the lumen, and consists of a continuous layer of epithelial cells. The mucosa is responsible 
both for the secretion of a number of agents to facilitate digestion and digestive transit, and for 
the selective transfer of nutrients from the lumen of the intestine into the blood supply.
1.1.2.2 Organisation of the epithelium
The mucosal lining of the intestine consists of a simple columnar epithelium. The 
epithelium is organised into finger-like projections into the lumen of the intestine, called villi, 
which are surrounded by invaginations of the epithelium known as the crypts of Lieberkuhn 
('crypts') (See Figure 1.1). These structures serve to greatly increase the absorptive surface area of 
the epithelium, and also compartmentalise the epithelium into regions of immature cells (the 
crypt) and mature cells (the villus) (Sancho et al., 2003).
The intestinal epithelium is constantly being renewed. Cells originate from stem cells, 
thought to be located towards the bottom of the crypt (see below). The stem cell divides slowly; 
approximately once every 24 hours in mice (Potten et al., 1990), though this is thought to be up to 
eight times slower in humans (Potten et al., 1992). The slowly dividing stem cell gives rise to a 
population of immature epithelial progenitor cells, known as transit amplifying (TA) cells. These 
cells proliferate extremely rapidly in order to generate the large numbers of cells needed to 
repopulate the epithelium. This region of highly proliferative cells within the crypt is known as the 
transit amplifying zone (Sancho et al., 2003). As TA cells move up the crypt-villus axis they become 
progressively more differentiated, which is coupled with loss of their proliferative capacity. By the 
time cells exit the TA zone, they have terminally differentiated into one of the mature epithelial 
cell types of the intestine. All mature cells reside on the villus, with the exception of Paneth cells, 
which reside at the very base of the crypt. Paneth cells secrete antimicrobial agents into the 
lumen of the intestine, which act to regulate the composition of the intestinal flora (Cheng, 
1974b). Of the mature cell types on the villus, the most predominant are enterocytes. The primary 
function of these cells is the absorption of nutrients (Cheng and Leblond, 1974a), and together 
they form the brush border (Crane, 1968). Enterocytes also secrete hydrolases, to aid the 
digestion of food within the lumen. At numerous points within the villus, the brush border is 
interrupted by the presence of Goblet cells. These are mucin-secreting cells, providing lubrication 
and protection for the epithelium (Cheng, 1974a). Also present are hormone-secreting 
enteroendocrine cells, which function to allow paracrine control of secretions within the intestine 
(Cheng and Leblond, 1974b). Rarely, a fifth mature epithelial cell type is found; the microfold or 
'M ' cell (Owen and Jones, 1974). These cells are found exclusively in epithelium over-lying Peyer's
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patches (Rosner and Keren, 1984), and function as antigen-presenting cells, transferring antigens 
by transcytosis from the intestinal lumen to the underlying lymphoid tissue.
Once on the villus, all differentiated cell types continue to migrate up the crypt-villus axis. 
As cells approach the end of the villus, they either undergo apoptosis or are shed into the 
intestinal lumen and undergo anoikis, with the entire migratory process taking just a few days 
(Heath, 1996) (See Figure 1.1).
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Figure 1.1: Structure and Organisation o f the mammalian small intestinal epithelium.
Scanning Electron Microscopy of the mouse small intestine (A) reveals organisation of the epithelium into 
invaginations into the mucosa, known as crypts of Lieberkuhn ('crypts') and projections into the lumen of 
the intestine, known as villi. Image courtesy of Alastair Watson, University of Liverpool.
Histological appearance of normal small intestinal epithelium (B) reveals distinct layers of the intestine, 
including the epithelium, the underlying stroma, and the smooth muscle layer. Scale bar indicates 100pm. 
Cartoon representation of a single crypt-villus unit (C). Epithelial cells are born in the stem cell zone, and 
proliferate rapidly and become progressively more differentiated as they move up the crypt-villus axis 
through the TA zone (Yellow). Mature, differentiated cells reside on the villus, with the exception of Paneth 
cells (Pale blue), which are found at the base of the crypt. The villus is supplied by cells from many crypts, 
and is comprised of differentiated enterocytes (Pale pink), Goblet cells (Green) and Enteroendocrine cells 
(Dark blue). Cells continue to migrate up the crypt-villus axis until they reach the villus tip, where they 
undergo apoptosis and/or are shed into the lumen of the intestine.
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1.1.2.3 Epithelial homeostasis
As with any renewing tissue, the balance of proliferation and cell loss must be closely 
regulated in order to prevent either ablation of the epithelium or aberrant accumulation of cells. 
Within the intestinal epithelium, the processes of proliferation, cell death, differentiation, 
migration and cell positioning are closely linked. Regulation of these processes is controlled by the 
combined action of a number of signalling pathways, the principal pathways involved being Wnt 
signalling, Notch/Delta signalling, Transforming growth factor-beta (TGF-beta) and bone 
morphogenic protein (BMP) signalling, Hedgehog (Hh) signalling and Phosphatidylinositiol 3- 
kinase (PI3K)/Akt signalling. With the exception of the PI3K/Akt pathway, each of these pathways 
is briefly described below (See also Figure 1.2), and pertinent examples of murine in vivo evidence 
for their role in intestinal epithelial homeostasis are outlined. The PI3K/Akt pathway and Pten are 
discussed in detail in section 1.2.
Wnt Signalling
The canonical Wingless-type murine MMTV integration site family (Wnt)/beta-catenin 
pathway is one of the best studied regulatory pathways within the intestinal epithelium. This is 
probably largely due to the fact that dysregulation of the Wnt pathway is frequently associated 
with colorectal tumourigenesis.
When Wnt ligands are absent, the pathway is inactive. In this state, a protein complex 
forms in the cytoplasm, known as the 'beta-catenin destruction complex'. This complex consists of 
Glycogen Synthase (GSK) 3-beta, Axin2 and Ape. Axin2 and Ape act as structural supports for the 
interaction of GSK3-beta with beta-catenin, and also with casein kinase (CK). GSK-3beta and CK 
can then phosphorylate beta-catenin, which directs its ubiquitination and subsequent 
proteasomal degradation (See Clevers, 2006 for review). In the presence of Wnt ligand, the 
pathway is activated. Wnt ligand binds to a member of the frizzled family of receptors and its co­
receptor, Low-density lipoprotein receptor related protein (LRP) 5/6, at the cell surface. This 
results in activation of dishevelled within the cytoplasm, and also in phosphorylation of the LRP 
co-receptor, which can recruit and bind axin. Although the exact mechanism remains unclear, it is 
known that these events ultimately result in the disassembly of the beta-catenin destruction 
complex. Beta-catenin is therefore stabilised, it can accumulate within the cytoplasm and 
translocate to the nucleus. Once in the nucleus, beta-catenin can interact directly with members 
of the T-cell factor (TCF)/Lymphoid enhancer factor (LEF) family of transcription factors to 
stimulate transcription of a variety of Wnt target genes (For review see Clevers, 2006, Sancho et 
al., 2004).
A gradient of Wnt activity is known to exist within the intestine, with active Wnt signalling 
being at its highest at the base of the crypt and gradually decreasing up the crypt-villus axis
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(Gregorieff et al., 2005). This gradient of signalling is arguably one of the major influential factors 
on epithelial homeostasis.
A number of studies, using a variety of approaches, have demonstrated that Wnt activity 
in the crypt is essential for maintenance of the proliferative compartment. Early studies indicated 
that constitutive deletion of the Wnt effector TCF-4 causes complete loss of the proliferative 
compartment of the embryonic epithelium, but has no effect either on the development of 
epithelium from primitive gut endoderm, or on differentiated enterocytes and goblet cells on the 
villus (Korinek et al., 1998). More recently, Pinto et al. (2003) and Kuhnert et al. (2004) have 
demonstrated that inhibition of Wnt signalling (by ectopic expression of the Wnt antagonist 
Dickkopf-1 [Dkk-1]) in the adult mouse small intestine results in loss of epithelial proliferation and 
rapid degeneration of the crypt-villus architecture. Additionally, loss of the proliferative zone and 
ablation of the epithelium is also observed following conditional deletion of the critical Wnt 
transducer and effector, beta-catenin (Ireland et al., 2004). Interestingly, these phenotypes are 
replicated following deletion of the well-characterised Wnt target gene cellular-Myelocytomatosis 
oncogene (c-Myc) (Muncan et al., 2006), suggesting that stimulation of proliferation by wnt 
signals is entirely dependent upon c-Myc. In a similar but opposite approach, both Sansom et al. 
(2004) and Andreu et al. (2005) find that activation of Wnt signalling by deletion of Ape results in a 
'crypt progenitor' phenotype, with a dramatic increase in proliferative cells within the crypt. This 
is also coupled with a complete block in cell migration and impaired apoptotic response, which 
probably also contribute to the proliferative phenotype. Associated with its role in controlling 
proliferation in the crypt, Wnt activity is also postulated to be essential for maintenance of the 
intestinal stem cell; this role is described in more detail in section 1.1.3.
There is also evidence to suggest that Wnt signals are important for the differentiation of 
cell types within the epithelium. As described above, Korinek et al. (1998) find that inhibition of 
Wnt signalling by deletion of TCF-4 causes loss of proliferation in embryonic gut. Interestingly, this 
study also notes that, while goblet cells remained present in the epithelium, enteroendocrine cells 
were entirely absent. It has also been demonstrated that, not only is Wnt signalling required for 
correct localisation of paneth cells, but also for their full maturation (van Es et al., 2005a). 
Concurrent with these observations, it has also recently been shown that abrogation of wnt 
signalling by deletion of beta-catenin results in a skew in differentiation pattern towards the 
enterocytic cell lineage (Fevr et al., 2007).
Wnt signalling is also known to be important for cell positioning within the crypt, 
particularly for the paneth cell. Activation of Wnt signalling by deletion of Ape has been shown to 
cause loss of paneth cell location at the very base of the crypt, with diffuse distribution of cells 
throughout the crypt observed instead (Sansom et al., 2004, Andreu et al., 2005). A similar 
phenotype is observed following inactivation of Wnt signalling by deletion of the Frizzled 5
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receptor (van Es et al., 2005a), suggesting that paneth cell localisation is dose-dependent, with 
both too much and too little Wnt activity resulting in aberrant cell positioning. Further to this, 
work has indicated that a particular group of Wnt target genes are particularly influential with 
regard to cell positioning within the intestine; the B-type Eph receptors, EphB2 and EphB3. EphB 
receptors and their cognate ligands, the cell surface proteins of the ephrinB family, are expressed 
in a reciprocal fashion along the length of the crypt-villus. EphB receptor expression is strongest in 
the lower regions of the crypt, concurrent with the fact that the receptors are targets of Wnt 
signalling, whereas ephrinB ligand expression is observed only on the villus (Batlle et al., 2002). 
Following deletion of both EphB2 and EphB3 genes in the mouse, cell positioning was found to be 
greatly perturbed in the crypt, with observation of defects similar to those occurring following 
deletion of Ape. That is, Paneth cells were found to be distributed throughout the crypt rather 
than restricted to the crypt base, and the proliferative zone was found to be poorly organised, 
with intermingling of proliferative progenitor cells with other more differentiated cell types within 
the crypt and lower villus. Additionally, loss of migratory direction up the crypt-villus axis was also 
observed (Batlle et al., 2002). Consequently, the conclusion of this study was that Wnt signalling 
exerts its regulatory effect on cell positioning within the epithelium principally through 
modulation of expression of EphB receptors (See also Clevers and Batlle, 2006 for review).
Notch/Delta Signalling
Notch signalling is known to play a number of important roles in the homeostasis of self- 
renewing tissues, including regulation of proliferation, differentiation and cell fate specification 
(Wilson and Radtke, 2006).
Notch pathway activation is achieved by binding of the Notch cell surface receptor to one 
of the Delta-like or Jagged family of membrane-bound ligands on an adjacent cell. This stimulates 
cleavage of the Notch receptor, both extracellularly, by Tumour necrosis factor (TNF)-alpha 
converting enzyme (TACE), and intracellularly, by gamma-secretase. The intracellular portion of 
the notch receptor, which is released following cleavage by gamma-secretase, is known as the 
Notch intracellular domain (NICD). The NICD is then able to translocate to the nucleus where, 
together with the essential transcription factor CSL, it activates transcription of its target genes 
(Wilson and Radtke, 2006).
In the intestine, a number of elegant experiments have demonstrated the importance of 
Notch signalling for the differentiation of epithelial secretory cell lineages and for maintenance of 
the undifferentiated state of TA cells.
One of the first direct studies investigating the role of notch signalling in vivo in the 
intestine was that of van Es and colleagues (van Es et al., 2005b). Upon deletion of the essential 
notch transcription factor CSL/RBP-J, transit amplifying cells were found to be replaced with
mature, differentiated goblet cells. Closer analysis revealed almost complete loss of all replicative 
cells within the crypt, and their replacement with post-mitotic cells. The impact of this was that 
repopulation of the crypt-villus axis was absolutely inhibited. The presence of enteroendocrine 
cells and paneth cells was found to be unaffected. An identical phenotype was obtained following 
treatment of mice with a specific inhibitor of gamma-secretase. The authors conclude that notch 
signalling is essential for preventing differentiation of immature proliferative cells, and also for 
specifying cell fate.
At the same time as this study, a reverse approach was being pursued by Fre et al. (2005), 
who overexpressed a constitutively active form of the Notch-1 receptor in the mouse intestine. 
This study essentially observed an exact reciprocal phenotype to that described above, in that 
activation of notch signalling resulted in severe deficiency of secretory cell types in the intestine. 
Paneth cells, enteroendocrine cells and goblet cells were totally undetectable following notch 
activation. Absorptive enterocytes were found to be present; however they exhibited some 
abnormalities, particularly of the apical brush border. In addition to this, expansion of the 
proliferative compartment was observed.
One further study has added an additional layer of complexity to the role of notch 
signalling in the intestine. In a similar approach to Fre et al. (2005), a constitutively active form of 
Notch-1 receptor has been expressed in the intestine by Zecchini and colleagues (2005). However, 
in this case the experimental approach employed results in much stronger expression of the 
mutant receptor. Zecchini et al. observed a phenotype much more similar to that of van Es et al. 
(van Es et al., 2005b), with a dramatic increase in the numbers of goblet cells observed, however 
in this case they were found to be predominantly on the villus rather than within the crypt. 
Interestingly, this study also reports no effects on the proliferative zone of the crypt. Taken 
together, these data therefore suggest that whilst the presence of notch signalling is essential for 
maintenance of the transit amplifying zone, dose-dependency of signalling operates with respect 
to control of cell differentiation. It appears that a fine balance of notch signalling must be present 
within the intestine to adequately maintain differentiation down secretory cell lineages. Indeed, 
such sensitivity to levels of notch signalling has also been implied from work performed in 
intestinal cells of Drosophila (Ohlstein and Spradling, 2007).
TGF-beta and BMP Signalling
Transforming growth factor (TGF)-beta signalling is known to modulate proliferation and 
differentiation of cells in a number of tissue types. In the intestine, the observation that 
disruption of TGF-beta signalling is linked to the progression of colorectal cancers suggests that 
this pathway may play a role in homeostasis of the epithelium (Sancho et al., 2004).
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Bone morphogenic proteins (BMPs) are part of the Transforming growth factor-beta (TGF- 
beta) superfamily. BMP signalling is required both for development and maintenance of the 
intestinal epithelium, and plays a particularly interesting role in regulating the interaction 
between epithelial cells and the underlying mesenchyme (Ishizuya-Oka, 2005). Mutations in BMP 
pathway components are also known to be the cause of Juvenile polyposis syndrome (JPS) in 
humans, a condition characterised by the development of multiple intestinal lesions at a young 
age (OMIM, 2008). Loss of BMP signalling has also been reported in a large proportion of sporadic 
colorectal tumours (Kodach et al., 2008b).
Both TGF-beta proteins and BMPs are soluble, extracellular signalling proteins. TGF-beta 
proteins bind preferentially to TGF-beta type II receptors (TBRII), which then associate with the 
type I receptor (TBRI). Conversely, BMPs bind preferentially to their type I receptors (BMPRI), 
which then dimerise with the BMP type II receptor (BMPRII) (Shi and Massague, 2003). In both 
cases, the type I receptor can then be phosphorylated and activated by the type II receptor. These 
events activate an intracellular signalling cascade involving the activation of members of the 
Mothers Against Decapentaplegic homolog (SMAD) family of signal transducers. Receptor- 
associated SMADS (R-SMADS), including SMADs 1, 2, 3, 5 and 8, are phosphorylated and activated 
by type I receptors. SMAD2 and 3 are preferentially phosphorylated by the TGF-beta type I 
receptor, whereas BMP type I receptor signalling is usually transduced by SMAD1, 5 or 8. 
Activated R-SMADs then associate with SMAD4 (also known as common or co-SMAD), and 
translocate to the nucleus. Once in the nucleus, the active SMAD complex can then modulate 
gene expression in combination with transcriptional coactivators or corepressors, the presence of 
which is largely determined by cell type (For review see Shi and Massague, 2003).
Abrogation of BMP signalling in the intestine has previously been shown to disrupt 
intestinal homeostasis (He et al., 2004). Deletion of the BMP type I receptor (BMPRI) was found to 
result in an increase in proliferation within the epithelium, and the development of intestinal 
polyps similar to that seen in human JPS. This study also proposes a role for BMP signalling in 
maintenance of the intestinal stem cell, which is discussed below (Section 1.1.3.4). A further study 
investigating the effect of attenuating BMP signalling employed the use of an inhibitor of BMP 
signalling, Noggin (Haramis et al., 2004). Haramis and colleagues found that transgenic expression 
of Noggin resulted in mildly abnormal villus structure, and the development of ectopic crypt 
structures. The crypts which formed appeared normal in structure and composition, but were 
mis-localised. This led the authors to conclude that BMP signalling is important for interactions 
between epithelial cells and underlying mesenchymal cells to coordinate the development of 
epithelial structures in the correct context. Like He et al. (He et al., 2004), this study also reports 
the development of intestinal tumours reminiscent of human JPS. The results of this study have 
also been corroborated by a very similar independent study (Batts et al., 2006).
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To further investigate the role of BMP signalling in interaction between intestinal 
epithelial cells and their surrounding cell types, Kim et al. (2006) (Kim et al., 2006) have deleted 
SMAD4 in both intestinal epithelial cells and in T-cells. This study found that deletion of SMAD4 in 
intestinal epithelial cells results in a surprising lack of phenotype. However, deletion of SMAD4 
from T-cells was found to result in a number of alterations in the intestinal epithelium, including 
aberrant growth of crypt structures similar to that seen by Haramis et al. (Haramis et al., 2004). 
This study also reports the development of intestinal polyps and invasive carcinomas of the 
intestine following T-cell specific deletion of SMAD4, which raises the hypothesis that human JPS 
may, in some cases at least, arise due to loss of BMP signalling in T-cells rather than within the 
epithelium itself.
The role of epithelial TGF-beta signalling in the maintenance of intestinal homeostasis 
appears to be less well understood. Studies employing the expression of a dominant negative 
TGF-beta type II receptor to abrogate TGF-beta signalling have indicated that TGF-beta signalling 
is dispensable in normal mouse epithelium (Beck et al., 2003). However, TGF-beta signalling 
appears to be essential for re-establishing homeostasis of the epithelium following injury. Again, 
the dominant negative TGF-beta type II receptor model has been used to demonstrate that mice 
deficient for TGF-beta signalling activity show increased susceptibility to both colitis (Beck et al., 
2003) and to tumourigenesis (Hahm et al., 2002) following treatment with chemical inducing 
agents. Several other models employing different strategies to diminish TGF-beta signalling have 
also confirmed the finding that pre-existing intestinal lesions are predisposed to progression in 
the context of reduced TGF-beta signalling (Sancho et al., 2004).
Hedgehog Signalling
Hedgehog (Hh) signalling in the intestine plays its most important role during embryonic 
development of the gastrointestinal tract, where hedgehog proteins act as morphogens which are 
critically important for establishment of crypt-villus architecture of the gut (For extensive review, 
see van den Brink, 2007). Although mutations of the hedgehog pathway are only very rarely 
reported to be associated with colorectal cancers, study has suggested that hedgehog signalling 
plays a role in maintaining intestinal homeostasis in the adult organ.
The hedgehog family of proteins consists of Sonic hedgehog (Shh), Indian hedgehog (Ihh) 
and Desert hedgehog (Dhh). In the absence of Hedgehog proteins, the signalling pathway is 
inactive. Unbound cell surface receptors of the Patched family (Ptchl and Ptch2) elicit an 
inhibitory effect upon the transmembrane signal transducer, Smoothened (Smo). Inactive Smo 
permits the intracellular formation of a protein complex consisting of Costal-2 (Cos-2) and Fused 
(Fu), which assemble together with microtubules. This complex is able to bind the Hh effector and 
transcription factor, Glioma-associated oncogene homolog (Gli), which serves to both sequester
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Gli away from the nucleus, as well as to target its proteolytic cleavage and inactivation. 
Hedgehogs are able to bind to Ptch receptors, and in doing so allow release of the repressive 
activity of the unbound Ptch receptor on Smo. This in turn allows activation of the serine- 
threonine kinase (STK) 36, which both inhibits formation of the Cos-2/Fu-containing protein 
complex as well as activating Suppressor of Fused (SuFu). These events allow accumulation of full- 
length Gli, which can then translocate to the nucleus and activate transcription of its target genes 
(For review see Lees et al., 2005, Katoh and Katoh, 2006).
Much of the study into the role of hedgehog signalling in the small intestine has focused 
on its role during development. However, such studies have provided some clues as to how 
hedgehog signals may be involved in homeostasis in the fully mature adult. Nullizygosity for either 
Shh or Ihh has been shown to cause serious malformation of the entire gastrointestinal tract, 
resulting in lethality (Ramalho-Santos et al., 2000). Closer analysis of the embryonic small 
intestine of Ihh'1' mice revealed a marked reduction of cell proliferation resulting in villus atrophy. 
The authors suggest that this implies a role for hedgehog signalling in maintaining proliferation of 
the intestinal stem cell. A dramatic reduction in enteroendocrine cells is also observed, suggesting 
a further role for hedgehog signalling in cell fate determination in the epithelium (Ramalho-Santos 
et al., 2000). In contrast to this study, complete abrogation of hedgehog signalling in the intestine 
by expression of the inhibitory hedgehog interacting protein (Hhip) has been shown to result in 
hyperproliferation of the epithelium. Hhip was expressed in the intestinal epithelium throughout 
development from the Villin gene promoter, and animals were analysed at very early stages of life 
(up to postnatal day P5). The crypt-villus architecture of the epithelium was found to be 
perturbed, caused by hyperproliferation of epithelial cells, along with ectopic crypt development 
and abnormal branching of villi (Madison et al., 2005). This study also reports abnormalities in 
differentiation of epithelial cells following Hh inhibition, but in this case defects in absorptive 
enterocytes are reported, resulting in the generation of an incomplete and ineffective brush 
border (Madison et al., 2005). The discrepancy in phenotype observed between these studies 
could be due to a number of reasons, for instance the latter study examines the effect of 
abrogation of all Hh signals, whereas Ramalho-Santos and colleagues have examined the specific 
effects of blocking signalling only through Ihh. This suggests that the outcomes of hedgehog 
signalling initiated by different hedgehog proteins may not be equivalent in the intestine.
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Figure 1.2: Major regulatory signalling pathways influencing homeostasis of the intestinal epithelium.
A: Wnt Signalling. Absence of Wnt ligand permits formation of the '3-catenin destruction complex', comprised of Axin, Ape and GSK33, which binds 3-catenin and mediates its phosphorylation 
and proteasomal degradation. Binding of Wnt ligand to Frizzled (Fz) receptor and LRP5/6 co-receptor results in activation of Dishevelled (Dsh) and phosphorylation of LRP5/6, which together 
inhibit the 3-catenin destruction complex, allowing accumulation and translocation of 3-catenin to the nucleus where, genes with Tcf/Lef factors, it activates transcription of Wnt target.
B: TGF-3/BMP Signalling. BMPs orTGF3s bind to their cognate type I/ll receptors, resulting in phosphorylation of the type I receptor. BMP signals are transduced through SMAD1/5/8, TGF3 
signals through SMAD2/3. Both result in activation of SMAD4, which translocates to the nucleus and acts with co-activators (CoA) or co-repressors (CoR) to modulate target gene expression.
C: Notch Signalling. Binding of notch receptor by cell-surface ligands of the Delta/Jagged family stimulates cleavage of the Notch receptor by TACE and y-secretase (y-Sec). Cleavage by y- 
secretase releases the notch intracellular domain (NICD), which translocates to the nucleus and acts with the transcription factor CSL to activate expression of target genes.
D: Hedgehog Signalling. Unbound Patched (Ptch) receptors inhibit the smoothened (Smo) signal transducer, allowing formation of Cos-2/Fu complex with microtubules (MT), which binds the 
Gli transcription factor, sequestering it away from the nucleus and targeting its cleavage. Binding of Hedgehogs (Hh) to Ptch, releases repression of Smo, which in turn activates STK36. 
Suppressor of Fused (SuFu) is activated, and the Cos-2/Fu-containing complex can not form. Full-length Gli accumulates, and translocates to the nucleus, where it activates target genes.
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1.1.3 The intestinal stem cell
1.1.3.1 Function, Properties and Environment
Repopulation of the intestinal epithelium is driven by adult stem cells residing within 
crypts (Cheng and Leblond, 1974c). Previously the subject of some debate, it is now generally 
considered that each crypt is monoclonal - that is, it contains a single functional stem cell (Scoville 
et al., 2008).
The intestinal stem cell, like all stem cells, resides within a stem cell niche. The existence 
of the stem cell niche was first proposed by Schofield in 1978. This niche is defined as the 
microenvironment in which the stem cell exists, and is comprised of surrounding cells, including 
epithelial cells, mesenchymal cells (myofibroblasts), enteric neurons and infiltrating immune cells, 
as well as extracellular matrix components and paracrine signals (Brittan and Wright, 2002). These 
factors interact to maintain the properties of 'sternness' of the stem cell.
'Sternness' is characterised by two fundamental properties; firstly, the possession of 
limitless potential to self-replicate, and secondly, the ability to generate committed daughter cells 
which go on to differentiate and produce all mature cell types of the tissue, whilst the stem cell 
itself remains undifferentiated.
By definition, stem cells are able to replicate indefinitely. Replication and renewal of the 
intestinal stem cell must be controlled precisely and dynamically, in order generate enough 
daughter cells to adequately repopulate the tissue and balance the loss of epithelial cells from the 
villus tip, but without aberrant accumulation of cells occurring. Replication of the stem cell can 
result in three conceivable outcomes (Potten and Loeffler, 1990). Firstly, and most commonly, 
division is asymmetric, producing one daughter progenitor cell and one stem cell, thus allowing 
both self-maintenance of the stem cell compartment and the generation of cells to repopulate 
the crypt-villus. Rarely, symmetric division of the stem cell is thought to occur. This can result in 
two possible outcomes; firstly, two identical daughter progenitor cells may be produced, which 
both go on to differentiate, resulting in loss of the stem cell. Alternatively, symmetric division may 
result in the production of two identical stem cells. Symmetric division may operate to allow 
maintenance of the correct number of stem cells within the crypt, allowing both reduction in the 
number of stem cells present and also replacement of stem cells, for instance following damage. 
Alternatively, a number of 'potential' stem cells are thought to exist transiently within the TA 
zone, each of which has the capacity to replenish the stem cell compartment should the need 
arise (Potten and Loeffler, 1990).
The intestinal stem cell is thought to be multipotent -  that is, whilst it is capable of 
producing all intestinal cell lineages, it is itself only partially committed towards an intestinal fate 
(and can therefore not produce cells of other tissues). In order to achieve homeostasis of the
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intestinal epithelium, this partially undifferentiated state must be maintained. A number of 
signalling pathways are known to contribute to this, and are discussed below (see section 1.1.3.3).
1.1.3.2 Location and Markers of the intestinal stem cell
The exact location of the intestinal stem cell within the crypt has been the subject of 
much debate, and this debate has recently been revived with vigour. Undoubtedly, one of the 
major factors hampering the definitive identification of the location of the stem cell is the lack of 
a good marker of the ISC. Conversely, many of the candidate markers of the stem cell currently 
known have been identified based on their restricted expression within a small number of cells 
within candidate stem cell regions. It is therefore apparent that identification of the location of 
the stem cell and of a good marker of it, are closely linked.
The stem cell zone is widely thought to be located at around positions +4 to +6 (i.e. 4 to 6 
cell positions from the base of the crypt) (See Figure 1.3), directly above the paneth cell 
compartment. Evidence for this was based largely on long-term label-retention studies (See 
Potten, 1998 for review). The rationale behind such studies lies in the differential kinetics of cell 
replication and migration occurring within the crypt. Labelling of replicating cells can be achieved 
by exposing cells to short pulses of labelled bases, such as tritiated (H3-) thymidine or 
Bromodeoxyuridine, which are incorporated into DNA during replication. This approach will label 
both stem cells and TA cells within the crypt. However, TA cells rapidly proliferate and migrate out 
of the crypt. Thus, delayed 'chasing' and detection of labelled cells can allow differentiation 
between rapidly migrating and immotile cells, and hence visualisation of the presumptive 
population of stem cells, or 'label-retaining cells' (LRCs). Such experiments, as performed in a 
series of studies by Christopher Potten and colleagues, revealed that the LRC is normally found in 
the lower region of the crypt, with the most common position being between 4 and 9 cells from 
the crypt base (Potten, 1998).
An alternative position for the stem cell was originally proposed by Cheng and Leblond 
(Cheng and Leblond, 1974c, Also reviewed in Bjerknes and Cheng, 2005a). This alternative 
position is within the slender cells which are found intercalated between Paneth cells at the very 
bottom of the crypt, and are known as crypt base columnar cells (CBCs). This model proposes that 
cells below position 4 in the crypt are slowly dividing, and are able to maintain an undifferentiated 
state, whereas cells in positions 5 and above are more rapidly cycling and are committed to 
differentiation.
Following much investigation, a number of putative markers of the ISC have recently been 
proposed. However, these markers do not necessarily label the same populations of cells, and 
apparently show only limited overlap in labelling patterns.
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One of the first proposed molecular markers of the intestinal stem cell was the RNA- 
binding protein, Musashi-1 (Potten et al., 2003). Originally identified in Drosophila as regulator of 
asymmetric division in neural precursor cells (Nakamura et al., 1994), Musashi-1 has also been 
shown to be a negative regulator of the Notch pathway in neuronal stem cells (Okano et al., 
2005). Expression of Musashi-1 has been shown to be high in murine neonatal small intestinal 
crypts, which at this stage, are thought to be rich in stem cells. In adult murine tissue, Mushashi-1 
expression is seen to be restricted to the lower region of the crypt, with labelling most frequent at 
approximately position +5 (Potten et al., 2003). Interestingly, this study also observes staining of 
CBC cells, between paneth cells at the very base of the crypt. Following radiation injury, the 
regenerative clonogenic response of the intestine is seen to coincide with a rise in expression of 
Musashi-1, as well as a more widespread expression pattern within the repopulating crypt 
structure. It was, however, noted that not all proliferating cells participating in crypt repopulation 
were positive for Musashi-1 staining. Finally, this study shows that Musashi-1 is found to be highly 
expressed in adenomas of ApcMIN mice. The authors therefore propose that Musashi-1 is a marker 
of both the intestinal stem cell, and of very early intestinal cell lineages, but does not mark all 
proliferative cells within the crypt.
More recently, three markers have been proposed which may more specifically mark the 
stem cell; Doublecortin and Calmodulin-kinase like-1 (DCAMKL-1), Leucine-rich repeat containing 
G-protein coupled receptor 5 (Lgr5) and B-lymphoma Mo-MLV insertion region 1 polycomb ring- 
finger oncogene (Bmil).
DCAMKL-1 is a microtubule-associated kinase expressed throughout the central nervous 
system, specifically in post-mitotic neurons (Ohmae et al., 2006). Recent work has identified that 
DCAMKL-1 is expressed within progenitor cells of the crypt (May et al., 2008). Further 
investigation into this revealed that only a very limited number of cells within the crypt express 
DCAMKL-1, and these are generally located in approximately the +4 position, though cells within 
the CBC cell population were also occasionally labelled. Additionally, positively-stained cells were 
observed in only one in six crypts in tissue sections, which is approximately consistent with the 
notion that crypts are monoclonal. Further investigation into the properties of DCAMKL-l-positive 
cells revealed them to be very slowly cycling, suggesting that the ISC is quiescent, but mitoses 
expressing DCAMKL-1 were found to be present following irradiation, suggesting that the 
quiescent stem cell had become activated. These data appear to provide good evidence for 
DCAMKL-1 being a specific marker of the ISC. However, it should be noted that occasional staining 
of cells on the villus was also reported. This may suggest that DCAMKL-1 actually labels a mature 
cell type and its precursors, and from the frequency of staining and the morphology of the stained 
cells presented, it seems possible that the cell type identified may in fact be of an
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enteroendocrine lineage. Furthermore, this study lacks functional evidence to suggest that 
DCAMKL-1 positive cells are indeed ISCs, and without this validation the study lacks conviction.
Lgr5 (also known as G-protein coupled receptor 49, Gpr49) was identified as a candidate 
marker of the ISC based on a screen of Wnt-target genes (Barker et al., 2007). Localisation of Lgr5 
revealed positively-stained cells to be within the CBC cell population at the very base of the crypt, 
and these cells were shown to be distinct from both the paneth cell population and from the cells 
of the transit amplifying zone. Additionally, Lgr5-positive cells were observed within adenomas 
arising in ApcMIN mice. In contrast to the quiescent DCAMKL-1 labelled cells described above, Lgr5- 
expressing CBC cells were found to be rapidly cycling, with cells incorporating BrdU following a 
short pulse-chase, and increasing in numbers over 24 hours. The authors go on to describe 
generation of knock-in mice bearing combined EGFP reporter and inducible cre-expressing 
construct under the control of the endogenous Lgr5 promoter. These mice confirmed that Lgr5 
expression is specific to CBC cells between paneth cells. These mice were also crossed to mice 
bearing the Rosa26-LacZ allele, and then used to trace cell lineages within the intestine. Upon 
activation of Cre, the entire crypt-villus was populated with LacZ-expressing cells. The significance 
of this finding is that it elegantly proves that all epithelial lineages within the intestine are derived 
from cells which, at some point, have expressed Lgr5. This provides convincing functional 
evidence that Lgr5-positive cells are indeed intestinal stem cells. However, these results are 
controversial in that they appear to go against the previously proposed concepts of the stem cell 
residing at position +4, and the stem cell being quiescent in normal tissue.
Very recently, the oncogene Bmil has also been proposed as a marker of the ISC 
(Sangiorgi and Capecchi, 2008). Bmi-1 is a polycomb group protein, which is known to play a role 
in renewal of stem cells of both haematopoietic (Park et al., 2003) and neuronal systems 
(Molofsky et al., 2003), and more recently of the breast epithelium (Pietersen et al., 2008). In their 
study, Sangiorgi and Capecchi have generated mice expressing an inducible form of Cre under the 
control of the Bmil promoter, which were then crossed to reporter mice bearing either the 
Rosa26-LacZ transgene or a Rosa26-YFP transgene. Using this approach, the authors observe that 
reporter-expressing cells are most commonly located at positions +4 and +5 in the crypt, directly 
above paneth cells. Rarely, Bmil-expressing cells were also observed between paneth cells, within 
the CBC population. However, it is also noted that a large number of crypts contain more than 
one labelled cell, which is not consistent with the notion that crypts are monoclonal. The authors 
propose that these cells may be the early mitotic progeny of Bmil positive cells. In a similar 
lineage-tracing experiment to that performed by Barker et al. (2007), LacZ-positive cells were 
found to completely populate the majority of whole crypts at day 17 after Cre induction, and 
stable LacZ expression was observed on the crypt-villus axis up to 9 months after induction. Again, 
this indicates that cells expressing Bmil populate the crypt-villus epithelium. Further to this, it
was demonstrated that Bmil-positive cells give rise to all differentiated cell types of the 
epithelium, but do not themselves express any markers of the differentiated cell types. Unlike 
Barker et al., who report that Lgr5-positive cells are rapidly cycling, Sangiorgi and Capecchi note 
that Bmil-positive cells are slowly cycling. Finally, the effects of activating Wnt signalling or 
completely deleting Bmil-positive cells were investigated. Activation of Wnt signalling was 
achieved by conditional expression of a constitutively activated form of beta-catenin, driven by 
the Bmil-CreER construct. Following Cre induction, animals were rapidly found to develop 
epithelial hyperplasia along with the formation of numerous adenomas, indicating that Wnt 
activation in Bmil-expressing cells is sufficient to generate much of the phenotype associated 
with more widespread Wnt activation. Ablation of the presumptive stem cell population was 
achieved by expression of diphtheria toxin from the Rosa26 allele which was driven by the Bmil- 
CreER construct. Cre induction was found to result in rapid lethality, caused by extensive death of 
cells within the intestine, and complete loss of crypt structures from large areas of the mucosa. 
These studies therefore provide convincing evidence that Bmil-expressing cells play a key role in 
the repopulation of the crypt-villus.
These data are compelling, providing thorough evidence that Bmil labels the intestinal 
stem cell. However, much of this data is clearly at odds with that proposed by Barker et al., and it 
appears that Bmil and Lgr5 may label distinct populations of cells. However, the overlap between 
Bmil-expressing cells and Lgr5-expressing cells has, as yet, not been fully investigated. Based on 
the observed difference in cell cycle kinetics between Bmil-positive and Lgr5-positive cells, 
Sangiorgi and Capecchi propose that these markers may in fact label different populations of 
stem cells, with Bmil being a marker of quiescent cells and Lgr5 labelling more active stem cells, 
with the possibility of cells migrating between the two observed stem cell niches (Also discussed 
by Battle, 2008).
One final proposed marker of the stem cell is also particularly noteworthy; inactive 
phosphorylated Pten. He et al. (2004) have observed that long-term BrdU-retaining cells within 
the crypt, which are located approximately at positions +4 and +5, co-stain for phosphorylated 
(inactivated) Pten. Due to inactivation of Pten, these LRCs also exhibit activation (by 
phosphorylation) of Akt, which lies downstream of Pten in the PI3K/Akt pathway. In addition, LRCs 
(referred to as 'stem cells' by the authors) which are phospho-Pten-positive also show nuclear 
accumulation of beta-catenin and activation of Wnt signalling. Actively dividing phospho-Pten- 
positive LRCs are also shown to retain nuclear localisation of beta-catenin. Quiescent, phospho- 
Pten-negative LRCs were shown not to exhibit nuclear accumulation of beta-catenin. This 
observation led the authors to conclude that inactive Pten may influence Wnt signalling within the 
ISC to promote stem cell division, but is not necessarily sufficient to initiate division.
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However, these conclusions have been the subject of some debate. Bjerknes and Cheng 
(2005b) argue that, based on their morphology, the phospho-Pten labelled cells identified by He 
et al. within the crypt are in fact early enteroendocrine cells. Furthermore, in the hands of 
Bjerknes and Cheng, the antibody used by He et al. to detect phospho-Pten was also found to 
label a number of cells throughout the crypt-villus. All phospho-Pten-positive cells were also 
found to co-stain with Chromogranin A, a marker of enteroendocrine lineages, though not all 
Chromogranin A-positive cells were found to be phospho-Pten-positive, suggesting that Pten is 
inactivated in only a subset of enteroendocrine cells. Furthermore, Bjerknes and Cheng point out 
that it has not currently been proven that BrdU label-retaining cells and intestinal stem cells are 
equivalent. These observations therefore cast significant doubt over the fact that inactivated Pten 
may be a reliable marker of the ISC.
1.1.3.3 Maintenance and regulation of the intestinal stem cell
The lack of a definitive marker of the intestinal stem cell has clearly held back direct 
studies investigating the roles of various signals in maintaining the characteristics of sternness. 
However, indirect evidence has implicated a number of signals in maintenance and homeostasis 
of the ISC. These signals are both intrinsic to the stem cell, including signalling pathways such as 
Wnt, BMP, Notch and PI3K/Akt, as well as extrinsic to the stem cell, including signals from 
surrounding cellular components comprising the stem cell niche.
As described above, Wnt signals are known to be critical for maintenance of the 
proliferative capacity of the crypt and repopulation of the crypt-villus axis. Ablation of Wnt signals 
results in loss of the proliferative compartment and inhibition of repopulation of the crypt-villus 
axis. Conversely, aberrant activation of Wnt signalling results in expansion of the proliferative 
zone and induction of a 'crypt progenitor' phenotype, along with loss of compartmentalisation of 
cells within the crypt. The aberrant progenitor cells which arise following activation of Wnt 
signalling have not directly been identified as stem cells, however they are found to express the 
putative stem cell marker, Musashi-1 (Sansom et al., Unpublished data). The consequence of 
modulating Wnt signalling on the whole intestinal epithelium is relatively well characterised, 
however attempts to characterise the effects of Wnt modulation specifically within the stem cell 
population are less common. Recently, one study has attempted to characterise the effects of 
deletion of beta-catenin more specifically in the ISC. Fevr et al., have used conditional 
transgenesis to delete beta-catenin from the adult intestinal epithelium (Fevr et al., 2007). 
Essentially, this study recapitulates the phenotype seen previously by Ireland et al. (2004) in a 
similar study, with loss of the proliferative compartment and progressive ablation of the 
epithelium. However, the authors go on to examine the effects of beta-catenin loss more 
specifically in the stem cell population, or at least within label-retaining cells. Proliferating cells
were labelled using tritiated (3H-) thymidine by treating animals over a course of four days. 
Following an interval of three weeks, loss of beta-catenin was induced. Crypts of wild-type mice 
were observed to contain LRCs at the crypt base, between paneth cells, as expected. However, 
four days following loss of beta-catenin, LRCs were found scattered throughout the crypt and 
villus. These LRCs were found to co-stain for fatty-acid binding protein (FABP), a marker of 
differentiated enterocytes. Thus, it was concluded that active Wnt signalling is needed to 
maintain the undifferentiated state of label-retaining stem cells, with loss of signalling resulting in 
differentiation of LRCs and entry into the normal migratory program of differentiated enterocytes.
PI3K/Akt signalling has previously been reported to be essential for cell proliferation 
within the intestine, and particularly for regeneration of the crypt-villus axis following injury 
(Sheng et al., 2003). This therefore suggests that P13K/Akt signalling may be essential for 
activating stem cell replication within the intestine. As described above, He et al. (2004) have 
proposed that inactive phosphorylated Pten is a key feature of ISCs, allowing activation of Akt and 
modulation of Wnt activity within the stem cell to promote division. Further to this, the same 
group have investigated the effects of Pten deletion from the intestine (He et al., 2007). Following 
Pten deletion, putative stem cells were identified in the crypt based on both long-term retention 
of label and on positive staining for Musashi-1. It was noted that Musashi-l-positive LRCs, which 
were also deficient for Pten, were much more rapidly cycling compared to Mushashi-l-positive 
LRCs which remained proficient for Pten. This excess of stem cells was seen to result in crypt 
fission within the intestine, and subsequent development of hamartomatous polyps. The authors 
therefore conclude that inactivation of Pten (and hence activation of the PI3K/Akt pathway) 
influences the kinetics of stem cell division. However, it remains unclear whether this study is 
truly examining Pten deficiency within the intestinal stem cell, rather than in a population of 
progenitor cells.
As previously described, BMP signalling is known to play a role in regulating proliferation 
within the intestine, and also in defining the location of the proliferative zone (see section 
1.1.2.3). In their study identifying phospho-Pten as a putative marker of the intestinal stem cell, 
He and colleagues (2004) went on to analyse the effect of inactivating BMP signalling on the 
intestinal stem cell. They found that inactivation of BMP signalling by conditional deletion of the 
BMP type I receptor resulted in an increase in phospho-Pten-positive 'stem cells', and also in an 
increase in crypt number within the intestine. The authors therefore propose that BMP signals 
inhibit renewal of the stem cell by regulating Pten activity.
Although poorly characterised in the intestine, evidence from other organisms and other 
tissue systems indicates that signals from the stem cell niche are critical for homeostasis of the 
stem cell itself (Reviewed extensively, including Jones and Wagers, 2008). Indeed, the fact that
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intestinal epithelium and its stem cells have not yet been established in cell culture points to the 
fact that signals from the microenvironment of the stem cell may be critical for its maintenance. 
Other cell types within the niche which may interact with the stem cell include epithelial 
progenitor cells (daughter cells of the stem cell), mesenchymal cells (including myofibroblasts) 
and infiltrating immune cells (See Figure 1.3).
Again, the lack of a robust marker of the intestinal stem cell has hampered efforts to 
study the interaction of the stem cell with its niche, however a small number of studies have 
pointed to the importance of cells adjacent to the epithelium in maintaining intestinal 
homeostasis. One example of this is the study of the mesenchymally-expressed transcription 
factor, Fkh6 (now known as FoxLl) (Kaestner et al., 1997). Kaestner et al. generated mice null for 
the Fkh6 gene. Despite the fact that Fkh6 is not normally expressed in epithelial cells, they noted 
marked epithelial abnormalities in the intestines of Fkh67' mice. During embryogenesis, Fkh6-null 
intestines were found to show delayed development of the intestinal epithelium, with abnormally 
small and sparse villus structures. Embryonic intestinal epithelium was also found to be poorly 
organised, with loss of definition of the proliferating zone. Examination of intestines from adult 
Fkh6'/_ mice revealed expansion of crypt size and elongation of villi. This was coupled with 
increased proliferation and also perturbation of the normal differentiation program, with an 
excess of goblet cells present within mutant crypts. These data therefore hint at the fact that 
expression of factors within the mesenchyme may influence the behaviour of the stem cell, with 
relation to both proliferation and maintenance of the undifferentiated state. Although the stem 
cell itself is not explicitly studied, these data highlight the importance of signals originating in 
mesenchymal cells for normal homeostasis of the intestine.
One further elegant example illustrating the importance of non-epithelial cell types on 
intestinal homeostasis is described by the work of Kim et al. (2006). This study examines the role 
of TGF-beta/BMP signalling both in the intestinal epithelium itself, and in circulating T-cells, by 
conditional deletion of SMAD4. Following conditional inactivation of SMAD4 specifically in the 
intestinal epithelium, the authors surprisingly observed no significant effect on intestinal function 
or homeostasis, and did not observe tumourigenesis of the intestine. However, following T-cell- 
specific deletion of SMAD4, a marked intestinal phenotype was observed, despite the fact that 
TGF-beta signalling remains intact in the epithelial cells themselves. The intestinal phenotype 
observed included marked thickening of the mucosa, with evidence of stromal and immune cell 
infiltration. Rapid development of intestinal polyps, adenomas and invasive carcinomas was 
observed, described as being reminiscent of that seen in human juvenile polyposis syndrome 
(JPS). Again, although this study does not attempt to directly examine the intestinal stem cell, the 
rapid epithelial hyperplasia and subsequent tumourigenesis observed implies that the ISC may be 
dysregulated following TGF-beta signalling abrogation in T-cells.
21
1.1.3.4 An intestinal cancer stem cell?
The 'cancer stem cell' hypothesis was originally described by Schofield in 1978 (Schofield, 
1978). This hypothesis proposes that tumour growth is maintained by one or a small number of 
replicative cells, which bear similarities to normal tissue stem cells. For many cancers, the idea 
that a 'cancer stem cell' population is responsible for the growth of a tumour is becoming 
increasingly popular. Indeed, if such a population of cells exists, it would provide a very attractive 
therapeutic target to facilitate effective destruction of a tumour by removing the very source of 
tumour growth.
Evidence for the existence of the cancer stem cell has been derived mainly from 
xenotransplantation studies. These studies are exemplified by the early work of Bonnet and Dick 
(1997), who showed that transplantation of a small subset of sorted cells (those which were 
CD34++/CD38-) derived from human acute myeloid leukaemia was sufficient to induce leukaemic 
transformation in immune-compromised (Non-obese diabetic/severe combined immunodeficient; 
NOD/SCID) mice. The fact that not all subsets of cells are able to initiate transformation suggests 
that some groups of cells contain cancer stem cells, which drive cancer initiation and 
development.
A small number of similar studies have been performed involving transplantation of 
sorted cells derived from human colorectal cancers (Dalerba et al., 2007, Ricci-Vitiani et al., 2007, 
O'Brien et al., 2007). In each of these studies, samples were removed from human colorectal 
tumours and sorted based on the expression of cell surface markers before being transferred into 
NOD/SCID mice. Success of the transfer was assessed on the basis of the ability of the sorted 
tumour cells to colonise the site of implantation, and to generate a tumour which was 
morphologically comparable to the original tumour from which the cell samples were derived. 
Successful transplantation was considered to be indicative of the presence of the cancer stem cell 
population within the cell fraction isolated. Dalerba et al. found that the cell fractions which were 
most successful at initiating tumourigenesis upon transplantation were characterised by high 
expression of epithelial cell adhesion molecule (EpCAM) and cell surface expression of CD44 and 
CD166 (EpCAMHlgh/CD44+/CD166+). Both Ricci-Vitiani et al. and O'Brien et al. found that subsets of 
cells expressing the surface marker CD133 were particularly tumourigenic following 
transplantation, and propose that CD133+ cells include the colorectal cancer stem cell. It has also 
been mooted that CD133 may be a marker for the normal intestinal stem cell. However, contrary 
to this data, a recent similar study has indicated that CD133' colorectal cancer cells are also 
capable of initiating tumourigenesis upon xenotransplantation, and are in fact equally if not more 
tumourigenic than CD133+ cells. Furthermore, expression of CD133 has been detected throughout 
the crypt-villus axis of the epithelium, with no indication of specific expression within the stem or
progenitor cell compartments (Shmelkov et al., 2008). It is therefore clear that the search for a
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specific marker of the intestinal cancer stem cell is likely to be as challenging as for that of the 
normal intestinal stem cell.
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Figure 1.3: Candidate locations of 
the intestinal stem cell and 
components of the stem cell niche.
The crypts of the small intestine 
house the intestinal stem cell.
Candidate locations of the ISC
include within the crypt base 
columnar (CBC) cell population 
(Brown) and within the label- 
retaining cell population at 
approximately position +4 (Purple). 
Putative markers of the ISC have 
been identified for both candidate 
locations., and different properties 
of the stem cell are associated with 
each location (Red boxes).
The stem cell resides within a stem 
cell niche, which is critical for
maintaining the properties of
'sternness', including limitless 
replication and maintenance of a 
relatively undifferentiated state. 
Components of the intestinal stem 
cell niche (Blue text) include
proliferative precursor cells, 
mesenchymal cells, stromal 
components and infiltrating immune 
cells.
1.1.4 Multi-step carcinogenesis of the intestine
1.1.4.1 Step-wise development of disease
The widely accepted model of acquisition of multiple genetic mutations in a step-wise 
fashion leading to CRC was initially proposed almost 20 years ago (Fearon and Vogelstein, 1990). 
In this study, Fearon and Vogelstein examined data from mutational profiles of colorectal cancers 
at various stages of disease. From their observations, they proposed that 4 to 5 mutational 'steps' 
are necessary to result in colorectal malignancy. These steps involve both the activation of 
oncogenes and the inactivation of tumour suppressor genes, though the latter is more common. 
Although the order in which mutations are acquired was not thought to be important for the 
overall tumour phenotype, it was noted that mutations tend to occur in a preferential sequence. 
The mutations involved in the stepwise model are shown schematically in Figure 1.4 and are 
described below. Despite the fact that this model was proposed some time ago, it is remarkable 
that current research data still largely substantiate the mutational mechanism of colorectal cancer 
initiation and progression originally proposed. This mechanism of carcinogenesis is now 
commonly referred to as the 'Chromosomal instability' pathway. It should be noted that other 
pathways of colorectal carcinogenesis have also been identified, including the 'microsatellite 
instability' pathway (For review, see Laurent-Puig et al., 1999, Jass et al., 2002b). As the 
chromosomal instability pathway is still thought to be the most common mutational pathway of 
colorectal disease, other pathways will not be discussed in detail here.
1.1.4.2 Initiation of colorectal neoplasia
Current dogma dictates that first steps towards malignancy in the intestinal epithelium 
involve hyperproliferation of the epithelium, formation of aberrant crypt foci and subsequent 
development of a benign adenoma. Study of familial colorectal cancer predisposition syndromes, 
namely FAP, have long suggested that mutation of the 'gatekeeper' tumour suppressor gene, Ape, 
is a key initiating event in colorectal cancer (Kinzler and Vogelstein, 1996). Although Ape is a 
multifunctional protein, mutations of Ape in colorectal cancers have been shown to consistently 
lead to activation of Wnt signalling (Morin et al., 1997). Indeed, the great majority of sporadic 
colorectal cancers show activation of the Wnt pathway, and in more than 80% of cases, this is 
attributed to mutational inactivation of Ape (Kinzler and Vogelstein, 1996). Of the remaining 
cases, which are wild-type for Ape, about half show mutational activation of the Wnt effector, 
beta-catenin (Sparks et al., 1998). The remainder are thought to harbour mutations in other 
components of the Wnt pathway, for instance, mutation of Axin2 has been shown to be an 
alternative mechanism resulting in activation of beta-catenin (Liu et al., 2000).
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Although Wnt activation is generally accepted as the crucial initiating step of colorectal 
neoplasia, it should also be noted that other, alternative mechanisms of initiation have been 
proposed. The major alternative pathway proposed involves loss of genes involved in DNA 
mismatch repair, either by mutation or epigenetic silencing. This mechanism of initiation seems to 
parallel that seen in the human hereditary disease HNPCC, whereas initiation of colorectal cancers 
by activation of Wnt signalling (as described above) is thought to parallel that seen in FAP. In 
particular, it is postulated that loss of mismatch repair proteins is the underlying mechanism for 
initiation of colorectal lesions which exhibit high levels of microsatellite instability (MSI). In such 
lesions, lack of DNA repair activity is thought to provide a genetically unstable environment, 
paving the way for mutation acquisition within other genes (Jass et al., 2002a).
1.1.4.3 Progression of disease
Progression of disease, and the eventual adenoma-to-carcinoma transition of a tumour, 
represents the switch from a benign to a malignant tumour phenotype. Disease advancement is 
characterised by sustained abnormal proliferation of cells resulting in an increase in mass of the 
tumour, and by progressive loss of normal structure and anatomy of the intestine. Proliferative 
cells are often found to be poorly or incompletely differentiated. Further advancement of disease 
eventually results in the ability of tumour cells to invade the submucosa. This change in
phenotype resulting in invasive behaviour is complex, and is thought to involve a number of
different mechanisms for modulating gene expression, including mutation and epigenetic 
modification.
A large array of gene and protein expression changes have been identified which are 
associated with progression of disease. However, for many of these changes, what remains 
unclear is whether these changes are causative, and therefore result in the advanced phenotype, 
of whether they are simply an epiphenomenon of disease progression.
According to the multistep model proposed by Fearon and Vogelstein, the events 
absolutely required for progression of disease following initiation of disease by activation of Wnt 
signalling include activation of the oncogene Kirsten-Ras, loss of chromosome 18q, and loss of 
expression of the tumour suppressor p53 (Fearon and Vogelstein, 1990). This pathway is
commonly known as the 'chromosomal instability' (CIN) pathway, and is responsible for
progression of the majority of sporadic colorectal cancers (For review, see Ilyas et al., 1999).
Kirsten-Ras
The Rat sarcoma viral oncogene homology (Ras) family is comprised of Harvey (H or Ha)- 
Ras, Kirsten (K or Ki)-Ras and Neuroblastoma (N)-Ras. This group of small G-proteins are 
commonly found to be activated in cancers of various origins (Bos, 1989). Ras proteins become
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activated upon binding to GTP, which is stimulated by a number of Guanine nucleotide exchange 
factors (GEFs). GEFs themselves are activated in response to a number of cellular signals, 
including activation of growth factor receptor tyrosine kinases (RTKs) and the production of 
second messenger molecules such as calcium and diacylglycerol. Once bound to GTP, active Ras 
can then trigger numerous downstream pathways. Of these, the best characterised is the Raf- 
MEK-ERK mitogen-activated protein kinase (MAPK) cascade. Also of note, it has been shown that 
Ras-GTP can directly activate the catalytic subunit of PI3K, and thus directly stimulate PI3K/Akt 
signalling (Kodaki et al., 1994). Ras activity is antagonised by GTPase-activating proteins (GAPs), 
which catalyse hydrolysis of GTP to GDP, which remains bound to Ras and renders it inactive (See 
Malumbres and Barbacid, 2003 for review).
Oncogenic mutations of Ras generally result in its constitutive activation. Mutations in 
different members of the oncogenic Ras family are generally associated with certain types of 
tumours. In intestinal cancers, mutation of Kirsten (K)-Ras is much more common than mutations 
in the other family members, however the reason for this remains unclear (Malumbres and 
Barbacid, 2003).
In humans, several studies have examined biopsies of histologically normal intestinal 
tissue taken from patients bearing k-Ras mutant colorectal tumours, and surprisingly found that k- 
Ras mutations exist within this normal tissue (Zhu et al., 1997, Minamoto et al., 1995, Yamada et 
al., 2005). This clearly suggests that activation of k-Ras alone is not sufficient to perturb intestinal 
homeostasis. As proposed by Fearon and Vogelstein, activation of Ras signalling appears to occur 
after tumour initiation, but still at a relatively early stage of tumourigenesis; during adenoma 
growth (Fearon and Vogelstein, 1990). In sporadic colorectal cancers in humans, studies have 
placed k-Ras mutation frequency at between 38% and 50% of all tumours (van Engeland et al., 
2002, Sancho et al., 2004). When very early stage colorectal cancers are specifically selected for 
examination, the incidence of k-Ras mutation is still found to be high at 26% (Andreyev et al., 
1997). This supports the notion that k-Ras mutation is an early event following tumour initiation. 
However, this study also noted that in early stage tumours, there was no correlation between k- 
Ras mutation and prognosis. In contrast to this, a number of other reports, including one large, 
multi-centre study, have revealed a strong link between k-Ras mutation, particularly at codon 12, 
and poor prognosis (Andreyev et al., 2001, Conlin et al., 2005), again suggesting that k-Ras 
mutation drives tumourigenesis.
Animal models of intestinal-specific k-Ras activation have reported somewhat discrepant 
results. One study has expressed a Codon 12 glycine-to-valine point mutant form of activated k- 
Ras (k-RasV12) from a strongly expressed intestinal-specific promoter (that of the Villin gene) 
(Janssen et al., 2002). This study reports that k-Ras mutation alone is sufficient for development 
of intestinal lesions of varying severity, from aberrant crypt foci (ACF) to invasive
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adenocarinomas, with high penetrance. This is in direct contrast to data obtained from humans, 
as described above, where k-Ras mutations are detected in histologically normal mucosa (Zhu et 
al., 1997, Minamoto et al., 1995, Yamada et al., 2005). Arguably, one of the problems with the 
experimental model presented by Janssen et al. is that the k-Ras oncogene has been both 
mutated and over-expressed in the intestinal epithelium. It is therefore conceivable that this may 
result in a phenotypic difference compared to mutation alone. To address this, a similar mutant 
form of k-RasV12 has more recently been developed which is expressed from its endogenous 
promoter (Guerra et al., 2003). Indeed, expression of this mutant form of k-Ras in the mouse 
intestine recapitulates the observations seen in humans much more closely. Activation of k-Ras 
alone was found to have no significant impact on the homeostasis of otherwise normal intestinal 
epithelium. However, following loss of Ape and activation of the Wnt cascade, k-Ras activation 
was found to result in both an increase in tumour incidence, and a phenotype of tumour 
invasiveness into the submucosa and muscularis (Sansom et al., 2006). As such, this study 
supports a role for k-Ras activation in the progression, rather than initiation, of disease. Another 
form of k-Ras mutant transgene has more recently been developed by Tuveson et al. (2004), 
which is a different codon 12 point mutant form of k-Ras, but is again driven from its endogenous 
promoter. Intestinal-specific expression of this glycine-to-aspartate (G12D) form of k-Ras was 
found to result in widespread hyperplasia of the epithelium. This study therefore adds a further 
layer of complexity to the consequences of k-Ras mutation in the intestine, indicating that certain 
mutant forms of the oncogene may indeed be able to initiate intestinal neoplasia.
Loss of 18q
Following activation of k-Ras, the next 'step' toward malignancy, as proposed by Fearon 
and Vogelstein, is loss of the long arm of chromosome 18. Indeed, loss of 18q has been observed 
in around 70% of colorectal cancers (Fearon et al., 1990). One candidate for involvement in 
colorectal cancer progression found at this locus is the Deleted in Colorectal Carcinoma (DCC) 
tumour suppressor gene. Of the 70% of colorectal carcinomas which exhibit loss of 18q, the 
deleted region has been shown to include the DCC gene in 9 out of 10 cases (Fearon et al., 1990).
The product of the DCC gene is a transmembrane protein (Hedrick et al., 1994), the major 
cellular role of which is as a component of a receptor complex which binds the Netrin family of 
proteins (Keino-Masu et al., 1996). The role of Netrin signalling has been most thoroughly 
described in neural tissue, where it is known to provide cues for axon guidance and cellular 
migration (Mehlen and Furne, 2005). As such, the role of DCC in cancers was initially puzzling. 
However, more recent data has suggested that DCC may function as a 'dependence' receptor, 
acting as a pro-apoptotic factor when not bound to netrin (Mehlen and Fearon, 2004). Clearly, 
loss of DCC may then result in evasion of apoptosis. This notion is supported by the observation
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that in the intestine, netrin expression is high at the base of the crypt, where apoptosis is 
relatively rare, and decreases along the crypt-villus axis. At the top of the villus, netrin expression 
is low and DCC therefore exists in its unbound state. It is therefore postulated that apoptosis of 
old cells, before they are shed into the intestinal lumen, is initiated by the presence of unbound 
DCC (Mehlen and Fearon, 2004). Indeed, it has been shown in mice that forced expression of 
netrin results in hyperplasia and neoplasia in the intestine, suggesting that DCC may indeed 
mediate cell survival (Mazelin et al., 2004). Despite this evidence, some uncertainty regarding the 
role of DCC as a tumour suppressor does remain. Perhaps the most confounding evidence has 
been obtained from the study of mice constitutively deleted for DCC (Fazeli et al., 1997). Whilst 
Dec7' mice exhibited marked neuronal abnormalities consistent with the previously proposed role 
for DCC in axon guidance, aged Dcc+/' mice were found to have no increased susceptibility to 
tumourigenesis of any tissue. Furthermore, Fazeli et al. unexpectedly found that deletion of Dec in 
the context of the Ape Multiple Intestinal Neoplasia (ApcMIN) mutation had no effect on tumour 
multiplicity, size or histology. Surprisingly, these data therefore suggest that DCC may not play a 
role either in initiation or in progression of intestinal disease.
Another factor which may discredit the role of DCC in colorectal cancer progression is that 
the SMAD4-encoding gene is present in very close proximity (at 18q21.1) to the DCC-encoding 
gene (at 18q21.3) on chromosome 18, and is present within the region most commonly deleted in 
colorectal cancers (Thiagalingam et al., 1996). As described above, SMAD4 is an essential 
component of both the TGF-beta and BMP signalling pathways (See section 1.1.2.3). The evidence 
for the role of SMAD4 as a tumour suppressor in colorectal cancers is somewhat more compelling 
than that for DCC. First and foremost, germline mutation of SMAD4 is known to be a causative 
factor of human Juvenile polyposis syndrome (JPS). Reports attribute SMAD4 mutation to 
approximately 20-25% of JPS cases (Friedl et al., 2002, Howe et al., 2004). In sporadic colorectal 
cancers, loss of the BMP signalling pathway has recently been reported as a frequent event (in 
70% of specimens examined in this study), which is caused by loss of expression of either BMPRII, 
SMAD4 or both (Kodach et al., 2008b). Furthermore, a parallel study by the same group has 
shown that loss of BMP signalling is characteristic of adenocarcinomas but not of colonic 
adenomas (Kodach et al., 2008a). This clearly supports the hypothesis of BMP pathway 
inactivation (through loss of SMAD4) being a late event in the adenoma-carcinoma sequence. 
Further supporting this, murine studies have also placed a role for SMAD4 deletion in carcinogenic 
progression. Takaku et al. (1999) have deleted Smad4 (which, at the time of this study, was also 
known as Dpc4), both alone and in the context of an Ape mutation which is intestinal tumour- 
predisposing. Homozygous deletion of Smad4 was found to result in embryonic lethality, whereas 
Smad4 heterozygous mice exhibited no phenotypic differences compared to wild-type 
littermates. However, in Apc+/';Smad4+/' mice, intestinal lesions were found to show increased
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malignancy compared to Apc+/' control mice. Tumours were found to be larger in mass, showed 
an increased desmoplastic response and were more invasive, consistent with a role for Smad4 
loss resulting in progression of disease.
p53
According to Fearon and Vogelstein, the final transformation required for full-blown 
malignant disease is loss of the short arm of chromosome 17, which harbours the TP53 gene, 
encoding the tumour suppressor p53. As the first tumour suppressor gene identified, p53 is 
probably the most extensively studied and best-characterised gene involved in malignancy. 
Germline mutations of p53 are known to cause the cancer-prone Li-Fraumeni syndrome (Li et al., 
1988). The p53 pathway is found to be inactivated in many cancers of a huge variety of origins, 
either through loss of p53 itself, or of one of its isoforms (p63 and p73) (For review, see Bourdon,
2007). The predominant normal cellular function of p53 is as a sensor of cell stress and DNA 
damage; in normal cells it is rendered inactive by Mdm2, which binds to p53 and mediates its 
ubiquitination. Following cellular stress or damage to DNA, p53 is released from Mdm2- 
dependent suppression, and acts to coordinate the relevant response to trauma by selective 
transcription of target genes. This may result in cell cycle arrest, stimulation of DNA repair, 
senescence or cell death by apoptosis (Reviewed extensively, including Vogelstein et al., 2000, 
Vousden and Lane, 2007, Helton and Chen, 2007).
Loss of p53 is seen in approximately 50% of colorectal cancers (lacopetta, 2003). As 
observed with other tumour suppressor genes involved in disease progression, loss of p53 is 
normally associated with late-stage carcinomas rather than early adenomas in humans (Purdie et 
al., 1991). Despite these observations in human samples, animal models examining the effect of 
p53 nullizygosity in a tumour-prone context have produced conflicting results. The work of 
Halberg et al. (2000) produced the expected results; deletion of p53 in mice bearing the ApcMIN 
mutation was found to cause an increase in the number of tumours observed, and an increase in 
their invasiveness. However, a very similar study previous to this, by Clarke et al. (1995) showed 
that whilst p53 mutation in the ApcMIN mouse causes acceleration of tumourigenesis in the 
pancreas, no changes in tumour progression were observed within the intestine. In support of 
this, very recent work has shown that conditional loss of p53 has very little effect on the acute 
phenotype observed following conditional loss of both alleles of Ape in the intestine (Reed et al.,
2008). These data therefore suggest that the tumourigenic effects of p53 loss may only be 
manifest following the accumulation of more mutations than that of Ape alone, which is again 
consistent with the proposal that p53 mutation is a very late stage event in the intestinal 
adenoma-carcinoma sequence.
30
AB
Figure 1.4: Multi-step tumourigenesis of the intestinal epithelium
Step-wise accumulation of mutations leading to intestinal cancer formation and proposed by Fearon and Vogelstein (1990) (A). Inactivation of tumour suppressor genes 
(Red) and activation of oncogenes (Green) are proposed to cause step-wise progression of disease.
Histological appearance of multi-step tumour progression in the mouse (B). Images of hyperproliferation and early adenoma taken from the Mouse Tumour Biology 
Database (Naf et al., 2002), images of intermediate adenoma and carcinoma taken from Boivin, 2003.
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1.2 PTEN: A tumour suppressor
1.2.1 Discovery, structure and function of Pten
1.2.1.1 A candidate tumour suppressor gene at 10q23.3
Abnormalities at the 10q23 locus have long been associated with sporadic cancers of a 
number of tissues, and also cancer-predisposing genetic diseases in humans. In 1997, a candidate 
tumour suppressor gene was identified, cloned and characterised by three separate groups (Li 
and Sun, 1997, Li et al., 1997, Steck et al., 1997), and was found to have phosphatase activity 
directed towards both protein tyrosine residues and lipids. This was the first potential tumour 
suppressor gene to be identified which has phosphatase activity, even though it had been 
recognised for many years that protein kinases are commonly oncogenic (Dahia, 2000). All three 
groups also found that the novel protein identified had a large degree of homology to the 
cytoskeleton-associated proteins tensin and auxilin.
The novel tumour suppressor gene identified by these groups is now most commonly 
known by the acronym coined by Li et al.; Pten (Phosphatase and tensin homolog, mutated on 
chromosome 10). However, due to the fact that Steck et al. initially designated this novel protein 
as MMAC1 (Mutated in Multiple Advanced Cancers 1), and Li and Sun named it TEP1 
(Transforming growth factor [TGF]-regulated and epithelium-enriched phosphatase), Pten is still 
occasionally referred to by these pseudonyms in the literature.
1.2.1.2 Structure and function of Pten
The PTEN gene is located on chromosome 10q23 in humans, and on chromosome 19 in 
the mouse. Coding regions of the gene are highly conserved between the two species.
PTEN protein consists of 2 major domains; the N-terminal domain and the C-terminal 
domain (Reviewed by Waite and Eng, 2002) (See Figure 1.5). The N-terminal domain contains the 
phosphatase catalytic core of the protein, including the CKAGKGR phosphatase motif, which 
corresponds to the general phosphatase consensus sequence of HCXXGXXR (Simpson and 
Parsons, 2001, review). Solution of the crystal structure of PTEN showed the phosphatase motif 
forms a loop, known as the 'P-Loop' (Lee et al., 1999) (See Figure 1.5). The more complex C- 
terminal domain is comprised of three types of sub-domain; the C2 domain, two PEST domains 
and a PDZ domain (Waite and Eng, 2002). The presence of a C2 domain is characteristic of a 
protein involved in membrane-binding and signal transduction. C2 domains are also known to be 
involved in the binding of phospholipids, and the C2 domain of PTEN has been shown to have 
affinity for phospholipid membranes in vitro (Lee et al., 1999). PEST domains are known to play a 
role in the targeting of proteins for proteasomal degradation (Chu and Tarnawski, 2004). Finally,
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PDZ motifs are regions associated with protein-protein interactions. The PDZ domain of PTEN is 
also thought to aid both recruitment of PTEN to the plasma membrane as well as assisting in 
orientation of the active site of the phosphatase domain so that it comes into optimal contact 
with its substrate (Lee et al., 1999).
PTEN functions predominantly as a lipid phosphatase in vivo (Maehama and Dixon, 1998). 
Maehama and Dixon found that overexpression of PTEN in cell lines resulted in decreased levels 
of the cellular phospholipid second-messenger, phosphatidylinositol-3,4,5-trisphosphate (PIP3). 
The same effect was not seen in a catalytically-dead mutant of PTEN. Further investigation 
showed that PIP3 was specifically dephosphorylated at the D3 position of the inositol ring 
structure to generate phosphatidylinositol-4,5-trisphosphate (PIP2). It was therefore concluded by 
Maehama and Dixon that PTEN directly antagonises Phosphatodylinositol-3 kinase (PI3K) by 
dephosphorylation of PIP3 to give PIP2, and generates a product which can be recycled as a 
substrate for PI3K (See below, and Figure 1.5).
PTEN also has limited activity towards phosphoprotein substrates. In vitro, PTEN has been 
shown to directly associate with and dephosphorylate Focal Adhesion Kinase (FAK), and is also 
implicated in the dephosphorylation of She which, in turn was shown to result in downregulation 
of the Mitogen-activated protein (MAP) kinase pathway (Gu et al., 1999). However, the protein 
phosphatase activity of PTEN has not been demonstrated in vivo.
1.2.1.4 Regulation of PTEN
Control of the activity of PTEN is complex, involving activation and repression at both the 
transcriptional level and the post-translational level, and regulation of the subcellular localisation 
of the protein (For review, see Tamguney and Stokoe, 2007). As such, the detailed mechanisms of 
PTEN regulation will not be discussed here.
However, several aspects of PTEN regulation are particularly notable with respect to 
intestinal homeostasis.
Firstly, as described above, inactive phosphorylated PTEN has been proposed as a feature 
of the intestinal stem cell (He et al., 2004). Phosphorylation of PTEN in the region of residues 380- 
385 in the C-terminal tail is known to attenuate PTEN activity. The mechanism proposed for this is 
that the phosphorylated tail region acts as a pseudo-substrate, blocking the active site of PTEN, 
and hence resulting in self-inhibition (Odriozola et al., 2007). Casein Kinase 2 (CK2) has previously 
been shown to phosphorylate PTEN at residues Ser380, Thr382, Thr383 and Ser385 both in vitro 
and in intact cells (Torres and Pulido, 2001). Torres and Pulido also observed that phosphorylation 
at these residues renders PTEN resistant to proteasomal degradation, thus it would appear that C- 
terminal tail phosphorylation both stabilises and inactivates PTEN. This may therefore represent a 
mechanism which allows very dynamic and rapid control over PTEN activity.
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Secondly, PTEN has been shown to be regulated through interaction with other proteins 
present within the cell. Interestingly with respect to the intestine, beta-catenin and other 
components of the adherens junction have been shown to play a role in maintaining PTEN levels. 
One such component, vinculin, has been shown to be critical for interaction of PTEN with the 
adherens junction proteins beta-catenin and membrane-associated guanylate-kinase inverted 2 
(MAGI-2). Maintenance of this interaction was shown to be critical for preservation of cellular 
PTEN protein levels, whilst not affecting levels of Pten mRNA (Subauste et al., 2005). Thus, 
modulation of other adherens junction components, such as beta-catenin, may play a critical role 
in regulating the normal activity of PTEN.
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Figure 1.5: Structure and function of PTEN
A: Schematic diagram of PTEN protein, which is divided into two regions; the N-terminal region (Red) and 
the C-terminal region (Blue). The N-terminal region contains the catalytic core of the protein (Black). The C- 
terminal region is comprised of the C2 domain, two PEST domains and a PDZ domain.
B: Crystal structure of PTEN protein as solved by Lee et a!., with the N-terminal region shown in Red and the 
C-terminal region in Blue. Critical active site residues, Argl30 and Cysl24, which are situated within the P- 
loop (Green), are labelled.
C: PTEN functions principally as a lipid phosphatase, and acts to remove the Phosphate group (yellow) from 
position 3 of the inositol ring of phosphatidylinositol-3.4.5-trisphopshate, generating phosphatidylinositol- 
4,5-bisphosphate. PTEN directly reverses the reaction catalysed by PI3K. Adapted from Vivanco and Sawyers, 
2002.
1.2.2 The PI3K/Akt pathway
Phosphatidylinositol-3 kinase (PI3K)/Akt signalling plays a crucial role in mediating cellular 
proliferation, growth and cell survival in a number of tissues. As a critical regulator of these 
processes, PI3K/Akt signalling is known to play a major role in tumourigenesis of a number of 
tissues. In particular, activating mutations in the PI3K/Akt pathway have been reported in up to 
40% of all sporadic colorectal cancers in humans (Parsons et al., 2005).
Normal function of the PI3K/Akt pathway and the cellular consequences of its activation 
are discussed below.
1.2.2.1 Activation of the PI3K/Akt pathway
Activation of the PI3K/Akt pathway is dependent on activation of PI-3 kinase itself. PI-3 
kinases are heterodimeric, composed of a p llO  catalytic subunit and a p85 regulatory subunit. In 
its normal cellular state, PI3K exists in the cytoplasm in a catalytically inactive state, which is 
maintained by the repressive effect of the p85 regulatory subunit on the p llO  catalytic subunit. 
Activation of p llO  can be achieved in several ways. Firstly, p llO  may be directly activated by 
active Ras signalling, as Ras-GTP has been shown to be capable of direct binding and activation of 
p llO  (Kodaki et al., 1994). Alternatively, p85 may bind to activated receptor tyrosine kinases 
(RTKs), either directly or through adapter proteins such as insulin receptor substrates 1/2 (IRS1/2). 
RTKs themselves are activated by autophosphorylation of intracellular tyrosine residues following 
binding of a cognate ligand to the receptor on the cell surface. Generic examples of ligand- 
receptor complexes which are able to activate PI3K signalling include insulin and the insulin 
receptor, and growth factors and growth factor receptors. Following this, activation of the p llO  
subunit is achieved in two ways. Firstly the binding of p85 to either an activated RTK or to IRS1/2 
causes a conformational change in the protein structure which is thought to relieve repression of 
pllO . Secondly, the binding of p85 to RTKs or IRS1/2 brings the p llO  subunit in close physical 
proximity to the plasma membrane, where its substrate exists.
The principal substrate of PI3K is phosphatidylinositol-4,5-bisphosphate (PIP2), which it 
phosphorylates at the 3 position of the inositol ring to generate a local rise in levels of the active 
signalling molecule, phosphatidylinositol-3,4,5-trisphosphate within the phospholipid membrane 
(Extensively reviewed, including Vivanco and Sawyers, 2002, Cully et al., 2006) (See also Figure 
1.6).
1.2.2.2 Activation ofAkt
The principal effect of PIP3 production is the activation of the serine-threonine kinase, 
Akt. Akt is recruited to the membrane through its PIP3-binding pleckstrin homology (PH) domain. 
Two other PH-domain-containing proteins, phosphoinositide-dependent kinases 1 and2 (PDK1
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and 2) are also recruited to the membrane following PIP3 production. The close physical proximity 
of PDK1 and 2 to Akt allow them to phosphorylate Akt at residues Thr308 and Ser473 respectively. 
Phosphorylation of Akt at Thr308 is necessary for its activation, whilst phosphorylation at Ser473 
results in its maximal activation (See Figure 1.6) (See Vivanco and Sawyers, 2002, Cully et al., 2006 
for review).
1.2.2.3 Downstream targets of Akt
The downstream targets of Akt are extremely numerous and varied. A number of targets 
of Akt pertinent to tumourigenesis are outlined in Figure 1.7. One well-characterised downstream 
effect of Akt which is of particular note is modulation of the mammalian target of rapamycin 
(mTOR) pathway. The cellular role of the mTOR pathway is to integrate signals generated by both 
growth factor signalling (via the PI3K/Akt pathway) and nutrient stress (via LKB-1 and AMPK), and 
coordinate an appropriate response of translational modulation by acting on ribosomal S6 kinase 
(S6K), or on the translation initiation factor 4E binding protein (elF4E-BPl) (Fingar et al., 2004, See 
also Tee and Blenis, 2005 for review). Dysregulation of the mTOR pathway itself is associated with 
human polyposis syndromes, such as Tuberous sclerosis (TSC) and Peutz-Jeghers syndrome (PJS) 
(Reviewed by Inoki et al., 2005).
Akt acts to directly phosphorylate the Tuberous sclerosis 2 (TSC2) gene product, Tuberin 
(Manning et al., 2002). This prevents formation of the TSC complex, allowing GTP-binding and 
activation of a Ras homolog, Rheb. Active Rheb in turn can directly phosphorylate and activate 
mTOR at serine residue 2448. Active mTOR then phosphorylates and activates S6K, and 
inactivates elF4E-BPl by phosphorylation. Both of these effects result in promotion of translation 
within the cell, facilitating cell growth and division (Hay and Sonenberg, 2004).
1.2.2.4 PI3K/Akt signalling and intestinal homeostasis
Although not classically thought of as a major regulatory pathway within the intestine, 
some evidence has suggested that PI3K/Akt signalling plays a role in intestinal homeostasis. In 
particular, the work of Sheng et al. (2003), mentioned above, has suggested a role for PI3K 
signalling in proliferation and regeneration of the intestine following injury. Having noted that 
PI3K inhibition (using the specific inhibitors, Wortmannin or LY-294002) resulted in at least an 
80% reduction in proliferation of intestinal epithelial cell lines, Sheng and colleagues pursued 
these observations in a mouse model. The number of proliferating cells in the intestine was 
reduced by subjecting mice to a liquid diet for 72 hours, followed by reinstatement of solid diet. 
This resulted in rapid regeneration of proliferative cells, as assessed by expression of proliferating 
cell nuclear antigen (PCNA). PCNA-expressing cells were also found to be characterised by 
increased levels of phospho-AktSer473. Treatment of mice with LY-294002 at the time of solid food
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reinstatement was found to completely block the generation of PCNA-expressing cells, indicating 
that this process is entirely dependent upon PI3K/Akt signalling.
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Figure 1.6: Activation of PI3K and Akt
Binding of growth factors (GFs) to growth factor receptors (GFRs) (which are also receptor tyrosine kinases [RTKs]) causes receptor activation by 
autophosphorylation of tyrosine residues. This allows the binding of PI-3 kinase through the SH2 domain of the p85 subunit and IRS1/2. Binding of the p85 
regulatory subunit causes allosteric activation of the p llO  catalytic subunit. Alternatively, the catalytic p llO  subunit can be directly activated by Ras. Ras is 
activated when bound to GTP, which is stimulated by guanine nucleotide exchange factors (GEFs). GEFs are activated in response to a range of signals, 
including growth factors, calcium (Ca2+) and diacylglycerol (DAG). Stimulation of the GTPase activity of Ras by GTPase-activating proteins (GAPs) attenuates Ras 
activity.
Once activated, the catalytic p llO  subunit of PI3K then locally produces PI-3,4,5-P3 from PI-4,5-P2 in the plasma membrane. This reaction is antagonised by 
the catalytic activity of PTEN. The PH-domain containing proteins PDK1, PDK2 and Akt are then recruited to the plasma membrane, and bind PIP3 through 
their PH domains. Here, due to the close physical location of the proteins, PDK1 and 2 are able to phosphorylate Akt at residues Thr308 and Ser473 
respectively. Phosphorylation of Akt at these sites leads to its complete activation, and it can then act on its cellular substrates.
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Figure 1.7: Downstream Targets of Akt
The cellular targets of Akt kinase are numerous and varied. Here, the action of Akt on a number of its targets is shown, grouped according to the 
resultant cellular effect of Akt activation. In general, the effects of Akt activation promote processes associated with acquired tumourigenic properties 
of cancer cells, as described by Hanahan and Weinberg, 2000.
1.2.3 Pten and carcinogenesis
1.2.3.1 Somatic mutation of Pten in human cancers
Loss of PTEN is a frequent event in sporadic human cancers. Cairns et al. (1997) report 
deletion of the chromosome region containing the PTEN gene in 23 of 80 prostate tumour 
samples. Loss of heterozygosity (LOH) of PTEN was evident in 10 of these cases. Similarly, 
mutation of PTEN is found to be common in sporadic breast (Saal et al., 2008) and endometrial 
cancers, with one study reporting a mutation frequency of up to 50% in endometrial carcinomas 
(Tashiro et al., 1997). LOH of 10q23 is also common in cervical cancers, with a PTEN loss rate of 
over 35% (Kurose et al., 2000). Finally, inactivating PTEN mutations are reported in samples taken 
from malignant melanoma. In one study, 38% of primary lesions showed mutation of PTEN, 
though analysis of metastases revealed an increase in mutation rate to 58%, suggesting that PTEN 
plays a role in the progression of disease (Birck et al., 2000).
1.2.3.2 PTEN Hamartoma Tumour Syndromes (PHTS)
Germline mutation of PTEN in humans is known to be the causative factor in a number of 
cancer-predisposition disorders. These syndromes, known under the umbrella term 'PTEN 
Hamartoma Tumour Syndromes' (PHTS), include Cowden's disease (CD), Bannayan-Riley- 
Ruvalcaba syndrome (BRRS; also known as Bannayan-Zonana syndrome) and Proteus syndrome.
The most common PHTS is Cowden's disease, which is still rare, with an incidence of 
approximately 1 in 200,000 (Nelen et al., 1999), though it is thought that CD is under-diagnosed. 
CD was first described in 1963 (Lloyd and Dennis, 1963), and is linked to mutation of the PTEN 
gene in approximately 80% of instances (Marsh et al., 1998). The clinical features of CD include 
mucocutaneous lesions (including lipomas, fibromas, facial papules and oral papilloma), 
abnormalities of the thyroid, susceptibility to carcinoma of the breast, endometrium and thyroid, 
macrocephaly, mental retardation and gastrointestinal hamartomas (Reviewed by Eng, 2003). 
Mucocutaneous lesions are the most common feature of CD, and are present in almost all cases. 
Thyroid abnormalities are also common, ranging in severity from goitre to follicular carcinoma. 
The reported incidence of gastrointestinal lesions varies widely depending on the study, and has 
been estimated to be present in between 35% to 75% of cases (Carlson et al., 1984, Merg and 
Howe, 2004). The observed histology of gastrointestinal tumours in CD cases also appears to vary 
widely, though it is clear that most lesions are benign, with progression to carcinoma reported in 
only a handful of cases (Merg and Howe, 2004).
1.2.3.3 Mouse models of Pten deficiency
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A null mutation for the mouse Pten gene was generated simultaneously by three 
independent groups (Podsypanina et al., 1999, Di Cristofano et al., 1998, Suzuki et al., 1998). All 
three groups report embryonic lethality in the homozygous mutant at between embryonic (E) 
days E6.5 and E9.5. Analysis of mice heterozygous for Pten has revealed predisposition to a 
number of neoplasias. Suzuki et al. (1998) report spontaneous tumourigenesis in 14% of mutant 
mice before the age of 28 weeks. Mutant mice were found to be predisposed to lymphoma, 
leukaemia, liver hyperplasia, teratocarcinoma and prostate neoplasia. In addition to this, many of 
the animals examined were found to have microscopic lesions of the intestinal mucosa, described 
as being hamartomatous. Similarly, Di Cristofano et al. (1998) report multiple system 
tumourigenesis at a young age. By the age of 14 weeks, heterozygotes were commonly found to 
have prostate hyperplasia and skin hyperkeratosis. Like Suzuki et al., this study also reports a high 
incidence of gastrointestinal hyperplasia, and additionally the occurrence of colonic carcinoma is 
reported in 3 out of 18 mice studied. Finally, Podsypanina et al. show a similar phenotype of 
cancer predisposition, however the tumour spectrum reported included neoplastic changes of the 
thyroid and endometrial hyperplasia. Adenoma of the colon is also reported, most of which were 
found to be lymphoid-associated.
In order to circumvent the problem of embryonic lethality, a number of studies have 
employed the use of conditional transgenesis to examine the effect of homozygous Pten mutation 
in the adult and within specified tissues. Lu et al. (2007) have employed a strategy to globally 
delete both copies of Pten in the adult mouse, driven by the ROSA26 ubiquitously-expressed 
promoter. Following a latency period of 11 weeks and 21 weeks for females and males 
respectively, tumourigenesis was found to ensue. Lymphoma was the most common malignancy 
reported across both sexes, and epidermal squamous cell carcinoma was also found to occur in 
both males and females. Additionally, female mutants were found to develop endometrial 
carcinoma, and males were found to be susceptible to both prostate and intestinal cancers. The 
intestinal lesions reported in males were described as colorectal carcinomas, and were found to 
be one of the latest-developing malignancies in experimental animals.
Tissue-specific deletion of Pten has revealed a clear role for Pten in carcinogenesis of the 
liver (Stiles et al., 2004, Horie et al., 2004), breast (Li et al., 2002), prostate and skin (Backman et 
al., 2004). Further, deletion of Pten specifically within the intestine has been shown to lead to 
rapid polyposis (He et al., 2007). Within one month after induction of Pten loss, intestinal lesions 
were observed, which were found histologically to be hamartomatous. Thus, this study 
established a role for Pten in suppression of tumourigenesis in the intestine.
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1.3 Modelling colorectal cancer in the mouse using conditional transgenesis
1.3.1 Mouse models of intestinal tumourigenesis
Murine models of human cancers are invaluable both for furthering knowledge into the 
basic biology of disease, and for providing a platform in which to test novel and potential 
therapeutic agents.
However, for the maximum possible benefit to be gleaned from such models, they need 
to accurately and faithfully recapitulate the disease situation as it would occur in humans.
For intestinal tumourigenesis, the classic example of a mouse model of disease is the 
ApcMIN mouse. This model was generated using a random mutagenesis approach, involving 
exposure of mice to the mutagen ethylnitrosourea (ENU). This led to the isolation of a line which 
was found to spontaneously develop intestinal tumours within both the large and small intestine 
with very high penetrance (Moser et al., 1990). Following the establishment of this pedigree, the 
mutant line was sequenced and found to bear a mutation in the gene encoding Ape, at codon 850 
(Su et al., 1992). This mutation is analogous to that commonly found in human FAP, and the 
ApcMIN mouse has since been established as a good murine model of this disease, and also of 
sporadic tumour formation.
As such, the ApcMIN mouse has been valuable both to allow study of tumour initiation and 
neoplastic development in an in vivo setting (Shoemaker et al., 1997), and has also allowed 
exploration of the potential efficacy of a number of therapeutic agents. For instance, the use of 
non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin (Sansom et al., 2001) and 
Sulindac (Boolbol et al., 1996), have been explored in the ApcMIN mouse, both for prophylaxis and 
for treatment of pre-existing intestinal tumours. Boolbol et al. reported dramatic suppression of 
tumourigenesis following treatment of mice with Sulindac, and these data have also been 
recapitulated in human FAP patients treated with the same agent (Giardiello et al., 2002), 
providing very convincing evidence validating the use of the ApcMIN mouse model.
However, it should be noted that the ApcMIN mouse has limitations with respect to 
modelling human disease. The distribution of tumours observed in ApcMIN mice is considerably 
different to that observed in humans. In humans, small intestinal lesions are rare (Cancer 
Research UK, 2007), either in FAP or in sporadic disease. In contrast, the ApcMIN mouse commonly 
develops tumours within the small intestine as well as in the colon (Moser et al., 1990). 
Furthermore, whilst ApcMIN mice tend to bear a large tumour burden in terms of the number of 
lesions which develop, the severity of these lesions is rarely seen to advance past the stage of 
adenoma. In contrast, lesions in human FAP patients often progress to full-blown carcinoma, and 
indeed this is often the case in sporadic disease also.
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Thus, although models such as the ApcMIN mouse have been important for allowing 
research into intestinal tumourigenesis in vivo, it is clear that more sophisticated models of 
disease must be developed in order to model the finer aspects of tumour development and 
progression which occurs in humans.
1.3.2 Constitutive versus conditional transgenesis
The advent of directed transgenic technology in the mouse came in 1987 with the 
development of the first targeted knockout, bearing deletion of the hypoxanthine-guanosine 
phosphoribosyl transferase (HPRT) gene (Kuehn et al., 1987). Since then, numerous murine 
constitutive knockout models have been generated, with varying degrees of success. Although 
such studies have provided valuable insights into the in vivo function of a number of genes, it is 
becoming clear that constitutive models are beginning to fall short in their ability to assess more 
subtle aspects of gene function.
One of the most obvious flaws of constitutive models is that the expression of many 
genes is absolutely required during embryonic development. Thus, the generation of an adult 
mouse deleted for these genes is impossible. This rules out the use of constitutive transgenesis to 
study of a large number of genes, and it could be argued that these may be among some of the 
most interesting genes to study in vivo, particularly in the field of cancer biology. Indeed, many 
known tumour suppressor genes and oncogenes are absolutely required for embryonic 
development.
A second problem with constitutive knockout mice is that all the cells within the organism 
are deleted for the particular gene of interest. This poses several issues with regard to the study 
of gene function. Firstly, the study of a gene within a particular tissue may be precluded by more 
severe phenotypes occurring within other tissues of the organism. Secondly, the interaction 
between different cell types within a tissue may be altered, as all cell types within that tissue will 
be deficient for the gene of interest. This is particularly pertinent with regards to the study of 
neoplasia, as tumours generally arise due to the mutation of a single cell, without effect on any of 
its neighbouring cells or other components of its microenvironment.
Finally, constitutive gene deletion provides a large opportunity for developmental 
compensation within the organism. This may potentially mask the true cellular role of a gene.
In order to circumvent many of these problems, approaches employing the use of 
conditional transgenesis have been developed, and their use is becoming increasingly popular.
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1.3.3 Conditional transgenic approaches
The basic principle of conditional transgenesis is that modification of gene expression will 
occur only once defined conditions have been met. This allows much finer control of gene 
deletion or activation, both spatially and temporally.
In its very simplest form, conditional transgenesis involves the use of a tissue-specific 
promoter to drive expression of a gene of interest. Clearly, this approach is generally applied to 
the study of overexpression rather than deletion of genes of interest. For example, the Villin gene 
promoter has been used to drive gene expression specifically in the small and large intestine 
(Pinto et al., 1999). This approach often successfully avoids problems of embryonic lethality and 
of over-riding phenotypes in other tissues. However, the fact that gene expression within the 
tissue is still constitutive means that the problem of developmental adaptation is not addressed. 
In order to do this, an element of control over the exact time in development in which is gene is 
lost needs to be introduced.
Early attempts to generate a temporally 'switchable' transgene involved the use of 
exogenous agents such as steroids, heat shock or heavy metals (Schweinfest et al., 1988, Hu and 
Davidson, 1990). However, such approaches were plagued with problems, such as toxicity of 
inducing agents and poor levels of recombination being achieved.
Recently, more sophisticated approaches have been used to develop truly switchable 
strategies. Such approaches are generally bipartite in mechanism, consisting of both an 'effector' 
transgene and a 'target' transgene. Examples of these approaches, which have been used in the 
mouse, include Causes recombination (Cre)-Locus of crossover of bacteriophage P I (LoxP), Flp-Flp 
recognition target (Frt) and Tetracycline (Tet-) regulated techniques. The Cre-LoxP approach has 
proven particularly popular, and is described in detail below.
1.3.4 The Cre-LoxP approach
1.3.4.1 Mechanism of action
The Cre-LoxP system operates as a binary mechanism. Cre recombinase, the 'effector' 
component of the Cre-LoxP system, was originally isolated from Bacteriophage P I (Abremski and 
Hoess, 1984). It is a site-specific DNA recombinase, which recognises sequences termed LoxP sites 
(Hoess et al., 1982, Sternberg and Hamilton, 1981). Upon recognition of a pair of LoxP sequences, 
cre recombines between these sites, excising the material in between. This can be utilised 
experimentally by engineering a gene of interest such that LoxP sites are inserted either 
surrounding the entire gene, or surrounding an essential coding region of the gene. Thus the gene 
has been 'targeted' for recombination. When the gene is then exposed to Cre recombinase, the 
region between LoxP sites is excised, or 'floxed' out, resulting in complete inactivation of the
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gene. Activation of transgenes can also be achieved using the Cre-LoxP system; in this case the 
target transgene contains a 'STOP' cassette flanked by LoxP sites. Upon exposure to cre, the STOP 
cassette is excised and expression of the transgene is permitted.
Spatial and temporal control over this system can be readily attained through modulation 
of expression and activity of cre recombinase. Strategies which have been employed to achieve 
this in the intestine are discussed below (Section 1.3.3).
1.3.4.2 Benefits and disadvantages o f the Cre-LoxP system
Undoubtedly, one of the major benefits of the Cre-LoxP system is its popularity; 
numerous murine genes have been targeted by insertion of LoxP sites, and Cre recombinase 
constructs have been generated to allow controlled expression of Cre in many different situations 
(Nagy, 2008). The variety of different promoters to drive Cre expression also means that 
modulation of gene expression can be controlled both temporally as well as spatially. Finally, 
different experimental approaches can allow either activation or deletion of a selected gene (as 
described above).
However, some drawbacks to the system also exist. One of the main problems of the 
system is that once activated and the target region excised, this can not be reversed, and the 
system can not be restored to its original state. Although less commonly used in the mouse, Tet- 
regulable systems do allow the switching on and off of transgenes at will (Gossen and Bujard, 
1992).
Another common problem with many cre-expressing transgenes is that they allow a 
certain level of aberrant cre expression, or 'leakiness'. In some instances however, this cre 
leakiness has been exploited, and it has been argued to be one of the benefits of the system.
Finally, it has been proposed that expression of cre recombinase in mammalian cells may 
promote genomic instability. This point has been reinforced by the discovery of pseudo-LoxP 
sequences in mammalian genomes (Thyagarajan et al., 2000), upon which Cre recombinase may 
be able to act to cause double-stranded DNA breaks.
1.3.5 Regulation of Cre activity in the intestine
The requirement for tightly-restricted Cre activity within given cell types has led to the 
development of a number of ingenious strategies allowing transcriptional and post-translational 
regulation of Cre. The major approaches used within the intestine are described below, and are 
also summarised schematically in Figure 1.8.
1.3.5.1 Use o f tissue-specific promoters
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Tissue-specific promoters have been used to drive the expression of Cre in much the same 
way as they are used to drive the expression of other genes of interest, as described above 
(Section 1.3.2). However, in this case the system can be devised such that either the expression or 
deletion of a gene can be driven by recombination.
Within the intestine, both the Villin (el Marjou et al., 2004, Madison et al., 2002) and the 
Fatty acid binding protein (Fabp) (Saam and Gordon, 1999) gene promoters have been used to 
drive cre expression within all epithelial cell types .
As with tissue-specific promoter driven transgenes, this approach does not circumvent 
the problem of developmental compensation within the tissue in response to gene loss or 
activation. However, the use of tissue-specific promoters to drive cre expression can be used in 
combination with other methods of cre regulation to achieve finer control of recombination 
patterns (see below).
1.3.5.2 Use o f inducible promoters
Inducible promoters require the administration of a xenobiotic agent in order to become 
active and allow the transcription of the cre transgene. Inducible promoters are commonly used 
to drive recombination in the intestine. The promoter of Cytochrome P450 1A (CYP1A1) is used to 
drive expression of cre in the AhCre construct specifically in the intestinal epithelium in response 
to administration of aryl hydrocarbons such as beta-naphthoflavone (Campbell et al., 1996, 
Ireland et al., 2004). Another example of the use of an inducible promoter to drive recombination 
in the intestine is MxlCre, which drives recombination in both the epithelium and in underlying 
stromal cells (Schneider et al., 2003). Induction by treatment using either interferon or 
polyinosinic-polycytidylic acid (which stimulates interferon production in the host) is required to 
activate transcription of MxlCre (Kuhn et al., 1995).
Such promoters have the advantage that as well as exhibiting spatially controlled 
expression, they also allow temporal control of cre activity. However, inducible promoters often 
exhibit some level of leakiness, depending on the promoter used.
1.3.5.3 Post-translational regulation o f Cre activity
Approaches to regulate cre activity much more tightly have also been developed, 
employing the use of post-translational regulation through dependence on ligand binding. Several 
different studies have reported the generation of a fusion protein of cre and a modified estrogen 
receptor (ER) (el Marjou et al., 2004, Feil et al., 1996, Feil et al., 1997, Metzger et al., 1995). After 
transcription and translation of the fusion protein, the estrogen receptor (ER) domain of the 
fusion protein sequesters cre recombinase in the cytoplasm, preventing it from acting upon its 
target sequences which are contained within the nucleus. The estrogen receptor domain bears a
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point mutation so that it is unresponsive to the binding of endogenous estrogens present in the 
host animal. However, upon binding of the ER to the estrogen analog, Tamoxifen, the nuclear 
localisation signal of the receptor is exposed, allowing the translocation of the CreER fusion 
protein to the nucleus, where cre can then act on its targets.
1.3.5.4 Combinatorial approaches
The most sophisticated forms of cre regulation employ the use of a combination of either 
a tissue specific promoter or an inducible promoter with a post-translationally regulated form of 
cre. For example, in the intestine, the Villin promoter has been coupled to a CreER fusion protein 
to allow temporal control over Cre expression within the epithelium (el Marjou et al., 2004). Also 
in the intestine, the inducible Ah promoter has been used to drive expression of a CreER fusion 
protein. Thus, cre activity requires induction both with an aryl hydrocarbon, to stimulate 
transcription of the transgene, and with Tamoxifen, to post-translationally activate cre (Kemp et 
al., 2004).
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Figure 1.8: Strategies for regulation of Cre 
activity in the intestine
A: Regulation of Cre activity by use of a tissue- 
specific promoter (TSP). The Cre transgene is 
under the control of a promoter which is expressed 
only in certain tissues, for instance, the Villin or 
Fabp gene promoters are commonly used within 
the intestine. When the promoter is active, the cre 
transgene is expressed, and transcribed and 
translated in the cytoplasm. Cre can then freely 
enter the nucleus, and act on genes targeted with 
LoxP sites.
B: Use of an inducible promoter (IP) to allow 
temporal control of Cre activity. Expression of the 
cre transgene is restricted by use of an inducible 
promoter, such as the Cyp1A1 promoter which is 
used to drive Cre expression in the intestine. The 
IP is only activated following administration of an 
exogenous inducing agent, for example beta- 
naphthoflavone efficiently induced Cyp1A1 
promoter expression. The Cre transgene is then 
expressed, transcribed and translated as 
described above (A).
C: Tissue-specific expression of a Cre-Estrogen 
receptor (CreER) fusion protein to allow post- 
translational control of Cre activity. The CreER 
fusion protein is expressed in a tissue specific 
manner from a TSP as descibed in A. However, 
following transcription and translation of CreER, 
the protein requires binding to tamoxifen (which is 
added exogeneously) in order to access the 
nucleus and act on its target sequences.
D: Combined use of an inducible promoter and a 
CreER fusion protein. Expression of CreER 
requires induction of the promoter, as described in 
B. Following promoter induction, the CreER fusion 
protein is transcribed and translated, but must bind 
tamoxifen in order to access the nucleus, as 
described in C. In the intestine, the Cyp1A1 
promoter may be used to drive expression of the 
CreER fusion protein, thus induction with both 
beta-naphthoflavone and tamoxifen is required for 
cre-mediated recombination to occur.
1.4 Project Aims
PTEN is well recognised as a tumour suppressor, and is known to play an important role in 
both sporadic cancers and heritable cancer predisposition disorders in humans. In addition to this, 
there is evidence that PTEN plays a role in suppressing tumourigenesis specifically in the intestine, 
and may also play an important role in regulation of the intestinal stem cell.
The principal aim of this project is to characterise the effects of homozygous Pten 
deletion exclusively in the adult murine small intestinal epithelium. Both the short term effects of 
Pten deletion on intestinal homeostasis and the longer term implications of Pten loss on tumour 
formation will be assessed. In particular, activation of the PI3K/Akt pathway following Pten loss 
will be investigated. Additionally, the characterisation of any effects on stem cell homeostasis will 
be attempted.
Further to this, the effect of Pten loss in the context of activation of other pathways will 
be examined, for instance activation of Wnt signalling. This will generate a tumour-prone context 
in which to study the function of Pten.
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Chapter 2: Materials and Methods
2.1 Experimental Animals
All experiments involving animals were conducted according to UK Home Office 
regulations, under valid personal and project licenses. Where experiments were conducted 
outside the UK by collaborators, appropriate local and national regulations were adhered to.
2.1.2 Animal Husbandry
2.1.2.1 Colony maintenance
Mice were maintained on an outbred background and housed in a standard facility. 
Animals had access to diet (Special Diets Service UK, RM3(E) expanded diet) and fresh drinking 
water ad libitum  unless specified.
2.1.2.2 Breeding
Adult animals of known genotype were generally bred in trios (one male, two females). 
After birth, pups remained with their mothers until large enough to be weaned, usually at four 
weeks of age.
2.1.2.3 Identification and Tail Biopsy
At weaning age, mice were marked by ear clipping for identification purposes. Surgical 
biopsy of 5mm of the tail tip was also taken under local anaesthetic to allow PCR genotyping of all 
animals (see below).
2.1.3 Experimental Procedures
2.1.3.1 Injection o f beta-Naphthoflavone
Expression of Cre recombinase from the AhCre transgene was induced using beta- 
naphthoflavone (bNF; Sigma) delivered in corn oil. Corn oil (Sigma) was heated in an amber bottle 
(to protect bNF from light) to 99°C and powdered bNF added to give a concentration of lOmg bNF 
per 1ml Corn oil. The solution was further heated and stirred vigorously to ensure complete 
dissolution of bNF. Aliquots were frozen in smaller amber bottles at -20°C until needed. Before 
injection, aliquots of bNF were defrosted, reheated to approximately 80°C to re-dissolve the bNF 
and kept at this temperature until just prior to injection to prevent precipitation. Animals were
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then injected intraperitoneally (ip) at a dose of 80mg bNF per kg body weight. To achieve maximal 
Cre expression, this dose was repeated once a day for a further 3 days (four treatments in total) 
unless otherwise stated.
To induce recombination in utero, timed matings were generated, and pregnant females 
were injected intraperitoneally with a single 80mg/kg dose of beta-naphthoflavone as described 
above at day 12.5 after the appearance of a copulatory plug.
2.1.3.2 Injection o f Tamoxifen
Animals expressing the Cre recombinase-Estrogen Receptor (CreER1) fusion protein were 
induced by treatment with Tamoxifen (Tam; Sigma), delivered in corn oil. Corn oil was heated to 
80°C and powdered Tamoxifen added to give a concentration of lOmg/ml. The solution was 
further heated and shaken until the Tamoxifen had completely dissolved, and was kept at this 
temperature until just prior to injection. Animals then received a single 80mg/kg dose ip once a 
day for 4 days unless otherwise stated.
2.1.3.3 Injection o f beta-Naphthoflavone and Tamoxifen
Animals bearing the AhCreER7 transgene required treatment with both bNF and Tam to 
induce Cre transcription and activity. bNF was dissolved in corn oil as described in 2.1.3.1. Upon 
reheating, Tamoxifen was added to a concentration of lOmg/ml as described in 2.1.3.2. Animals 
then received 4 daily doses of 80mg/kg of both bNF and Tam in a single ip injection unless 
otherwise stated.
2.1.3.4 Injection o f 5-Bromo-2-deoxyuridine
Where indicated, certain experimental animals received an excess of 5-Bromo-2- 
deoxyuridine (BrdU; Amersham Biosciences) in order to label cells in S-phase. Animals were 
injected ip with 0.2ml BrdU reagent either 2 hours or 24 hours prior to harvesting.
2.1.3.5 Whole-body gam m a-irradiation
Where indicated for clonogenic assays, animals were subjected to whole-body gamma- 
irradiation. Animals were restrained by placing in a small, well-ventilated Perspex chamber. 
Gamma irradiation of different doses (lOGy, 12.5Gy and 15Gy) was achieved by exposure to a 
Caesium-137 source delivering 2.2Gy per minute (IBL437C Irradiator, RPS Services).
2.1.4 PCR Genotyping
Genotyping was performed on all transgenic animals prior to experimental use using a 
PCR-based approach.
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2.1.4.1 Digestion o f tail biopsy samples
Tail biopsy samples were temporarily stored at -20°C to prevent degradation. To each 
biopsy, 500pl cell lysis solution (Puregene) containing 0.4mg/ml Proteinase K (from a 20mg/ml 
stock, Roche) was added. Samples were then digested overnight at 37°C with vigorous agitation.
2.1.4.2 Crude extraction o f DNA
Digested samples were cooled to room temperature and 200p.l protein precipitation 
solution (Puregene) added. Tubes were inverted to mix and centrifuged at 12000 x g for 5min to 
pellet all protein and insoluble material. The supernatant was removed into a clean tube 
containing 500pl isopropanol, and the pellet discarded. After mixing well by inverting, the mixture 
was centrifuged again at 12000 x g for 15 mins in order to pellet the precipitated DNA. The 
supernatant was then removed and the DNA pellet allowed to air-dry at room temperature for 1 
hour. The dried pellet was then dissolved in 500|J sterile, PCR-grade water (Sigma) at 37°C with 
agitation.
2.1.4.3 Generic protocol fo r  PCR genotyping
All PCR genotyping primers were designed using the Primer3 web-based program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi) unless previously published 
sequences were available. Sequences were verified using Blast 
(http://www.ncbi.nlm.nih.gov/blast) or Ensembl (http://www.ensembl.org) databases to check 
for mis-priming. Primers were then synthesised by Sigma-Genosys.
All PCR reactions were performed either in thin-wall 96-well PCR plates or in thin-wall 
0.2ml strip tubes (both Greiner Bio-One) and run on a PTC-100 Peltier thermal cycler (MJ 
Research). Pipetting of all samples was performed using filtered pipette tips to prevent aerosol 
contamination of samples. Appropriate volumes of crude DNA extract (See Table 2.1) and a PCR- 
Grade water (Sigma) control (2.5pl) were loaded into wells using a multi-channel pipette. A 
master mix for all samples was then prepared containing all other reaction components (GOTaq 
DNA Polymerase [Promega] or DreamTaq DNA polymerase [Fermentas], GOTaq 5X PCR buffer 
[Promega], PCR-grade water [Sigma], Magnesium chloride [Sigma], dNTPs [Bioline], Primers 
[Sigma-Genosys]) according to Table 2.1. Master mix was added to each well to make the reaction 
volume up to 50pl, with gentle pipetting to ensure thorough mixing of master mix with crude DNA 
extract. Samples were gently tapped on the bench to remove air bubbles and ensure the reaction 
mixture was at the bottom of the well. 96-well plates were sealed with aluminium foil tape and 
strip tubes with appropriate caps (both Greiner Bio-One). Reactions were then run according to 
the cycle conditions detailed in Table 2.1.
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2.1.4.4 Multiplex detection o f Cre and LacZ transgenes
Detection of both the Cre and LacZ transgenes was performed in a single reaction. The 
reaction was set up and run as described above in section 2.1.4.3 and in Table 2.1. Presence of the 
Cre transgene yielded a PCR product of 1000 base pairs (bp) in size. Presence of the LacZ 
transgene yielded a PCR product of 512bp in size.
2.1.4.5 Confirmation of Responder status
Genotyping for the aryl hydrocarbon (Ah) receptor polymorphism was performed as 
described in section 2.1.4.3 and Table 2.1. The responder polymorphism generated a PCR product 
of 196bp in size. The non-responder polymorphism generated a PCR product of 178bp in size.
2.1.4.6  Genotyping fo r the LoxP-targeted Pten allele
Genotyping for presence of the LoxP-targeted Pten allele was performed as described in 
section 2.1.4.3 and Table 2.1. Homozygotes for the LoxP-targeted allele produced a PCR product 
of 335bp in size. Homozygotes for the wild-type Pten allele generated a PCR product of 228bp in 
size. Heterozygotes for the targeted Pten allele generated products of both sizes.
2.1.4.7  Genotyping fo r the LoxP-targeted Ape allele
Genotyping for presence of the LoxP-targeted Ape allele was performed as described in 
section 2.1.4.3 and Table 2.1. The targeted Ape allele generated a PCR product of 315bp in size, 
and the wild-type Ape allele a product of 226bp in size.
2.1.4.8  Genotyping fo r the LoxP-targeted p53 allele
Genotyping for presence of the LoxP-targeted p53 allele was performed as described in 
section 2.1.4.3 and Table 2.1. Homozygotes for the LoxP-targeted allele produced a single PCR 
product of 370bp in size. Homozygotes for the wild-type p53 allele generated a single PCR product 
of 288bp in size.
2.1.4.9 Detection o f the k-Ras transgene
Genotyping for presence of the k-Ras transgene was performed as described in section
2.1.4.3 and Table 2.1. Presence of the transgene resulted in a PCR product of 621bp in size. The 
wild-type k-Ras allele generated a PCR product of 403bp in size.
2.1.4.10 Visualisation o f PCR products
Following PCR reactions, products were visualised by gel electrophoresis. To each sample, 
5pl DNA loading dye (50% Glycerol [Sigma], 50% distilled (d)H20 , 0.1% [w/v] Bromophenol blue
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Cre/LacZ Responder PtenLoxP ApcLoxP p53LoxP k-Ras
PCR Reaction components:
Crude DNA Extract (See Section 2.1.4.2) 2.5pl 2.5|il 2.5|il 2.5|il 2.5pl 2.5|il
M aster Mix:
PCR-grade W ater (Sigma) 31.5pl 31.7pl 31.7|il 31.7pl 31.7|il 31.7pl
GO Taq PCR Buffer (5X; Promega) lOpI lOpI lOpI lOpI lOpI lOpI
Magnesium Chloride (25m M ) 5^1 5|il 5|il 5pl 5pl 5pl
dNTPs (25m M ; dATP, dCTP, dGTP, dTTP) 0.4|il 0.4|il 0.4pl 0.4pl 0.4|il 0.4pl
Primer 1 (Sigma Genosys, lOOmM) O.lpil O.lpl O.lpl O.lpl O.lpl O.lpl
Primer 2 (Sigma Genosys, lOOmM) 0.1[x\ O.lpl O.lpl O.lpl O.lpl O.lpl
Primer 3 (Sigma Genosys, lOOmM) 0.1[x\ N/A N/A N/A N/A N/A
Primer 4 (Sigma Genosys, lOOmM) O.l^il N/A N/A N/A N/A N/A
Taq DNA polymerase 0.2pil 0.2\x\ 0.2pl 0.2|il 0.2|il 0.2|il
Brand o f Taq DNA polymerase GO Taq Dream Taq Dream Taq Dream Taq Dream Taq Dream Taq
Total Reaction Volume: 50|il 50pl 50pl 50|il 50|il 50|il
Cvclina conditions:
Initial denaturation step (Time; Temperature) 3min; 94°C 5min; 94°C
2min 30sec; 
95°C 3min; 95°C 3min; 94°C 5min; 94°C
Step 1: Denaturation (Time; Temperature) 30sec; 95°C 20sec; 94°C lmin; 94°C 30sec; 95°C 30sec; 94°C lmin; 94°C
Step 2: Annealing (Time; Temperature) 30sec; 55°C 20sec; 57°C lmin; 58°C 30sec; 60°C 20sec; 58°C lmin; 60°C
Step 3: Extension (Time; Temperature) lmin; 72°C 30sec; 72°C lmin; 72°C lmin; 72°C lmin; 72°C lmin; 72°C
Number o f Cycles 30 30 35 30 30 30
Final Extension (Time; Temperature) 5min; 72°C 5min; 72°C 5min; 72°C 5min; 72°C 5min; 72°C 5min; 72°C
Hold (Time; Temperature) 15°C 15°C 15°C « ;  15°C oo; 15°C «>; 15°C
Table 2.1: PCR Genotyping reaction conditions
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[Sigma]) was added. All samples were then loaded (along with an appropriate marker if 
necessary, such as lOObp ladder [Promega]) onto a 2% agarose (Eurogentech) gel (made in 1 X 
Tris-Borate-EDTA [TBE] Buffer [Sigma]) containing 0.007% [v/v] Ethidium bromide (Sigma) with 
the exception of products of the Responder status PCR reaction, which were loaded onto a 4% 
agarose (Eurogentech) gel (made in 1 X TBE) containing 0.007% [v/v] Ethidium bromide (Sigma). 
Gels were run in TBE buffer at 120V for approximately 30 minutes. Products were then visualised 
under UV light on a GelDoc (BioRad).
Target Forward Primer Sequence (5' to 3') Reverse Primer Sequence (5' to 3')
Cre TGA CCG TAC ACC A A A  A T T  TG A TT  GCC CCT GTT TCA CTA TC
LacZ CTG GCG T T A  CCC AAC T T A  A T A T A  ACT GCC GTC ACT CCA AC
Responder TCA CCA AAC CCT CCA T C A  GT AGG TTC CCT GGG ACT TGT TT
Pten LoxP CTC CTC TAC TCC A T T  CTT  CCC ACT CCC ACC AAT GAA CAA AC
ApeLoxP
GTT CTG TAT CAT GGA AAG A T A  
GGT GGT C
CAC TCA AAA CGC T TT  TGA GGG 
TTG ATT C
p53LoxP CAC AAA AAC AGG T T A  AAC CCA G AGC ACA TAG GAG GCA GAG AC
k-Ras AGG GTA GGT GTT GGG A T A  GC CTG AGT CAT TTT  CAG CAG GC
Table 2.2: P rim er Sequences used fo r  PCR G enotyp ing
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2.2 Tissue sampling and processing
2.2.1 Removal of tissues
Upon dissection, tissue samples were removed and placed in appropriate fixatives as 
quickly as possible. In general, samples of the following tissues were taken routinely for analysis: 
Small and large intestine, liver, spleen, pancreas, kidney, stomach and genitourinary tract. Prior to 
fixation, small and large intestines were flushed well with water to remove debris from the 
intestinal lumen.
2.2.2 Tissue fixation for histology
Tissues were preserved for subsequent histological examination and 
immunohistochemical analysis by fixing either in Methacarn or Formalin.
2.1.2.1 Methacarn fixing
Small and large intestines (either whole or defined sections) were removed and flushed as 
described above. The intestine was then placed on a sheet of 3M M  filter paper (Whatman) and 
opened longitudinally along the proximal-distal axis. Intestines were then completely immersed in 
a bath of freshly-prepared Methacarn (a 4:2:1 ratio of Methanol:Chloroform:Acetic acid, e.g. 
300ml methanol, 150ml chloroform, 75ml glacial Acetic acid) and fixed overnight. The following 
day, intestines were rolled in swiss-roll fashion from stomach to caecum or from caecum to anus, 
secured with a needle and placed in 96% Ethanol for subsequent processing.
2.1.2.2 'Quick' fixing in formalin
Selected intestines or regions of intestine were chosen to be fixed in formalin (4% neutral 
buffered formaldehyde in saline, Sigma) rather than Methacarn. Intestinal samples were flushed 
with water and were either bundled using surgical tape (Micropore) or were opened 
longitudinally, rolled from end-to-end (without fixing) and secured with a needle as described 
above (section 2.1.2.1). Intestinal samples and samples of other tissues were then immersed in ice 
cold (4°C) formalin for between 12 and 24 hours. After this time, samples were either 
immediately processed as described below (section 2.2.3) or were transferred to ice cold (4°C) 
70% Ethanol (in distilled H20 ) and stored at 4°C until processed.
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2.2.3 Tissue processing and sectioning
2.2.3.1 Dehydration o f tissue
Tissue was processed using an automatic processor (Leica TP1050). Tissue was 
dehydrated in increasing concentrations of alcohols, xylene and paraffin (70% ethanol for 1 hour, 
95% ethanol for 1 hour, 2 x 100% ethanol for 1 hour 30 mins, 100% ethanol for 2 hours, 2 x Xylene 
for 1 hour, paraffin for lhour, 2 x paraffin for 2 hours). After processing, tissue was embedded in 
paraffin wax.
2.2.3.2 Tissue sections
Paraffin blocks were sectioned on a microtome (Leica RM2135) at a thickness of 5[im. 
Sections were then floated onto poly-L-lysine (PLL) coated slides (Polysine, Thermo Fisher) and 
baked for 24 hours at 58°C before use.
2.2.4 Cryosectioning of tissues
2.2.4.1 Preservation o f fresh tissues fo r  cryosectioning
A number of tissues were preserved without fixing for cryosectioning. Small samples of 
tissue were removed and frozen on dry ice completely surrounded by OCT cryoprotectant 
medium (R. A. Lamb). Samples were frozen either on tin foil, on cork discs (R. A. Lamb) or directly 
onto aluminium chucks. Frozen samples were stored at -80°C until sectioned.
2.2.4.2 Sectioning o f frozen tissues
Frozen tissue samples in OCT medium at -80°C were warmed up to -30°C for 30 mins just 
prior to sectioning, and were then adhered to aluminium chucks using OCT (if not already on a 
chuck). Sections were then cut on a cryostat at 15pm. Sections were removed onto Histobond 
slides (R. A. Lamb) and allowed to air-dry for approximately 20 mins. Sections were stored, 
wrapped in tin foil, at -80°C until needed.
2.2.5 Preservation of whole tissues for future protein, RNA or DNA extraction
2.2.5.1 For protein extraction
Tissue samples intended for future protein extraction were removed as quickly as possible 
to prevent protein degradation. Tissue was then places in an eppendorf tube fitted with a locking 
lid. Samples were then quickly immersed in liquid nitrogen (LN2) to snap freeze tissue. When 
convenient, tissue was removed from LN2 and stored at -80°C until needed.
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2.2.5.2 For RNA extraction
Whole tissues intended for RNA extraction were removed quickly and immersed in 
RNA later (Sigma). Samples were then either stored at 4°C (for several weeks) or -20°C (for several 
months).
2.2.5.3 For DNA extraction
Tissue samples intended for DNA extraction were removed and placed into a clean 
eppendorf tube. Samples were then kept on ice until transferred to a freezer at -20°C for storage. 
DNA extraction was then usually performed within 2 weeks.
2.2.6 Analysis of beta-galactosidase activity
Mice bearing the Rosa26/LacZ reporter transgene were used to assess levels of 
recombination in various tissues. For intestinal tissue, either whole intestines or defined regions 
of the intestine were removed, prepared as wholemounts and stained for beta-galactosidase 
activity. For other tissues, small samples of tissue were removed, frozen and sectioned as 
described in section 2.2.4.
2.2.6.1 Intestinal wholemounts
Whole intestines or defined sections of intestine were removed and flushed well, once 
with ice cold (4°C) Phosphate-buffered Saline (PBS; Gibco) and once with ice cold (4°C) X-Gal 
fixative solution (2% formaldehyde [Sigma], 0.1% Glutaraldehyde [Sigma] in PBS). Intestines were 
then laid out and opened longitudinally. Opened intestines were pinned luminal side up onto wax 
plates (hot paraffin wax [Sigma] with 10% mineral oil [Sigma] added, poured into a 15cm petri 
dish and allowed to cool) using insect pins (Watkins & Doncaster).
2.2.6.2 Fixation and demucification o f intestinal wholemounts fo r beta-galactosidase analysis
Intestinal wholemounts were fixed for no longer than 1 hour in X-Gal fixative solution. 
Plates were then washed with PBS before adding demucifying solution (10% Glycerol [Sigma], 20% 
Ethanol [Fisher scientific], 0.01M Tris [pH8.2], 0.003% [w/v] Dithiothreitol [DTT, Sigma] in Normal 
Saline [0.9% Sodium Chloride]). Intestines were incubated with demucifying solution with 
agitation for 30-60 mins. Demucifying solution was then poured off, and plates washed with PBS. 
Mucins were removed by pipetting PBS with force onto the intestine using a Pasteur pipette, and 
examined under a dissection microscope to ensure complete removal of mucins. This process was 
repeated using fresh PBS until intestines were clean.
2.2.6.3 Fixation and preparation o f cryosections fo r  beta-galactosidase analysis
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Cryosections were prepared and stored as described in section 2.2.4. Section were 
removed from the -80°C freezer and allowed to acclimatise to room temperature for 
approximately 10 mins. Sections were then fixed in X-Gal section fixative solution (2% 
Formaldehyde [Sigma], 0.2% Glutaraldehyde [Sigma], 0.02% NP-40 in PBS) for 10 mins. After 
fixing, sections were washed twice for 10 mins each time in PBS.
2.2.6.4 Staining with X-Gai substrate
X-Gal buffer (Im M  Magnesium chloride, 3mM potassium ferricyanide, 3mM potassium 
ferrocyanide in PBS) was prepared in advance and stored in the dark at 4°C. Just prior to use, X- 
Gal substrate was added (from a 5% stock in DMF [Promega]). For staining of intestinal 
wholemounts, X-Gal was added to a concentration of 0.02% and for staining of cryosections, X-Gal 
was added to a concentration of 0.04%. Wholemounts or sections were then stained overnight in 
the dark with agitation. Wholemounts were stained at room temperature and sections were 
stained at 37°C.
X-gal staining solution was then removed, and plates/sections washed once with PBS. 
Wholemounts were then fixed in formalin for 1 hour, before being stored in PBS. Sections were 
counterstained for 2 mins using nuclear fast red (0.1% [w/v] nuclear fast red [Sigma], 70mM  
Aluminium sulphate [Sigma] in dH20 ) before being dehydrated, cleared and coverslipped as 
described in section 2.4.1.9.
2.2.7 Isolation of intestinal epithelium
2.2.7.1 Isolation o f epithelial cells
A method for enrichment of intestinal epithelial cells was developed based on that of 
Bjerknes and Cheng (Bjerknes and Cheng, 1981).
Intestines were removed and flushed well with water. A 10cm stretch of intestine from a 
defined location was used for epithelial cell extraction. The intestine was tied off at one end using 
non-soluble suture (Mersilk, Ethicon) and the intestine carefully inverted over a spiral-shaped 
glass rod. The intestine was then placed into a 50ml Falcon tube containing approximately 30ml 
epithelial extraction buffer (lOm M EDTA pH8.0 [Sigma] in Hanks' balanced salt solution [HBSS, 
Gibco]) which had been pre-warmed to at 37°C. The tube was then shaken at the lowest setting 
on a vortex mixer for 15 mins, generating the first 'fraction' of epithelial cell extract. After this 
time, the intestine was removed to a clean, pre-warmed tube of epithelial extraction buffer. The 
tube was then shaken in the same fashion for a further 15 mins, generating the second 'fraction' 
of epithelial cell extract.
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2.2.7.2 Processing o f crude epithelial cell suspensions
Epithelial cell suspensions in epithelial cell extract buffer were centrifuged immediately at 
3000 x g at 4°C for 15 mins to yield a pellet containing crudely purified epithelial cells. The 
supernatant was aspirated and the pellet processed either for future protein extraction (section 
2.2.7.3) or RNA extraction (2.2.7.4).
2.2.7.3 Preservation of extracted epithelium fo r  protein extraction
Epithelial cell extracts from the second fraction were used for protein extraction as these 
fractions were generally less mucinous than the first fraction. Epithelial cell pellets were washed 
by re-suspending in 5ml ice cold PBS, and then re-pelleted by centrifugation at 3000 x g at 4°C for 
15 mins. The PBS was carefully aspirated, and the pellets snap frozen in LN2 and stored at -80°C 
until used.
2.2.7.A Preservation o f extracted epithelium fo r  RNA extraction
For RNA extraction, the first fractions of epithelial cell extracts were used. Pellets were re­
suspended in 1ml Trizol (Invitrogen), transferred to a 1.5ml eppendorf tube, and stored at -20°C 
until needed.
2.2.7.5 Epithelial cell isolation by gut scraping
In some cases, epithelial cells were obtained by scraping of the gut rather than by the 
epithelial cell isolation protocol described above (section 2.2.7.1). To do this, defined regions of 
small intestine were selected and flushed well with water. The intestine was the opened 
longitudinally and laid out on a piece of 3M M  filter paper (Whatman). The surface of the intestine 
was then gently scraped using a rounded blade disposable scalpel (Swann-Morton) to remove the 
surface epithelium. The scraped material was then transferred to an eppendorf tube, and was 
either frozen at -20°C for future DNA analysis, or was snap frozen in liquid nitrogen for future 
protein extraction, or was suspended in 1ml Trizol reagent (Invitrogen) for future RNA extraction.
2.3 Histological Analysis
2.3.1 Haematoxylin and Eosin (H&E) staining of tissue sections
Tissue sections were de-waxed and rehydrated as described in section 2.4.1.1. Sections 
were then stained in Mayer's Haemalum (R. A. Lamb) for 5 mins followed by washing in running 
tap water for 5 mins. Sections were then stained in 1% aqueous Eosin (R. A. Lamb) for 5 mins
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followed by two 15 second washes in water. Sections were then dehydrated, cleared and 
mounted as described in section 2.4.1.9.
2.3.2 Quantification of H&E-stained tissue sections
Quantification of histological sections was performed on an Olympus BX41 light 
microscope fitted with a Colorview III (5 megapixel, Soft Imaging Systems) camera and with the 
aid of AnalySIS (Version 3.2, Build 831, Soft Imaging Systems) software. Areas of section were 
chosen which were not cross-cut and were free from any other sectioning artefacts. For all 
comparisons, sections from at least 3 animals of each genotype were scored to allow statistical 
analysis. A running mean was also calculated, to ensure convergence towards the overall mean.
2.3.2.1 Crypt size
Crypt size was scored by counting the total number of epithelial cells from the base to the 
top of the crypt. This was performed for 50 whole crypts per section.
2.3.2.1 Villus length
Villus length was scored by counting the number of epithelial cells from the base of the 
villus to the villus tip. This was performed for 50 half villi per section. Care was taken to ensure 
that comparable regions of the longitudinal axis of the intestine were selected for scoring, as villus 
length is known to vary along the length of the intestine.
2.3.2.2 M itotic index
Mitotic cells were identified on H&E stained sections based on their morphological 
appearance. Number of mitotic figures was scored per crypt for at least 25 crypts per section. The 
average (mean) number of mitoses per crypt for each section was then calculated, and then the 
mean across all sections of the same genotype calculated. This generated an overall mean value. 
Standard deviation of the mean was calculated according to standard methods. Significance of 
any differences observed was confirmed using the Mann-Whitney-U test (see section 2.7.2 for 
details).
2.3.2.3 Apoptotic index
Apoptotic cells were identified on H&E stained sections based on their distinctive 
morphological appearance. Scoring was conducted in exactly the same way as for scoring for 
mitotic cells (Section 2.3.2.2).
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Scoring of Apoptotic cells from Caspase-3 stained sections was also conducted to confirm 
morphology-based scoring results. Numbers of positively stained cells per crypt were scored per 
crypt in 25 full crypts per section. Mean values, standard deviations and significance analysis was 
conducted as described above (section 2 3 .2 .2 ).
2.3.3 Use of special stains to identify specific cell types
2.3.3.1 Grimelius method
The Grimelius staining method was used to stain for argyrophilic enteroendocrine cells. 
Methacarn-fixed tissue was selected, and sections de-waxed and rehydrated as described (section 
2.4.1.1). All Glassware was rinsed with ultrapure (dd) H20  before use. 1% [w/v] Silver nitrate 
(Sigma) was dissolved in Acetate buffer (0.02M Acetic acid (Fisher scientific), 0.02M Sodium 
acetate (Sigma) in ddH20 ) and preheated to 65°C in a slide jar in a hot water bath. Slides were 
then immersed in this solution (and kept at 65°C) for 3 hours. Meanwhile, reducing solution 
(0.04M Sodium sulphite [Fisher scientific], 0.1M  hydroquinone [Sigma] in ddH20 ) was freshly 
prepared and preheated to 45°C. Slides were then transferred from silver solution into reducing 
solution, where they remained for approximately 5 minutes, or until tissue appeared yellow in 
colour. Sections were then dehydrated, cleared and mounted as described in section 2.4.1.9.
2.3.3.2 Staining with Alcian blue
Alcian blue staining for mucins was used to identify mucin-secreting Goblet cells. Tissue 
sections were de-waxed and rehydrated as described (section 2.4.1.1). Slides were then immersed 
in Alcian blue staining solution (1% [w/v] Alcian blue [Sigma] in 3% [v/v] Acetic acid [Fisher 
scientific]) for 5 mins Slides were then washed well in running tap water for 5 mins. Tissue 
sections were then counterstained in 0.1% Nuclear fast red (0.1% [w/v] nuclear fast red [Sigma], 
0.07M Aluminium sulphate [Sigma] in dH20 ) for 5 mins. Sections were washed well in running tap 
water for 5 mins before being dehydrated, cleared and mounted as described in section 2.4.I.9.
2 .3 .3 3  Staining with Periodic acid/Schiff's solution (PAS)
Periodic Acid/Schiff's solution staining was used as an alternative to Alcian blue staining 
for Goblet cells. Sections were de-waxed and rehydrated as described in section 2.4.1.1. Sections 
were then treated with 1% [w/v] Periodic acid (Sigma) in dH20  for 5 minutes. Slides were then 
rinsed in running tap water for 5 mins before being treated with Schiff's reagent (Sigma). Slides 
were rinsed again in running tap water for 10 mins. Sections were then counterstained in Mayer's 
haematoxylin, dehydrated, cleared and mounted as described in section 2.4.1.9.
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2.3.3.4 Alkaline phosphatase staining
Alkaline phosphatase activity was detected as a marker of enterocytes. Slides were de- 
waxed and rehydrated as described in section 2.4.1.1. Fast Red substrate (DAKO), prepared as 
described in the manufacturer's instructions, was applied to slides for 20 mins at RT. Sections 
were then rinsed in dH20, and counterstained in Mayer's haematoxylin as described in section
2.4.1.9. As Fast Red staining is not stable in solvents, slides were cover-slipped using aqueous 
mounting medium (DAKO).
2.4 Immunohistochemistry (IHC)
2.4.1 Generic Immunohistochemistry protocol
All immunohistochemistry was performed following the generic protocol described below 
with specific conditions/modifications to the protocol for each target described in Table 2.3. All 
incubations were performed at room temperature (approximately 18-22°C) in a humidified 
chamber where necessary to prevent tissue sections drying out. The protocol for anti-beta- 
catenin IHC differed more significantly from the generic protocol, and this is described in section 
2.4.2.
2.4.1.1 De-waxing and rehydration o f tissue sections
Tissue sections were de-waxed by washing for 2 x 5 mins in Xylene (Fisher scientific). 
Sections were rehydrated by sequential washes in decreasing concentrations of alcohols; 2 x 2  
mins in 100% ethanol (Fisher Scientific), 1 x 2  mins in 95% ethanol, 1 x 2  mins in 70% ethanol. 
Sections were then washed in dH20  before continuing.
2.4.1.2 Retrieval o f antigens
Antigens were retrieved by heat treatment in a boiling water bath or microwave in either 
citrate buffer (Labvision) or a custom made buffer (See section 2.4.2), as described in Table 2.3. 
For retrieval in a boiling water bath, adequate buffer was preheated to 99.9°C in a glass slide jar 
(e.g. Coplin jar [R. A. Lamb]) before slides were immersed in the solution. For microwave antigen 
retrieval, adequate buffer was preheated in a plastic container for 5 mins in a domestic 
microwave at high power (850W). Slides were then immersed in the hot solution in a plastic slide 
rack, and further heated at high power for 3 x 5 mins. Care was taken to ensure the slides did not 
boil dry, with additional buffer added as necessary.
Following heat treatment, slides were allowed to cool (in antigen retrieval buffer) at room 
temperature for at least 30 mins before continuing. Slides were then rinsed once in dH20  and
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once in wash buffer. Wash buffers used were either PBS (Gibco) or TBS/T (Tris buffered saline 
[Gibco] plus 0.1% TWEEN-20 [Sigma]) as detailed in Table 2.3.
2.4.1.3 Blocking o f endogenous tissue peroxidase activity
Endogenous peroxidase activity of tissue sections was blocked by treatment with 
hydrogen peroxide. Hydrogen peroxide (30% aqueous solution, Sigma) was diluted in dH20  just 
prior to use (appropriate concentrations detailed in Table 2.3), or Peroxidase block solution 
provided with the Envision* Kit (Dako) was used. Slides were immersed in the solution for an 
appropriate amount of time, before being removed and washed once in dH20  and once in wash 
buffer.
2.4.1.4 Serum blocking
Non-specific binding of antibodies was blocked by incubation with normal serum from the 
species in which the secondary antibody was raised (e.g. if the secondary antibody was goat anti­
rabbit, goat normal serum was used). Normal serum was diluted in wash buffer as described in 
Table 2.3. Slides were dried around the tissue sections using tissue paper, and the tissue circled 
using a water-resistant wax pen (Dako). Normal serum was applied and slides incubated for the 
times indicated in Table 2.3. Following incubation, normal serum was removed from the slide, and 
primary antibody applied without washing of slides.
2.4.1.5 Primary antibody
Primary antibodies were used either at a concentration recommended by the 
manufacturer, or the optimal concentration of primary antibody was determined. Primary 
antibody was appropriately diluted before use (Table 2.3) in serum block solution. Antibody was 
added to slides, and incubated under appropriate conditions (Table 2.3).
After incubation, primary antibody was removed from the section, and sections washed 3 
x 5 mins in wash buffer.
2.4.1.6 Secondary antibody
Secondary antibodies (Dako) were either diluted 1/200 in serum block, or Horseradish 
perosidase (HRP)-conjugated secondary antibody polymer from the Envision+ kit (Dako) was used 
undiluted. Secondary antibody was applied to the slides, which were then incubated for an 
appropriate amount of time (Table 2.3). Slides were then washed 3 x 5  mins in wash buffer.
2.4.1.7  Signal amplification
65
Where Envision+ kits (Dako) were not used, a signal amplification step was incorporated 
into the protocol. This was provided by formation of an Avidin-Biotin Complex (ABC) using the 
'Vectastain' ABC kit (Vector Labs). ABC reagent was prepared 30 mins before use as described by 
the manufacturer, and was then kept at room temperature until needed. ABC reagent was then 
applied to slides for 30 mins, then slides were washed 3 x 5  mins in wash buffer.
2.4.1.8  Signal detection using 3,3'-diam inobenzidine (DAB)
The 3,3'-diaminobenzidine (DAB) method was used for colourimetric detection of signal. 
DAB substrate buffer and DAB chromogen from the DAB+ kit (Dako) were mixed in the ratio lm l: l 
drop before use. DAB solution was then applied to slides at room temperature, and sections were 
monitored for development of the colourimetric signal. In general, this took between 2 mins and 
10 mins. Slides were then washed 2 x 5  mins in wash buffer and 2 x 5  mins in dH20.
2.4.1.9 Counterstaining, dehydration, clearing and coverslipping o f sections
Sections were counterstained for 45 secs with Mayer's Haemalum (R. A. Lamb) followed 
by thorough washing in running tap water for 5 mins.
Sections were then dehydrated by washing in increasing concentrations of alcohols ( l x l  
min in 70% ethanol, l x l  min in 95% ethanol 2 x 1  min in 100% ethanol) and cleared by washing 
in xylene ( 2 x 5  mins). Sections were then mounted and coverslipped in DPX mounting medium 
(R.A. Lamb).
2.4.2 Specific Immunohistochemistry protocols
2.4.2.1 Anti-beta-Catenin IHC
Slides were de-waxed and rehydrated as described in 2.4.1.1. Endogenous peroxidase 
activity was quenched by immersing slides in 1.5% hydrogen peroxide (Sigma) in peroxidase 
buffer (0.02M citric acid [Sigma], 0.06M  disodium hydrogen phosphate-2-hydrate [Sigma], plus 
0.1% [w/v] sodium azide [Sigma] in dH20). Slides were rinsed briefly in dH20  before antigen 
retrieval which was achieved by immersing slides in a large volume (1.5L) of boiling custom 
Tris/Ethylenediamine-tetraacetic acid (EDTA) buffer (0.04M Tris [Sigma], Im M  EDTA [Sigma] in 
dH20, pH8.0) for 50 mins. Slides were then allowed to cool in the antigen retrieval buffer on the 
bench for 1 hour. After briefly rinsing in dH20  and then in PBS, sections were circled with water 
repellent pen (as described in section 2.4.1.4) and 1% [w/v] Bovine Serum Albumin (BSA, fraction 
V, lyophilised [Sigma]) in PBS applied to each section. Slides were incubated at room temperature 
for 30 mins, after which the serum block was removed and replaced with anti-beta-catenin 
antibody diluted in serum block as described in Table 2.3. Slides were then washed 3 x 5  mins in
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PBS. Secondary antibody was HRP-conjugated anti-mouse secondary from the mouse Envision+ 
kit (Dako) which was applied for 1 hour at room tem perature. Slides were then washed 3 x 5  mins 
in PBS, before signal detection, counterstaining and mounting as described in sections 2.4.1.8 and
24.1.9.
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Target Pten beta-Catenin Villin
Commercial source of Transduction
primary Ab Cell Signalling 
9559, Clone
Labs Santa Cruz
Catalog/Clone Number 138G6 610154 SC 7672
Primary Ab raised in Rabbit (pAb) 
Boiling water
Mouse (mAb) Goat (pAb) 
Boiling water
Antigen retrieval
bath, Citrate 
buffer
Boiling water 
bath, custom
bath, Citrate 
buffer
(Labvision) buffer (Labvision)
Peroxidase block
3% H202, 
20mins
1.5% H202, 
30mins
3% H202, 
20mms
' 10% NRS,
Serum block 5% NGS, 45mins 1% BSA, 30mins 30mins
Wash buffer TBS/T PBS TBS/T
1/100, o/n at 1/300, 2 hours 1/500, 1 hr at
Conditions for primary Ab 4 X at RT 
HRP-conjugated
RT
Secondary Ab
Biotinylated anti-mouse Biotinylated
Goat anti-Rabbit (Envision+ Kit, Rabbit anti-
(Dako) Dako) Goat (Dako)
Conditions for secondary 1/200, 30mins at 1/200, 30mins
Ab RT lh r a t R T at RT
ABC kit (Vector ABC kit (Vector
Signal amplification Labs) N/A Labs)
Signal detection DAB+ (Dako) DAB+ (Dako) DAB+ (Dako)
Lysoiyme
Neomarkers
RB 372 
Rabbit (pAb) 
Boiling water 
bath, Citrate 
buffer 
(Labvision)
1.5% H202, 
30mins
10% NGS, 
30mins 
TBS/1
1/100, l h r a t RT  
HRP-conjugated 
anti rabbit 
(Envision-r Kit, 
Dako)
30min at RT
N/A 
DAB+ (Dako)
BrdU
Becton
Dickinson
N357580  
Mouse (mAb) 
Boiling water 
bath, Citrate 
buffer 
(Labvision) 
Lnvision + Kit 
peroxidase 
block, 20mms
1% BSA, 30mins 
PBS
1/150, l h r a t R T
HRP-conjugated 
anti-mouse 
(Envision+ Kit, 
Dako)
lh r  at RT
N/A 
DAB+ (Dako)
Ki67
Vector Labs
VP K452 
Mouse (mAb) 
Boiling water 
bath, Citrate 
buffer 
(Labvision)
0.5% H202. 
20mms
20% NRS, 
20mms 
1BS/T 
1/50, lh r  at  
RT
Biotinylated 
Rabbit anti- 
Mouse (Dako) 
1/200, 30mins 
at RT 
ABC kit 
(Vector Labs) 
DAB+ (Dako)
Caspase-3
R&D Systems
AT835 
Rabbit (pAb) 
Boiling water 
bath, Citrate 
buffer 
(Labvision)
2% H202, 45secs
10% NGS, 
45mms 
PBS 
1/750, o/n at 
4°C
Biotinylated 
Goat anti-Rabbit 
(Dako) 
1/200, 30mins at 
RT
ABC kit (Vector 
Labs)
DAB+ (Dako)
pAkt
(Ser473)
Cell Signalling 
3787, clone 
736L11 
Rabbit (pAb) 
Boiling water 
bath, Citrate 
buffer 
(Labvision)
3% H202, 
20mins
5% NGS, 45mins 
TBS/T
1/50, o/n at 4°C
Biotinylated 
Goat anti-Rabbit 
(Dako) 
1/200, 30mins at 
RT
ABC kit (Vector 
Labs)
DAB+ (Dako)
Table 2.3, Part I: Sum m ary o f IHC protocols
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pmTOR p M E K l/2 p E rk l/2
Target (Ser2448) (Ser221) (Thr202/Tyr204)
Commercial source of
primary Ab Cell Signalling Cell Signalling Cell Signalling
Catalog/Clone Number 2971 2338 4376
Primary Ab raised in Rabbit (pAb) Rabbit (pAb) Rabbit (pAb)
Microwave, Microwave, Microwave,
Antigen retrieval Citrate Buffer Citrate Buffer Citrate Buffer
(Labvision) (Labvision) (Labvision)
Peroxidase block
3% H202, 
20mins 
10% NGS,
1.5% H202, 
ISmins 
10% NGS,
1.5% H202, 
ISmins
Serum block 45mins 45mins 10% NGS, 45mins
Wash buffer TBS/T 
1/100, o/n at
TBS/T 
1/100, o/n at
TBS/T
Conditions for primary Ab 4°C
Biotinylated
4°C
Biotinylated
1/75, o/n at 4°C
Secondary Ab Goat anti- Goat anti- Biotinylated Goat
Rabbit (Dako) Rabbit (Dako) anti-Rabbit (Dako)
Conditions for secondary 1/200, 30mins 1/200, 30mins 1/200, 30mins at
Ab at RT at RT RT
ABC kit (Vector ABC kit (Vector ABC kit (Vector
Signal amplification Labs) | Labs) Labs)
Signal detection DAB+ (Dako) DAB+ (Dako) DAB+ (Dako)
pS6K pGSK3beta
(Thr421/Ser424) E-Cadherin
Transduction
(Ser9) Cytokeratin 19 DCAMKt-1
Cell Signalling Labs Cell Signalling Abeam Abeam
9204 C20820 9336 abl5463 ab37994
Rabbit (pAb) Mouse (mAb) Rabbit (pAb) Rabbit (pAb) Rabbit pAb
Microwave, Microwave, Microwave, Microwave, Microwave,
Citrate Buffer Citrate Buffer Citrate Buffer Citrate Buffer Citrate Buffer
(Labvision) (Labvision) (Labvision) (Labvision) (Labvision)
3% H202, 20mins
0.5% H202, 
20mins
1.5% H202, 
30mins
0 3% H202, 
20mins
0.3% H202, 
20mins
20% NRS, 10% NGS, 10% NGS,
10% NGS, 45mins 20mins 45mins 5% NGS, lOmins 45mins
TBS/T TBS/T TBS/T PBS/T TBS/T
1/100, o/n at 1/50, o/n at 1/100, o/n at 1/100, o/n at
1/100, 2hrs at RT 4°C 4°C 4°C 4°C
Biotinylated Goat Biotinylated Biotinylated Biotinylated Biotinylated
anti Rabbit Rabbit anti Goat anti Goat anti Goat anti
(Dako) Mouse (Dako) Rabbit (Dako) Rabbit (Dako) Rabbit (Dako)
1/200, 30mins at 1/200, 30mins 1/200, 1/200, 30mins 1/200, 30mins
RT at RT 30mins at RT at RT at RT
ABC kit (Vector ABC kit ABC kit ABC kit (Vector ABC kit (Vector
Labs) (Vector Labs) (Vector Labs) Labs) Labs)
DAB+ (Dako) DAB+ (Dako) DAB+ (Dako) DAB+ (Dako) DAB+ (Dako)
Table 2.3, Part II: Sum m ary o f IHC protocols
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2.5 Protein Analysis
2.5.1 Protein extraction from tissue samples
2.5.1.1 Preparation o f whole tissues
Whole tissue samples in eppendorf tubes (see section 2.2.5.1) were removed from 
storage at -80°C and placed on dry ice. A pestle and mortar were then pre-cooled using LN;. 
Tissue samples were removed one at a time, placed in the mortar and immersed in LN?. Before 
the LN; completely evaporated, the tissue was crushed using the pestle, and more LN? added. This 
process was repeated until a fine powder was produced. Before the tissue defrosted, 200pl cell 
lysis buffer (20m M  Tris-HCI pH 8.0, 2m M EDTA pH8.0, 0.5% [v/v] NP-40 [Sigma]) containing 
protease inhibitors (Complete mini protease inhibitor tablets [Roche]) and phosphatase inhibitors 
(25mM sodium beta-glycerophosphate [Calbiochem], lOOmM sodium fluoride [Sigma], 20nM  
Calyculin A from Discodermia calyx [Sigma], lO m M  sodium pyrophosphate [Sigma]) was added. 
The sample was allowed to warm up sufficiently for the tissue and lysis buffer to defrost, and this 
mixture was then removed to a clean eppendorf tube and kept on ice until proteins were 
extracted as described below (section 2.5.1.3). This process was repeated for all samples.
2.5.1.2 Preparation o f epithelial cell extracts
Epithelial cell extract samples (prepared as described in section 2.2.7.3 and section
2.2.7.5) were removed from storage at -80°C and placed on ice. To each pellet, 200pl cell lysis 
buffer containing protease and phosphatase inhibitors (described in section 2.5.1.1) was added 
immediately, and pellets allowed to slowly defrost in the buffer with occasional pipetting to mix. 
Samples were then removed into clean eppendorf tubes and kept on ice until protein extraction 
(Section 2.5.1.3).
2.5.1.3 Extraction of proteins
In order to shear cells, samples were passed through a 23 gauge needle using a syringe at 
least 20 times. Tubes were then centrifuged at 9500 x g for 10 mins at 4°C to remove insoluble 
material. The supernatant (protein extract) was then removed to a clean tube, divided into 
aliquots and snap frozen in LN,,.
2.5.2 Quantification of proteins
2.5.2.1 Bradford Assay
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Relative amounts of protein in each protein extract were assayed using the Bradford 
method (Bradford, 1976). Bradford reagent (Sigma) was diluted 1/5 in ultrapure water (ddH20) 
before use and 1ml of diluted Bradford reagent was used per assay. To each 1ml of diluted 
Bradford reagent, lp l of protein extract was added, or lp l cell lysis buffer was added to use as a 
blank. A standard curve was also generated by adding standard 2mg/ml BSA (Pierce) in varying 
volumes to 1ml diluted Bradford reagent to generate standards containing known concentrations 
(20, 10, 5, 2.5 and 1.25pg/ml) of protein. Samples were mixed well and the blue colour allowed to 
develop by incubating for at least 5 mins on the bench. Colour intensity of each sample was then 
read at 595nm  on a colourimeter. The standard curve was then used to extrapolate the relative 
concentration of protein in each experimental sample.
2.5.3 W estern Analysis
2.5.3.1 Preparation  o f protein samples fo r  western analysis
Samples were removed from storage at -80°C, defrosted on ice and appropriate volumes 
removed to a clean eppendorf tube. For intestinal protein extracts, 30pg of total protein was 
prepared for loading. Samples were made up to 25pl using Laemmli buffer (0.125M  Tris-HCI 
pH6.8, 4% [w /v] sodium dodecyl sulphate [SDS, Sigma], 40% [v/v] Glycerol [Sigma], 0.1% [w/v] 
Bromophenol blue [Sigma], 6% [v/v] beta-mercaptoethanol [Sigma] in ddH20 ). Just before 
loading, samples were heated to 95°C for 5-10 mins to denature proteins, and then quenched on 
ice.
2.5.3.2 Casting o f polyacrylam ide gels
Mini-Protean III (Bio-Rad) gel casting apparatus was used to prepare thick (1.5mm) 
polyacrylamide gels. Mixtures for 5% stacking and 10% resolving acrylamide gels were prepared in 
advance according to Table 2.4, but w ithout addition of TEMED. Casting plates were cleaned 
thoroughly in water and 70% ethanol before being assembled. TEMED was then added to the 10% 
resolving gel mix, and the gel poured to a level of approximately 1.5cm from the top of the gel. 
This was then overlaid with 500pl ultrapure water. Once the gel had set (approximately 30 mins), 
the water overlay was poured off onto tissue paper. TEMED was then added to the 5% stacking 
gel mix and this was poured over the 10% gel and a 10-well comb inserted into the apparatus. 
Once set, the gels were removed from the casting apparatus, combs removed and the wells rinsed 
with ddH20.
2.5.3.3 Protein separation by SDS-PAGE
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Gels were assembled in the Mini-Protean III (Bio-Rad) electrophoresis tank and adequate 
IX  tris-glycine SDS-PAGE running buffer (See Table 2.4) added. Prepared protein samples were 
then loaded into wells, along with two molecular weight markers -  full-range Rainbow molecular 
weight marker (Amersham) and broad-range pre-stained molecular weight marker (New England 
Biolabs) according to the manufacturer's instructions. Gels were then run at 120-200V until the 
dye front was seen to reach the end of the gel.
2 .5 .34  Transfer o f proteins to PVDF membrane
Gels were taken from the electrophoresis tank, separated from the glass plates and 
placed into Tris-glycine transfer buffer (See Table 2.4). Hybond-P polyvinylidene difluoride (PVDF) 
membrane (Amersham) was prepared before use by soaking in methanol for 30secs then dH20  for 
lm in before being equilibrated in Tris-glycine running buffer. Blots were then assembled layer-by- 
layer in a wet electroblotting system (Flowgen biosciences) as shown in Figure 2.1, with careful 
rolling out of air bubbles after the addition of each layer. The blotting tank was then packed in ice 
and run at 100V for 1 hour. Blotting apparatus was then dismantled, and blots washed briefly in 
TBS/T wash buffer before being blocked for non-specific binding of antibodies (See section
2.5.3.S).
Plastic blot support
Sponge
2 x sheets 3M M  paper (Whatman)
PVDF membrane (Amersham)
2 x sheets 3M M  paper (Whatman)
Sponge
Plastic blot support
Figure 2.1: Blotting apparatus set-up fo r Western Analysis
2.5.3.5 Generic protocol fo r probing of membranes
To block non-specific binding, blots were incubated in a large excess of blocking agent 
(either 5% BSA or 5% non-fat milk powder, see table 2.5 for details) diluted in TBS/T with agitation 
under the conditions described in Table 2.5. Primary antibody was diluted and applied to 
membranes with agitation as described in Table 2.5. Blots were then washed 3 x 10 mins in TBS/T. 
Secondary antibody was diluted in blocking solution and applied to membranes with agitation as 
described in Table 2.5. Blots were then washed again for 3 x 10 mins in TBS/T. Blots were then
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developed using appropriate ECL reagent kit (Amersham) according to manufacturer's 
instructions and as described in Table 2.5. Blots were then wrapped in cling film before immediate 
signal detection.
2.5.3.5 Detection o f  signal
Chemifluorescent signal was detected by autoradiograph exposure. Under safelight 
conditions, X-ray film (FujiPilm Super RX blue background) was exposed to the blot for varying 
amounts of time in order to generate clear images. Film was then processed on an automatic film 
processor (Xograph Compact X4 automatic X-ray film processor). Processed films were then 
aligned with the original blot to identify the position of molecular weight markers and allow 
identification of the target protein.
10% Polyacrylamide Gel mix (2 gels)
6 8ml Ultrapure (dd) H:0
8.4ml 30% Acrylamide/bisacrylamide (Sigma)
9.4ml 1M Tris-HCI pH8.8
250pl 10% [w/v] Sodium dodecyl sulphate (SDS,
Sigma)
72pl 25% [w/v] Ammonium persulphate
(Sigma)
13.2pl N,N,N',N' Tetramethylethylenediamine
(TEMED, Sigma)
5X Tris-Glycine SDS-PAGE Running Buffer (1L)
950ml d H ,0
15. lg Tris base (Sigma)
94g Glycine (Sigma)
50ml 10% [w/v] Sodium dodecyl sulphate (SDS,
Sigma)
T a b le
5% Polyacrylamide Gel mix (2 gels)
6.9ml Ultrapure (dd) H20
1.7ml 30% Acrylamide/bisacrylamide (Sigma)
1.3ml 1M Tris-HCI pH6.8
lOOpI 10% [w/v] Sodium dodecyl sulphate (SDS, !
Sigma)
66pl 25% [w/v] Ammonium persulphate
(Sigma)
13.2pl N,N,N',N'-Tetramethylethylenediamine j
(TEMED, Sigma)______________j
IX  Tris-Glycine Transfer Buffer (1L)_________________ I
800ml dH20
200ml Methanol (Fisher scientific)
2.9g Tris base (Sigma)
14.5g Glycine (Sigma)
.4 : W estern b lo ttin g  gel and  b u ffer compositions
73
Target Pten Pten Akt (Total) pAkt (Thr308) pAkt (Ser473) beta-Actin
Commercial source of Primary 
Antibody 
Raised in
Catalog Number
Labvision/Neomarkers 
Rabbit 
RB-072; Ab-2
Cell Signaling 
Rabbit 
9559
Cell Signaling 
Rabbit 
9272
Cell Signaling 
Rabbit 
9271
Cell Signaling 
Rabbit 
9275
Sigma
Mouse 
A5316; Clone AC- 
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Blocking Solution/conditions 10% TTM o/n at 4°C
5% TTM for 2 hrs 5% TTM for 2 hrs 5% TTM for 2 hrs 5% TTM for 2 hrs 5% TTM for 2 hrs
at RT at RT at RT at RT at RT
Primary Antibody conditions
1/500 in 10% TTM, 1 
hr at RT
1/1000 in 5% 1/1000 in 5% 1/1000 in 5% 1/1000 in 5%
BSA/TBST, O/N at BSA/TBST, O/N at BSA/TBST, O/N at BSA/TBST, O/N at
4°C 4°C 4°C 4°C
1/5000 in 5% TTM, 
1 hr at RT
Secondary Antibody
Secondary Antibody Conditions
Commercial source of  
Secondary Antibody
Detection reagents
HRP-conjugated anti- 
Rabbit
1/2000 in 10% TTM, 
lh r at RT
GE Healthcare
ECL
HRP-conjugated HRP-conjugated HRP-conjugated HRP-conjugated HRP-conjugated
anti-Rabbit
1/2000 in 5% 
TTM, lh r at RT
GE Healthcare
ECL plus
anti-Rabbit anti-Rabbit anti-Rabbit
1/2000 in 5% TTM, 1/2000 in 5% TTM, 1/2000 in 5% TTM,
lh r at RT 
GE Healthcare
lh r at RT 
GE Healthcare
lhr at RT 
GE Healthcare
anti-Mouse
1/5000 in 5% TTM, 
1 hr at RT
GE Healthcare
ECL plus | ECL advance ECL advance ECL
Table 2.5: Summary of Antibodies and Protocols used fo r  Western analysis
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2.6 Gene Expression analysis
2.6.1 Isolation of RNA
Care was taken during RNA isolation to ensure that all glass and plastic-ware used was 
RNase free All solutions used were made using Diethyl pyrocarbonate (DEPC, Sigma)-treated 
water, RNase-free water (Sigma) or other solutions known to be RNase-free. Bench tops and 
pipettes were treated with RNaseZAP (Sigma) before use. Sterile, filtered pipette tips were used 
throughout.
2.6.1.1 Homogenisation of whole tissues and epithelial cell extracts
Whole tissues were removed from storage in RNA/ofer (Sigma) and placed in 1ml Trizol 
reagent (Invitrogen). Epithelial cell extracts previously resuspended and frozen in 1ml Trizol 
(Invitrogen) were defrosted. Samples in Trizol were then transferred into screw-cap tubes 
containing 1.4mm ceramic beads (Lysing Matrix D tubes, MP Biomedical). Tissue samples were 
then homogenised by agitating the tubes in the Precellys 24 homogeniser (Bertin Technologies) at 
6000RPM for 2 cycles of 25 seconds. Tubes were then centrifuged at 9500 x g for 10 mins at 4°C to 
pellet cell debris and the ceramic beads.
2.6.1.2 Crude extraction o f  total RNA
Supernatants were removed into clean 1.5ml eppendorf tubes, 200pl ice cold chloroform 
(Fisher scientific) added to each and tubes shaken well. Tubes were then centrifuged at 9500 x g 
at 4°C for 15 mins. Supernatants were removed into clean 2ml eppendorf tubes and 600pl ice cold 
isopropanol (Sigma) added to each. Tubes were shaken well and incubated at 4°C overnight to 
precipitate RNA. Tubes were then centrifuged at 9500 x g at 4°C for 15 mins to pellet RNA. The 
supernatant was carefully aspirated from the pellet. Pellets were washed once by adding 500pl 
ice cold 75% ethanol, and were then centrifuged again (9500 x g at 4°C for 15 mins), ethanol 
carefully aspirated and pellets left to air dry at room temperature for 5-10 mins. Pellets were then 
re-dissolved in lOOpI RNase-free water (Sigma) with gentle heating (65°C) if necessary. 
Concentration and quality of RNA was quantified on the NanoDrop 1000 (Thermo Scientific).
2.6.1.3 Purification of RNA
Purification of RNA was achieved using the RNeasy mini kit (Qiagen). lOOpg RNA was used 
for purification, and the kit was used according to the manufacturer's instructions. RNA was 
eluted in two 30pl aliquots of RNase-free w ater (Qiagen), and concentration and quality of RNA 
re-checked on the NanoDrop 1000 (Thermo Scientific).
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2.6.1.4 Visual assessment of RNA quality
Quality of RNA was checked visually using a denaturing agarose gel (1.5% [w/v] Agarose 
(Eurogentech), 0 .02M  3-(N-Morpholino)propanesulfonic acid [MOPS, Sigma], 5m M Sodium 
acetate [Sigma] Im M  EDTA [Sigma] 1% [v/v] Formaldehyde [Sigma], 0.003% [v/v] Ethidium 
bromide [Sigma] in DEPC-treated dH;0 ). lp l 4X RNA loading buffer (0.1% [w/v] Bromophenol blue 
[Sigma], 20% [v/v] Glycerol [Sigma], 30% [v/v] Formamide [Sigma], 3% [v/v] Formaldehyde 
[Sigma], 0.08M  MOPS [Sigma], 0 .02M  Sodium acetate, 8mM EDTA [Sigma] in DEPC-treated dH20)  
was added to 3jal aliquots of each sample, and samples were heated to 60°C for 10 mins and then 
quenched on ice before being loaded onto the gel. The gel was then run in MOPS buffer (0.02M  
MOPS [Sigma], 5m M  Sodium acetate [Sigma], Im M  EDTA [Sigma] in DEPC-treated dH?0 ) at 120V 
for 30 mins.
2.6.2 Preparation of cDNA for quantitative PCR analysis
2.6.2.1 DNase treatm ent of RNA samples
Purified RNA samples were treated with DNase to remove any remaining contaminating 
DNA. 5pg samples of RNA were treated with RQ1 DNase (Promega) according to the 
manufacturer's instructions.
2.6.2.2 Reverse transcription
cDNA was synthesised from lp g  samples of purified, DNase-treated RNA. Reverse 
transcription was performed using the Superscript II RNase-H reverse transcriptase kit according 
to the manufacturer's instructions. Additional reagents used but not provided in the kit were 
dNTP mix ( Im M  dATP, dCTP, dGTP, dTTP per reaction [Bioline]) and Random Hexamers (20ng/pl 
per reaction [Invitrogen]). Controls were also prepared in exactly the same way but excluding the 
reverse transcriptase enzyme, to give control samples devoid of cDNA.
2.6.3 Q uantitative, Real-time (qRT) PCR analysis
2.6.3.1 Design of qRT PCR primer sets
Primer sets for qRT-PCR reactions were designed such that the resulting product was in 
the 100 120bp size range, and where possible, primers were designed across exon boundaries. 
Primers were designed using the Primer3 web-based program (http://frodo.wi.m it.edu/cgi- 
bin/prim er3/prim cr3 www.cgi) and primer sequences checked for mis-priming by performing in 
silico PCR (http:/ /g e n o m e .c s e . u csc .ed u /g g i-bin/hgPcr?command=start). Primers were then 
synthesised by Sigma-Genosys. Primer sequences used can be found in Table 2.6.
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Target Forward Primer Sequence (5* to 3*) Reverse Primer Sequence (5’ to 3')
Pten AGA CCA TAA CCC ACC ACA GC CGT CCC TTT CCA GCT TTA CA
SHIP TTG GAA CAT GGG TAA TGC AC ATG GGG GAT GTA GTC AGC AG
A ktl CTG AGG AGC GGG AAG AAT G TGA GTT GTC ACT GGG TGA GC
Akt2 TCC ACA AAC GTG GTG AAT ACA TC GGG GTA AGG TCT GGT CAG G
Akt3
TTC
TAA
AGA
AA
AGA GGG GAG AAT ATA TCC ACA TCT TGA GGT TTC TCC T
TSC1 AAG AAA CCA GGC CAT GTG AC CGC AGG AAG GAG ACG AAG T
TSC2 TGG AGG ACA GAT CCT ACA TGG TTG AGA GAG TAG AGC CGG TGA
mTOR GCA CAT TGA CTT TGG GGA CT GAC CCG TAA CCT CCA TAG CA
elFAE-BPl CCG GGA GGA ACC AGG ATT AT CAG GAA TGG CTG GCA GGT
Axin-2 GCT CCA GAA GAT CAC AAA GAG C AGC TTT GAG CCT TCA GCA TC
CyclinD2 GGG ATC CCT GTA CAC TCG AA TTG CAG GTA CGC ACA CTC TC
c-Myc TGA GCC CCT AGT GCT GCA T AGC CCG ACT CCG ACC TCT T
CD44 GGC AGA AGA AAA AGC TGG TG TCT GGG GTC TCT GAT GGT TC
M usashil GAT GCC TTC ATG CTG GGT AT TAG GTG TAA CCA GGG GCA AG
Bmil CCC CAC TTA ATG TGT GTC CTG TTG CTG GTC TCC AAG TAA CG
Lgr5 CCT TGG CCC TGA ACA AAA TA ATT TCT TTC CCA GGG AGT GG
Bet a-Act in ACA GCT TCT TTG CAG CTC CTT TGG TAA CAA TGC CAT GTT CAA T
T ab le  2 .6: P rim er sequences used fo r Q-PCR analysis
2.6.3.2 Running of qRT PCR reactions
All qRT PCR reactions were calibrated and run on the PTC-200 Peltier thermal cycler fitted 
with a Chromo4 continuous fluorescence detector (both MJ Research), in conjunction with 
Opticon Monitor (Version 2.03, MJ Research) software. Each reaction was performed in duplicate, 
and a minimum of biological triplicate (i.e. 3 mice of each genotype were compared). In addition 
to this, control samples devoid of cDNA (described in section 2.6.2.2) were run to ensure no 
contaminants were present in cDNA samples. On each plate, a reaction targeting at least one 
housekeeping gene (usually beta-actin) was run as a reference.
Master mixes were prepared containing DyNAmo Hot-Start (HS) SYBR green supermix 
(Finnzymes, supplied by GRI) as described by the manufacturer and O.lpg cDNA (see section
2.6.2.2). All reactions were made up to a final reaction volume of 25pl using PCR-grade sterile 
water (Sigma).
Forward and reverse primers were mixed in equal quantities, and loaded onto a white, 
thin-wall, 96-well PCR plate (Abgene) such that the final concentration of primers in each reaction 
was lp M . Master mix was then loaded onto the plate, and the plate sealed with optically clear 
sealing tape (GRI).
All reactions were run under the same cycling conditions (Initial denaturation at 95°C for 
15 mins followed by 40 cycles of [95°C for 30 secs; 57°C for 30 secs; 72°C for 30 secs] with the
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plate read after each cycle), a melting curve was constructed at the end of the reaction, and data 
collected automatically by the Opticon monitor package (MJ Research).
2.6 .3 .3  Analysis of qRT PCR data
Data was initially visually examined using Opticon monitor software (MJ Research). It was 
confirmed that all reactions devoid of cDNA were free of any product. Melting curves were also 
briefly examined, to confirm that each reaction yielded only one product, that this product was of 
the expected melting temperature, and that the formation of primer dimers was minimal.
Data was then analysed using the 2 AA(T method (Livak and Schmittgen, 2001). Cycle time 
(C ) for each reaction was recorded, and duplicates averaged. The difference in Ct (ACT) between 
samples amplified for a target gene of interest and corresponding samples amplifying a reference 
gene was then calculated. The average ACT across all biological replicates (i.e. samples of the same 
genotype) was then taken, and AAG calculated as the difference in ACT average between 
genotypes. Fold change was then calculated according to the formula 2 AACT.
2.6.4 PCR analysis of genomic recombination
2.6.4.1 Preparation o f  DNA from  tissue samples
DNA isolation from whole tissue samples, epithelial cell extracts or gut scrapes was 
performed exactly as described for tail tip biopsies in sections 2.1.4.1 and 2.1.4.2.
2.6.4.2  Pten recombined PCR
Primer sequences for Pten recombined-specific PCR were provided by Akira Suzuki, Akita 
University, Japan. Reactions were set up as described for PCR genotyping reactions (Section
2.1.4.3). Composition of the reaction mixture, cycling conditions and primer sequences are 
described in Table 2.7. Product sizes and approximate locations are shown schematically in Figure 
2 . 2 .
2.6.4.3  Ape recombined PCR
Primers used for detection of recombination of the Ape allele have been previously 
published (Shibata et al., 1997). Reactions were set up as described for PCR genotyping reactions 
(Section 2.1.4.3). Composition of the reaction mixture, cycling conditions and primer sequences 
are described in Table 2.7. Product sizes and approximate locations are shown schematically in 
Figure 2.2.
2.6.4.4 k-Ras recombined PCR
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Primers used to detect recombination in the mutant k-Ras transgene were previously 
published (Guerra et al., 2003). Reactions were set up as described for PCR genotyping reactions 
(Section 2.1.4.3). Composition of the reaction mixture, cycling conditions and primer sequences 
are described in Table 2.7. Product sizes and approximate locations are shown schematically in 
Figure 2.2.
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Pten Recombined Ape Recombined k-Ras Recombined
PCR Reaction components:
Crude DNA Extract 3pl 2.5pl 3pl
Master Mix:
PCR-grade Water (Sigma) 31.1pl 31.4pl 31. lp l
GO Taq PCR Buffer (5X; Promega) lOpI lOpI lOpI
Magnesium Chloride (25mM) 5pl 5pl 5p!
dNTPs (25mM; dATP, dCTP, dGTP, dTTP) 0.4pl 0.4pl 0.4pl
Primer 1 (Sigma Genosys, 100mM) O.lpl O.lpl O.lpl
Primer 2 (Sigma Genosys, lOOmM) O.lpl O.lpl O.lpl
Primer 3 (Sigma Genosys, lOOmM) O.lpl N/A O.lpl
Taq DNA polymerase 0.2pl, Go taq 0.2pl, Go Taq 0.2pl, GoTaq
Total Reaction Volume: 50pl 50pl 50pl ]
Cvclina conditions:
• .......... i^
Initial denaturation step (Time; Temp) 2min 30sec; 94°C 3min; 95°C 5 min; 94°C
Step 1: Denaturation (Time; Temp) 30 secs; 94°C 30sec; 95°C 1 min; 94°C
Step 2: Annealing (Time; Temp) 30 secs; 63°C 30sec; 60°C 1 min; 60°C
Step 3: Extension (Time; Temp) lm in ; 72°C lm in ; 72°C 1 min; 72°C
Number of Cycles 30 30 30
Final Extension (Time; Temp) 10 min; 72°C 5min; 72°C 10 min; 72°C
Hold (Time; Temp) °°; 15°C °°; 15°C 15°C
Primer Sequences IF 5'-GGCCTAGGACTCACTAGATAGC-3'
"" '  ...... . “ ... ” 1
P3 5'-GTTCTGTATCATGGAAAGATAGGTGGTC-3 510 5'-AGGGTAGGTGTTGGGATAGC-3'
2R 5'-CTCCCACCAATGAACAAACAGT-3' P4 5'-CACTCAAAACGCTTTTGAGGGTTGATTC-3' 3Exl S'-CTCAGTCAmTCAGCAGGC-S’
3F 5'-GTGAAAGTGCCCCAACATAAGG-3' P5 5'-GAGTACGGGGTCTCTCTGTCTCAGTGAA-3' 103rev 5'-CTGCTCTTTACTGAAGGCTC-3'
Table2.7: Recombined PCR conditions and prim er sequences
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LoxP -targeted  a lle le  3F/2R = 514bp
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Figure 2.2: Schematic representation of primer positions and product sizes for recombined-allele-specific PCR
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2.7 Statistical Analyses
2.7.1 Kaplan-Meier survival analysis
Survival curves and statistical analysis of survival times was performed using the Kaplan- 
Meier method. All analyses were performed with the aid of MedCalc statistical analysis software 
(Version 9.3.0.0, Available from http://w w w .m edcalc.be).
2.7.2 M ann-W hitney-U  Test
The Mann-W hitney-U Test was used to show statistical differences between non- 
parametric data sets. Mann-Whitney-U analysis was performed using the Minitab statistics 
package (Version 14.20). A significant difference between data sets was accepted if p values were 
less than 0.01.
2.7.3 Kolmogorov-Smirnov Analysis
Differences in distribution of data within a non-parametric data set were tested for using 
the Kolmogorov-Smirnov approach. This was performed exactly as described in Biometry: The 
Principles and Practise of Statistics in Biological Research (Sokal, 1981).
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Chapter 3: Analysing the short-term effects of AhCre-driven Pten deficiency 
in the intestinal epithelium
3.1 Introduction
PTEN is a potent tumour suppressor, identified based on the fact that it is found to be 
inactivated in human sporadic cancers of varying origins (Steck et al., 1997, Li and Sun, 1997, Li et 
al., 1997). Germline mutation of PTEN results in a number of cancer-predisposition disorders, 
known as the PTEN hamartoma tumour syndromes (PHTS), a feature of which is the development 
of intestinal lesions (Carlson et al., 1984, Merg and Howe, 2004).
PTEN functions as a negative regulator of the PI3K/Akt pathway (Maehama and Dixon, 
1998), which normally functions to promote proliferation and cell survival. Activating mutations 
within PI3K/Akt pathway components are common in cancers, and have been shown to be 
present in up to 40% of all human colorectal malignancies (Parsons et al., 2005).
Given its close link with human disease, in vivo study of Pten function has been the 
subject of much attention. Murine studies of constitutive Pten deficiency have indicated that 
complete deletion of Pten is incompatible with life (Di Cristofano et al., 1998, Podsypanina et al., 
1999, Suzuki et al., 1998), whilst heterozygous loss of Pten models some of the features 
associated with PHTS in humans, including predisposition to hamartoma of the gastrointestinal 
tract. Notably, Di Cristofano and colleagues report the development of invasive adenocarcinoma 
in the colon of Pten heterozygous animals.
Previous work has indicated that inactivation of Pten by phosphorylation is a feature of 
the elusive intestinal stem cell (ISC) (He et al., 2004). He et al. propose that, in the ISC, Pten may 
function to arbitrate the interaction between the BMP and Wnt pathways by mediating levels of 
activated (phosphorylated) Akt. Inactivation of Pten specifically in the stem cell is therefore 
proposed to promote Wnt signalling activity, which in turn enhances stem cell replication. 
However, this notion has been the subject of some debate (Bjerknes and Cheng, 2005b).
In a further study, He et al. have examined the effect of conditional Pten deletion in the 
adult intestine (He et al., 2007). By using the M x l  inducible promoter to drive Cre expression, He 
et al. have achieved deletion of Pten from both the epithelial and stromal cell compartments in 
the intestine. Following loss of Pten, they report proliferation of Pten-deficient ISCs, which leads 
to crypt fission and the rapid development of hamartomatous polyps within the intestine.
Thus, from studies published in the literature it would appear that Pten functions as a 
potent tumour suppressor within the intestine, though the specific role of Pten exclusively in the 
epithelial cell layer has not been thoroughly examined.
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In this chapter, I aimed to characterise the effects of Pten deletion specifically from the 
epithelial cell compartment in the adult mouse small intestine. The experimental approach 
employed to achieve this was that of conditional transgenesis, involving LoxP-targeted Pten alleles 
(Suzuki et al., 2001) together with the inducible AhCre transgene. The Cre-expressing AhCre 
transgene has previously been used to drive Cre expression specifically and efficiently within 
epithelial cells of the intestine (Ireland et al., 2004). The effects of epithelial-specific Pten deletion 
both on epithelial homeostasis and on the intestinal stem cell will be characterised.
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3.2 Results
3.2.1 AhCre drives recombination in the intestine w ith high efficiency
in order to examine the role of Pten specifically in the intestinal epithelium, animals 
bearing the AhCre transgene were crossed to animals bearing LoxP-targeted Pten alleles. This 
generated animals of an experimental genotype (AhCre*;Pten"‘, referred to throughout this 
chapter as 'Pten' ’') and appropriate controls (AhCre‘;P ten*'\ AhCre‘ ;Pten‘ *, AhCre ;Ptenv‘, AhCre 
;Pten‘ *, referred to here as 'controls').
Previous reports have indicated that AhCre drives recombination efficiently in the murine 
small intestinal epithelium following a treatm ent regime of 4 consecutive daily intraperitoneal 
injections of beta-naphthoflavone at a dose of 80mg/kg (Ireland et al., 2004). In order to confirm 
this was the case in the strain of mice I was using, mice were bred onto a background bearing the 
ROSA26R LacZ reporter transgene (Soriano, 1999). This reporter construct consists of the LacZ 
(beta-galactosidase) transgene, containing a LoxP-flanked STOP cassette. In unrecombined cells, 
the STOP cassette prevents expression of the LacZ transgene. Upon expression of Cre in the cell, 
the STOP cassette is excised from the transgene, allowing expression of LacZ. Exposure of cells 
expressing LacZ to X-Gal substrate results in a colourimetric change from colourless to blue, thus 
allowing identification of cells expressing Cre recombinase (See Figure 3.1A).
Control and P ten '' animals bearing the LacZ reporter construct (LacZ*), and those lacking 
the reporter construct (LacZ) were induced as described above. At day 5 post-induction (PI), 
animals were culled, intestines prepared as wholemounts, and exposed to X-Gal substrate. As 
expected, intestines from AhCre'LacZ" animals stained blue, showing a near-100% recombination 
frequency as previously reported (Ireland et al., 2004). No difference was observed between 
animals wild-type for Pten and those bearing the LoxP-flanked Pten alleles (Figure 3 .IB , i and ii 
respectively), indicating that Pten status does not affect recombination levels. Intestines from  
animals not bearing the LacZ transgene were found to be completely negative for any blue 
staining (Figure 3 .IB, iii), confirming that beta-galactosidase activity is not endogenous to the 
murine intestine. In order to confirm that the intestinal epithelium is repopulated from  
recombined cells (and thus indicating that recombination occurs within the stem cell population), 
intestines from AhCre*;LacZ ;Pten animals at over 100 days PI were stained with X-gal substrate. 
These intestines were found to stain equally as well as those at day 5 PI (Figure 3 .IB , iv), 
indicating that Pten deficiency is tolerated in the epithelium, and that the epithelium is not 
repopulated from unrecombined cells.
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LoxP LoxP
PGK-Neo STOP < LacZ
Cre Recombinase
B
Pten+/+ Ptenf/f
AhCre*;LacZ+ 
Day 5 PI
AhCre+;
Day5 PI
AhCre+;LacZ+; 
Ptenf/f 
Day 100 PI
Figure 3 .1 : Use of the ROSA26R LacZ reporter to indicate recombination in the intestine
The ROSA26R transgene was used to report recombination within the intestine (A). LoxP sites flank a 
PGK-Neo-STOP cassette inserted in the LacZ transgene. Following exposure to Cre recombinase, the PGK- 
Neo-STOP cassette is excised, allowing expression of beta-galactosidase from the LacZ transgene. Cells 
expressing beta-galactosidase can be detected by exposure to X-Gal substrate , which results in a 
colourimetric change from colourless to blue. Treatm ent of mice with 4 consecutive daily doses of 
80mg/kg beta-naphthoflavone results in near-100% recombination of the intestinal epithelium, as 
indicated by X-Gal staining of wholemount intestines (B). Recombination levels are independent of Pten 
status, as AhCre'jLacZ’jPten*/* intestines (i) stain identically to AhCre*;LacZ*;Ptenf/f intestines (ii) at day 5 
PI. Absence of the LacZ transgene results in no staining (iii). LacZ staining persists at over 100 days pi (iv), 
indicating that Pten deficiency is tolerated and that the epithelium is repopulated from recombined 
cells.
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3.2.2 Recombination results in loss of  Pten transcript and protein from the intestinal epithelium
Having confirmed that induction of Cre activity results in efficient recombination within 
the intestinal epithelium, I next examined the resulting effect upon levels of Pten transcript and of 
Pten protein within the epithelium of P ten" animals.
As recombination occurs only within the epithelial cell layer of the intestine, this first 
involved developing a protocol to generate samples enriched for epithelial cells, which could be 
used for both gene expression analysis and protein analysis. A protocol based on that of Bjerknes 
and Cheng (1981) was developed1 (see Section 2.2.7). This allowed removal of the epithelial layer 
into suspension, whilst remaining intestinal tissue, including stromal cells and smooth muscle, 
could be discarded (Figure 3.2A i and ii).
cDNA produced from RNA extracted from epithelial-enriched samples was used to 
perform quantitative real-time (Q-) PCR directed towards exon 5 of the Pten transcript, which is 
excised following recombination. At day 5 PI, samples from control animals were found to have 
an average cycle time (± standard deviation, normalised against beta-actin expression) of 
6.6 0 H .2 4  compared to Pten’ ' animals which had an average cycle time of 9.72±0.77 (Figure 
3.2B). This increase in average cycle time indicates significantly decreased levels of Pten transcript 
in Pten’ * animals (Mann-W hitney U test, n=3, p<0.0001), which is equivalent to an 8.68-fold 
reduction of Pten transcript in Pten’ ’ samples compared to controls. Similarly, samples obtained 
at day 50 PI were found to have a significantly (M ann-W hitney U test, n=3, p<0.0001) lower 
average cycle time of 6 .1 7 H .6 5  in control samples compared to 9.5710.94 in Ptenf/f samples 
(Figure 3.2C), equivalent to a 10.62-fold reduction in Pten expression.
Loss of Pten protein from the epithelium following recombination was also assessed, both 
qualitatively (using IHC) and quantitatively (using western analysis). Immunohistochemistry 
revealed strong staining for Pten in the epithelium, stroma and smooth muscle of tissue sections 
from control animals at both day 5 and day 50 PI. In contrast, staining for Pten was absent from 
the epithelium of intestines from Pten" animals at both timepoints, whilst staining of the stroma 
and smooth muscle was retained (Figure 3.3A). Supporting the observation that recombination 
occurs within the intestine at just lower than 100% efficiency using this system, occasional crypts 
from Pten" animals at day 50 PI were found to retain positivity for Pten in the epithelium, 
surrounded by Pten-deficient tissue (Figure 3.3B).
Western analysis on protein extracted from epithelial-enriched samples was used to 
examine loss of Pten protein in a quantitative manner. This revealed a dramatic reduction in Pten 
protein levels in Pten" animals compared to controls at day 5 PI, and Pten was virtually 
undetectable in Pten" samples at day 30 PI and day 50 PI compared to controls. Level of Pten
* This protocol was developed with the assistance of Dr Richard Kemp, University of Cambridge,
protein level was also assessed in a Cre Pten‘ ‘ animal at day 50 PI, which was not found to be 
different to Pten' * controls. This indicates that LoxP-targeting of the Pten allele does not result in 
a hypomorphic effect upon expression of Pten protein compared to wild type Pten alleles (Figure 
3.3C).
Thus, these data indicate that induction of AhCre according to the published protocol 
(Ireland et al., 2004) results in recombination within the intestine. Pten is efficiently and 
specifically deleted from the small intestinal epithelium, resulting in significant loss of both Pten 
transcript and Pten protein from day 5 after induction.
AW hole Villi Stroma Smooth Muscle
Figure 3.2: Epithelial enrichment o f intestinal tissue samples, and use o f epithelial extracts 
to confirm loss o f Pten transcript a fte r induction
A protocol for enrichment of epithelium from fresh whole intestinal samples was developed 
(A), yielding samples containing predominantly epithelial cells (left) with whole villi clearly 
identifiable (indicated), whilst remaining intestinal tissue (right), composed of stroma and 
smooth muscle (indicated), was discarded. Scale bar indicates 100pm.
Quantitative real-time PCR analysis of Pten expression in epithelial-enriched samples derived 
from controls (grey bars) and Pten,/f (white bars) animals reveals an increase in average cycle 
time (C(tJ) needed for product amplification following induction at both day 5 (B) and day 50 
(C) PI. This indicates a significant reduction (Mann-W hitney U test, p<0.001) of Pten 
transcript levels in Ptenf/^  animals following recombination. Error bars indicate ±Standard 
deviation.
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Figure 3.3: Confirmation of loss of Pten protein from the intestinal epithelium after induction
IHC against Pten reveals loss of Pten protein from the epithelium of Ptenf/f intestines compared to 
controls, which retain epithelial staining against Pten, at both day 5 and day 50 after induction (A). IHC 
against Pten at day 50 PI reveals occasional crypts which retain positivity for Pten (B, filled arrows) 
surrounded by crypts deficient for Pten (open arrows), reflective of the recombination frequency of just 
under 100%. Scale bars indicate 100pm. Western analysis (C) of epithelial-enriched samples from control 
and Ptenf/f animals confirms reduction of Pten protein (detected at a size of approximately 55kDa) at day 
5 PI, and levels of Pten protein are virtually undetectable at days 30 and 50 PI. Pten protein is detected 
in all controls. Beta-actin (45kDa) is shown as a loading control.
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3.2.3 Recombination outside the intestine recapitulates previously observed phenotypes
Although the AhCre transgene drives recombination efficiently within the small intestinal 
epithelium, it is also known to drive recombination in other tissues with relatively high efficiency, 
such as the liver, forestomach, oesophagus and gall bladder (Ireland et al., 2004).
As such, deletion of Pten was observed to result in phenotypes outside the intestine, 
many of which have previously been reported in the literature.
In the liver, Pten loss was found to rapidly result in abnormal tissue pathology, 
reminiscent of steatosis of the liver. Hepatic steatosis was not observed in tissues from control 
animals (Figure 3.4A). Liver steatosis was also found to be accompanied by significant 
hepatomegaly in Pten' ‘ animals compared to controls. At day 5 PI, average weight of the whole 
liver of control animals was 1.32g (± standard deviation of 0.13, n=5) compared to 2.2g (± 
standard deviation of 0.29, n=4) in Pten animals. This trend was also maintained at day 14 PI, 
where the average liver weight of control animals was 1.3g (± standard deviation of 0.15, n=3) 
compared to 2.2g ( i  standard deviation of 0.36, n=4) in Ptenv‘ animals (Figure 3.4B). The increase 
in liver weight in Pten* animals is significant in both instances (Mann-W hitney U test, p<0.02). In 
one case, a Pten" * animal was found to develop hepatocellular carcinoma (HCC) (Figure 3.4C). The 
phenotypes observed in the liver following Pten loss are consistent with those observed in two 
previous studies, where Pten was deleted specifically from adult hepatocytes (Horie et al., 2004, 
Stiles et al., 2004).
Pten’ ‘ animals were also noted to be predisposed to lymphoma formation (Figure 3.4D), 
which was rarely observed in controls. Again, this observation is consistent with previous reports 
in a number of Pten-deficient mouse models which report common incidence of lymphoma (Lu et 
al., 2007, Suzuki et al., 1998, Di Cristofano et al., 1998, Podsypanina et al., 1999).
Induced female Pten“  animals were found to be susceptible to complex atypical 
hyperplasia of the endometrium (Figure 3.4E), which was not observed in control genotypes. 
Again, the development of endometrial hyperplasia and cancer in mouse models of Pten loss has 
previously been reported (Lu et al., 2007, Podsypanina et al., 1999).
Finally, significant behavioural defects were observed in both induced and uninduced 
Pten ' animals, including ataxia, which was not observed in controls. This phenotype has 
previously been reported following specific deletion of Pten from the brain during development 
(Backman et al., 2001). As this phenotype is observed in uninduced Ptenf/< animals, it is clear that 
AhCre must be spontaneously activated in the brain at some point during development or early 
life. In many instances, this phenotype forced the premature culling of P ten/ animals, which has 
precluded the characterisation of very long term  Pten loss from the intestine in this study.
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Figure 3.4: Pathologies outside the intestine observed following Pten deletion
Induction of AhCre drives phenotypes associated with Pten loss in other tissues, which have previously 
been reported in other studies. Pten,/f animals were found to be susceptible to steatosis of the liver (B, 
outlined area shows example of steatosis) compared to controls (A). This was accompanied by a 
significant increase in liver weight (B) of Pten,/f animals (white bars) compared to controls (grey bars), 
evident from day 5 PI (left) and also at day 14 PI (right) (Mann-Whitney U test, p<0.02). Error bars indicate 
standard deviation. In once case, HCC developed in a Ptenf/f animal (C). A high incidence of lymphoma (D) 
was also observed in Ptenf/f mice, but not in controls. Female induced Ptenf/f animals were found to 
commonly develop complex atypical hyperplasia of the endometrium (E, right, inset shows digital 
magnification of the area indicated), which was not seen in controls (left). Scale bars indicate 100pm.
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3.2.4 Pten deficiency does not perturb gross structure or histology of the intestinal epithelium
Having validated this model of Pten deficiency, and confirmed loss of Pten from the 
intestinal epithelium, I next went on to characterise both the immediate and more protracted 
effects of Pten deletion specifically on intestinal homeostasis.
Upon dissection of control and Pten animals at all timepoints, intestines were removed 
and examined closely for any gross changes in intestinal structure or for macroscopic appearance 
of any abnormal lesions. No differences between control and Pten/ animals were observed, and 
no tumours were detected at any timepoint (Numbers of control and Pten*' animals respectively 
examined were; at Day 5 PI: n=38 and n = 22; at Day 14 PI: n=21 and n=9; at Day 30 PI: n=3 and 
n=5; at Day 50 PI: n = 33 and n = 35).
H&E-stained intestinal tissue sections of controls and Pten7‘ animals at day 5 and 50 PI 
were examined microscopically, and intestines from Pten7‘ animals were found to be 
histologically indistinguishable from controls at both timepoints (Figure 3.5A). No perturbations in 
crypt or villus structure were observed, and no dramatic difference in levels of apoptosis or 
mitosis within the epithelium was noted. IHC against the maker of proliferative cells, Ki67, was 
used to examine the location and numbers of proliferating cells in the crypt. This showed that 
again, control and Pten tissue samples at day 50 PI were indistinguishable. The proliferative 
compartment was correctly located and approximate numbers of replicating cells were 
unchanged in the context of Pten deficiency (Figure 3.5B).
In order to reveal any subtle changes in structure or homeostasis of the epithelium, crypt 
and villus size and apoptosis and mitosis within the crypt were quantified. Crypt size was scored 
as the average number of epithelial cells within whole crypts. Numbers of cells (± standard 
deviation) per crypt were found to be unchanged in control versus Ptenf/f tissue at either day 5 PI 
(44.30±0.87, n=5 Vs. 44.36±1.35, n=3) or day 50 PI (44.67±2.33, n=4 Vs. 44.34±1.28, n=5) (Figure 
3.6A). Similarly, villus size was scored as the number of epithelial cells from the crypt-villus 
junction to the top of the villus. Care was taken to select comparable regions along the proximal- 
distal axis of the intestine, as villus length decreases along the proximal-distal axis of the intestine. 
Numbers of cells (± standard deviation) along the length of the villus was again found to be 
unchanged in control versus Pten tissue respectively at either day 5 PI (157.01±8.48 n=3, Vs. 
157.13 + 5.95, n = 3) or day 50 PI (139.67±9.51, n=3 Vs. 143.31+9.76, n=3) (Figure 3.6B).
Levels of apoptosis and mitosis within the crypt were scored from H&E-stained sections 
and quantified as average apoptoses or mitoses as a percentage of the total number of cells per 
crypt. Percentage of apoptosis per crypt was not significantly changed (Mann-Whitney U test, 
n>3, all p-values > 0.38) in Pten7' compared to control samples across all four timepoints (Days 5, 
14, 30 and 50 PI) (Table 3.1, Figure 3.7A). Similarly, scoring for mitosis revealed no significant
93
change (Mann-W hitney U test, n>3, all p-values > 0.38) in mitotic index between Ptenf/f and 
control genotypes across all timepoints (Table 3.1, Figure 3.7B).
Timepoint
Day 5
Day 14 
Day 30 
Day 50
PI Genotype
Average  
Percentage  
Apoptosis (%)
± Standard  
Deviation
Average  
Percentage 
Mitosis (%)
± Standard 
Deviation
Control 1.34 0.67 6.55 4.37
Pten'” 0.91 0.07 5.03 4.10
Control 0.86 0.06 7.74 3.79
Pten"’ 0.56 0.29 10.88 1.76
Control 0.60 0.19 6.00 2.93
Pten"' 0.54 0.18 5.67 0.56
Control 0.99 0.47 5.77 0.97
Ptenf* 0.92 0.39 : 5.20 1.44
Table 3.1: Scoring of Apoptosis and mitosis in 
control and Pterf^ intestines reveals no 
significant difference compared to controls
These data therefore indicate that, up to 50 days after induction, Pten loss is tolerated 
within the intestine, and does not perturb the normal architecture of the intestine or basic 
homeostasis of the epithelium.
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Figure 3.5: No changes in histology or location of TA zone following epithelial Pten loss
H&E-stained sections of intestinal tissue from control and Ptenf/fanimals at days 5 and 50 PI revealed 
gross changes in histological appearance. IHC against the proliferation marker Ki67 (B) revealed no 
change in the location of the transit amplifying (TA) at day 50 after Pten loss.
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Figure 3.6: Quantification of crypt and villus size following Pten deletion
Scoring o f  th e  n u m b e r  o f cells p re s e n t p e r fu ll c ryp t (A) o r p e r h a lf villus (B) re v e a le d  no d iffe re n ce  
b e tw e e n  c o n tro l (g re y  bars) and P ten f/f (w h ite  bars) in tes tin es  a t e ith e r  d ay  5 o r day 5 0  PI (M a n n -  
W h itn e y  U te s t, p>  0 .6 6 ) .
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Figure 3 .7 : Quantification o f levels of apoptotic and mitotic cells within the crypt
Apoptosis (A) and m itosis (B) w as scored fro m  in testinal tissue sections o f contro l (grey bars) and 
P tenf/f(w h ite  bars) m ice a t days 5, 14, 30  and 50  PI. No significant d iffe ren ce  (M a n n -W h itn e y  U test, 
p>0 .3 8  fo r all com parisons) in e ith e r  apoptosis o r m itosis w as observed b e tw e e n  contro l and P tenf/f 
genotypes across all tim e p o in ts .
3.2.5 Pten-deficient cells show a normal apoptotic response to DNA damage
P rev io u s w o rk  has in d ic a te d  th a t  P ten  p h ys ica lly  in te ra c ts  w ith  th e  p ro -a p o p to tic  fa c to r , 
p 5 3 , an d  plays a ro le  in p ro m o tin g  its s ta b ilis a tio n  (F re e m a n  e t  a l., 2 0 0 3 ) .  W ith in  th e  in te s tin e , th e  
a p o p to tic  resp o n se  to  g a m m a  ir ra d ia tio n  is k n o w n  to  be c r itic a lly  d e p e n d e n t  u p o n  p 5 3 -  
d e p e n d e n t m ec h a n is m s  ( M e r r i t t  e t  a l., 1 9 9 7 ) .  As such, I d e c id e d  to  te s t  w h e th e r  P te n -d e fic ie n t  
in te s tin e s  s h o w  an y  im p a ir m e n t in a p o p to t ic  re sp o n se  to  D N A  d a m a g e  in d u c e d  by ir ra d ia tio n .  
This w ill a llo w  an y  re d u c tio n  in leve ls  o r  a c tiv ity  o f  p 5 3  to  be in fe rre d .
C o n tro l an d  P te n f/f a n im a ls  a t  d a y  5 0  PI w e r e  ir ra d ia te d  w ith  a d o se  o f  5 G y  o f g a m m a -  
ir ra d ia tio n  fro m  a caes iu m  so u rce . A f te r  th r e e  h o u rs , a n im a ls  w e r e  cu lle d  an d  in te s tin e s  
h a rv e s te d . H & E -s ta in e d  sec tio n s  o f  in te s tin e  f r o m  c o n tro l an d  P ten f/f a n im a ls  w e r e  e x a m in e d  fo r  
th e  p re s e n c e  o f a p o p to tic  fig u res . B rie f e x a m in a t io n  o f  se ctio n s re v e a le d  th a t  a p o p to tic  b o d ies  
w e r e  p re s e n t in b o th  c o n tro l an d  P te n -d e f ic ie n t  in te s tin e s , an d  w e re  p re s e n t in a p p ro x im a te ly  
e q u a l n u m b e rs  in each  g e n o ty p e  (F ig u re  3 .8 A ). Q u a n t if ic a tio n  o f  th e  p e rc e n ta g e s  o f  a p o p to s e s  
an d  m ito ses  p re s e n t in th e  c ry p t fo llo w in g  ir ra d ia tio n  (F ig u re  3 .8 B ) re v e a le d  th a t  th e  p e rc e n ta g e  
o f a p o p to tic  cells (±  s ta n d a rd  d e v ia t io n ) in c o n tro l ve rsu s  P te n -d e fic ie n t in te s tin e s  re s p e c tiv e ly  
(1 6 .4 7 ± 1 .3 0  Vs. 1 6 .7 7 1 1 .3 0 )  w a s  n o t s ig n ific a n tly  d i f fe re n t  (M a n n -W h itn e y  U te s t, n = 3 , p = 0 .7 ) , n o r  
w as th e  p e rc e n ta g e  o f  m ito t ic  cells (5 .3 8 1 2 .4 6  Vs. 5 .6 2 + 2 .0 1 ,  M a n n -W h itn e y  U te s t; n = 3 , p = 0 .7 ).
Thus, it a p p e a rs  th a t  p 5 3 -d e p e n d e n t  a p o p to s is  is n o t im p a ire d  in th e  c o n te x t o f  P ten  
d e fic ien c y , im p ly in g  th a t ,  in th e  in te s tin e , P ten  d o es  n o t in flu e n c e  th e  s ta b ility  o r  a c tiv ity  o f  p 5 3 .
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Figure 3 .8: No impairment of apoptotic response to DNA damage following Pten loss
In o rd er to  assess th e  a p o p to tic  response to  DNA dam ag e  in th e  co n tex t o f Pten d efic iency, m ice w ere  
irrad ia ted  w ith  5G y g a m m a -irra d ia tio n . This induces an ap o p to tic  response in th e  in tes tin e  (A), and  
ap op to tic  figures (a rro w s) w e re  fou nd  to  be p resen t in bo th  controls and P ten f/f an im als . Scale bars 
indicate 1 0 0 p m . Q u an tific a tio n  o f levels o f apoptosis and m itosis fo llo w in g  irrad ia tio n  (B) show ed no 
d ifferen ce  in levels o f e ith e r apoptosis or m itosis in controls (grey bars) co m p ared  to  P tenf/f (w h ite  bars) 
anim als (M a n n -W h itn e y  U te s t, p =0 .7  fo r both  com parisons). Error bars show  standard  d ev ia tio n .
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3.2.6 Epithelial cells differentiate normally in the absence of Pten
In order to examine the presence and localisation of the mature, differentiated cell types 
of the intestinal epithelium, IHC or specific stains were used to allow visualisation of cell types.
Tissue from control and Ptenf/f animals at day 50 PI was stained immunohistochemically 
against lysozyme, a marker of Paneth cells. Positively-stained cells were present in both control 
and Ptenf/f tissue samples, and were found to be located at the very base of the crypt, regardless 
of Pten status (Figure 3.9A).
Similar tissue samples were used for IHC against villin, a marker of mature enterocytes. 
Staining patterns indicated no alteration in the location of the brush border or differentiation of 
enterocytes in the context of Pten deficiency (Figure 3.9B).
The Periodic Acid-Schiffs reagent (PAS) stain and the Grimelius method were used to 
detect Goblet cells and enteroendocrine cells respectively. PAS stains mucins released by goblet 
cells, allowing their identification. This revealed that Goblet cells are present in Pten-deficient 
tissue compared to controls, and are correctly localised. The Grimelius method allows 
identification of enteroendocrine cells by the presence of silver deposits in the cells, which stain 
cells black. Again, this revealed no difference in the presence or localisation of enteroendocrine 
cells in the context of Pten loss.
Using these stained sections, the numbers of Goblet cells and enteroendocrine cells 
present in the crypt and on the villus was quantified in both control and Ptenf/f tissue samples at 
day 50 PI. The average number of goblet cells (± standard deviation) present in the crypt of 
control (4.95±0.55) and Ptenf/f (5.73±0.36) tissues and on the villus of control (13.87±3.24) and 
Ptenf/f (13.87±1.51) tissue samples was not significantly different (Mann-Whitney U test, n=3, 
p>0.19) (Figure 3.10A). Similarly, the numbers of enteroendocrine cells (± standard deviation) 
observed in control versus Ptenf/f tissue sections in the crypt (0.76±0.17 Vs. 0.67±0.02) or on the 
villus (1.55±0.14 Vs. 1.95±0.35) was not significantly different (Mann-Whitney U test, n=3, p>0.27) 
(Figure 3.10B).
Thus, it is clear that epithelial cells are able to differentiate normally in the absence of 
Pten, with all mature cell types being present, correctly localised and at the expected frequency 
compared to control tissue.
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Figure 3 .9 : Identification of differentiated epithelial cell types following Pten loss
Anti-lysozyme IHC was used to label paneth cells (A, arrows) at the base of the crypt, which were 
found to be correctly localised in Pten-deficient tissue at day 50 PI. Anti-villin IHC, Periodic acid- 
Schiff s stain (PAS) and the Grimelius method were used (B) to identify the brush border, goblet 
cells (arrows) and enteroendocrine cells (arrows) respectively, in tissue from control and Ptenf/f 
animals at day 50 PI. In no case was the presence or localisation of differentiated cell types affected 
by Pten loss. Scale bars indicate 100pm.
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Figure 3 .1 0 : Quantification of Goblet cells and enteroendocrine cells following Pten loss
N u m b ers  o f G o b le t cells (A) and e n te ro e n d o c rin e  cells (B) p resen t in th e  cryp t and villus o f contro l 
(grey bars) and P ten f/f (w h ite  bars) an im als a t day 5 0  PI w e re  q u a n tifie d . No d iffe re n ce  was  
observed  in th e  n u m b ers  o r location  o f th ese  d iffe re n tia te d  cell types  in P ten -d e fic ie n t tissue  
co m p ared  to  co n tro ls  (M a n n -W h itn e y  U te s t, p > 0 .1 9  fo r all com parisons). E rror bars ind icate  ± 
S tandard  d e v ia tio n .
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3.2.7 Pten-deficient cells exhibit no block in migratory ability
Previous work has indicated that Pten can directly dephosphorylate focal adhesion kinase 
(FAK), blocking migration of cells in culture (Gu et al., 1999). Furthermore, Pten has also been 
shown to associate with adherens junctions (Subauste et al., 2005). Taken together these results 
suggest that Pten could play a role in regulating migration of epithelial cells in the intestine.
In order to test this hypothesis and examine the migratory ability of epithelial cells 
deficient for Pten up the crypt-villus axis, I performed a BrdU-label pulse-chase experiment.
Control and Ptenf/f animals at either day 5 or day 50 PI were treated with an excess of 
Brdll reagent to label replicating cells during S-phase of the cell cycle. Animals were then culled 
either 2 hours or 24 hours following treatment with BrdU, and intestines harvested. Intestinal 
tissue sections were then subjected to IHC against BrdU, in order to visualise labelled cells.
Anti-BrdU IHC revealed strong staining for BrdU in the nuclei of labelled cells, as expected 
(Figure 3.11A and B). In control and Ptenf/f tissues at both day 5 PI (Figure 3.11A) and day 50 PI 
(Figure 3.11B), IHC revealed BrdU-labelled cells to be confined to the crypt at 2 hours after 
labelling. At 24 hours after labelling, labelled cells were found to have migrated up the crypt-villus 
axis, out of the crypt and onto the lower portion of the villus. This pattern of migration was 
evident in both control and Ptenf/f tissue samples at both day 5 and day 50 PI. This indicates that 
loss of Pten does not result in a blockade in migration of epithelial cells.
Migration of cells was quantified in order to reveal any subtle differences in cell 
movement between control and Ptenf/f genotypes. In order to do this, the positions of labelled 
cells were scored, and cumulative frequency distributions of cell position were generated.
At day 5 PI, 50% of labelled cells at 2 hours after administration of BrdU were found to be 
located at cell position 15 or lower, regardless of Pten status. Similarly, at 24 hours after BrdU 
administration, the median position of labelled cells had increased to position 35 in both 
genotypes, indicating migration up the crypt-villus. The distribution of labelled cells in control 
versus Pten-deficient intestines was therefore not significantly changed either at 2 hours or 24 
hours after BrdU labelling (Kolmogorov-Smirnov [KS] test for difference in distribution, not 
significant at 99% confidence) (Figure 3.12A).
At day 50 PI, a very similar pattern of distribution of labelled cells at both 2 hours and 24 
hours after BrdU labelling is observed (Figure 3.12B). However, at Day 50 PI, the distribution of 
labelled cells in control and Ptenf/f tissue is significantly different (KS test for difference in 
distribution; distributions are significantly different with a confidence level of 99%). Surprisingly, 
Pten-deficient cells are found to migrate more quickly than control cells, as indicated by a shift to 
the right of the cumulative frequency curve.
This pattern supports the predicted observation based on the published data described 
above, which would be that Pten deficiency would enahnce migration. Indeed, it appears that loss
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of Pten does not result in any insufficiency in migratory ability, and may in fact enhance migration 
rates within the epithelium.
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Figure 3.11: BrdU labelling o f cells reveals no deficiency in cell m igration following Pten loss
BrdU was administered to Ptenf/f and control animals at day 5 (A) or day 50 (B) PI. Intestines were 
harvested either 2 hours or 24 hours after BrdU labelling, and IHC used to detect labelled cells. This 
revealed no block in the migratory ability of Pten-deficient cells compared to controls, either at day 5 
or day 50 PI. Scale bars indicate 100pm.
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Figure 3.12: Q uantification o f epithelia l BrdU-labelled cell m igration
Migration of BrdU-labelled cells in control mice (red lines) compared to Ptenf/fmice (blue lines) at 
days 5 (A) and 50 (B) PI was quantified. Positions of labelled cells were recorded as a cumulative 
frequency. In both genotypes, labelled cells were shown to move up the crypt villus axis between 2 
hours (solid lines) and 24 hours (dashed lines), as indicated by a shift to the right of the cumulative 
frequency curve. At day 50 PI, a significant difference in migration was observed between control 
and Pten-deficient cells (Kolmogorov-Smirnovtest, 99% confidence interval), with Pten-deficient 
cells showing a faster rate of migration up the crypt-villus (asterisk).
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3.2 .8  Akt is activated fo llo w ing  ep ith e lia l Pten deletion
Having established that Pten deficiency results in no obvious perturbation in intestinal 
structure of homeostasis, I next determined whether Pten loss has any effect upon activation of 
the PI3K/Akt pathway within the epithelium.
It is well documented that activation of Akt occurs principally through phosphorylation, 
with phosphorylation at Thr308 being necessary for activation of Akt, and phosphorylation at 
Ser473 being required for its maximal activation (Vivanco and Sawyers, 2002). I therefore 
assessed levels of both total Akt and of the phosphorylated and activated forms of Akt in the 
contexts of Pten deficiency and proficiency.
Total proteins were extracted from epithelial-cell enriched intestinal samples from control 
and Ptenf/f animals at days 5 and 50 PI. Protein extraction was conducted using lysis buffer 
containing protease inhibitors, to prevent degradation of proteins, and also in the presence of 
phosphatase inhibitors, in order to preserve the phosphorylation status of extracted proteins.
Western analysis was then used to assess levels of target proteins. First, Pten status was 
confirmed in samples. This revealed that all Ptenf/f genotypes showed deficiency for Pten protein 
at both timepoints examined, whilst control samples retained Pten protein. Equal loading of 
proteins was confirmed by visualising levels of the housekeeping standard protein, beta-actin, 
which indicated no difference in the amount of protein loaded between samples (Figure 3.13). 
Western analysis was then directed towards the phosphorylation status and total levels of Akt in 
these samples. Levels of Akt phosphorylated at residue Thr308 (pAktThr308) were found to be 
increased in Pten-deficient epithelial samples at both day 5 and day 50 PI, in comparison to 
controls, where pAktThr308 was barely detectable at either timepoint. In contrast to this, levels of 
Akt phosphorylated at residue Ser473 (pAktSer473) were found to be elevated in Pten-deficient 
tissue at both timepoints, but was also found to be high in control samples at day 5 PI, though 
was virtually absent in control samples at day 50 PI. This observation most likely reflects a 
response in the intestine to induction of recombination, and may either be due to treatment of 
mice with beta-naphthoflavone, or perhaps due to cellular expression of Cre recombinase itself. 
This effect is not apparent in controls at day 50 PI, presumably once beta-naphthoflavone or Cre 
activity is no longer present in cells.
Levels of total, unphosphorylated Akt were not found to change with respect to genotype 
or timepoint after induction.
It is therefore clear that, whilst loss of Pten protein does not affect total levels of Akt 
protein, Akt is phosphorylated at residue Thr308 in response to Pten deficiency, both at day 5 and 
day 50 PI. Furthermore, levels of pAktSer473 in Pten-deficient tissue at day 50 PI are elevated
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compared to controls, though at day 5 PI no conclusion can be drawn regarding a difference 
between control and Ptenf/f genotypes.
108
Day 5 PI Day 50 PI
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PTEN
(55kDa)
(3-Act in 
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Figure 3.13: D eletion  o f  Pten results in activation  o f A kt
Western analysis of proteins from epithelial-enriched tissue samples taken from control and 
Ptenf/fanimals at days 5 and 50 PI confirmed loss of Pten protein from the epithelium. Beta- 
actin was used to ensure equal loading of proteins. In samples deficient for Pten, an increase 
in levels of activated (phospho-) Akt was observed (pAktSer473 and pAktThr308). Total levels of 
Akt were found to be unchanged.
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3 .2 .9  D ow nstream  targets  o f A k t a re  n o t activated  fo llow ing  Pten loss
Having found that loss of Pten from the epithelium results in an increase in activation 
status of Akt, I next examined downstream targets of Akt in order to assess the cellular effect of 
Akt activation in the epithelium.
Activation of Akt is known to result in activation of the mammalian target of rapamycin 
(mTOR) pathway (Manning et al., 2002), which is characterised by the phosphorylation of mTOR 
protein itself at residue Ser2448 (Hay and Sonenberg, 2004). To assess the effect of Pten 
deficiency and Akt activation of the mTOR pathway within the intestinal epithelium, IHC was 
performed used an antibody specific to the phospho-Ser2448 form of mTOR (p-mTORSer2448). 
Intestinal tissue sections from control and Ptenf/f animals at day 50 PI were subjected to p- 
mTORSer2448 IHC, and then examined microscopically for any apparent difference in staining 
pattern. Staining was observed to occur mainly at the lumenal surface of cells within the crypt, 
with occasional cells showing strongly positive cytoplasmic staining for p-mTORSer2448 (Figure 
3.14A). No significant difference in staining pattern was observed between control and Ptenf/f 
tissue samples at day 50 PI.
To confirm that mTOR signalling is not activated following epithelial Pten loss, the 
activation status of a target of mTOR, S6 kinase, was examined. IHC for S6 kinase phosphorylated 
at residues Thr421 and Ser424 (pS6KThr421/Ser424) was performed on control and Ptenf/f intestinal 
tissue samples at day 50 PI. Strong nuclear staining for pS6KThr421/Ser424 was observed in tissue of 
both genotypes, and similar to the p-mTORSer2448 staining pattern observed, occasional cells within 
crypts were found to show strong cytoplasmic staining (Figure 3.14B). Again, no difference in 
staining patterns between control and Ptenf/f tissue samples was noted, reflecting the observation 
that mTOR activity is not significantly different between genotypes.
To further assess any changes in the Akt pathway, the expression levels of a number of 
Akt pathway components was determined using Q-PCR analysis. cDNA was made from RNA 
extracted from control and Ptenf/f epithelial-cell enriched tissue samples at day 50 PI. This was 
then used to perform Q-PCR with primers directed towards the genes for SH2-containing inositol 
phosphatase (SHIP), Akt isoforms 1, 2 and 3 (Aktl, Akt2 and Akt3), Tuberous sclerosis genes 1 and 
2 (TSC1 and TSC2), mTOR and eukaryotic initiation factor 4E binding protein 1 (elF4E-BPl).
Expression levels of SHIP were of interest as SHIP is also an inositol phosphatase, and 
modulation of SHIP levels may provide a possible compensatory mechanism to inactivation of 
Pten. However, expression levels of SHIP were found to be unaltered in the context of Pten 
deficiency (Figure 3.15A).
Of the other components of Akt signalling examined, the expression of only one transcript
was found to be significantly altered in the context of Pten loss; Akt3. Average cycle time (±
no
standard deviation) of the product of the Akt3 gene was 10.77±0.10 in controls compared to 
13.30±0.51 in Ptenf/f samples, which is a significant increase of cycle time in Ptenf/f samples 
compared to controls (Mann-Whitney U Test, n=3, p<0.0001). This is equivalent to a 5.78-fold 
reduction in Akt3 transcript in Ptenf/f samples compared to controls. However, the significance of 
this finding is unclear. All other transcripts examined were found not to show any alteration in 
expression levels following deletion of Pten (Figure 3.15A). However, this is perhaps not surprising 
given that activation of the Akt pathway generally occurs through phosphorylation of pathway 
components, rather than modulation of transcription levels (Cully et al., 2006).
Previous work has suggested a role for activated Akt in mediating activation of the Wnt 
pathway in the intestine, particularly in intestinal stem cells (He et al., 2004). As I have shown that 
Akt is activated following loss of Pten, I decided to test the hypothesis proposed by He et al., and 
investigated the activation status of the Wnt signalling pathway following Pten deletion.
Q-PCR directed towards several well-characterised targets of the Wnt pathway was 
performed as described above for components of the Akt pathway. Expression levels of Axin2, c- 
myc and CD44 were found not to be changed in the context of Pten deficiency (Average cycle 
times ± Standard deviation for control versus Ptenf/f samples were Axin-2: 8.23±0.90 Vs 8.57±0.67; 
CD44: 15.42±0.73 Vs 14.4810.31; c-myc: 7.46+0.98 Vs 7.64+0.37), whereas cycle time of CyclinD2 
in controls was found to be significantly reduced compared to Ptenf/f samples (6.37+0.46 Vs 
7.57+0.46) (Mann-Whitney U test, n=3, p=0.08), indicating a reduction of CyclinD2 expression in 
Ptenf/f intestines (Figure 3.15B). This therefore indicates that activation of Akt within the 
epithelium does not result in activation of the Wnt pathway as previously proposed, with no 
increase in expression of Wnt signalling targets observed in Pten-deficient epithelial cells 
compared to controls.
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Figure 3.14: D o w n stream  targets  o f  A k t a re  n o t activa ted  fo llo w in g  Pten deletion
IHC against known targets of Akt signalling was performed to assess activation of the Akt 
pathway. Phospho-mTORSer2448 (A) and phospho-S6 kinaseThr421/Ser424(B) IHC of tissue 
taken from mice at day 50 PI revealed no difference in staining patterns between 
control and Ptenf/f tissue. Scale bars indicate lOOpm.
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Figure 3.15: Q-PCR analysis ofPI3K/Akt pathway components and Wnt signalling components in 
Pten-deficient intestinal epithelium
Quantitative real-time PCR was used to examine transcriptional activation of the PI3K/Akt pathway 
(A) and of the Wnt pathway (B) in epithelial-enriched tissue samples of control (grey bars) and 
Ptenf/f (open bars) mice at day 50 PI. Expression PI3K/Akt pathway components (A) was generally 
found to be unchanged following Pten loss, with the exception of Akt3, which was significantly 
downregulated in Pten-deficient epithelium compared to controls (Mann-Whitney U test, p<0.01). 
Expression of Wnt target genes Axin2, c-myc and CD44 were found to be unchanged in the context 
of Pten deficiency (B), whereas CyclinD2 expression was significantly reduced in the context of Pten 
deficiency (Mann-Whitney U test, p=0.08). Asterisks indicate a significant difference in expression 
between genotypes.
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3.2.10 Pten loss has no effect on multiplicity of intestinal stem cells
Recent work has indicated that inactivation of Pten by phosphorylation may be a feature 
of the intestinal stem cell (He et al., 2004). Furthermore, deletion of Pten from the stromal and 
epithelial cell compartments has recently been shown to lead to tumourigenesis in the intestine, 
which is reported as being due to an increase in number of stem cells (He et al., 2007).
Based on these observations, I next investigated the effects of Pten deletion upon the 
stem/clonogenic cell population more thoroughly.
I previously described that LacZ reporter assays show that the intestinal epithelium 
remains populated with recombined cells at 100 days after induction (Section 3.3.1 and Figure 
3.1). This indirectly indicates that the stem cell which normally drives repopulation of the 
epithelium has undergone recombination. From this, it can be inferred that in experimental Ptenf/f 
tissues, the functional stem cell which drives repopulation of the epithelium is also deficient for 
Pten. This is confirmed by the fact that epithelial deficiency of Pten is maintained at day 50 PI 
(Section 3.3.2).
In order to indirectly examine the number of clonogens present in control and Ptenf/f 
intestinal epithelium, I performed a clonogenic survival assay. Control and Ptenf/f animals at day 
50 PI were irradiated with varying doses of gamma-irradiation. The rationale behind this is that 
crypts will be 'cleansed' of a certain number of clonogenic cells, which are sensitive to DNA 
damage, in a manner proportional to the dose of irradiation (Hendry et al., 1992). Following 
irradiation, intestines are left to repopulate for 72 hours, after which time the intestine is 
harvested. The number of repopulating crypts is then scored per radial circumference of intestine, 
with the assumption that a crypt will only repopulate from a surviving clonogen. An increase in 
repopulation levels at the same dose of gamma irradiation would therefore indirectly indicate an 
increase in the number of clonogens present before irradiation.
Control and Ptenf/f animals were subjected to single doses of lOGy, 12.5Gy or 15Gy 
gamma-irradiation from a caesium source. Average numbers of repopulating crypts per intestinal 
circumference in controls compared to Ptenf/f animals (± standard deviation) were found to be 
117.44110.25 Vs 109.9211.24 at a dose of lOGy, 94.41+11.17 Vs 101.06+7.89 at a dose of 12.5Gy 
and 58.13+14.79 Vs 52.13+7.87 at a dose of 15Gy. At all doses, no significant difference in the 
numbers of repopulating crypts was observed (Mann-Whitney U test, for all comparisons n>4, 
p>0.31) (Figure 3.16). Contrary to previous data, this therefore indicates that the number of 
clonogenic cells present in Pten-deficient epithelium is not significantly different from that in 
control epithelium.
To further explore any changes in the intestinal stem cell population following Pten 
deletion, I then examined the expression of a number of putative stem cell markers.
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Nuclear localisation of the W nt effector beta-catenin has previously been mooted as a 
marker of the intestinal stem cell. Further, localisation of beta-catenin is thought to be controlled 
by the Akt pathway, with increased Akt signalling resulting in increased nuclear beta-catenin, 
which drives stem cell renewal (He et al., 2007). To investigate this in the model presented here, 
IHC against beta-catenin was used to examine the subcellular localisation of beta-catenin in 
control and Ptenf/f tissue samples at day 50 PI. Staining patterns revealed predominantly 
cytoplasmic and cell-surface localisation of beta-catenin in epithelial cells of the crypt in both 
control and Ptenf/f tissues (Figure 3.17A). In both genotypes, occasional cells were observed at the 
very base of the crypt which showed strong nuclear localisation of beta-catenin. These cells may 
represent clonogenic cells, but may equally be paneth cells. Regardless of this, the staining 
patterns observed in control and Ptenf/f intestines were indistinguishable, indicating that nuclear 
localisation of beta-catenin is not affected by epithelial-specific deletion of Pten.
Recent data has proposed that DCAMKL-1 is a potential marker of the intestinal stem cell 
(May et al., 2008). IHC against DCAMKL-1 was performed on intestinal tissue sections of control 
and Pten-deficient tissue at day 50 PI. In both genotypes, a number of cells stained positively for 
DCAMKL-1 which were located on the villus, and morphologically appeared to be enteroendocrine 
cells. However, a small number of cells were also observed to stain within the crypt, at 
approximately position +4 above paneth cells. Presumably, it is this population of cells which May 
et al. identified as being the intestinal stem cell. DCAMKL-1 staining patterns within the crypt 
were identical in Pten-deficient intestines compared to controls, again indicating no expansion of 
the intestinal stem cell population, or at least no expansion in DCAMKL-l-positive cells (Figure 
3.17B).
Finally, Q-PCR was used to analyse expression patterns of other recently proposed stem 
cell markers in Pten proficient compared to Pten deficient tissue. As previously, epithelial-cell 
enriched tissue samples were used to generate cDNA for analysis. Q-PCR directed at the putative 
stem cell markers Musashi-1 (Potten et al., 2003), Bmil (Sangiorgi and Capecchi, 2008) and Lgr5 
(Barker et al., 2007) was performed. Average cycle times needed for amplification of products in 
control compared to Ptenf/f samples (± standard deviation) were: 14.89±1.67 Vs 16.52±0.86 for 
Musashi-1, 11.1311.17 Vs 11.23+0.16 for Bmil and 14.22+0.50 Vs 15.25+1.23 for Lgr5 (Figure 
3.17C). In no instance was a significant difference in expression of any of these markers detected 
in Ptenf/f compared to control tissue (Mann-Whitney U test, n=3, p>0.38). Again, this indicates 
that there is no significant expansion of the stem cell compartment in Pten-deficient tissue 
compared to controls. These data are therefore at odds with published data, in that I show that 
deletion of Pten from the epithelial cell compartment (and from the clonogens maintaining the 
epithelium) does not result in an increase in the number of clonogenic cells or in putative stem 
cells within the intestine.
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Figure 3.16: C lonogenic su rv iva l assay reveals  no d ifference in e p ith e lia l repopu la tion  
fo llo w in g  g a m m a -irra d ia tio n  in th e  co n tex t o f  Pten deficiency
Control (grey bars) and Ptenf/f (white bars) animals at day 50 PI were subjected to varying 
doses of gamma -irradiation (10,12.5 or 15Gy) in order to ablate clonogenic cells from the 
intestine. Animals were culled 3 days after exposure, and repopulation of the epithelium 
assessed by quantification of the numbers of repopulating crypts. No significant difference 
in numbers of surviving crypts was observed between control and experimental mice 
across all doses of irradiation (Mann-Whitney U test, p>0.31 for all comparisons), indirectly 
indicating that the number of clonogens in Pten-deficient intestines is the same as that in 
controls. Error bars indicate standard deviation.
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F ig u re  3 .1 7 :  No difference in expression o f pu ta tive  stem cell markers fo llow ing  Pten loss
IHC fo r nuclear b e ta -ca ten in  (A) and DCAMKL-1 (B) was perform ed on tissue sections from  
contro l and P tenf/f m ice a t day 50 PI to  assess stem  cell num bers. No d ifference  in staining  
patterns b e tw e e n  contro l and P tenf/f tissue was observed. Scale bars indicate 100pm . 
Q u an tita tive  re a l-tim e  PCR on contro l (grey bars) and Ptenf/f (w h ite  bars) ep ithelia l-enriched  
tissue sam ples at day 50  PI revealed no significant d ifference in expression o f th e  putative  
stem  cell m arkers M usashi-1 , B m il o r Lgr5 (M a n n -W h itn e y  U test, p>0 .38 ). Error bars 
indicate standard dev ia tion .
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3.2.11 Pten is not required for normal embryonic development of the intestinal epithelium
In order to assess a potential role for Pten during development of the intestinal 
epithelium, a number of control and Ptenf/f animals were induced in utero at day E12.5 by 
treatment of pregnant females with beta-naphthoflavone. After birth, control and Ptenf/f pups 
were aged to approximately 50 days before being culled and intestines examined. In no cases 
were any lesions of the intestine apparent macroscopically at dissection.
The LacZ reporter construct was used as previously described in order to confirm that 
recombination occurred within the intestine of experimental Ptenf/f pups when induced in utero, 
and that recombined cells remained present in the adult intestine. Intestines were found to stain 
blue following exposure to X-gal substrate, indicating the presence of recombined cells. 
Recombination frequency was noted to be much lower than that observed in animals induced as 
adults (Figure 3.18A).
Many of the phenotypes observed in Ptenf/f animals induced as adults were also found to 
be present in animals induced during development, including hepatomegaly, susceptibility to 
lymphoma and behavioural defects. In addition to this, Ptenf/f in utero-induced animals were also 
found to have a more shaggy, ruffled appearance to their coat compared to controls (Figure 
3.18B). This is again a previously reported phenotype of Pten deficiency, resulting from 
recombination occurring within the skin (Backman et al., 2004).
IHC against Pten protein was used to confirm that recombination did indeed result in loss 
of Pten protein from the epithelium. As previously, control animals were found to have 
widespread staining for Pten in all cell layers of the intestine. In comparison to this, in utero- 
induced Ptenf/f animals were found to show specific loss of Pten from the epithelial cell layer 
(Figure 3.18C). Levels of Pten loss from the epithelium as assessed by IHC were found to 
approximately reflect the level of recombination identified by staining for LacZ activity. Tissue 
sections stained immunohistochemically against Pten protein were used to microscopically assess 
the histological structure of Pten-deficient tissue. Pten deficient tissue was indistinguishable from 
surrounding tissue which was wild-type for Pten staining, and was indeed also indistinguishable 
from intestinal tissue samples obtained from controls. No perturbations in gross structure or 
organisation of the epithelium were apparent in Pten deficient tissue. Furthermore, IHC against 
the proliferation marker Ki67 was used to examine the location and numbers of proliferating cells 
in tissue which had lost Pten during development and that which had remained proficient for Pten 
(Figure 3.18D). The proliferative compartment was found to be correctly localised and of 
approximately the correct size in tissue deficient for Pten in comparison to controls.
These data therefore indicate that Pten is not needed for normal embryonic development 
of the intestinal epithelium from day E12.5 of life. Loss of Pten in utero does not result in any 
perturbation in intestinal structure or proliferation status of cells in the adult animal.
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Figure 3 .18 : Loss of Pten during development of the intestine does not perturb epithelial structure
Induction of Pten loss in utero at day E14.5 was used to determine a role for Pten in development of the 
intestinal epithelium. The LacZ reporter (A) reveals recombination levels much lower than that in mice 
induced as adults. In addition to the phenotypes outside the intestine previously reported, in utero induced 
Ptenf/f mice were also observed to have a shaggy coat compared to controls (B). IHC against Pten was used 
to confirm loss of Pten protein from the epithelium (C). Staining patterns reflect the lower rate of 
recombination, with a large number of Pten-proficient (solid arrows) as well as Pten-deficient (open 
arrows) crypts present in Ptenf/f mice. Histology and IHC against Ki67 (D) revealed no changes in the 
structure of the intestine or organisation of the prolifertive zone in Ptenf/f animals. Scale bars indicate 
100pm.
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3.3 Discussion
The role of Pten in suppressing tumourigenesis in humans is well established, being 
originally identified based on its frequent mutation in a number of sporadic malignancies (Li and 
Sun, 1997, Li et al., 1997, Steck et al., 1997). Pten exerts its anti-tumourigenic effect through 
antagonism of Akt activation (Maehama and Dixon, 1998), the normal effect of which is to 
promote cell survival, cell cycling and growth (Vivanco and Sawyers, 2002). Heterozygous 
inactivation of the Pten gene in mice has confirmed its role as a tumour suppressor gene in vivo 
(Podsypanina et al., 1999, Di Cristofano et al., 1998, Suzuki et al., 1998). This, together with 
evidence from other in vivo studies indicates that Pten suppresses neoplasia specifically within 
the intestine (Lu et al., 2007, He et al., 2007). These lines of evidence therefore provide 
compelling evidence that Pten functions to suppress tumourigenesis within the intestine. 
However, these studies fail to examine the differential effect of Pten loss from distinct cell 
compartments within the intestine.
I therefore sought to examine the effects of Pten in the adult murine intestine, specifically 
from the epithelial cell compartment. To achieve this, a Cre-LoxP-based approach was employed, 
using LoxP-targeted Pten alleles and an inducible form of Cre recombinase which directs high- 
level recombination to the intestinal epithelium (Ireland et al., 2004).
Following generation of Ptenf/f and control animals, I first set about confirming that Pten 
is deleted from the intestinal epithelium following induction of Cre recombinase activity by 
treatment with beta-naphthoflavone. Recombination within the intestine was assessed using the 
ROSA26 reporter allele, and visualised by X-gal staining for beta-lactosidase activity. This 
confirmed that recombination occurs in almost 100% of epithelial cells regardless of Pten status. 
Furthermore, recombination within the epithelium was found to be stable, with recombined cells 
populating the crypt-villus at extended timepoints after induction of Cre activity. This indicates 
firstly that recombined cells are not deleted from the epithelium, and secondly that the stem 
cell(s)/clonogens responsible for normal repopulation of the epithelium has undergone the 
recombination event. Loss of Pten protein in Ptenf/f animals following induction of recombination 
was also confirmed, both by IHC and by western analysis. IHC on tissue sections revealed near- 
100% loss of Pten from the epithelium, consistent with the level of recombination indicated using 
the LacZ reporter construct. Western analysis on proteins obtained from tissue samples enriched 
for epithelial cells further supported the fact that induction results in loss of Pten protein from the 
epithelium. Finally, Q-PCR analysis of epithelial-enriched samples indicated a significant reduction 
in levels of Pten expression in the intestine following recombination. This therefore clearly 
indicates that, following induction, efficient recombination occurs within the intestinal 
epithelium, which results in rapid loss of both Pten transcript and Pten protein.
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I also report that, in Ptenf/f animals, a number of phenotypes were manifest in tissues 
outside the intestine. All of the observed phenotypes are previously reported consequences of 
Pten loss, including hepatic steatosis (Horie et al., 2004, Stiles et al., 2004), predisposition to 
lymphoma (Lu et al., 2007, Suzuki et al., 1998, Podsypanina et al., 1999, Di Cristofano et al., 1998) 
and endometrial hyperplasia (Lu et al., 2007, Podsypanina et al., 1999). Whilst these observations 
are not novel, they serve to confirm that the targeted Pten allele is truly a null allele, and that 
recombination driven by this system in other tissues results in a clear effect upon phenotype 
consistent with that previously observed.
3.3.1 Epithelial Pten is not required for normal intestinal homeostasis
Having established that the Pten allele in use here is a true null allele, and that Pten is lost 
from the intestinal epithelium in Ptenf/f animals, I next set out to examine the effect of Pten loss 
on normal intestinal homeostasis. As Pten is the principal negative regulator of the PI3K/Akt 
pathway, one could predict that Pten loss would result in activation of this pathway, which would 
result in increased proliferation and inhibition of apoptosis in the epithelium.
In contrast to this hypothesis, I report here that deletion of Pten from the epithelium has 
no dramatic effect upon homeostasis up to 50 days after induction. No perturbations in gross 
histology were identified, and no change in proliferative status was observed, either from anti- 
Ki67 IHC or from scoring of mitotic index from H&E-stained sections. Levels of apoptosis were 
unchanged in Pten-deficient tissue, even after irradiation, despite the fact that Pten is implicated 
in maintaining stability of the pro-apoptotic factor, p53 (Freeman et al., 2003). Qualitative and 
quantitative analysis of the normal differentiation program of epithelial cells revealed that the 
presence, location and frequency of mature cell types was unaffected by Pten loss. Finally, 
analysis of the migratory ability of Pten-deficient epithelial cells revealed no dramatic alteration in 
migration. Work in cell culture has indicated that Pten functions as a suppressor of cell migration 
(Gu et al., 1999). In agreement with this, I do report a slight increase in migration of Pten-deficient 
cells at day 50 PI. However this effect is relatively subtle, and is not observed at day 5 PI despite 
the fact that I have shown the epithelium to be deficient for Pten at this timepoint. This suggests 
that the observed increase in migration may be an experimental artefact.
Having observed no dramatic phenotype in Pten-deficient tissues I next investigated the 
activation status of Akt and its downstream targets. Western analysis revealed that Akt was 
indeed activated by phosphorylation following Pten loss, as indicated by increased levels of both 
pAktThr308 and pAktSer473 at day 50 PI. However, IHC against the downstream targets of Akt, 
phospho-mTOR and phospho-S6 Kinase, revealed no increase in activation. Q-PCR analysis was 
used to examine any effects on expression of PI3K/Akt pathway components, though no
121
significant changes were observed. Finally, as Pten has previously been proposed to control 
activity of the Wnt pathway in the intestine through activated Akt (He et al., 2004), I examined 
activity of the Wnt pathway by analysing expression of a number of well-characterised Wnt target 
genes. Expression of each of these targets (Axin-2, CyclinD2, c-myc, CD44) was either found to be 
unchanged or reduced following Pten loss, indicating no activation of the Wnt pathway in the 
context of Pten deficiency.
Taken together, these data therefore indicate that, despite the fact that deletion of Pten 
results in a detectable increase in activation of Akt, this does not translate into any cellular 
effects. This may imply that a 'threshold' effect operates with respect to Akt activation in the 
intestine. The observed increase in Akt activity following Pten loss is clearly not sufficient for 
activation of downstream targets of Akt to occur. It may be the case that simple removal of Pten 
results in a level of activation of Akt which is below the threshold required for it to have a 
significant effect upon its targets. This notion also fits with the known role of Pten within the 
PI3K/Akt pathway. Pten is a 'permissive' tumour suppressor, in that it suppresses activation of the 
pathway (Maehama and Dixon, 1998) but does not directly activate it. Thus, if the pathway itself 
is not activated upstream of Pten, it can be imagined that removal of Pten will not have a major 
effect upon Akt activity. Thus, if Akt pathway activity is normally low within the intestinal 
epithelium (as is likely to be the case based on western analysis of pAktThr308 and pAktSer473 levels 
in control tissue), removal of Pten is unlikely to have any cellular effects. This means that the 
tumour suppressive function of Pten will only become relevant in a PI3K/Akt pathway-activated 
environment.
3.3.2 Pten loss in the epithelium does not alter stem cell number or result in immediate 
tumourigenesis
Evidence from the literature indicates that Pten plays a role in stem cell maintenance in a 
number of tissues, including the prostate (Wang et al., 2006), lung (Yanagi et al., 2007) and 
haematopoietic system (Zhang et al., 2006). Recent data has suggested that the intestine is no 
exception, with Pten reported to control multiplicity of the intestinal stem cell. He et al. (He et al.,
2007) report that conditional deletion of Pten from the epithelial and stromal cell compartments 
of the adult murine intestine results in an increase in stem cell number, which in turn causes 
polyp formation in the intestine within 3 months following Pten loss. Based on these data, it 
would therefore be predicted that, in the model I present here, deletion of Pten will cause an 
expansion of the stem cell population within the crypt, and will result in tumourigenesis.
To address these predictions, I first determined whether any increase in intestinal stem 
cell number was evident following Pten loss. Firstly, I performed a clonogenic assay in order to
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indirectly determine the relative number of clonogenic cells in Pten-deficient tissue compared to 
control tissue. This showed that there was no alteration in repopulation of the epithelium 
following irradiation, indicating no change in the number of clonogens in Pten-deficient tissue. 
The caveat with this experimental approach is that it is not a direct method for examination of 
stem cell number. Given that recent work has identified a number of good candidate markers of 
the ISC, I next attempted to examine the effect of Pten deletion upon the stem cell compartment 
more directly. Nuclear beta-catenin has been proposed as a marker of the ISC, and has been 
suggested to drive stem cell replication through activity of the Wnt pathway, mediated by 
inactivation of Pten (He et al., 2004). Based on this data, I would therefore expect to see an 
increase in nuclear beta-catenin-positive cells following Pten loss. However, in Pten-deficient 
tissue I observe no change in staining pattern compared to control tissue, indicating that this 
notion does not hold true in this model. Another recently proposed marker of the intestinal stem 
cell is DCAMKL-1, which labels occasional cells at position +4 within the crypt (May et al., 2008). 
IHC against DCAMKL-1 revealed no alteration in distribution or increase in number of positively- 
labelled cells in the crypts of Pten-deficient tissue compared to controls, again indicating no effect 
upon the stem cell compartment. Finally, Q-PCR was used to assess the expression of a number of 
other proposed ISC markers; Musashi-1 (Potten et al., 2003), Bmil (Sangiorgi and Capecchi, 2008) 
and Lgr5 (Barker et al., 2007). This indicated again that no significant increase in expression of 
these reportedly stem cell-specific genes was observed in Pten-deficient epithelium, confirming 
no expansion of the stem cell population.
These observations are compelling evidence for the fact that epithelial Pten deletion does 
not modulate the stem cell compartment in the intestine. However, they are also clearly at odds 
with the recently published study of He et al. (2007). In their study, He et al. use the Mxl-Cre 
construct to drive deletion of Pten from the adult intestine. Although not clearly stated in their 
paper, previous work has shown that M xl-Cre drives recombination both in the epithelial and 
stromal cell populations within the intestine (Schneider et al., 2003). This experimental approach 
is therefore different to that presented here, as I have used the AhCre construct to drive Pten 
deletion, the expression of which is tightly restricted to the epithelial cell layer (Ireland et al., 
2004). Together, the data published by He et al. and the data presented here indicate a 
differential role for Pten in regulation of the stem cell compartment and suppression of 
tumourigenesis depending upon the cell type it is lost from. Epithelial-specific deletion of Pten has 
no immediate effect upon intestinal stem cell homeostasis or susceptibility to tumourigenesis, 
whereas deletion of Pten from both the epithelium and underlying stroma causes stem cell 
expansion and rapid tumourigenesis (See Figure 3.19).
What remains unclear from these studies is whether stromal deficiency of Pten alone is 
sufficient for perturbation of the stem cell niche, or whether the stem cell itself and/or its
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surrounding epithelial cells must also be Pten-deficient to allow manifestation of the observed 
phenotypes. Several lines of evidence have recently indicated that tissue-specific deletion of 
tumour suppressor genes outside of the epithelial cell population (and indeed, outside of the 
intestine) can have a profound effect upon homeostasis of intestinal epithelial cells themselves. 
Kim et al. (2006) have previously reported that, whilst deletion of the tumour suppressor SMAD4 
from the intestine itself has no effect upon intestinal homeostasis, deletion specifically from T- 
cells results in rapid intestinal polyposis. This is found to occur in intestinal tissue which is shown 
to remain wild-type for SMAD4. It is therefore clear that aberrant signalling originating in 
infiltrating immune cells can have a significant impact upon normal epithelial and/or stromal cells. 
Furthermore, a very recent paper from Tomi Makela's group has investigated the effects of 
mesenchymal-specific deletion of the tumour suppressor gene Lkbl/STK ll (Katajisto et al., 2008). 
They have specifically deleted Lkbl from intestinal smooth muscle cells, but not from intestinal 
epithelial cells. Mesenchymal Lkbl deletion is shown to cause in an increase in SMAD signalling 
within the stroma, which in turn causes increased proliferation in overlying epithelial cells. This 
results in polyp formation similar to that observed in constitutive Lkbl+/‘ mice. This argues for the 
fact that the loss of heterozygosity (LOH) event which initiates intestinal tumour formation in 
Lkbl+/ mice may actually occur within a mesenchymal cell, and not necessarily in an epithelial 
cell.
Parallels between this data and the information available for Pten in intestinal 
tumourigenesis can be drawn. Intestinal cancer has been shown to be a feature of constitutive 
Pten+/_ mice (Di Cristofano et al., 1998), yet I report here that epithelial-specific deletion of Pten 
does not perturb the intestine. This suggests that the tumour initiating event in Pten+/' mice may 
occur within a non-epithelial cell type of the intestine. The data of He et al. (2007) would support 
this being within an underlying stromal cell. Thus, it could be concluded that normal Pten activity 
(and hence regulated levels of Akt activity) within stromal cells is critically important for both 
control of intestinal stem cell renewal and also for suppression of intestinal tumourigenesis.
It could also be argued that I did not observe any intestinal tumours here due to a time 
effect; He et al. report tumourigenesis at 3 months following Pten loss, whereas I have only 
examined mice up to a timepoint of 50 days after induction. In my study, examination of mice 
older than 50 days was generally not possible due to phenotypes caused by loss of Pten in other 
tissues. However, in the event that tumourigenesis would have been apparent in my model at 
extended timepoints after induction, I would expect that perturbation in epithelial homeostasis, 
early signs of neoplasia and even perhaps even some early lesions would have been evident at 
day 50 PI. These were never observed, which therefore implies that tumourigenesis is unlikely to 
occur in this model, even if I was able to age mice up to 3 months after induction.
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Figure 3.19: Epithelial versus Stromal deletion of Pten in the intestine
D e le tio n  o f  P te n  s p e c ific a lly  fr o m  th e  e p ith e lia l cell c o m p a r tm e n t (B ) is sh o w n  h e re  n o t  
to  cau se a p e r tu r b a t io n  in in te s tin a l h o m e o s ta s is  c o m p a re d  to  th e  w ild - ty p e  s ta te  (A ), 
an d  tu m o u r ig e n e s is  is n o t  o b s e rv e d  up to  5 0  days a f te r  loss o f P te n . In c o n tra s t to  th is , 
He et al. (2 0 0 7 )  h a v e  s h o w n  th a t  d e le t io n  o f  P ten  fro m  b o th  th e  e p ith e lia l an d  s tro m a l 
cell c o m p a r tm e n ts  re s u lts  in an  e x p a n s io n  o f  s te m  cells w ith in  th e  in te s tin e , w h ic h  
causes ra p id  tu m o u r ig e n e s is  (D ). W h a t  re m a in s  u n c le a r fro m  th e s e  s tu d ie s  is w h e th e r  
d e le t io n  o f  P te n  fr o m  th e  s tro m a  a lo n e  (C) is s u ffic ie n t to  p e r tu rb  in te s tin a l h o m eo s tas is  
an d  in it ia te  tu m o u r ig e n e s is .
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3.3.3 Pten is not required for in utero  development of the intestinal epithelium
Many tumour suppressor genes are absolutely required for normal embryonic 
development, and indeed Pten is no exception, with homozygous inactivation of the gene 
resulting in early embryonic lethality (Di Cristofano et al., 1998, Podsypanina et al., 1999, Suzuki et 
al., 1998).
Having established that deletion of Pten has no overt effect upon the adult intestinal 
epithelium, I next examined whether deletion of Pten specifically in the intestine during 
development would have any effect upon normal establishment of the epithelium. This was 
achieved by inducing Cre activity in utero at day E12.5, and examining intestines of mice at 
approximately day 50 of post-natal life. Analysis of LacZ activity was used to confirm that 
recombined epithelial cells remained present in the adult animal, indicating that areas of the 
epithelium were Pten-deficient throughout the latter period of embryonic development. Loss of 
Pten protein was confirmed using IHC, and levels of Pten-deficient tissue were found to 
approximately recapitulate the recombination frequency observed using the ROSA26 reporter 
allele. However, despite deletion of Pten during development, intestines were found to appear 
histologically normal, with no evidence of epithelial overgrowth, as would be predicted from an 
increase in Akt signalling. Furthermore, Ki67 IHC confirmed that there was no gross expansion or 
relocalisation in the proliferative compartment of the epithelium. Thus it is clear that antagonism 
of PI3K/Akt signalling through Pten is not necessary for normal development of the epithelium 
from embryonic day 12.5. This either indicates that development of the epithelium is not sensitive 
to levels of Akt signalling, or alternatively, as described above, simple removal of Pten from the 
epithelium without additional activation of the Akt pathway is not sufficient to activate Akt to a 
level at which cellular effects are produced.
3.3.4 Summary and Future Directions
In summary, three major conclusions can be drawn from the data I present in this 
chapter. First, Pten appears to be redundant with respect to epithelial homeostasis and epithelial 
Pten deficiency does not result in tumourigenesis up to 50 days after induction. Secondly, in 
contrast to published data, I find that Pten has no overt effect on the intestinal stem cell 
population. And finally, I find that Pten is not required for normal development of the intestine 
from day E12.5 of development.
These conclusions raise a number of interesting questions with regard to both Akt 
signalling in the intestine and regarding the role of Pten in epithelial-stromal interactions and the 
intestinal stem cell, and provide a number of avenues which warrant further investigation.
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My data presented here suggest that a threshold level of Akt signalling must be reached 
to produce phenotypic consequences within the intestine, and that straightforward removal of 
Pten is not sufficient for this threshold to be reached. Thus, analysis of the effect of Pten deletion 
in the context of activated Akt signalling would confirm whether this 'threshold' hypothesis holds 
true. This could potentially be achieved by activation of the Akt pathway using an exogenous 
agent, for example insulin or growth factors; however, such agents are likely to have a number of 
off-target effects. Alternatively, genetic manipulation could be employed to more specifically 
activate the PI3K/Akt pathway, for instance using constitutively active forms of PI3K itself. Such 
investigation would reveal whether activation of Akt signalling specifically in the intestinal 
epithelium will result in any consequences upon normal homeostasis, or whether the intestinal 
epithelium is refractory to the effects of activated Akt.
Clearly one major caveat of the work I describe here is that I have only analysed the 
effects of Pten deficiency up to 50 days. Given that tumourigenesis is observed by He et al. in their 
Pten-deficient model at 3 months after Pten loss, examination of intestines at longer timepoints 
after Pten loss would certainly be warranted in the system I present here. However, as described, 
this is precluded by the Cre transgene I have used, which also drives recombination in other 
tissues, causing over-riding phenotypes outside the intestine. In order to circumvent these 
problems, another transgene expressing Cre recombinase would need to be used, which shows 
more tightly regulated expression following induction.
The implied phenomenon of stromal loss of Pten initiating stem cell expansion and 
tumourigenesis in the intestine also needs to be confirmed. This could be unequivocally proven 
through use of a Cre recombinase which is expressed only within mesenchymal cells of the 
intestine, such as that used by Katajisto et al. (2008). If this results in tumourigenesis, it would 
indicate that stromal loss of Pten does indeed provide an initiating event for intestinal cancer. If 
this does not result in tumourigenesis, then further questions are raised with regard to whether 
the entire epithelium overlying Pten-deficient stroma also needs to lose Pten for tumourigenesis 
to ensue, or whether Pten deletion specifically from the intestinal stem cell is sufficient. ISC- 
specific Pten deletion could potentially be achieved using a transgene expressing Cre driven by 
the promoter of one of the recently proposed ISC markers, such as Bmil (Sangiorgi and Capecchi,
2008) or Lgr5 (Barker et al., 2007).
Finally, the fact that Pten is observed to be mutated in a significant proportion of sporadic 
cancers, yet apparently plays a less significant role in tumour initiation, suggests that loss of Pten 
may be a late-stage event in the 'multi-step' model of tumour progression as proposed by Fearon 
and Vogelstein (Fearon and Vogelstein, 1990). Thus, it would also be pertinent to examine the 
role of epithelial Pten in an intestinal tumour predisposition model, such as the ApcMIN mouse.
127
This would allow establishment of Pten as a suppressor of tumour progression rather than tumour 
initiation within the intestine.
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Chapter 4: Analysing the long-term effects of Pten deficiency in the 
intestine using AhCreER1
4.1 Introduction
The role of PTEN in suppression of tumourigenesis in the intestine has been well 
established in a number of transgenic mouse models (Di Cristofano et al., 1998, Lu et al., 2007, He 
et al., 2007). However, in Chapter 3, I describe work indicating that, surprisingly, loss of Pten from 
the murine intestinal epithelium does not immediately result in tumourigenesis. I found Pten 
deletion to have no effect on homeostasis of the epithelium, with respect to gross structure, 
proliferation, migration and differentiation of cells. Furthermore, I have shown that Pten loss does 
not alter the epithelial stem cell compartment, as would be predicted from evidence in the 
literature.
The major caveat in this work was that, due to over-riding phenotypes in tissues other 
than the intestine, analysis of the effects of very long term Pten loss from the intestinal 
epithelium was not possible. The most problematic of these phenotypes, forcing premature 
culling of many AhCre+;Ptenf/f animals and precluding analysis of Pten loss past 50 days after 
induction, was that of behavioural abnormalities and ataxia. This was presumably caused by 
spontaneous activation of the AhCre transgene and deletion of Pten in the brain during 
development, as a similar phenotype has previously been reported (Backman et al., 2001).
Background activation of Cre expression is a commonly reported problem with Cre-Lox 
transgenesis, though has also been exploited as a useful characteristic of the system, delivering 
low-level recombination to selected tissues, such as the prostate (Pearson et al., 2008). In order 
to circumvent problems with uninduced expression of transgenes, more tightly regulated forms of 
Cre recombinase have been developed. One such example of this is the dually-regulated AhCreER1 
transgene, the activity of which is controlled both at the transcriptional level and at the post- 
translational level (Kemp et al., 2004). As with AhCre, transcriptional control is achieved using the 
inducible CYP1A1 promoter, which is activated in response to exposure to aryl hydrocarbons such 
as beta-naphthoflavone (Ireland et al., 2004, Campbell et al., 1996). However, in the case of 
AhCreER1, this drives expression of a Cre-Estrogen receptor fusion protein. The estrogen receptor 
domain of the fusion protein, when unbound, sequesters Cre in the cytoplasm, rendering it 
inactive. The Estrogen receptor is modified such that it binds to the estrogen analog Tamoxifen 
with high affinity, but does not respond to endogenous estrogens. Exogenous treatment with 
Tamoxifen is therefore needed to permit entry of Cre into the nucleus and thus allow 
recombination. As such, problems with uninduced activation of Cre recombinase are avoided.
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In this chapter, I aim to make use of this more tightly regulated form of Cre, AhCreER7, in 
order to examine the effects of Pten loss specifically from the epithelium at timepoints longer 
than 50 days, the latest timepoint previously examined using AhCre.
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4.2 Results
4.2.1 Low-level recombination in the intestinal epithelium following induction of AhCreER1
Previous reports have indicated that treatment of animals bearing AhCreER1 with both 
beta-naphthoflavone and Tamoxifen drives expression of cre recombinase within epithelial cells 
of the intestine (Kemp et al., 2004). In order to ensure that this was the case in the strain of mice I 
was using, I first generated animals bearing both the AhCreER7 transgene and the ROSA26 LacZ- 
expressing reporter allele (Soriano, 1999). Animals were induced by treatment with beta- 
naphthoflavone and Tamoxifen, administered in a combined intraperitoneal injection at a dose of 
80mg/kg, which was repeated daily for four consecutive days (Section 2.1.3.3). At day 7 after 
induction, animals were culled, intestines removed and whole-mounted and subjected to X-gal 
staining as described (Section 2.2.6). Induced animals bearing both the AhCreER7 transgene and 
the ROSA26 LacZ reporter allele were found to bear blue-stained epithelial cells within both the 
crypt and villus of the small intestine, indicating recombination in a proportion of epithelial cells. 
Animals lacking the AhCreER7 transgene did not show any background blue staining of cells, 
indicating that recombination had not occured in these tissues (Figure 4.1A). Examination of X-gal 
stained whole intestines from induced AhCreER7+;LacZ+ animals indicated that levels of 
recombination vary along the longitudinal axis of the intestine. Recombination was observed to 
occur with the highest frequency at the end of the intestine closest to the stomach, with a gradual 
decrease in the number of positively-stained epithelial cells along the length of the intestine 
(Figure 4 .IB). At the very distal end of the small intestine and within the colon, recombination 
within the epithelium was found to be rare, but not absent. Based on these findings, all future 
analyses performed upon intestines of animals bearing the AhCreER7 transgene were either 
performed on comparable regions of the small intestine, or else recombination status of the 
epithelium was first confirmed.
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Figure 4.1: Analysis o f recombination in the intestine driven by AhCreER7
The ROSA26 LacZ reporter allele was used to confirm that induction of AhCreER7 drives recombination 
within the intestinal epithelium. Animals bearing the AhCreERTand the LacZ reporter transgene were 
induced by treatm ent with 4 consecutive daily doses of 80mg/kg beta-naphthoflavone and tamoxifen in 
one combined intraperitoneal injection. At day 7 PI, recombination was assessed by staining of whole- 
mounted intestines with X-Gal, which is converted from colourless to blue in recombined cells 
expressing the LacZ reporter. Levels of recombination were observed to be variable between individual 
mice, but was typically found to occur in approximately 50% of epithelial cells (A). Mice lacking the 
AhCreER7 transgene did not show any background LacZ activity. Levels of recombination were observed 
to vary along the intestine of induced mice (B). Recombination was found to be most frequent in the 
small intestine, in the region proximal to the stomach (S), with levels of recombination decreasing along 
the length of the small intestine to the end proximal to the caecum (C). Recombination in the colon was 
noted to be rare, with no change in distribution of recombined regions along the length of the colon 
from caecum (c) to anus (a).
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4.2.2 Ptenf/f animals show a reduced lifespan compared to controls
In order to examine the effects of long-term epithelial-specific deletion of Pten, an aging 
cohort study was designed and performed. Animals bearing the AhCreER1 transgene and those 
bearing the LoxP-targeted Pten alleles (Suzuki et al., 2001) were interbred in order to generate 
both AhCreERT+;Ptenf/f experimental animals (herein referred to as 'Ptenf/f') and AhCreERT+;Pten+/+ 
controls (referred to as 'WT'). Large cohorts of Ptenf/f (n=30) and WT (n=29) mice were induced as 
described above, at approximately 10 weeks of age. These mice were then aged, whilst being 
closely monitored for signs of ill-health. At the point where animals were found to be sick, they 
were culled and dissected. The majority of Ptenf/f animals were found to display abnormal 
swelling of the abdomen prior to death. Symptoms of intestinal disease (rectal prolapse and 
bleeding, anaemia) were only very rarely observed in Ptenf/f animals before culling.
Upon dissection, many Ptenf/f animals analysed were noted to have abnormal livers 
compared to WT controls (18 of 25 animals analysed), with livers appearing enlarged and pale, 
and in many cases having a 'spotted' appearance to the surface. In approximately half of these 
cases, macroscopic lesions within the liver were also clearly identifiable, appearing as solid white 
masses (9 of 18 animals which showed liver abnormalities). A large proportion of Ptenf/f mice 
were also noted to bear abnormalities of the male genitourinary system (16 of 22 animals 
analysed), of which similar lesions were not seen in WT controls. Lymphoma was noted to occur in 
one Ptenf/f animal, which was never observed in controls. Finally, 11 out of 24 Ptenf/f animals 
analysed were noted to bear macroscopic, pedunculated lesions of the intestinal mucosa which 
were found to be present in both the small and large intestine.
Kaplan-Meier survival analysis was performed for both the Ptenf/f experimental cohort 
and the WT control cohort (Figure 4.2). This revealed WT animals to have a median survival time 
of 801 days after induction. In comparison, the median survival time of Ptenf/f animals was 407 
days. This represents a significant reduction in lifespan of Ptenf/f animals compared to WT controls 
(p<0.001, X2=54.61, DF=1).
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Figure 4.2: Reduced survival ofPtenf/f animals compared to controls
Large cohorts of control (WT) and experimental (Ptenf/f) animals were induced and aged whilst being 
monitored for signs of disease. Animals were culled when moribund, and Kaplan-Meier survival was 
performed. Experimental Ptenf/f animals were observed to have a much reduced survival probability 
compared to controls, and had a reduced median survival time of 407 days compared to that of controls, 
which was 801 days. Reduction in survival probability in experimental animals compared to controls was 
found to be highly statistically significant (p<0.001, x2=54.61, DF=1).
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4.2.3 Multiple tissue phenotypes associated with Pten deficiency
Having determined that Ptenf/f animals show a reduced lifespan compared to WT 
controls, and that phenotypes in a number of tissues are present, I next compared tissue sections 
from control and Ptenf/f animals in order to establish the nature of these phenotypes.
Examination of H&E-stained sections of the male genitourinary tract of Ptenf/f and WT 
animals revealed that Ptenf/f animals were susceptible to lesions of the prostate. A range of 
lesions were identified, which included prostate intraepithelial neoplasia (PIN) and 
adenocarcinoma of the prostate (Figure 4.3). Similar pathologies were not noted in tissue sections 
of WT mice.
Given that macroscopic assessment of the liver had clearly identified lesions upon 
dissection, H&E-stained sections of the liver were closely examined for abnormalities. Striking 
steatosis of the liver was apparent in Ptenf/f animals, apparent both as microvesicular steatosis 
and macrovesicluar steatosis (Figure 4.3). A range of other lesions of the liver were also apparent, 
arising within epithelial cells of the biliary system (8 out of 24 animals). Benign biliary 
microhamartoma (also known as Von Meyenberg's complexes) were commonly observed within 
Ptenf/f livers. In a minority of cases, cholangiocarcinoma was also found to develop (2 of 24 
animals). These lesions were noted to be variable in their histology. Some lesions were 
histologically typical of human cholangiocarcinoma, clearly comprised of ductal cells surrounded 
by a characteristically pale, desmoplastic stroma. Other lesions were less clearly defined, having a 
mixed histology. Cells comprising such lesions were found to be more of a mixed ductal-like and 
hepatocyte-like appearance, and bore a less typical stromal desmoplasia surrounding the lesion2 
(Figure 4.3).
Histological examination of intestinal tissue sections of Ptenf/f animals also confirmed the 
presence of intestinal polyposis. The histology of these lesions is described in more detail below.
2 Characterisation and description of these lesions was kindly provided by Prof Geraint T. Williams, 
Department of Pathology, University Hospital of Wales, Cardiff University, UK.
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F ig u re  4 .3 :  Aged Pten*/f mice are susceptible to prostate neoplasia, hepatic steatosis and  
cholangiocarcinoma o f varying histology
In o rder to  assess tissue pathologies outside th e  intestine in Ptenf/f animals, H&E-stained tissue 
sections o f control and exp erim enta l anim als w ere  com pared. Ptenf/f animals w ere  found to  be 
susceptible to  neoplasia o f th e  p rostate  (A, Left panel: W T, Right panel: Ptenf/f, arrow s indicate  
areas o f neoplasia), w hich was not observed in W T  controls. Liver steatosis was also com m on in 
Ptenf/f anim als (B, right hand panel, dashed line indicated area o f steatosis) com pared to  
controls (B, le ft hand panel). Lesions o f bile duct origins w ere  also noted in Ptenf/f livers, which  
w ere  not noted in contro l (C, le ft panel). Types o f lesions identified included non-m alignant 
biliary m icroham artom as (C, right panel) and cholangiocarcinom a, which presented as tw o  
distinct histological form s; cholangiocarcinom a which was histologically typical of th a t seen in 
hum an disease (D, le ft panel) and th a t which was atypical of hum an disease (D, right panel). 
Scale bars indicate 100p m .
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In order to quantify the frequency of various tissue pathologies in Ptenf/f animals 
compared to WT controls, H&E-stained tissue sections were examined for the presence of 
intestinal lesions, prostate neoplasia, liver steatosis and lymphoma, and the incidence of each 
lesion type recorded. Microscopically visible intestinal lesions were found to occur in 61.9% of 
Ptenf/f animals, representing 13 of 21 individuals analysed (Figure 4.4). In contrast, just one WT 
animal was found to have abnormalities of the intestinal epithelium. The most common recorded 
pathology of Ptenf/f animals was that of prostate neoplasia, which was found to affect 90.5% (19 
of 20) animals. In contrast, no single incidence of prostate neoplasia was noted in WT controls 
upon microscopic examination. Steatosis of the liver was also common in Ptenf/f animals, 81.0% 
(17 of 21) showing obvious microscopic evidence of hepatic steatosis. In contrast, just one WT 
control animal was noted to show limited steatosis of the liver. Finally, microscopic assessment 
for lymphoma indicated that one Ptenf/f animal bore a tumour of this type, and no WT control 
animals showed any evidence of lymphoma development.
In summary, aged Ptenf/f animals show susceptibility to intestinal tumourigenesis, 
steatosis of the liver accompanied by other liver lesions of varying histology, neoplasia of the 
prostate and lymphoma. These phenotypes are much less commonly reported in WT control 
animals of a comparable age.
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Figure 4.4: Ptenl/{ animals are predisposed to intestinal lesions, prostate neoplasia, liver steatosis 
and lymphoma
H&E-stained sections of tissues removed at dissection from aged Ptenf/f (white bars) and WT (grey 
bars) animals were assessed microscopically for any tissue abnormalities. Intestinal lesions, 
prostate lesions, steatosis of the liver and lymphoma were the most common abnormalities 
observed. In Ptenf/f animals, 61.9% of animals examined (13 out of 21 individuals) were observed to 
bear intestinal lesions, compared to an incidence of just 4.8% (1 of 21 individuals) in WT controls. 
Prostate lesions were common in Ptenf/f animals, with prostate intraepithelial neoplasia (PIN) being 
the least severe type of lesion observed. Whilst PIN was not observed in any WT control animals, 19 
of 21 Ptenf/f animals (90.5%) were observed to show PIN or more severe lesions. Steatosis of the 
liver was also common in Ptenf/f animals, at a frequency of 81.0% (17 of 21 animals), and was much 
less common in controls (4.6%, 1 out of 22 individuals). Finally, lymphoma was observed in one of 
22 Ptenf/f animals (4.6%), which was not noted in controls.
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4.2.4 Delayed onset of intestinal tumourigenesis following deletion of Pten
As mentioned above, aged Ptenf/f animals were noted to bear polyps of the small and 
large intestine in a number of cases.
I next examined more closely the timescale in which intestinal tumourigenesis ensues in 
Ptenf/f animals compared to WT controls. Kaplan-Meier analysis was employed to determine the 
probability of intestinal polyposis with increasing time PI of animals (Figure 4.5). This indicated 
that, at 250 days PI, all animals remained free of intestinal tumours. After this point, the 
probability of finding intestinal lesions in Ptenf/f animals at death increased. The time at which 
50% of animals will bear tumours at death was found to be 372 days. In contrast, WT control 
animals were all found to be free of intestinal tumours until over 700 days PI. After this, the 
probability of detecting intestinal tumours increases slightly, but the point at which 50% of 
animals will bear intestinal lesions is not reached. The increased probability of intestinal 
tumourigenesis in Ptenf/f animals was found to be statistically significant compared to controls 
(p<0.001, x2=34.56, DF=1). Thus, it is clear that Ptenf/f animals show an increased predisposition to 
the development of intestinal polyps compared to WT controls.
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Figure 4.5: Probability o f  Ptenf/ f  and  control anim als bearing intestinal tumours increases w ith  
tim e
In order to visualise the tim escale w ith which intestinal tumourigenesis occurs in experimental 
compared to control animals, Kaplan-M eier analysis was employed to determ ine the probability 
of presence of intestinal lesions in animals culled when symptomatic of disease. At less than 250  
days, all animals culled and dissected w ere found to  be free of intestinal lesions. After this point, 
the probability o f Ptenf/f animals having intestinal lesions increases, w ith the median tim e of 
tum our developm ent being 372 days PI. W T control animals were only observed to bear 
intestinal lesions when culled at over 700 days, and the point at which half of all control animals 
were found to bear intestinal lesions (median tim e) was not reached. The increased probability 
of the presence of intestinal lesions in experim ental animals compared to controls was found to  
be highly statistically significant (p<0.001, x2=34.56, DF=1).
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4.2.5 Intestinal tumours show varied histology, and are partly comprised of Ki67-positive cells
As described above, a large proportion of Ptenf/f animals were noted to bear macroscopic 
polyposis of the intestine at dissection, which was confirmed microscopically. During this analysis, 
it was noted that overt polyposis of the colon was much more common and prominent than that 
of the small intestine. As such, further investigations were concentrated on polyps arising within 
the large intestine.
In order to further characterise these lesions, expert histopathological descriptions of the 
typical lesions occurring in these animals was sought. Variations in the histology of colonic lesions 
arising in Ptenf/f animals were noted (Figure 4.6). The most typical lesions were found to be 
associated with lymphoid follicles present within the submucosa (Figure 4.6A and B). Lesions of 
this type were found to be Adenomatous, showing moderate to high grade dysplasia. In a number 
of lesions, a desmoplastic response of the stroma was evident. These lesions were not generally 
found to show typical characteristics of malignant carcinoma. More rarely, a second histological 
type of lesion was observed. Such lesions were found to have a hamartomatous tissue pathology 
reminiscent of that seen in juvenile polyps. Lesions were noted to be well differentiated, with no 
apparent signs of dysplasia3 (Figure 4.6C).
Anti-Ki67 IHC was next performed upon large intestinal lesions of Ptenf/f animals in order 
to visualise the proliferative nature of these tumours. Ki67-positive epithelial cells were noted to 
be a feature of all adenomatous lesions identified, indicating proliferation of epithelial cells within 
these tumours (Figure 4.7). In particular, the areas apparently containing the highest density of 
Ki67-positive epithelial cells were observed to be located adjacent to lymphoid tissue present 
within the tumour. Thus, tumours arising in Ptenf/f animals are found to be actively proliferating, 
with a potential association between high levels of proliferation and close proximity to lymphoid 
cells.
3 Histopathological descriptions of the intestinal tumours arising in Ptenf/f were provided by both 
Marnix Jansen, Hubrecht Institute, The Netherlands and by Prof Geraint T. Williams, Department of Pathology, 
University Hospital of Wales, Cardiff University, UK.
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AFigure 4.6: Intestinal tumours in aged Ptenf/f animals show varied histopathology
H&E-stained intestinal tissue of Ptenf/f animals were examined in order to characterise the 
phenotype of large intestinal lesions arising in these mice. Typical lesions were observed to be 
adenomatous, and were frequently associated with lymphoid follicles (A and B are typical examples). 
These lesions showed moderate to high levels of dysplasia. More rarely, lesions of a second 
histological type were identified (C). These lesions were found to show a hamartomatous pathology 
reminiscent of juvenile polyposis, with no apparent dysplasia of epithelial cells within the tumour. 
Scale bars indicate 100pm.
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Figure 4.7: Anti-K i67-positive cells a re  present w ith in  in testinal lesions o f Ptert/f  mice 
In order to assess levels o f proliferation w ithin large intestinal lesions of Ptenf/f experim ental animals, 
anti-Ki67 IHC was perform ed. All lesions examined revealed that Ki67-positive epithelial cells were  
present within abnorm al areas o f tissue (A and B, representative lesions from tw o individual animals are 
shown). Proliferating cells appeared to  be particularly associated with areas of lymphoid tissue within  
lesions. For each panel, high-power magnifications (right) of the areas indicated (left) are shown. Scale 
bars indicate 100pm .
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4.3 Discussion
Previously, I have attempted to characterise the effects of Pten in suppressing 
tumourigenesis of the intestinal epithelium (Chapter 3). However, I was only able to analyse the 
effects of Pten loss up to 50 days following deletion, due to the presence of over-riding 
phenotypes in other tissues. In this chapter, I therefore attempted to circumvent problems 
encountered due to recombination in different tissues using a more tightly-regulated form of Cre 
recombinase-expressing transgene, AhCreER1. This form of Cre-expressing transgene has 
previously been reported to show lower levels of uninduced background recombination 
compared to the AhCre transgene, which was used in Chapter 3 (Kemp et al., 2004).
I first confirmed that induction of animals bearing AhCreER1 by treatment with beta- 
naphthoflavone and Tamoxifen results in recombination within the intestinal epithelium, as has 
been published (Kemp et al., 2004). The ROSA26 LacZ reporter transgene (Soriano, 1999) was 
used to visualise recombination within the intestine. This indicated that recombination occurred 
specifically within the epithelium of the intestine, in both the crypt and villus. Levels of 
recombination were found to decrease along the proximal-distal longitudinal axis of the intestine. 
As such, it was noted that subsequent analyses of tissue should be performed on regions of 
intestine obtained from comparable regions along the length of the intestine, or that 
recombination in tissues should be confirmed prior to analysis.
Having confirmed that AhCreER1 drives recombination within the intestinal epithelium, I 
next generated AhCreERT+;Pten+/+ ('W T') and AhCreERT+;Ptenf/f ('Ptenf/f') animals in order to 
determine the phenotype of long-term Pten loss compared to controls. Animals were induced as 
adults, and aged until culling was necessary due to ill health.
Survival analysis of induced cohorts of animals revealed that a significant reduction in 
lifespan was apparent in Ptenf/f cohort animals compared to WT animals. Ptenf/f animals were 
found to have a median survival time of 407 days, a significant decrease compared to the 801 day 
median survival time of WT controls. Thus, it is clear that induction of Pten deficiency within 
transgenic animals results in a significant decrease in survival compared to controls.
4.3.1 Multiple tissue phenotypes associated w ith deletion of Pten
At dissection, the observed reduction in lifespan and general ill-health observed in Ptenf/f 
animals was found to be attributable to pathologies within the genitourinary tract, liver and 
intestine.
In the genitourinary tract, Ptenf/f animals were noted to be susceptible to development of 
prostate neoplasia, which was not observed in WT controls. Severity of disease was found to be 
variable, with lesions varying in histopathology from intraepithelial neoplasia (PIN) to
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adenocarcinoma of the prostate in some cases. This phenotype has previously been reported in 
other models of prostate-specific Pten deletion (Backman et al., 2004). Thus, whilst these findings 
are not novel, they are useful in that they confirm that recombination in this system drives 
deletion of the Pten allele.
A number of liver pathologies were observed in Ptenf/f animals, which were not noted to 
be present in aged WT animals. Steatosis of the liver was a common finding, with 81.0% of Ptenf/f 
animals affected, compared to just 4.6% of WT controls. Again, this phenomenon has previously 
been reported in response to liver-specific deletion of Pten (Stiles et al., 2004). However, in this 
study I have also observed the occurrence of a number of other liver pathologies, varying in 
severity from biliary microhamartoma to cholangiocarcinoma of varied histopathology, both 
typical and less typical of that observed in human disease. These phenotypes are not currently 
described in the literature as consequences associated with deletion of Pten. However, one study 
has noted that combined deletion of Pten and of the tumour suppressor and TGF-beta/BMP 
pathway transducer, SMAD4, results in formation of bile duct abnormalities and eventually 
cholangiocarcinoma (Xu et al., 2006). Thus, the phenotype observed here and that of Xu et al. 
may together suggest that Pten deficiency alone causes susceptibility to cholangiocarcinoma, but 
that combined deletion of both Pten and SMAD4 causes a rapid acceleration of this phenotype. 
However, the cholangiocarcinoma which has been observed here has so far only been 
preliminarily characterised. Thus, further investigation is needed in order to fully characterise the 
phenotype observed here, and a comparative study to that of Xu et al. is needed to confirm a 
potential relationship between the phenotypes arising in these mice.
4.3.2 Delayed onset of intestinal tumourigenesis in Ptenf/f animals
Previously published data has indicated that conditional deletion of Pten from the 
intestinal epithelium results in tumourigenesis within 3 months (90 days) following induction (He 
et al., 2007). In Chapter 3, I reported that epithelial-specific deletion of Pten does not result in 
tumourigenesis up to day 50 PI. Here, I can expand on these data and report that tumour 
development does ensue following epithelial-specific deletion of Pten, but that this only occurs at 
much delayed timepoints. In this study, animals at less than 250 days PI were found to be free of 
intestinal tumours. After this timepoint, the probability of animals bearing intestinal tumours at 
death was found to increase, with a 50% probability of tumourigenesis occurring at day 372 PI. 
Thus, the timescale reported here for development of intestinal tumours following Pten deletion 
is some 4 times slower than that reported by He et al. (2007). WT animals were not noted to 
develop intestinal tumours until over 700 days PI, and even at this late time point, intestinal 
tumourigenesis was rare, with only 1 out of 21 individuals affected. The data reported here and
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that of He et al therefore indicate that, whilst epithelial-specific deletion of Pten will eventually 
result in intestinal tumourigenesis, this is apparently substantially accelerated by additional 
deletion of Pten from the stromal component of the intestine.
In this study, I find that the intestinal tumours which develop in Ptenf/f intestines are of 
varied histology. In most cases, tumours were found to be associated with lymphoid follicles, and 
were of an Adenomatous histology, with marked dysplastic changes. Rarely, tumours of a second 
histological type were observed. In these cases, tumours appeared to be of a juvenile-type 
histopathology, displaying no signs of dysplasia. The variation of tumour histology observed in 
these animals raises the question of what causes the formation of different histological types of 
tumour, and whether one tumour type arises within another. It is possible that Adenomatous- 
type lesions arise within and are a more advanced form of polyps bearing a hamartomatous 
histology. If this were the case, the low incidence of hamartomatous lesions would suggest rapid 
progression of tumourigenesis. However, the preliminary data collected here has not allowed 
determination of whether this is truly the case, and therefore warrants further investigation in 
the future. In their study, He et al. report the development of lesions of a typically 
hamartomatous histology in Pten-deficient intestines. These lesions are histologically similar to 
the lesions observed here. Thus, this further supports the notion that He et al. report an 
acceleration of the same phenotype characterised here, but again further investigation is required 
in order to fully validate this notion.
Finally, I have examined the proliferative properties of intestinal tumours arising in Ptenf/f 
animals by use of Anti-Ki67 IHC. This revealed that a proportion of epithelial cells comprising each 
polyp were Ki67-positive, indicating that these cells were actively replicating. In particular, an 
interesting pattern was noted in that a greater density of proliferative epithelial cells was found to 
lie adjacent to lymphoid tissue comprising the tumour. This raises the possibility that signals from 
cells comprising the lymphoid tissue may drive proliferation of epithelial cells within the tumour. 
However, as this data is again very preliminary, this is currently only speculation and a more 
detailed investigation of this is needed in order to confirm that this is indeed the case.
4.3.3 Summary and future directions
In summary, the data presented in this chapter indicate that conditional deletion of Pten 
results in neoplasia of a number of different tissues, including the genitourinary tract, liver and 
intestine. Cholangiocarcinoma develops within the liver, which is a novel finding not previously 
reported before following conditional deletion of Pten alone. This phenotype has currently only 
been preliminarily characterised here, and its novel nature warrants a more in-depth analysis of 
these tumours in the future.
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In the intestine, delayed tumourigenesis is observed to occur at over 250 days following 
deletion of Pten specifically from the epithelium. Tumours arise of both a hamartomatous and 
adenomatous histopathology. Given that previous reports have indicated that Pten deletion from 
both the epithelium and stroma causes tumourigenesis at 90 days PI, this implies that differential 
deletion of Pten from specific cell compartments results in tumourigenesis at different paces. 
Deletion of Pten from both the epithelium and underlying stroma causes relatively rapid tumour 
development (He et al., 2007), whereas epithelial-specific Pten deletion results in tumour 
development at later timepoints. Additionally, I find that tumours of hamartomatous histology 
occur less commonly than those of adenomatous histology, whereas He et al. (2007) report the 
exclusive development of hamartomas. The exact reason for this delay tumourigenesis, and 
change in histopathology of incident tumours, is currently unclear. Indeed, the initiating factor 
required for tumourigenesis also remains obscure. It could be speculated that another mutation 
may be needed in order to initiate tumourigenesis, which then progresses rapidly in a Pten- 
deficient environment. However, this has not been attempted to be characterised in this chapter, 
and should therefore be investigated in the future.
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Chapter 5: Investigating the effects of epithelial Pten loss in the context of 
activated Wnt signalling
5.1 Introduction
Work described in chapters 3 and 4 indicates that, whilst epithelial-specific Pten loss does 
not immediately predispose to lesion development, tumours may arise in very aged animals. The 
reason for such a delay in onset of tumourigenesis in the intestine is unclear, but one plausible 
explanation is that another genetic mutation must be acquired in order to initiate tumour 
formation, and that the Pten-deficient environment then permits rapid tumour development 
once this occurs. In order to address this possibility, and examine the role of Pten as a suppressor 
of tumour progression rather than initiation, I have investigated the effects of epithelial deletion 
of Pten in the context of activated Wnt signalling.
Wnt signalling is well documented as a critical regulator of intestinal homeostasis 
(Clevers, 2006), and is commonly activated in human colorectal cancers. As a critical mediator of 
the Wnt pathway, the Adenomatous polyposis coli gene product (Ape) is frequently mutated in 
human cancers, and heritable mutation in Ape leads to the tumour predisposition syndrome, FAP 
(Kinzler and Vogelstein, 1996). The role of activated Wnt signalling in homeostasis and 
tumourigenesis of the intestine has been extensively investigated using murine models of Ape 
mutation (Taketo, 2006). Use of such models has indicated that constitutive homozygous 
disruption of Ape results in early embryonic lethality (Moser et al., 1995). Studies of heterozygous 
inactivation of Ape using several different approaches show predisposition to intestinal polyp 
formation, reminiscent of human FAP (Moser et al., 1990, Shibata et al., 1997). Conditional 
deletion of both copies of Ape in the adult intestine using the Cre-LoxP approach results in rapid 
and catastrophic perturbation of epithelial homeostasis, within 5 days of Ape loss. Homeostatic 
defects observed following Ape deletion include hyperproliferation, blockade of epithelial 
migration and aberrant cell positioning (Sansom et al., 2004, Andreu et al., 2005).
Recent work investigating the role of Pten mutation in the context of Ape deficiency has 
indicated that mutation in Pten causes acceleration and progression of disease (Shao et al., 2007). 
Shao et al. report that constitutive heterozygosity for Pten on the ApcMIN background results in an 
increase in size, number and severity of intestinal lesions compared to those seen on the ApcMIN 
background with no mutation in Pten. Pten-deficient lesions are observed to be more commonly 
invasive and show an enhanced stromal response (desmoplasia), and are described by the authors 
as being characteristic of carcinoma.
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However, from data described here (Chapter 3) and elsewhere (He et al., 2007), there 
appears to be some discrepancy in the function of Pten as a tumour suppressor in the intestine, 
depending upon which cell compartment it is deleted from. Combined epithelial and stromal loss 
of Pten results in expansion of stem cell numbers and rapid tumourigenesis (He et al., 2007), 
whereas epithelial-specific Pten loss has little immediate effect (Chapter 3) but at very extended 
timepoints results in intestinal tumourigenesis (Chapter 4). As described above, Shao et al. 
employed the use of constitutive Pten deficiency in their studies based on the ApcMIN mouse. 
What remains unclear from their work is whether it is Pten deficiency within the epithelium itself 
which drives tumourigenesis, or whether this is the result of Pten loss in a different cell type, for 
instance in stromal cells.
In this chapter, I therefore aimed to determine the role of epithelial-specific Pten loss in 
the context of Wnt-initiated tumourigenesis. Activation of Wnt signalling was achieved by 
conditional deletion of Ape. Conditional inactivation of one allele of Ape has been characterised as 
a tumour-prone background (Shibata et al., 1997), and has previously been used to test the 
phenotypic effects of additional mutations (Sansom et al., 2006). Here, co-ordinate homozygous 
inactivation of Pten and inactivation of one or both alleles of Ape will be used to examine the role 
of epithelial Pten loss in the context of acute and long-term activation of Wnt signalling.
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5.2 Results
5.2.1 Activation and relocalisation of Akt in Pten-deficient, W nt activated intestinal epithelial 
cells
In order to examine the immediate, acute effects of combined loss of both Ape and Pten 
on the intestinal epithelium, mice homozygous for LoxP-targeted alleles of both Ape and Pten 
were generated. Experimental animals (AhCreERT+;Apcf/f;Ptenf/f, referred to as 'Apcf/f;Ptenf/f) and 
controls (AhCreERT+;Ptenf/f;Apc+/+ [Ptenf/f;Apc+/+] AhCreERT+;Pten+/+;Apcf/f [Pten+/+;Apcf/f] and 
AhCreERT+;Pten+/+;Apc+/+ [WT]) were induced and culled at day 5 PI.
IHC on intestinal tissue samples of all genotypes was then performed. As described in 
Chapter 4, AhCreER1 induces recombination at a relatively low level within the intestinal 
epithelium. In order to confirm that areas of tissues which were truly deficient for Ape and Pten 
were being examined, IHC was performed on serially-sectioned tissues. Anti-Pten IHC was used to 
confirm Pten status. Inactivation of Ape was confirmed indirectly by use of anti-beta-catenin IHC, 
as upregulated expression and strong nuclear localisation of beta-catenin is a previously reported 
consequence on Wnt pathway activation by Ape loss within the intestine (Sansom et al., 2004).
Examination of small intestinal crypts of stained sections revealed loss of staining for Pten 
protein in approximately 50% of epithelial cells (depending on the individual animal) in 
Apcf/f;Ptenf/f experimental mice and Ptenf/f;Apc+/+ controls (Figure 5.1). Pten staining was not lost 
from the underlying stroma, indicating that stromal cells were unrecombined and retained Pten 
expression, even after induction. Controls not bearing the LoxP-targeted Pten alleles 
(Pten+/+;Apcf/f and WT) were found not to show loss of Pten staining, as expected. Similarly, 
nuclear localisation of beta-catenin was observed at a similar frequency in epithelial cells of 
Apcf/f;Ptenf/f experimental tissues and Pten+/+;Apcf/f controls (Figure 5.1). Apc-proficient controls 
(Ptenf/f;Apc+/+ and Pten+/+;Apc+/+) were not observed to show aberrant staining for nuclear catenin, 
with the vast majority of cells showing a cytoplasmic and cell-surface staining pattern.
To examine activation of the PI3K/Akt pathway following deletion of Pten or Ape alone, or 
following deletion both genes, adjacent sections were stained immunohistochemically against 
activated phospho-AktSer473 (pAktSer473). In the crypt, both wild-type and single Apc-deficient 
tissues showed virtually no staining for pAktSer473 (Figure 5.1). In Pten-deficient crypts, a very slight 
increase in staining for pAktSer473 was evident, compared to directly adjacent epithelial cells which 
were Pten-proficient. Double-deficient tissue (Apcf/f;Ptenf/f) was observed to show a further 
increase in levels of pAktSer473, with staining found to be stronger than that of Pten deficient tissue 
and clearly stronger than adjacent wild-type tissue on the same section.
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Figure 5.1: Increase in activation of Akt within crypts following acute loss of Pten and Ape
Serial sections of tissue from Apcf/f;Ptenf/f and Apcf/f, Ptenf/f and WTcontrol animals ay day 5 PI were 
generated and subjected to IHC analysis.
Anti-Pten IHC revealed loss of staining for Pten protein in approximately 50% of epithelial cells of Ptenf/f 
genotypes, with no loss of staining of underlying stromal cells. Pten+/+ controls were found to retain 
positivity for Pten protein.
Anti-beta-catenin IHC was used as a surrogate marker of Ape loss, with strong expression and nuclear 
localisation of beta-catenin indicating activation of the Wnt pathway. Again, approximately 50% of 
epithelial cells in Apcf/f genotypes show strong nuclear staining for beta-catenin, whereas Apc+/+ tissue 
shows only cytoplasmic and cell-surface localisation of beta-catenin.
Anti-phospho-AktSer473 IHC was used to assess activation of the PI3K/Akt pathway. Low level staining for 
pAkt^1-473 was evident in WT tissue, with no difference in staining between WT and Apcf/f;Pten+/+tissue. 
Pten-deficient tissue showed a slight increase in pAktSer473 staining, but staining was clearly stronger in 
double mutant tissue (digital magnification of image is shown as an inset). Scale bars indicate 100pm.
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In contrast to this, staining on the villus of the same tissue sections was found to have a 
somewhat different pattern of pAktSer473 positivity. Again, serial sections of intestinal tissue were 
subjected to anti-Pten and anti-beta-catenin IHC in order to visualise areas of tissue deficient for 
Pten and Ape respectively (Figure 5.2). As above, anti-phospho-AktSer473 staining was then used to 
examine activation of the PI3K/Akt pathway, in this case on the villus, in the presence and 
absence of Pten and Ape. As previously observed, wild-type tissue was found to show virtually no 
staining for pAktSer473. Epithelial cells on the villus of the remaining three genotypes exhibited a 
different pattern of staining to that observed in the crypt. In Apcf/f;Pten+/+ tissue, cells on the 
villus, unlike the crypt, exhibited a clear increase in levels of activated Akt compared to 
surrounding wild-type tissue. Pten-deficient cells on the villus in Apc+/+;Ptenf/f tissues were found 
not to show an appreciable increase in levels of pAktSer473, which is again in contrast to the pattern 
observed in the crypt. Finally, the staining pattern for pAktSer473 observed in epithelial cells of the 
villus in double deficient tissue (Apcf/f;Ptenf/f) was striking. Not only was pAktSer473 observed to be 
clearly upregulated compared to control genotypes, it was additionally found to be more highly 
localised to the cell surface, an effect which was not evident in any control tissues or in the crypts 
of Apcf/f;Ptenf/f tissue samples (Figure 5.2).
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Anti-phospho-AktSer473Anti-B-Catenin
Figure 5.2: Increase in activation and relocalisation o f Akt in villus epithelium following acute loss of 
Pten and Ape
IHC against Pten and beta-catenin was performed on serial sections of intestine in order to identify 
areas of tissue deficient for Pten and Ape. Anti-phospho-Akt5er473 (pAktSer473) IHC was performed on 
adjacent sections. In tissue wild-type for Pten and Ape, minimal levels of staining for pAktSer473 was 
observed. In tissue deficient for Ape, a clear increase in staining against pAkt was observed, which was 
homogeneously cytoplasmic . No dramatic increase in staining was evident in Pten-deficient tissue. 
Tissue deficient for both Ape and Pten exhibited a strong increase in staining for pAktSer473, which was 
also coupled with strong membrane localisation, which was not seen in tissue of any control genotype. 
Insets show digital magnifications of the areas highlighted by dashed boxes. Scale bars indicate 100pm.
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5.2.2 Dramatically reduced lifespan of Pten-deficient mice in the context of Ape heterozygosity
In order to examine the effect of Pten deficiency in the context of susceptibility to 
intestinal tumours, experimental mice bearing the AhCreER1 transgene and also heterozygous for 
the LoxP-targeted Ape allele and homozygous for the LoxP-targeted Pten alleles (AhCreERT+ 
Apcf/+;Ptenf/f) were generated (herein referred to as 'Apcf/+;Ptenf/f') and control mice wild-type for 
Pten (AhCreERT+Apcf/+;Pten+/+, referred to as 'Apcf/+') were generated. Large cohorts of these mice 
(n>30) were induced and aged, whilst being monitored for signs of disease, and culled when 
moribund.
Analysis of survival times using the Kaplan-Meier method revealed that Apcf/+;Ptenf/f 
animals had a much reduced lifespan compared to Apcf/+ controls (Figure 5.3A). The median 
survival time of Apcf/+ control animals was 490 days PI, which in experimental Apcf/+;Ptenf/f 
animals was found to be significantly reduced to just 85 days PI (Kaplan-Meier analysis, p<0.0001, 
X2=102.71, DF=1). In comparison to other possible control genotypes (AhCreERT+;Apc+/+Ptenf/f, 
referred to as 'Ptenf/f' and AhCreERT+;Apc+/+Pten+/+, referred to as 'wild-type'), which are described 
in Chapter 4, both Apcf/+ controls and Apcf/+;Ptenf/f animals show a reduction in lifespan (Figure 
5.3B), with the median survival times of Ptenf/f controls and wild-type controls being 407 days PI 
and 801 days PI respectively.
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Figure 5 .3 : Pten loss in the context o f Ape heterozygosity reduces longevity
Kaplan-Meier analysis reveals experim ental Apcf/+;Ptenf/f mice (Red dashed line) to  have a reduced 
lifespan, w ith  a median survival tim e  o f 85 days, compared to  Apcf/+ controls (blue line), which have a 
median survival tim e o f 490 days (A). This reduction in survival is statistically significant (p<0.0001, 
X2=102.71, DF=1). In comparison to  Ptenf/f (Orange dashed line) and W ild-type (WT; Green dashed line) 
controls, Apcf/+;Ptenf/f experim ental mice also show a reduction in survival tim e. The median survival 
tim e fo r Ptenf/f contro l mice was 407 days, and fo r w ild -type  mice, 801 days.
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5.2.3 Increased multiplicity of small intestinal tumours, but not large intestinal tumours, 
following Pten loss
At dissection, intestines from Apcf/+ and Apcf/+;Ptenf/f animals were removed, opened 
longitudinally and examined carefully for the presence of any abnormalities or lesions of the 
mucosal surface of the intestine. Control Apcf/+ animals were observed to bear polyp-like, 
pedunculate lesions of both the small and large intestines, as have previously been described 
(Shibata et al., 1997). In Apcf/+;Ptenf/f animals, whilst similar lesions were found in the large 
intestine, macroscopically different lesions were observed in the small intestine. These lesions 
were flattened compared to the surrounding normal mucosa, and had an ulcerated, necrotic 
appearance to the surface of the centre of the lesion (Figure 5.4A). Initial macroscopic assessment 
of these lesions did not allow their identification as bona fide intestinal tumours. Intestinal tissues 
were therefore fixed, sectioned and H&E-stained. Subsequent microscopic assessment of typical 
examples of these lesions (Figure 5.4B) revealed them to be malignant lesions of the small 
intestinal mucosa.
Having identified the lesions arising in Apcf/+;Ptenf/f animals as being malignant, I next 
examined whether there was a significant difference in tumour burden between Apcf/+ and 
Apcf/+;Ptenf/f animals, in both the small and large intestines. Total numbers of lesions identifiable 
macroscopically were counted in whole small and large intestines of Apcf/+;Ptenf/f animals at death 
(n=14), and control Apcf/+ animals which were culled either at 190 days (n=6) or at 250 days PI (n= 
11), and the average number of lesions per mouse calculated (Figure 5.5). In the small intestine, 
Apcf/+;Ptenf/f animals were found to bear more tumours than controls at either day 190 PI or day 
250 PI (average number of lesions ±SD were: Apcf/+;Ptenf/f animals: 6.9315.43, Apcf/+ controls at 
day 190 PI: 1.0011.67, Apcf/+ controls at day 250 PI: 1.75+1.96). Although there was a large 
variation in the number of lesions present per mouse, as indicated by the large standard 
deviation, the increase in tumour burden observed in Apcf/+;Ptenf/f mice was significant compared 
to controls at day 250 (Mann-Whitney U test, p=0.005). In the large intestine, no clear 
relationship between genotype and tumour burden was apparent. As expected, the number of 
tumours in control Apcf/+ large intestines increased between 190 days PI and 250 days PI (average 
number of lesions +SD were 5.3315.92 and 8.7318.44 respectively). In contrast to the small 
intestine, the average number of tumours in the large intestine of Apcf/+;Ptenf/f animals (average 
number +SD was 6.6415.00) was not significantly different (Mann-Whitney U test, p=0.87) to the 
number of tumours observed in control Apcf/+ mice at day 250 PI. It is therefore clear that in the 
context of Ape heterozygosity, Pten suppresses tumour development in the small intestine, but 
not in the large intestine.
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F ig u re  5 .4 :  Gross appearance and histology o f tumours arising in Apcf/+;P ten ff mice
At dissection, experim ental animals w ere found to bear numerous lesions in the small 
intestine. Macroscopic assessment of lesions in wholem ounted, unfixed intestine (A, viewed 
from  the lumenal face of the intestine) revealed areas of abnormal appearance (L, 
approxim ate boundary outlined) which were flattened compared to the surrounding normal 
mucosa (N M ), with an ulcerated appearance at the centre. Histological assessment of 
typical examples of these lesions from  H&E-stained tissue sections (B) revealed the majority 
to be invasive adenocarcinomas. Scale bars indicate 100pm .
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Figure 5.5: Increase in small intestinal tumour burden in Apcf/+;Ptenf/f animals.
Frequency of tumours evident in Apcf/+;Ptenf/f and Apcf/+ control small and large intestines was scored as 
total number of lesions per mouse (n>6 for all genotypes and timepoints). Error bars indicate standard 
deviation. In the small intestine, experimental animals (white bars) had a clear increase in tumour 
number compared to Apef/+ controls at either day 190 (black bars) or day 250 (grey bars) PI. Despite the 
large variation in tumour number between mice, the difference in number of tumours in the small 
intestine in experimental mice compared to control at day 250 is statistically significant (Mann-Whitney 
U Test, p=0.005). In contrast to this, in the large intestine, no difference in numbers of lesions was 
observed between experimental animals and controls at either timepoint.
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5.2.4 Small intestinal tumours arising in Pten-deficient Ape heterozygotes are more advanced 
compared to controls
As described above, both macroscopic and microscopic assessment of lesions arising in 
Apcf/+;Ptenf/f animals indicated that they were histologically different from those observed in 
control Apcf/+ mice, both observed here and reported elsewhere (Shibata et al., 1997).
In order to investigate this more thoroughly, H&E-stained sections of intestinal tumours 
from both Apcf/+ and Apcf/+;Ptenf/f animals were directly compared. The great majority of lesions 
in control Apcf/+ animals were observed to be benign adenomas confined to the mucosa, which 
did not show signs of ulceration or of invasion into underlying tissues. Occasional lesions showed 
early signs of invasion of tumour epithelial cells into the underlying stroma, and this was found to 
elicit a limited desmoplastic response. In direct contrast to this, the most common type of lesion 
observed in experimental Apcf/+;Ptenf/f mice were ulcerating adenocarcinomas, which were found 
to arise within severely dysplastic adenomas. In these lesions, clear signs of malignant invasion 
into the submucosa were evident, and in a number of cases showed destructive invasion through 
the muscularis of the small intestine into the peritoneal cavity, where localised peritonitis was 
induced. Invasion was accompanied by a strong, fibroblast-rich desmoplastic response of the 
stroma, and also a clear inflammatory cell reaction4.
Based on these histopathological descriptions, I next quantified the numbers of each 
tumour type observed in Apcf/+ and Apcf/+;Ptenf/f intestines. Each tumour was classified either as 
'microadenoma or adenoma', as 'early invasive adenocarcinoma' or as 'advanced invasive 
adenocarcinoma'. The criteria for classification were as follows: lesions confined to the mucosa, 
either pedunculated or non-pedunculated, with no evidence of invasion into the submucosa were 
classified as microadenoma/adenoma (mAd/Ad); lesions showing clear invasion into the 
submucosa but with the muscularis remaining intact were classified as early invasive 
adenocarcinoma (EIA); and lesions showing clear invasion into the submucosa, through the 
muscularis and into the peritoneal cavity were classified as advanced invasive adenocarcinoma 
(AIA). Tissue sections of intestines from Apcf/+ (n=16) and Apcf/+;Ptenf/f (n=15) mice were 
examined, and lesions identified and categorised (See Figure 5.6). In control mice, 86% of lesions 
were found to be mAd/Ad and the remaining 14% of lesions were classed as EIA (numbers of 
lesions in each category were 12 and 2 respectively, out of a total of 14 lesions). No lesions were 
observed in control animals which fulfilled the requirements for classification as AIA. In contrast 
to this, Apcf/+;Ptenf/f animals showed a reduction in the number of lesions classified as mAd/Ad, at 
47% (26 of 56 lesions). An increase in incidence of EIA was observed, with 32% (18 of 56) of
4 H istopathological descriptions o f tum ours in control and experim ental animals w ere  kindly provided by Prof 
G erain t T. W illiam s, D ep artm e n t o f Pathology, University Hospital o f W ales, Cardiff University, UK.
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lesions classified in this category. Finally, 21% (12 of 56) of lesions were found to  be sufficiently 
advanced to be classified as AIA (See Figure 5.7).
From these data, it is therefore clear that in the context of Ape heterozygosity, additional 
loss of Pten results in rapid progression of tumours, and advancement of disease state, compared 
to tumours arising in control intestines.
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Figure 5.6: Histological 
categorisation o f 
varying grades of 
tumour severity seen in 
Apcf/+;Ptenf/f intestines 
and Apcf/+ controls 
Assessment of H&E- 
stained sections of small 
intestinal tumours from  
Apcf/+and Apcf/+;Ptenf/f 
mice revealed varying 
grades of tumour 
severity. In 
Apcf/+controls (A), 
adenomas were 
identified (top panel), 
which were confined to 
the mucosa. In addition, 
early invasive 
adenocarcinomas 
showing invasion into 
the submucosa were 
identified (bottom  
panel). In Apcf/+;Ptenf/f 
animals (B), adenomas 
confined to the mucosa 
were also evident (top 
panel), as were early 
invasive
adenocarcinomas 
(middle panel), though 
these appeared 
histologically different 
to those seen in Apcf/+ 
controls, with a more 
pronounced 
desmoplastic response. 
Apcf/+;Ptenf/f animals 
were additionally found 
to bear advanced 
invasive
adenocarcinomas, 
characterised by 
evidence of invasion 
through the muscularis 
propria of the intestinal 
wall into the peritoneal 
cavity (bottom panel). 
Scale bars indicate 
100pm.
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Figure 5.7: Increased severity of small intestinal tumours in Apcf/+;Ptenf/f compared to 
control mice
Intestinal tum ours arising in control Apcf/+ (left) and Apcf/+;Ptenf/f, (right) mice w ere  
assessed histologically and categorised according to  grade of severity o f the tum our. The 
m ajority o f lesions (86% ) in control animals w ere found to  be adenoma or m icroadenom a  
(Ad/m Ad), w ith  a small num ber (14% ) o f lesions showing progression to early invasive 
adenocarcinom a (EIA). M icroadenom as and adenomas w ere also present in experim ental 
animals, but at a low er frequency (47% ). An increased proportion of lesions in experim ental 
animals showed progression to  EIA (32% ), compared to controls. A subset o f lesions (21% ) 
w ere also found to  progress fu rther than EIA, and w ere categorised as advanced invasive 
adenocarcinom a (AIA).
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5.2.5 Moderate activation of Akt in Pten-proficient tumours arising in Ape heterozygotes
As described above, I previously observed a moderate increase in activation status of Akt, 
as assessed by IHC staining for phospho-AktSer473, following acute loss of both copies of Ape alone. 
This observed increase in activation of Akt was not associated with any change in subcellular 
localisation. I therefore sought to examine whether the same pattern was apparent in tumours 
arising in Apcf/+ control mice.
I first confirmed that tumours were indeed deficient for Ape using anti-beta-catenin IHC 
as a surrogate marker for Ape loss, as previously. Non-tumour epithelial tissue in Apcf/+ control 
intestines was observed to have a cytoplasmic and cell-surface staining pattern for beta-catenin, 
whereas epithelial cells within tumours showed both upregulation and nuclear localisation of 
beta-catenin, consistent with activation of the W nt pathway and indicative of loss of Ape (Figure 
5.8). Tumours arising in Apcf/+ mice were also confirmed to be wild-type for Pten by use of Anti- 
Pten IHC. This indicated that there was no loss of Pten staining either in tumours or in 
surrounding normal epithelium (Figure 5.8).
Tumours from Apcf/+ mice were then subjected to IHC against phospho-AktSer473 
(pAktSer473). This revealed that staining for pAktSer473 was stronger in tumour-associated epithelial 
cells compared to surrounding control epithelium. The most strongly positive cells were observed 
to be at the surface of the tumour, closest to the lumen of the intestine. Cellular staining of 
pAktSer473 was noted to be homogeneously cytoplasmic, within no obvious increase in staining at 
the cell surface. These observations are therefore consistent with the staining patterns described 
in section 5.2.1, indicating that loss of Ape results in an increase in activation of Akt, but does not 
alter its subcellular localisation.
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Figure 5.8: IHC on tum ours arising in Apcf/+ control animals confirms loss o f Ape and retention  
o f Pten, and indicates a  m oderate increase in activation o f Akt.
IHC was performed on serial sections of tumours from control Apcf/+ mice. Anti-beta-catenin IHC 
(A, top panel) revealed strong upregulation and nuclear localisation of beta-catenin, indirectly 
indicating loss of Ape. Anti-Pten IHC (A, bottom panel) confirmed that tumours arising in control 
mice retained positivity for Pten staining. Anti-pAktSer473 IHC indicated a moderate upregulation 
of pAkt levels in control tumours compared to surrounding normal tissue. Staining for pAkt was 
found to be homogeneously cytoplasmic, as shown in the digital enlargement of the region of the 
tumour indicated by a dashed box. Scale bars indicate 100pm.
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5.2.6 Consistent strong activation and relocalisation of Akt in Pten- and Apc-deficient small 
intestinal tumours
Having found that tumours arising in control Apcf/+ mice show an increase in Akt 
activation similar to that observed following short-term loss of Ape, I next examined the effect 
upon Akt signalling in tumours arising in Apcf/+;Ptenf/f mice.
I first confirmed that the tumours arising in Apcf/+;Ptenf/f animals were deficient for both 
Pten and Ape. As above, IHC against beta-catenin was used to indicate Ape loss. Tumours in 
Apcf/+;Ptenf/f mice were found to show a similar staining pattern to that observed in control 
tumours, with an increase in expression of beta-catenin, coupled with strong nuclear staining of 
epithelial cells within tumours, compared to surrounding normal tissue (Figure 5.9). Anti-Pten IHC 
was performed on adjacent sections of tumour tissue to examine loss of Pten protein from the 
epithelium. This indicated that epithelial cells within tumours arising in Apcf/+;Ptenf/f tissues were 
indeed negative for Pten staining, whilst the stromal component of these tumours retained 
positivity for Pten, as expected (Figure 5.9).
Recombination of both the Ape and Pten alleles within tumours was also confirmed using 
recombined-allele-specific PCR (see Section 2.6.4 and Figure 2.2). Genomic DNA was extracted 
from tumour tissue dissected macroscopically from the intestinal mucosa, which therefore 
contains all cell types within the tumour. Recombined-allele-specific PCR for the Pten locus on 
DNA extracted from tumour samples revealed presence of a band corresponding to 705bp in size 
in all tumour samples analysed, indicating recombination of the Pten gene. Products generated 
from the targeted but unrecombined alleles were also present at 514bp and approximately 1.2kb, 
indicating that the population of cells within the tumour are not all recombined. This is consistent 
with my observations from IHC analysis of Pten protein expression. Control samples of DNA 
extracted from tail biopsies of Apcf/+;Ptenf/f and wild-type mice confirmed that the recombined 
allele was not detected either in uninduced tissues, or in cells which do not bear the LoxP- 
targeted Pten alleles (Figure 5.10A). A similar strategy employed to assess recombination status of 
the Ape allele again confirmed that products corresponding to both the recombined Ape allele (at 
258bp in size) and the LoxP-targeted but unrecombined allele (at 314bp in size) were generated 
from each tumour sample. DNA extracted from tail biopsies of wild-type and uninduced mice 
bearing the Apcf/f alleles were again used to confirm that the product corresponding to the 
recombined allele of Ape was not present, but products corresponding to the wild-type Ape allele 
(at 226bp in size) and the targeted but unrecombined Ape allele (at 314bp) were present 
respectively in each sample (Figure 5.10B).
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Anti-Pten Anti-beta-catenin
Figure 5.9: IHC on tumours arising in Apcf/+;Ptenf/f  animals indicates loss o f Pten and Ape in 
epithelial cells
Serial sections of tumours arising in Apcf/+;Ptenf/f animals were subjected to anti-Pten IHC and anti- 
beta-catenin IHC. Epithelial cells within tumours were found to be consistently negative for anti-Pten 
staining (Left panel), indicating loss of Pten protein. Staining of adjacent sections revealed epithelial 
cells of tumours to show upregulation and nuclear localisation of beta-catenin, indirectly confirming 
loss of Ape and activation of the Wnt pathway in tumours. Three examples of invasive 
adenocarinomas from individual Apcf/+;Ptenf/f animals are shown. Scale bars indicate lOOpm.
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Figure 5 .10: Recombined-specific PCR indicates recombination at Pten and Ape alleles in tumours
Recombined-specific PCR was used to confirm presence of the recombined Pten allele (A) or the 
recombined Ape allele (B) in genomic DNA extracted from intestinal tumours of Apcf/+;Ptenf/f animals. 
For Pten recombined PCR, a specific product corresponding to 705bp in size was generated from all 
tumour samples, indicating presence of the recombined allele. Products corresponding to 514bp and 
approximately 1.2kbp were also generated, indicating presence of the targeted but unrecombined Pten 
allele. Control, unrecombined samples did not generate a product corresponding to the 514bp 
recombined-specific product. In reactions specific for the Ape recombined allele, a product of 258bp 
indicating recombination at the Ape allele was generated from all tumour samples. Product 
corresponding to 314bp in size, indicating the targeted but unrecombined allele and 226bp in size, 
indicating the wild-type Ape allele were also generated (as expected as animals are Apcf/+). Control, 
unrecombined samples did not generate a product corresponding to the 258bp recombined-specific 
product.
Activation of Akt was then assessed in Ape- and Pten-deficient tumours. Anti-pAktSer473 
IHC revealed an increase in staining of epithelial cells of the tumour compared to surrounding 
normal epithelial cells in all tumours examined. The strongest staining was observed at the  
lumenal face of tumours, in a pattern similar to that observed in control tumours arising in Apcf/+ 
mice. Epithelial cells which were apparently invading the submucosa were not generally observed  
to show an in Akt activation compared to epithelial cells at the surface of the tumour. In addition, 
areas of epithelial cells were observed to show strong cell surface localisation of pAktSer473, similar 
to that observed in Apcf/f;Ptenf/f tissues at very early timepoints (as described in Section 5 .2 .1). 
Again, the regions of epithelial cells showing this alteration in subcellular localisation of pAktSer473 
tended to be located towards the lumenal surface of the tumour rather than within the invasive 
epithelial component (Figure 5.11).
From these data, it is therefore apparent that cell surface localisation of pAktSer473 in 
epithelial cells is a phenomenon associated with loss of both Pten and Ape, but is not associated 
with loss of Ape alone. In addition, relocalisation of Akt seems to be a feature of epithelial cells 
present at the lumenal interface of the tumour, but is surprisingly absent in cells found deep  
within the bulk of the tumour, and in cells invading underlying stromal tissue.
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Figure 5.11: Activation and cell-surface localisation of Akt in intestinal tumours arising in Apcf/+;Ptenf/f 
animals
Serial sections of tumours from Apcf/+;Ptenf/f mice, previously confirmed using IHC to be deficient for 
both Pten and Ape (See Figure 5.9) were subjected to anti-phospho-AktSer473 (pAkt) IHC. All tumours were 
found to show upregulated expression of pAkt in subsets of epithelial cells of tumours, compared to 
surrounding unaffected tissue (Left hand panel). Staining for pAkt was generally found to be most 
intense at the lumenal surface of the tumour. Regions of all tumours also showed relocalisation of pAkt 
to the cell surface (digital magnification of areas indicated with dashed boxes shown in right hand 
panel), which was not seen in surrounding tissue or in tumours arising in control Apcf/+ animals (See 
Figure 5.8). Scale bars indicate 100pm.
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5.3 Discussion
Previous work has shown that epithelial deletion of Pten results in no immediate 
perturbation of intestinal homeostasis (Chapter 3), but eventually permits tumourigenesis at very 
extended timepoints (Chapter 4). This raises the notion that an initiating mutation must be 
acquired in order for intestinal tumourigenesis to ensue, and that progression of disease is then 
facilitated by the Pten-deficient environment. One study examining the role of Pten in 
suppressing tumourigenesis in a tumour-prone background (the ApcMIN mouse) notes that 
constitutive heterozygosity for Pten promotes intestinal tumourigenesis (Shao et al., 2007), 
indicating that this hypothesis may be correct. However, work described here and elsewhere (He 
et al., 2007) has also indicated that the tumour suppressive function of Pten in the intestine is 
dependent upon the cell type(s) from which it is lost, with loss of Pten from both the epithelium 
and stroma apparently having a more potent effect compared to deletion from the epithelium 
alone. Due to the experimental approach employed by Shao et al., their study fails to address the 
differential effects of Pten loss from specific cell types in the context of a tumour-prone, Wnt- 
activated background. I have therefore examined the effects of epithelial-specific Pten loss in the 
context of activated Wnt signalling, achieved by conditional deletion of either one or both copies 
of the Ape allele.
5.3.1 Synergistic effect of Pten and Ape loss upon activation and subcellular localisation of Akt
I first examined the effect of Pten deletion following acute activation of Wnt signalling by 
deletion of both copies of Ape. Experimental (Apcf/f;Ptenf/f) and control (Apcf/f;Pten+/+, 
Apc+/+;Ptenf/f and Apc+/+;Pten+/+) animals were induced and culled at day 5 PI. Loss of Pten and Ape 
from the intestine was confirmed by IHC against Pten and against beta-catenin, a surrogate 
marker for Ape loss, on serial sections of tissue. This allowed visual identification of areas of tissue 
showing deficiency for Ape, Pten or both. Activation of the PI3K/Akt pathway was then assessed in 
adjacent tissue sections using IHC against phospho-AktSer473 (pAktSer473). This revealed that Akt was 
differentially activated in the crypt and villus of the intestine depending upon genotype. Epithelial 
tissues wild-type for both Pten and Ape were not observed to show activation of Akt, either on 
the crypt or villus. Epithelial cells singly-deficient for Ape alone did not show activation of Akt 
within the crypt compared to adjacent wild-type tissue, but a clear increase in staining for 
pAktSer473 was apparent on the villus. On the villus, staining was observed to occur in a 
homogeneously cytoplasmic fashion, with no observed alteration in subcellular localisation of 
activated Akt. In contrast to this, epithelial cells deficient for Pten alone were found to show a 
slight increase in staining for pAktSer473 in the crypt, but this was not apparent on the villus. Again, 
the cellular pattern of staining was observed to be homogeneously cytoplasmic. In tissue deficient
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for both Pten and Ape, a clear increase in activation of Akt is observed in the crypt, again with no 
change in subcellular localisation. On the villus (at the 'leading edge' of Pten- and Ape- deficient 
tissue), the increase in staining intensity for pAktSer473 is observed to be much more profound. In 
addition to this increase in staining, a clear alteration in subcellular localisation of pAkt is also 
observed, with much stronger staining evident at the cell surface. This is a significant finding, as 
cell-surface localisation of Akt has previously been associated with an increase in oncogenic 
potential, both in vitro and in a transgenic mouse model (Mende et al., 2001).
The differential staining patterns observed between crypt and villus may be attributed to 
the age of epithelial cells being examined. The kinetics of cell turnover in the epithelium dictates 
that the youngest epithelial cells reside in the crypt, with cells increasing in age up the crypt-villus 
axis towards the villus tip, where the oldest cells will reside (Heath, 1996). Thus, cells at the base 
of the crypt have arisen from a recombined stem cell, and will have been deficient for Pten and/or 
Ape for a relatively short period of time in their epithelial lifespan. Cells residing on the villus will 
have been Pten- and/or Apc-deficient for a more extended amount of time. Taking this into 
account, it appears that young epithelial cells deficient for Pten alone show an increase in 
activation of Akt, which then decreases over time as cells migrate up onto the villus. In a 
reciprocal pattern to this, epithelial cells deficient for Ape alone initially show no increase in 
activation of Akt, but with time levels of pAkt increase, and cells on the villus show a clear 
increase in Akt activation. When mutation of both Pten and Ape is combined in the epithelium, it 
could be hypothesised that these two scenarios combine and become synergistic. Double­
deficient epithelial cells show activation of Akt in the crypt, presumably driven by Pten deficiency 
at this stage. Activation of Akt in double-deficient cells on the villus is maintained, and at this 
point is presumably driven by activation of W nt signalling. In older cells on the villus, 
relocalisation of pAkt to the cell surface is also observed, which is not observed in single mutant 
controls. This is apparently a synergistic effect of loss of Pten and Ape, with increased expression 
of pAkt presumably driven by loss of Ape, and its relocalisation to the cell surface permitted by 
loss of Pten.
These data therefore imply that activation of Wnt signalling and loss of Pten may 
synergise to cause increased oncogenicity, through increased activation and cell-surface 
localisation of Akt. However, intestinal deletion of both copies of Ape is catastrophic for intestinal 
homeostasis, resulting in morbidity within approximately 5-7 days (Sansom et al., 2004). Thus, this 
model cannot be used to truly test the oncogenic potential of synergy between Wnt and PI3K/Akt 
signalling. For this reason, I next went on to examine the effect of epithelial Pten loss in the 
context of a Wnt-driven tumour-prone background, achieved by conditional deletion of one allele 
of Ape.
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5.3.2 Rapid progression of W nt-initiated tumourigenesis in the context of Pten deficiency
Experimental animals (Apcf/+;Ptenf/f) and controls (Apcf/+;Pten+/+, also referred to as 
'Apcf/+') were generated, induced and aged whilst being monitored for signs of intestinal disease. 
Apcf/+;Ptenf/f animals were found to have a significantly reduced lifespan, with a median survival 
of just 85 days, compared to Apcf/+ controls, which had a median survival time of 409 days. Upon 
dissection, Apcf/+;Ptenf/f animals were found to contain macroscopically different, flattened 
lesions within the small intestine and also polyp-like lesions within the large intestine. Histological 
analysis of small intestinal lesions revealed them to be bona fide malignant lesions of the mucosa. 
Multiplicity of tumours in the small and large intestines of Apcf/+;Ptenf/f animals and control Apcf/+ 
animals at timepoints of 190 and 250 days PI was scored. Apcf/+;Ptenf/f animals were found to 
have a significant increase in tumour burden within the small intestine. No difference in tumour 
multiplicity was observed in the large intestine, however it is notable that the tumour burden in 
the large intestine of Apcf/+;Ptenf/f animals was comparable to Apcf/+ controls at 190 and 250 days 
PI, given that the median survival time of Apcf/+;Ptenf/f animals is reduced to 85 days. These data 
therefore indicate that additional deficiency of Pten increases predisposition to tumour formation 
in both the small intestine and large intestine in an Ape heterozygous background.
Closer assessment of the small intestinal tumours arising in Apcf/+;Ptenf/f animals revealed 
them to be obviously histologically different to the tumours arising in small intestines of Apcf/+ 
controls. Tumours arising in Apcf/+;Ptenf/f animals were found to be more commonly invasive into 
both the stroma and the muscularis, showed a stronger desmoplastic response to the lesion and 
also showed signs of a host immune response to the tumour. These features were generally not 
observed in lesions of Apcf/+ animals, though occasional lesions showed early signs of invasive 
behaviour. Indeed, quantification of the severity of lesions arising in Apcf/+;Ptenf/f compared to 
Apcf/+ animals reflected these observations. In Apcf/+ animals, the majority of small intestinal 
lesions were found to be Adenomatous, with a small proportion of lesions found to show invasive 
characteristics (Early invasive adenocarcinoma; 14%). In contrast, fewer tumours in Apcf/+;Ptenf/f 
animals were found to be Adenomatous, with a larger proportion of early invasive 
adenocarcinomas compared to controls. A further, significant subset of tumours was found to 
have progressed to the advanced invasive adenocarcinoma stage.
It is therefore clear from these data that in the context of Ape heterozygosity, additional 
epithelial deletion of Pten drives both an increase in multiplicity of small intestinal lesions and 
also drives progression of those lesions to a malignant phenotype. The low level of background 
adenomas present in Apcf/+;Ptenf/f animals indicates that progression of disease is rapid in the 
context of Pten loss. In Apcf/+ animals, severity of intestinal disease was not observed to equal 
that of Apcf/+;Ptenf/f animals, even in very aged animals. This exemplifies the dramatic 
acceleration of disease progression resulting from epithelial Pten loss in the context of Ape
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heterozygosity. This finding is significant, as currently most mouse models of intestinal 
tumourigenesis model only the very early stages of disease initiation and polyp formation. 
However, here I have described a robust model of progression of intestinal tumours past the 
adenoma stage, with frequent development of advanced adenocarcinoma. However, it should be 
noted that the lesions described here were never observed to be metastatic, and this therefore 
represents a model of late-stage colorectal cancer, but not metastatic disease.
As described above, in the short-term, loss of both Pten and Ape synergise to cause 
activation and cell-surface localisation of Akt, which is associated with increased oncogenic 
potential. I next set about determining whether this phenomenon was associated with 
advancement of disease in Apcf/+;Ptenf/f animals compared to Apcf/+ controls.
I first confirmed that tumours in Apcf/+ small intestines were deficient for Ape but retained 
staining for Pten protein and that those in Apcf/+;Ptenf/f small intestines were deficient for both 
Ape and Pten. Adjacent serial sections were subjected to anti-Pten IHC and anti-beta-catenin IHC. 
This indicated that epithelial cells of tumours arising in Apcf/+ animals had lost Ape and showed 
increased expression and nuclear localisation of beta-catenin, but remained proficient for Pten 
protein. Tumours in Apcf/+;Ptenf/f animals were found to show similar increased expression and 
nuclear localisation of beta-catenin indicating loss of Ape, and were also found to show deficiency 
for Pten in epithelial cells, whilst the underlying stromal component retained positivity for Pten 
protein.
As above, adjacent sections of tumours were then immunohistochemically stained for 
pAktSer473. Tumours arising in Apcf/+ animals were found to show an increase in staining for pAkt 
compared to surrounding, unaffected tissue. Similar to single Ape mutant animals at day 5 PI, 
staining was observed to be homogeneously cytoplasmic, with no differential staining at the 
subcellular level. The strongest staining for pAkt was observed to be at the surface of the tumour, 
closest to the lumen of the intestine. Similarly, tumours from Apcf/+;Ptenf/f animals also showed an 
increase in staining for pAkt, which was also most apparent at the lumenal surface of the tumour. 
Additionally, tumours from Apcf/+;Ptenf/f animals were consistently found to contain regions 
where staining for pAkt was strongest at the cell surface of epithelial cells, similar to that seen in 
Apcf/f;Ptenf/f tissue at day 5 PI. These regions were also generally located at the surface of the 
tumour, closest to the lumen of the intestine, where pAkt was found to be upregulated. This 
therefore indicates that upregulation and cell surface localisation of pAkt may play a role in 
increased severity of disease in Apcf/+;Ptenf/f intestines. What is surprising, however, is that 
epithelial cells which are invading into the submucosa in these lesions do not show dramatic 
activation of Akt, and do not show an increase in cell surface staining for Akt. If cell surface 
localisation of activated Akt was the main influence driving progression of these lesions, it would 
be expected that these cells should stain in a similar fashion to those at the tumour surface. Thus,
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from these observations, I conclude that whilst the presence of activated Akt at the cell-surface of 
tumour epithelial cells is characteristic of tumours arising in Apcf/+;Ptenf/f animals, I cannot 
confirm that this phenomenon is directly driving progression (or at least invasion) of disease. 
However, the possibility that cell-surface localisation of pAkt is indirectly driving tumourigenesis 
remains, and in my opinion warrants further investigation.
5.3.3 Summary and future work
In summary, a number of conclusions can be drawn from the work presented in this 
chapter. Firstly, loss of Pten and Ape synergise to activate Akt, and also influence its subcellular 
localisation, resulting in increased association with the cell membrane. However, the implications 
of this on intestinal tumourigenesis remain unclear. One potential way of clarifying the role of 
membrane-associated Akt in driving tumourigenesis in Apcf/+ mice would be to make use of a 
conditionally-expressed membrane targeted form of Akt, such as that previously published 
(Mende et al., 2001). If Apcf/+ mice bearing this membrane-targeted form of Akt were found to 
phenocopy the observed increase in severity of intestinal disease reported here in Apcf/+;Ptenf/f 
mice, it would provide compelling evidence for the fact that disease progression is driven by 
altered subcellular localisation of Akt. Furthermore, it would be interesting to determine whether 
relocalisation of pAkt to the cell-surface is a feature of advanced human disease, as it may 
potentially provide a good prognostic marker for colorectal lesions5.
Secondly, in the context of Ape heterozygosity, it is clear that additional loss of Pten 
causes a rapid progression of tumourigenesis, resulting in invasive disease. The penetrance of 
invasive intestinal tumours in these mice is extremely high, meaning that this strain represents a 
robust model of advanced intestinal cancer, though does not model metastasis of disease. The 
generation of this model is a significant finding, as few good mouse models of more advanced 
disease states currently exist. The potential of this model for use both in developing therapies 
aimed at advanced disease, as well as to allow closer examination into the mechanisms 
underlying invasion and progression of intestinal lesions, is therefore great. Furthermore, 
additional mutations could be incorporated into this model in an attempt to generate a model of 
metastatic colorectal cancer. One good candidate for this would be E-Cadherin, a cell-surface 
adhesion protein, which is found to be downregulated in more advanced human disease, and has 
been associated with increased invasiveness and metastasis (Van Aken et al., 1993). If this were 
achieved, this series of models would then represent all the major stages involved in multi-step
5 A tissue array based on human colorectal cancer biopsies for presence and subcellular localisation 
of Akt is currently being carried out in collaboration with Dr Marnix Jansen of Hans Clevers' group, Hubrecht 
Institute, The Netherlands.
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colorectal tumourigenesis, from initiation of disease (in Apcf/+ mice), through progression and 
invasiveness of tumours (in Apcf/+;Ptenf/f mice) to full-blown metastatic disease (See Figure 5.12).
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Figure 5.12: The potential o f Ape and Pten-deficient mice to generate an anim al model o f step-wise 
progression o f colorectal cancer
Loss of one copy of Ape alone results in initiation of tumourigenesis and adenoma formation, as 
described here and elsewhere (Shibata et al., 1997, Moser et al., 1995). Additional loss of Pten 
results in an increase in severity of tumour phenotype, as indicated by increased dysplasia and 
invasiveness of epithelial cells and a strong desmoplastic and immune response. However, this does 
not model metastatic disease. Additional mutations could be incorporated into this model, for 
instance in the adhesion protein E-Cadherin, in order to promote metastasis of malignant cells.
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Chapter 6: Multiple tissue phenotypes associated with AhCreERT-driven 
deletion of Pten and activation of k-Ras
6.1 Introduction
In Chapter 3 , 1 described work indicating that, despite the fact that Pten is well recognised 
as a tumour suppressor gene, its loss has little immediate effect upon the intestinal epithelium. 
One explanation for the observed lack of perturbation in intestinal homeostasis and indeed for 
the absence of tumourigenesis immediately following Pten deletion is the fact that Pten is a 
'permissive' tumour suppressor. That is, its deletion does not directly stimulate activation of the 
PI3K/Akt pathway; rather it permits its activation. As such, if the PI3K pathway is not normally 
active within the cell from which Pten has been deleted, this will have little effect with regard to 
activation of downstream targets. It could therefore logically be argued that the tumour 
suppressive effects of Pten will only become relevant in the context of activation of the PI3K 
pathway.
The oncogene Kirsten (k)-Ras is frequently activated in human colorectal cancers 
(Malumbres and Barbacid, 2003). Previous work has indicated that k-Ras can directly activate the 
p llO  catalytic subunit of PI3K, independently of the regulatory p85 subunit (Kodaki et al., 1994). 
Through activation of k-Ras, the PI3K/Akt pathway can thus be activated without the influence of 
upstream signals, such as growth factors. K-Ras also participates in the Raf-MEK-ERK mitogen- 
activated protein kinase (MAPK) signalling pathway, with activated k-Ras resulting in activation of 
the signalling cascade. This in turn results in an increase in transcription of target genes, and 
progression of the cell cycle (Malumbres and Barbacid, 2003). As such, aberrant activation of k- 
Ras can be thought of as providing a 'double hit' to cells in terms of oncogenesis; causing 
activation of both the PI3K/Akt pathway and of the Raf-MEK-ERK MAPK pathway.
Synergy between activation of k-Ras and loss of Pten has been demonstrated in vivo in 
several tissue systems. Iwanaga et al. (2008) find that in the lung, additional loss of Pten in the 
context of activation of k-Ras results in acceleration of tumourigenesis. Furthermore, lesions 
arising in double mutant animals were found to be more advanced than those in k-Ras mutants 
alone, with an increase in tumour invasion, greater vascularisation of tumours and a marked host 
immune response. Co-operation between k-Ras and Pten has also been noted in the development 
of endometrioid ovarian cancer (Dinulescu et al., 2005). This study reports that, whilst mutation 
of either k-Ras or Pten alone results in the development of pre-neoplastic lesions of the female 
genitourinary tract, combined mutation of both genes results in rapid development of 
endometrioid ovarian adenocarcinomas. These cancers were found to be characterised by strong
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activation of the PI3K/Akt pathway, as evidenced by detection of high levels of phospho-Akt, 
phospho-mTOR and phospho-S6 kinase, as well as activation of the Raf-MEK-ERK pathway, as 
indicated by increased expression of phospho-ERK.
In mouse models such as these, conditional activation of the k-Ras oncogene is 
accomplished through expression of a constitutively active form of k-Ras, achieved by 
incorporation of an activating point mutation at codon 12 (Malumbres and Barbacid, 2003). The 
mutant k-Ras allele is normally kept in a transcriptionally silent state through use of a LoxP- 
flanked STOP cassette within the transgene. Thus, exposure to Cre recombinase permits the 
mutant form of k-Ras to be expressed.
In the intestine, studies employing this strategy have indicated that sensitivity exists both 
with respect to levels of activated k-Ras and with respect to the exact point mutant form of k-Ras 
which is used. Strong expression of the G12V mutant (glycine to valine substitution at codon 12) 
of k-Ras has been shown to result in rapid development of intestinal neoplasms (Janssen et al., 
2002). In contrast, more moderate expression of the same G12V mutant of k-Ras, driven by its 
endogenous promoter, results in a less severe spectrum of intestinal phenotypes. One study 
reports little effect upon intestinal homeostasis following activation of k-Ras (Sansom et al., 
2006), whilst a separate study identifies the formation of aberrant crypt foci, but no overt 
intestinal lesions (Guerra et al., 2003). Furthermore, use of the same endogenous promoter to 
drive a G12D point mutant for of k-Ras is reported to result in rapid and widespread hyperplasia 
and dysplasia of the epithelium (Tuveson et al., 2004). Thus it is clear that both levels of 
expression of k-Ras and the exact mutant form of the oncogene both have a bearing upon 
intestinal phenotype.
In the intestinal tumour-prone context of activated Wnt signalling, Sansom et al. have 
further shown that additional aberrant activation of k-Ras (using the endogenously expressed 
G12V mutation) causes moderate progression of tumour severity, with resulting tumours showing 
early invasive characteristics (Sansom et al., 2006). However, potential synergy between 
activation of k-Ras and deletion of Pten specifically within the intestine remains unexplored.
In this chapter, I aimed to investigate the role of Pten as a tumour suppressor in the 
context of activation of the PI3K pathway. This is achieved by conditional and co-ordinate 
activation of the endogenous k-RasV12 mutant transgene and deletion of Pten in the intestinal 
epithelium. This approach was chosen to allow me to address the notion that Pten is a 
'permissive' tumour suppressor, and that its loss only becomes significant in the context of 
activated PI3K signalling. In addition, any potential synergy between Pten loss and k-Ras activation 
with respect to activation status of the PI3K/Akt and Raf-MEK-ERK pathways will be assessed, and 
any resulting impact on intestinal homeostasis or tumourigenesis evaluated.
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6.2 Results
6.2.1 Mice with induced deficiency of Pten and activation of k-Ras show a dramatic reduction in 
survival time
Experimental animals, bearing LoxP-targeted Pten alleles (Ptenf/f) and heterozygous for 
the LoxP-STOP activated endogenous k-Ras G12V mutant transgene (kRas+/T) (Guerra et al., 2003) 
as well as the double-regulated Cre transgene, AhCreER1, were generated
(AhCreERT+;Ptenf/f;kRas+/T, herein referred to as 'Ptenf/f;kRas+/T'). Appropriate controls 
(AhCreERT+;Ptenf/f;kRas+/+, also referred to as 'Ptenf/f', AhCreERT+;Pten+/+;kRas+/T, also referred to as 
'kRas+/T', and AhCreERT+;Pten+/+;kRas+/+, referred to as 'WT') were also generated. Cohorts of all 
genotypes of mice, each comprised of more than 15 animals, were induced as described (Section 
2.1.3.3). Animals were then aged, whilst being monitored for signs of disease, and culled when 
moribund.
Induced Ptenf/f;kRas+/T cohort animals were found to rapidly become morbidly 
underweight, which in the majority of instances forced early culling of the animal. Weight loss was 
not observed in any control animals.
Kaplan-Meier survival analysis of all cohorts was performed (Figure 6.1). This revealed a 
prominent reduction in survival time of Ptenf/f;kRas+/T animals compared to all control genotypes. 
Ptenf/f;kRas+/T animals were found to have a median survival time of just 43 days after induction, 
compared to Ptenf/f controls and WT controls which had median survival times of 409 days and 
801 days respectively. Median survival time of the kRas+/T control cohort was not determined, as 
this experiment has not yet reached completion and more than 50% of the animals in the cohort 
currently remain healthy. The difference in survival times between all control and Ptenf/f;kRas+/T 
cohorts was found to be statistically significant (Kaplan-Meier analysis, p<0.001, DF=3, x2=125.45).
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Figure 6.1: Kaplan-Meier survival analysis of Ptenf/f;kRas+/T mice compared to controls
Ptenf/f;kRas+/T and controls (Ptenf/f; kRas+/Tand WT) were induced and aged, and culled when 
symptomatic of disease. Ptenf/f;kRas+/T animals were found to have a dramatically reduced survival 
time compared to all controls, with a median survival time of 43 days, compared to 409 days and 
801 days of Ptenf/f and WT controls respectively. Median survival time of kRas+/T controls was not 
determined as this experiment has not yet reached completion and more than 50% of the animals 
in the cohort currently remain healthy. Reduction in survival time of Ptenf/f;kRas+/T animals was 
found to be statistically significant (Kaplan-Meier analysis, p<0.001, DF=3, x2=125.45).
180
6.2.2 Highly penetrant phenotypes of gall bladder and bile duct lesions, and forestomach 
squamous hyperplasia in Ptenf/f;kRas+/T animals
Upon dissection, virtually all Ptenf/f;kRas+/a animals were found to bear macroscopically 
visible abnormalities of both the stomach and the gall bladder. Stomachs were found to be grossly 
enlarged, but rather than containing normal stomach contents were found to be filled with 
abnormal tissue, apparently arising from the forestomach. Gall bladders were found to be 
enlarged and distended, and in most cases were filled with clear fluid. A subset of Ptenf/f;kRas+A 
animals were also noted to develop mild skin lesions, which appeared as warty growths, 
commonly on the skin of the abdomen and face. No gross lesions of the intestine were evident 
upon dissection. Abnormalities of the stomach, gall bladder or skin of Ptenf/f, kRas+A or WT 
animals were not evident by macroscopic assessment at dissection.
Normal and abnormal tissues were removed from animals of each cohort, and were fixed 
and processed as described (Sections 2.2 and 2.3) in order to generate H&E-stained tissue 
sections for histological assessment. Microscopic examination of these sections confirmed that 
skin, forestomach and gall bladder tissue from Ptenf/f;kRas+A animals was histologically abnormal.
In order to quantify the frequency of abnormalities of the epithelium of the biliary system 
(gall bladder and intrahepatic bile ducts) and of the squamous epithelium of the forestomach 
arising in Ptenf/f;kRas+/T animals, the presence of these lesions was scored. All Ptenf/f;kRas+/T 
animals analysed (n=15) were found to bear hyperplastic lesions of the biliary epithelium, arising 
within both the gall bladder and hepatic bile ducts (Figure 6.2). In contrast, 33% of aged Ptenf/f 
control animals (8 out of 24 animals) were found to show microscopic evidence of abnormalities 
of the biliary epithelium, as described in Chapter 4 (Section 4.2.3). No abnormalities were 
observed in WT (n= 20) or kRas+/T (n=4) control animals. In the forestomach, hyperplasia was also 
clearly evident in all Ptenf/f;kRas+/T tissue examined (n=15). Abnormalities of the forestomach 
were never observed in WT, Ptenf/f or kRas+/T control cohorts (n=20, n=8 and n=4 respectively).
Thus, from this data, it appears that co-ordinate deletion of Pten and activation of k-Ras 
results in rapid development of epithelial abnormalities of both the biliary system and of the 
forestomach with complete penetrance.
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Figure 6.2: Scoring of pathologies found in P ten f^R as^ and control animals
Normal and abnormal tissues were removed from Ptenf/f, kRas+/T and WT controls and Ptenf/f;kRas+/T 
experimental animals, fixed and processed, and H&E-stained tissue sections generated. Tissues were 
then assessed microscopically for tissue abnormalities. All Ptenf/f;kRas+/T animals (White bars, 100%, 
n=15) were found to show evidence of hyperplasia of the epithelial cells of the gall bladder and/or 
hepatic bile ducts, as well as hyperplasia of the squamous epithelium of the forestomach. In contrast, 
Ptenf/f control animals (grey bars) were found to show histological evidence of gall bladder/bile duct 
epithelium hyperplasia in 33% of cases (8 out of 24 animals) and did not show evidence of forestomach 
hyperplasia. WT and kRas+/T control animals were not found to bear either type of lesion in any animal 
analysed (n=20 and n=4 respectively).
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6.2.3 AhCreER7 drives recombination in the gail bladder epithelium and forestomach squamous 
epithelium
Given that lesions of the forestomach and biliary system were apparently the cause of 
morbidity in Ptenf/f;kRas+/7 animals, and were present with high penetrance, I more thoroughly 
characterised these abnormalities.
In order to confirm that the phenotypes observed in Ptenf/f;kRas+/T animals occurred as a 
result of Cre-mediated recombination, I first set about confirming that AhCreER7 drives 
recombination within the epithelium of the biliary system and in the squamous epithelium of the 
forestomach using the induction protocol described (See Section 2.1.3.3). Animals bearing the 
AhCreER7 transgene and the ROSA26 LacZ reporter construct (Soriano, 1999) were induced and 
culled at day 7 PI. Tissues were removed and subjected to X-Gal staining as described (Section 
2.2.6) in order to visualise the location of recombined cells.
Staining of stomach wholemounts revealed the presence of LacZ-expressing cells at a 
relatively low frequency, indicating recombination within occasional cells in the forestomach 
(Figure 6.3A). Examination of X-Gal stained cryosections of stomach tissue revealed more 
precisely the exact location of recombined cells. Positively-stained cells were found to be present 
only within the layer of squamous epithelium of the stomach, and were absent from underlying 
stromal and smooth muscle cells.
Similarly, cryosections of gall bladder were X-gal stained to reveal LacZ-expressing cells. 
Positively-stained cells were apparent within the epithelium of the gall bladder, with levels of 
recombination noted to be higher than that observed in the forestomach (Figure 6.3B). Stained 
cells were found to be tightly restricted to the gall bladder epithelium, with no staining evident 
within any other cell types of the tissue.
Thus, it can be concluded that the induction protocol in use here drives low-level 
activation of Cre recombinase, and hence recombination at the ROSA26 allele within both the 
forestomach and the gall bladder, and in both cases is restricted to the epithelial cell population.
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F ig u re  6 .3 : Low-level recombination in the forestomach and gall bladder epithelium driven by 
AhCreERT
Animals bearing both the AhCreER7 and ROSA26 LacZ reporter transgenes w ere induced as described, 
and culled at day 7 PI. Subsequent X-Gal staining allowed visualisation of the location and frequency of 
recombined cells within the forestom ach (A) and gall bladder (B). W holem ount staining o f stomachs 
from  tw o  individual animals (A, top panels, as viewed from  the lumenal surface of the stomach) revealed 
occasional cells to  be positive fo r LacZ activity. Staining o f cryosections of the forestom ach (bottom  
panels, right hand panel shows a digital enlargem ent o f the indicated area in the left hand panel) 
revealed positively-stained cells to  be solely within the squamous epithelium of the forestom ach, with  
no staining for LacZ activity observed within any other cells types of the tissue. Staining of cryosections 
of the gall bladder (B, right panel shows a digital enlargem ent o f the region indicated in the left panel) 
revealed that recombination occurred within epithelial cells lining the gall bladder, but not in other cells 
types present. Scale bars indicate 100pm .
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6.2.4 Co-ordinate loss of Pten and activation of k-Ras results in hyperplasia and papilloma of 
both gall bladder epithelium and bile duct epithelium
Having established that AhCreER1 drives recombination in the biliary epithelium, I next 
characterised the histopathology of gall bladder and bile duct lesions arising in Ptenf/f;kRas+/T mice 
more thoroughly.
The advice of an experienced histopathologist was sought to assist with this6. The 
majority of lesions within the gall bladder of Ptenf/f;kRas+/T mice were identified as being 
hyperproliferative papilloma or dysplastic papillary adenomas of the epithelium (Figure 6.4A). A 
spectrum of lesion severity was identified, varying from mild epithelial hyperplastic foci to, in one 
case, the development of a moderately differentiated, invasive adenocarcinoma (Figure 6.4B). 
Comparable lesions of any grade were not identified in gall bladders of control animals of any 
genotype (Figure 6.4A). Epithelial lesions arising within intrahepatic bile ducts were found to be 
histologically similar to those of the gall bladder epithelium, though were generally found to be 
less severe. The majority of lesions were found to be multifocal papillomata, involving bile ducts 
of all sizes within the liver (Figure 6.5A). These papillomatous lesions were found to display 
varying degrees of dysplasia, which in isolated cases was found to amount to carcinoma in situ, 
but invasive disease or signs of cholangiocarcinoma were not identified. Ductal lesions arising in 
aged Ptenf/f controls (described in Chapter 4, Section 4.2.3) were identified as being histologically 
different to the lesions described here in Ptenf/f;kRas+/T animals. As such, these lesions will not be 
considered in further analyses within this chapter. Biliary epithelium in kRas+/T and WT animals 
within control cohorts was found to be of normal histological appearance (Figure 6.5A).
In order to confirm that the lesions observed in Ptenf/f;kRas+/T animals were derived from 
biliary epithelial cells, sections of histologically normal control tissues from WT and kRas+/T 
animals, and lesions arising in gall bladder and bile ducts of Ptenf/f;kRas+/T animals were subjected 
to Anti-cytokeratin (CK) 19 IHC, a marker of biliary epithelial cell types. Staining for CK19 was 
evident in normal bile duct epithelium and gall bladder epithelium of control (WT and k-Ras+/T) 
tissue sections (Figure 6.6). Positivity for CK19 was found to be retained in papillomata of both the 
bile duct and of the gall bladder epithelium in Ptenf/f;kRas+/T animals. Thus, this confirms that 
these lesions are indeed of biliary epithelial cell origin.
To qualitatively examine levels of proliferation within biliary epithelial lesions arising in 
Ptenf/f;kRas+/T animals, I next performed Anti-Ki67 IHC upon tissue sections as described in section 
2.4. This revealed that lesions arising in the biliary epithelium of Ptenf/f;kRas+/T animals were 
highly positive for nuclear Ki67, with the vast majority of epithelial cells comprising the lesion
6 The histopathological description and com parison o f lesions arising in gall b ladder and bile duct ep ithelia  o f 
P te n f/f;kR as+/T m ice and P tenf/f control m ice was kindly provided by Prof G erain t T. W illiam s, D ep artm e n t o f Pathology, 
U niversity Hospital o f W ales, C ardiff University, UK.
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showing positive staining (Figure 6.7). This staining pattern was in contrast to that of areas of 
tissue on the same section which were found to be histologically normal. Such normal areas of 
tissue were found to contain only very occasional epithelial cells which were positively stained for 
Ki67. These observations therefore confirmed previous histopathological observations, indicating 
that the lesions arising within the biliary epithelium of Ptenf/f;kRas+/T animals are highly 
proliferative and hyperplastic.
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Figure 6 .4 : Ptenf/f;Ras+/T mice are susceptible to hyperproliferative papilloma of the gall bladder epitheliurt1
Lesions arising within the gall bladder of Ptenf/f;kRas+^  animals were mostly identified as being 
hyperproliferative papilloma or dysplastic papillary adenomas of the epithelium (A). Similar lesions were not 
observed in gall bladder epithelia of control (Ptenf/f, kRas+/T and WT) animals. Rarely, more severe lesions o f  
the gall bladder were identified, including one moderately differentiated, invasive adenocarcinoma (B, right 
hand panel shows magnification of the area indicated in the left hand image). Scale bars indicate 100pm.
187
APtenf/f
Fig ure  6 .5 :  Pten}/f;Ras+/T mice show susceptibility to papilloma of the bile duct
Papillomatous lesions of the epithelium of intrahepatic bile ducts of all sizes were noted within 
Ptenf/f;kRas+/T animals (A). Similar lesions were not observed within bile ducts of control (Ptenf/f, kRas+/T 
or WT) animals. Papillomatous lesions arising in experimental animals were found to have varying 
degrees of dysplasia, which in some cases amounted to carcinoma in situ (B, Right hand panel is an 
enlargement of the indicated area of the left hand panel). Scale bars indicate 100pm. Asterisks indicate 
lumen of bile ducts.
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Figure 6.6: Anti-Cytokeratin 19 IHC reveals ductal origins o f gall bladder and bile duct 
papillom atous lesions
Anti-cytokeratin  19 IHC was perform ed on lesions o f the gall b ladder and bile ducts 
arising in Ptenf/f;kRas+/T animals in o rder to  confirm  th a t the  observed lesions arise from  
epithelial cells o f the biliary system. Norm al gall b ladder and bile duct epithelia l cells in 
W T and k-Ras+/T control animals w ere  found to  stain positively fo r CK19 expression. 
Papillom atous lesions w ith in  both the  gall b ladder and bile ducts o f Ptenf/f;kRas+/T 
animals w ere  also found to  show positive staining for CK19, indicating the lesions w ere  
indeed derived from  biliary epithelial cells. Scale bars indicate 100pm .
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Figure 6.7: Biliary papillom atous lesions arising in Ptenf/f;kRas+/T mice are Ki67 
an tigen-positive
In order to  assess pro liferation  w ith in  papillom ata o f the biliary ep ithelium , IHC 
against the m arker o f p ro liferation , Ki67, was used to  identify pro liferating cells. 
Lesions arising in th e  biliary ep ithelium  o f Ptenf/f;kRas+/T animals w ere  found to  be 
Ki67-positive, w ith  virtually  all cells o f the  lesions showing nuclear staining (Top 
panel, representative im age o f a papillom a arising in the bile duct o f a P tenf/f;kRas+/T 
anim al). In contrast to  this, histologically norm al bile ducts in th e  same tissue 
section w ere  found to  contain epithelial cells which w ere m ainly K i67-negative, 
indicating a low level o f pro liferation in norm al tissue (Lower panels, Asterisks 
indicate lum en of unaffected bile ducts. A rrow  indicates one exam ple o f an 
occasional ductal epithelial cell found to be Ki67-positive). Scale bars indicate  
100pm .
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6.2.5 Papillomatous lesions of the gall bladder are characterised by activation and membrane 
localisation of Akt
In order to assess activation of the PI3K/Akt pathway in papillomatous lesions of the gall 
bladder, I next performed Anti-phospho-AktSer473 IHC on serially-sectioned gall bladder tissue of 
Ptenf/f;kRas+/T and kRas+/T and WT control animals. First, Pten protein status was confirmed in the 
gall bladder epithelium of both control and Ptenf/f;kRas+/T animals using Anti-Pten IHC. This 
revealed that gall bladder epithelial cells of control mice (WT and kRas+/T) stained positively for 
the presence of Pten protein in all cases, with little staining of underlying stromal and smooth 
muscle cells (Figure 6.8). In comparison to the levels of staining observed in control animals, 
Ptenf/f;kRas+^  animals were found to show a significant reduction in Anti-Pten staining within the 
epithelial cell layer, although low-level staining was still evident in isolated areas of some lesions 
and in unaffected epithelial cells. This probably reflects the sub-100% frequency of recombination 
within the gall bladder epithelium observed by LacZ reporter analysis. I then performed IHC 
against activated Akt (phospho-AktSer473, pAkt) on adjacent tissue sections. In kRas+/T and WT 
control tissues, extremely low levels of staining for pAkt were apparent within the epithelium. In 
contrast to this, sections derived from Ptenf/f;kRas+/T animals were found to have an increased 
staining intensity for pAkt within lesions, though epithelial cells which were not associated with 
lesions did not show this increase in staining. Furthermore, gall bladder lesions were observed to 
contain areas of neoplastic epithelial cells which showed strong cell surface staining for pAkt 
(Figure 6.8). Epithelial cells showing this altered subcellular localisation of pAkt were not noted to 
be consistently located within any particular region of each lesion.
Thus, it appears that concomitant loss of Pten and activation of k-Ras results in both 
strong activation of Akt, and in its localisation to the cell surface. This phenomenon is comparable 
to that previously observed within the intestine following combined loss of Pten and Ape (Chapter 
5).
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F ig u re  6 .8 :  Upregulation and cell surface localisation ofpA kt5^ 473 in gall bladder lesions of 
Ptenf/fjkRas*/7 mice
Anti-Pten IHC confirm ed th a t gall bladder epithelial cells o f control genotypes (W T and k-Ras+/T) 
show positivity for Pten, whilst lesions arising in experim ental animals (Ptenf/f;kRas+/T, tw o  
independent lesions are shown) show a dramatic reduction in Anti-Pten staining. Anti-pAktSer473 
IHC was perform ed on adjacent serial sections o f tissue, which indicated that, whilst tissues from  
W T and kRas+/T control animals w ere essentially devoid of staining, upregulation of activated Akt 
was apparent in lesions of Ptenf/f;kRas+/T animals. In addition to an increase in activation of Akt, 
cell surface localisation of pAkt w ithin epithelial lesions was also observed (insets show digital 
enlargem ents of the areas indicated in the main image). Scale bars indicate 100pm .
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6.2.6 The mitogen-activated protein kinases, MEK and ERK, are activated in gall bladder 
papillomata
Having confirmed activation of the PI3K/Akt pathway in gall bladder epithelial lesions 
following loss of Pten and activation of k-Ras, I next assessed the activation status of the Ras-MEK- 
ERK pathway in these lesions. To do this, I performed anti-phospho-MEKSer221(pMEK) and anti- 
phospho-ERKThr202/Tvr204 (pERK) IHC as described in section 2.4, on serial sections of gall bladder 
from each cohort.
Staining for pMEK revealed low levels of expression within the epithelium across all 
genotypes. In control tissue sections (WT and kRas+/T), no staining for pMEK was evident in any 
cell type within the gall bladder (Figure 6.9). In Ptenf/f;kRas+/T tissue sections, low levels of 
epithelial-specific staining were evident within gall bladder lesions. Staining was not apparent in 
surrounding, uninvolved epithelial cells.
As staining for pMEK appeared to be weak, I next examined the activation status of the 
downstream cellular target of activated MEK, ERK. IHC against pERK revealed that, in control 
tissues, pERK was detected specifically within the epithelial cell layer (Figure 6.9). Staining was 
observed to be cytoplasmic, with a slight increase in staining intensity at the lumenal surface of 
cells. In contrast, lesions within Ptenf/f;kRas+/T animals were found to show increased activation of 
ERK, as indicated by an increase in staining intensity for pERK. Epithelial cells not associated with 
lesions were not observed to show an increase in staining intensity for pERK. The detected 
increase in activation of pERK within lesions arising in Ptenf/f;kRas+^  animals was also found to be 
coupled with strong nuclear localisation of the activated protein. This phenomenon was not 
observed either in kRas+^  or WT control tissues, or in uninvolved areas of epithelium in 
Ptenf/f;kRas+/T tissue sections.
These data therefore indicate that, in gall bladder lesions within Ptenf/f;kRas+^  animals, an 
increase in activation of both MEK and ERK is detectable, indicating activation of the Raf-MEK-ERK 
pathway within these neoplasms. Activation of this pathway is not evident in gall bladder 
epithelial cells of control tissues, or in histologically normal regions of gall bladder epithelium 
present in Ptenf/f;kRas+/T animals.
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Figure 6.9: Upregulation o f pM EK ^r221 and pERKThr202/Tyr204 in gall b ladder lesions o f Ptenf^;kRas+/T 
mice.
Activation of the Raf-MEK-ERK pathway in gall bladder papillomata of Ptenf/f;kRas+/T mice was 
assessed using anti-phospho-MEKSer221 and anti-phospho-ERKThr202/Tyr204 IHC. Staining for pMEK was 
not observed in gall bladder epithelial cells of either control (WT or kRas+/T) or Ptenf/f;kRas+/T 
animals, though a subtle increase in staining within lesions of Ptenf/f;kRas+/T animals was apparent. 
In tissues of WT and kRas+/T control animals, pERK staining was evident in epithelial cells, and was 
noted to be homogeneously cytoplasmic. In lesions of Ptenf/f;kRas+/T mice, an increase in staining 
intensity was observed, together with nuclear localisation of staining (inset images are digital 
enlargements of the areas indicated on the main image). Scale bars indicate 100pm.
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6.2.7 Akt is moderately activated, but not membrane localised in bile duct hyperplasia
Having established that activation of the PI3K/Akt pathway and of the Raf-MEK-ERK 
pathway is characteristic of papillomatous lesions of the gall bladder epithelium, I next 
determined whether the same pattern was true for histologically similar lesions arising within 
intrahepatic bile ducts.
As previously, I first confirmed Pten status within normal and abnormal bile duct 
epithelium in WT, Ptenf/f and kRas+^  control and Ptenf/f;kRas+/T experimental animals using anti- 
Pten IHC. Staining for Pten protein was detected in bile duct epithelial cells of WT and kRas+/T 
control genotypes (Figure 6.10). As expected, tissues from Ptenf/f control and Ptenf/f;kRas+/T mice 
were found to be deficient for Pten, indicating recombination had occurred within the biliary 
epithelium and that Pten protein was lost from these cells.
I next performed anti-pAktSer473 IHC on adjacent tissue sections. As observed in gall 
bladder epithelial cells (described above), low levels of staining for pAkt were detectable in WT 
and kRas+/T control ductal epithelial cells (Figure 6.10). Ductal cells in Ptenf/f controls, which were 
confirmed to be deficient for Pten, were found to show a slight increase in activity of Akt, as 
indicated by an increase in staining intensity. However, this level of Akt activation remained lower 
than that observed in ductal lesions within Ptenf/f;kRas+/fT animals. These lesions were consistently 
observed to show an increase in staining for pAkt compared to Ptenf/f, kRas+/T and WT control 
tissues and also in comparison to adjacent histologically normal ductal cells. In contrast to lesions 
arising within the gall bladder epithelium, in no instance was the subcellular localisation of pAkt 
found to be altered in ductal lesions.
Therefore, lesions arising within intrahepatic bile ducts of Ptenf/f;kRas+/T animals, which 
are histologically similar to lesions arising within the gall bladder, show activation of Akt, similar to 
that seen in gall bladder lesions. However, cell membrane localisation of pAkt, previously noted in 
gall bladder lesions, was not detected in lesions arising within intrahepatic bile ducts.
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Figure 6.10: Upregulation o f pAkt5^ 473 in bile duct lesions o f Ptenf/f;kRas+/T mice
Pten status and activation of Akt was determined in intrahepatic bile duct epithelial cells 
in WT, kRas+/T and Ptenf/f control and Ptenf/f;kRas+/T experimental tissues. Anti-Pten IHC 
confirmed Pten expression in epithelial cells of WT and kRasf/+ control animals, whilst loss 
of staining for Pten protein was observed in epithelial cells of Ptenf/f controls and in 
papillomatous lesions arising in Ptenf/f;kRas+/T animals. Activation of Akt was not 
observed in Pten-proficient ductal epithelia in WT and kRas+/T control animals. A slight 
increase in staining for pAkt was observed in Ptenf/f bile ducts, but the strongest staining 
was observed in lesions arising in Ptenf/f;kRas+/T animals. This increase in activation of Akt 
was not found to be associated with any change in subcellular localisation of the protein. 
Scale bars indicate 100pm. Asterisks indicate lumen of bile ducts.
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6.2.8 Activation of MEK and ERK in bile duct lesions
As activation of the Raf-MEK-ERK pathway was observed in lesions of the gall bladder in 
Ptenf/f;kRas+/T animals, I next assessed activation of the Raf-MEK-ERK pathway in serially-sectioned 
Ptenf/f;kRas+/T and control bile duct epithelia using anti-pMEK and anti-pERK IHC.
Anti-pMEK IHC indicated that pMEK was not detected within ductal epithelial cells of WT, 
Ptenf/f or kRas+/T control genotypes, or within either normal or abnormal ductal epithelium of 
Ptenf/f;kRas+A animals. No staining, either of epithelial cells or other cells types was noted across 
all tissue sections (Figure 6.11).
As staining for pMEK was previously noted to be weak, I examined the activation status of 
ERK, a downstream target of MEK, regardless of the fact that MEK activation was not detected in 
ductal lesions. Low levels of expression of pERK were observed in ductal epithelial cells of all three 
control genotypes (WT, kRas+/T and Ptenf/f). Despite the fact that MEK activation was not noted in 
lesions within ducts of Ptenf/f;kRas+/T animals, strong staining for activated ERK was noted. As 
observed in gall bladder lesions in Ptenf/f;kRas+/T animals, this increase in expression of activated 
ERK was also found to be associated with nuclear localisation of the protein (Figure 6.11).
From these data, I therefore conclude that, whilst activation of MEK is not detected, a 
clear activation of ERK in lesions of the intrahepatic bile duct epithelium of Ptenf/f;kRas+/T animals 
is observed. This activation and nuclear localisation of ERK is comparable to that noted in gall 
bladder epithelial lesions arising in animals of the same genotype.
197
A n ti-p M E K Ser221
CO
ro
cd
CD-t—i• 
Q_
Anti-pERKThr202/Tyr204- ‘ ' /  *
/ »*
• * -  
*
v  v•'.'V . '-v '- ** 
>■ • -
\  l  ^  ,?v.
* <£* * - •
:
•  *  • 1 - •* •  * •  - A •
l ♦;
;  « « ; * i  ♦
. " -• • * cnf* . »** •. <jlr* ' n C * *
> . * * * 4 • • V  ^ • r •
*1 *> * - * •  * . *• A
. . . .- % • i f  ' 
• “ * ♦ -* • * - 
'  r- .••>?» *• S „-•.a f* . r  ‘• V  .♦ # •. •* v ST * ,
*, X  - • • • •.• • • ^ . 1*^  •
- V  •* •
- . I V -  • *r> • * %
'  *  .  ©  • \ -  
- v  A  • " * *
;  A /a
-  C* *  ' *  t "  ’
D  *  "  u X ,U  # «  « •  „ I f * k * •
1  •  *
— -------------------------
.* •
• “ •  \ ** jI 'V * ff \ **“*tr '  i
r " * *rT H 'le • "** * «*
* <L ••
# m*
S v # r 5 v - ‘ * v : ; *
^  W - M v  . .
W  w
*
IHC against pMEK and pERK was used to determ ine  activation status o f the Raf-MEK- 
ERK pathw ay in lesions arising w ith in  in trahepatic  bile ducts in Ptenf/f;kRas+/T 
animals. Expression o f activated MEK (pMEK) was not detected w ith in  lesions of 
Ptenf/f;kRas+/T mice, or in norm al tissues from  W T, kRas+/Tor Ptenf/f control animals. 
Despite this, mild activation o f ERK (pERK) was observed in W T, kRas+/T and Ptenf/f 
control tissues. Lesions w ith in  Ptenf/f;kRas+/T animals w ere  found to  show an 
increase in staining intensity fo r pERK, to g eth er w ith  nuclear localisation o f the  
activated protein (Inset images show digital en largem ent o f the area indicated in the  
main im age). Scale bars indicate 100p.m. Asterisks indicate lum en o f bile ducts.
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6.2.9 Ptenf/f;kRas+/T animals develop hyperplasia of the forestomach squamous epithelium
As described in section 6.2.2, Ptenf/f;kRas+/T mice were also noted to be highly susceptible 
to abnormalities of the stomach, which was observed in 100% of Ptenf/f;kRas+/T mice analysed. 
Recombination of the LacZ reporter allele was also detected in squamous epithelial cells of the 
forestomach (Section 6.2.3), indicating that AhCreER1 is indeed induced and drives recombination, 
within this tissue.
In order to characterise this phenotype, H&E-stained tissue sections of WT, kRas+/T and 
Ptenf/f control animals and Ptenf/f;kRas+/T experimental animals were examined (Figure 6.12), and 
a detailed histopathological description of the lesions found in Ptenf/f;kRas+/a mice was obtained7. 
Lesions within Ptenf/f;kRas+/T animals were always found to arise from the forestomach. They were 
consistently characterised as diffuse papillomatous hyperplasias of the squamous epithelium, 
which were found to affect the vast majority of the tissue present on each tissue section 
examined. Florid hyperkeratosis was also noted on the lumenal surface of the forestomach. 
Occasional incidences of atypical features of basal cells were observed, but in no instance was this 
found to amount to squamous carcinoma. No evidence of invasive disease was observed. Lesions 
of this histological nature were not observed in any control animals.
Thus, loss of Pten and activation of k-Ras synergise within the squamous epithelium of the 
forestomach, resulting in dramatic and widespread hyperproliferation and hyperkeratosis of the 
squamous epithelium, but this is not found to result in malignant disease.
7 Histopathological descriptions of forestomach lesions arising in experimental mice was provided 
by Prof Geraint T. Williams, D e p a rtm e n t o f Pathology, University Hospital o f W ales, C ardiff University, UK.
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Figure 6.12: Susceptibility o f Ptenf/f;kRas+/T animals to papillomatous hyperplasia of the forestomach 
squamous epithelium
H&E-stained tissue sections o f forestom ach from  W T, Ptenf/f, kRas+/T and Ptenf/f;kRas+/T animals were  
examined in order to  d eterm in e  the histopathological nature o f forestom ach lesions arising in 
Ptenf/f;kRas+/T animals. Lesions w ith in  Ptenf/f;kRas+/T tissues w ere found to  be diffuse hyperplastic 
papillomatous lesions o f the  squamous epithelium , accompanied by florid hyperkeratosis. Lesions were  
not noted to  be m alignant. Lesions o f a similar histopathology w ere not noted in animals of any control 
genotype (W T, kRas+/T or Ptenf/f). Scale bars indicate 100pm .
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6.2.10 Activated Akt is present, but its levels are not increased in hyperplastic forestomach 
epithelium
Given that activation of the PI3K/Akt pathway and Raf-MEK-ERK pathway is observed in 
epithelial lesions of the biliary tree, I next determined whether activation of these pathways was 
also driving hyperplasia within the forestomach.
As previously, I first confirmed loss of Pten protein from Ptenf/f;kRas+/a and Ptenf/f control 
tissue sections by use of anti-Pten IHC. This revealed that normal squamous epithelium of WT and 
kRas+/T control tissues were positively stained for Pten (Figure 6.13). In contrast, squamous 
epithelial cells in Ptenf/f control and Ptenf/f;kRas+/a experimental tissues were found to show a 
reduction in staining intensity for Pten, indicating loss of Pten protein within this cell layer (Figure 
6.13).
I next performed anti-pAktSer473 IHC on adjacent tissue sections in order to visualise levels 
of activation and subcellular localisation of Akt in WT, Ptenf/f, kRas+^  and Ptenf/f;kRas+/T tissues. 
WT, Ptenf/f and kRas+/T tissue sections were found to show a comparable pattern of staining, 
regardless of Pten status. The squamous epithelium was noted to be positive for anti-pAkt 
staining, with an increase in intensity of staining at the lumenal, keratinised surface of the 
epithelium (Figure 6.13). A low level of nuclear staining for pAkt was also apparent in WT, Ptenf/f 
and kRas+A samples. In Ptenf/f;kRas+i7T tissues, staining for pAkt was noted to be retained in 
hyperproliferative epithelial cells. However, no increase in levels or change in subcellular 
localisation of staining was observed.
Thus, whilst activation of the PI3K/Akt pathway is observed in the context of combined 
loss of Pten and activation of k-Ras, the level of activation of the pathway is not different to that 
observed in control tissue samples, at least as detected by IHC.
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F ig u re  6 .1 3 :  H yp erp las tic  cells o f  fo res to m a ch  squam ous e p ith e liu m  in Ptenf/f;kR as+/T m ice  
express n o rm a l levels o f  pAkt?er473
A n t i - P t e n  IH C  w a s  u s e d  t o  c o n f i r m  lo ss  o f  P te n  f r o m  t h e  s q u a m o u s  e p i t h e l iu m  o f  t h e  
fo r e s t o m a c h .  W T  a n d  k R a s +/T c o n t r o l  t is s u e s  w e r e  fo u n d  t o  r e ta in  p o s i t iv i ty  f o r  P te n , as  
e x p e c t e d .  P t e n f/f c o n t r o l  a n d  P t e n f/f;k R a s +/T e x p e r im e n t a l  t is s u e s  w e r e  fo u n d  t o  h a v e  a 
s ig n if ic a n t  r e d u c t io n  in  s ta in in g  f o r  P te n ,  in d ic a t in g  lo ss  o f  t h e  p r o te in .  A n t i - p A k t Ser473 IH C  
w a s  p e r f o r m e d  o n  a d ja c e n t  t is s u e  s e c t io n s  in  o r d e r  t o  e x a m in e  a c t iv a t io n  o f  t h e  P I3 K /A k t  
p a t h w a y .  S ta in in g  f o r  a c t iv a t e d  A k t  w a s  fo u n d  t o  b e  p r e s e n t  in  W T ,  P t e n f/f a n d  k R a s +/T tis s u e s ,  
w it h  a n  in c r e a s e  in  s ta in in g  in te n s i t y  a t  t h e  lu m e n a l ,  k e r a t in is e d  s u r fa c e  o f  t h e  e p i th e l iu m .  In  
P t e n f/f;k R a s +/T t is s u e s , w h i ls t  s ta in in g  f o r  p A k t  w a s  r e t a in e d ,  n o  c h a n g e  in  in te n s it y  o r  
lo c a l is a t io n  o f  s ta in in g  w a s  o b s e r v e d .  S c a le  b a rs  in d ic a te  1 0 0 p m .
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6.2.11 Limited increase in expression of MEK and ERK in forestomach hyperplasia
Having determined that the PI3K/Akt pathway is not activated in squamous hyperplasia of 
the forestomach in Ptenf/f;kRas+/T mice compared to normal squamous epithelium of WT, Ptenf/f 
and kRas+/T controls, I next determined whether activation of the Raf-MEK-ERK pathway was 
driving the observed phenotype.
Anti-phospho-MEKSer221 IHC revealed that expression of activated MEK is virtually 
undetectable in squamous epithelial cells of WT, Ptenf/f and kRas+/a control tissues. In general, an 
increase in staining for pMEK was not apparent in Ptenf/f;kRas+/T tissues. However, isolated areas 
of abnormal tissue were found to stain positively for pMEK compared to surrounding tissues. 
These positively-stained areas tended to be located towards the lumenal surface of the lesions 
rather than within the basal region (Figure 6.14).
Despite no detectable activation of MEK in WT, Ptenf/f and kRas+/a control tissues, IHC 
against the activated downstream target of MEK, ERK, on adjacent tissue sections indicated that 
all controls show strong staining of both the cytoplasm and nucleus (Figure 6.14). In hyperplastic 
lesions of Ptenf/f;kRas+/T animals, the pattern of pERK staining was generally observed to be 
comparable to that in control, normal squamous epithelium. However, as with pMEK staining, 
defined regions of the epithelium were found to show a strong increase in cytoplasmic staining 
for pERK. Similar to pMEK, these regions were found to be towards the lumenal surface of the 
lesion, and when adjacent tissue sections stained for pMEK and pERK were compared, these 
regions were found to overlap. The subcellular staining pattern for pERK in these regions was 
notable in that no nuclear staining was observed, in contrast to surrounding areas of tissue which 
showed both a nuclear and cytoplasmic staining pattern (Figure 6.14).
In summary, it is apparent that activation of Raf-MEK-ERK signalling is not widespread 
within hyperplastic lesions of the forestomach squamous epithelium arising in Ptenf/f;kRas+/T 
animals. Defined areas of lesions are apparent which show activation of both MEK and ERK, 
however it is unclear whether these areas are sufficient to drive the neoplastic phenotype 
observed.
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F ig u re  6 .1 4 :  H yperplastic forestom ach  squam ous ep ith e lia l cells o f Ptenl^;kRas+/T mice show a 
lim ited  increase in expression o f  p M E K  and  pERK
pM EK and pERK IHC w as used to  assess ac tivatio n  o f th e  Raf-MEK-ERK p ath w ay  in fo restom ach  
lesions o f P ten f/f;kRas+/T an im als . A n ti-p M E K  staining reveals v irtu a lly  u n d etec tab le  levels o f 
MEK activa tio n  w ith in  W T , P ten f/f and kRas+/T contro l tissues. In general, lesions in P tenf/f;kRas+/T 
tissues show  no increase in ac tiva tio n  o f MEK, except fo r isolated areas located  to w ards  the  
lum enal surface o f th e  lesions w hich  show ed an increase in staining in tensity . Staining o f 
ad jacen t sections fo r a c tiva tio n  o f ERK revea led  presence o f pERK staining in W T , P tenf/f and 
kRas+/T contro l sections, desp ite  no d e tec tio n  o f ac tiva ted  MEK. In P ten f/f;kRas+/T tissues, 
staining levels and localisation  o f pERK was genera lly  observed to  be co m parab le  to  contro l 
tissues, excep t fo r d e fin ed  areas w h ich  show ed an increase in levels o f cytoplasm ic staining. 
These areas w e re  n o ted  to  be o verlapp ing  w ith  regions show ing strong expression o f pMEK. 
Inset im ages show  dig ital en la rg e m e n ts  o f th e  indicated areas o f m ain  im ages. Scale bars 
ind icate  1 0 0 p m .
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6.3 Discussion
In the intestine, I have previously found that loss of the tumour suppressor Pten has little 
immediate effect upon homeostasis of the epithelium (Chapter 3). This has raised the hypothesis 
that, due to its 'permissive' nature as a tumour suppressor, loss of Pten will only become relevant 
in the context of activation of the PI3K/Akt pathway.
Recent work published in the literature has indicated that loss of Pten and activation of 
the k-Ras oncogene synergise to promote tumourigenesis in both the lung (Iwanaga et al., 2008) 
and in the ovary (Dinulescu et al., 2005). In the latter case, tumourigenesis is found to be 
characterised by activation of both the PI3K/Akt pathway, and of the Raf-MEK-ERK pathway 
(Dinulescu et al., 2005). The observed activation of PI3K/Akt signalling in this model therefore 
supports evidence which indicates that activated Ras family proteins can activate PI3K/Akt 
signalling through direct activation of PI3K itself (Kodaki et al., 1994).
Based on these observations, I set out in this chapter to examine the tumour suppressive 
function of Pten in the intestine in the context of activation of PI3K. The experimental approach I 
employed to achieve this was to generate transgenic mice bearing both LoxP-targeted Pten alleles 
(Suzuki et al., 2001), as well as a LoxP-STOP-k-RasV12 mutant transgene (Guerra et al., 2003). Thus, 
in these animals, expression of Cre recombinase will result in loss of both alleles of the Pten gene 
as well as permitting expression of the constitutively active k-RasV12 mutant from its endogenous 
promoter. Having previously determined that the AhCreER1 transgene drives efficient cre 
recombinase expression within the intestinal epithelium with minimal uninduced background 
expression (Chapter 4), this was the form of Cre recombinase transgene I chose to use for this 
study.
Upon generation and induction of Ptenf/f;kRas+/T experimental animals and controls 
(Ptenf/f, kRas+/T and WT), it was immediately obvious that Ptenf/f;kRas+/T animals showed a 
dramatic reduction in survival time compared to controls. Upon dissection and examination of 
tissue from Ptenf/f;kRas+/T mice, it was apparent that ill-health in the vast majority of cases was 
attributable to dramatic papillomatous hyperplasia of both the forestomach squamous epithelium 
and of the epithelium lining the biliary system. At dissection, lesions of the intestinal epithelium 
were not apparent. This may simply reflect a difference in the timescale of development of lesions 
of different histological origins in Ptenf/f;kRas+/T mice. It is possible that hyperplasia development 
within the forestomach and biliary system is a much more rapid process than in other tissues, 
such the intestinal epithelium.
Scoring of the tissue pathologies present in Ptenf/f;kRas+/T animals compared to controls 
revealed that hyperplasia of the forestomach and of the biliary tree occurred with complete 
penetrance in Pten^kRas^1 animals. A proportion of Ptenf/f controls were noted to bear biliary 
lesions within the liver, but there were noted to be histologically different to the lesions observed
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in Ptenf/f;kRas+/T mice. Ptenf/f controls were not found to show abnormalities of the forestomach, 
and neither forestomach nor biliary system lesions were observed in kRas+/T and WT controls. 
Given that these phenotypes were considered to cause morbidity in Ptenf/f;kRas+/T animals, and 
were so highly penetrant, I focused my subsequent analyses on these tissues.
I first confirmed that induction of AhCreER7 as described here does indeed result in 
recombination within the gall bladder and the forestomach. Use of the LacZ reporter allele 
confirmed the previously reported observation that activity of AhCreER7 is induced in epithelial 
cells of the gall bladder (Kemp et al., 2004). I was also able to detect LacZ activity (and therefore 
recombination) within the squamous epithelium of the forestomach. These observations 
therefore indicate that Cre activity does indeed drive recombination within epithelial cells of 
these tissues.
Previous work has described synergy between k-Ras activation and Pten loss in a mouse 
model of ovarian carcinoma, which is driven by activation of the PI3K/Akt and Raf-MEK-ERK 
pathways (Dinulescu et al., 2005). I next set about characterising both the histological severity of 
lesions arising in Ptenf/f;kRas+Ar mice, and determining whether, as in ovarian carcinoma, 
activation of the PI3K/Akt and/or Raf-MEK-ERK pathways could be attributed to the observed 
phenotypes.
6.3.1 Activation of PI3K/Akt signalling and the Raf-MEK-ERK pathway drives papillomatous 
hyperplasia of the biliary epithelium
Histopathological assessment of the lesions arising in the gall bladder and in intrahepatic 
bile ducts of Ptenf/f;kRas+/7 animals revealed that a spectrum of lesions was present. Lesions of the 
biliary tree were most commonly identified as epithelial papillomata, but a range of lesions from 
hyperproliferative foci to invasive papillary adenocarcinoma were observed. The most severe 
lesions were only ever identified within the epithelium of the gall bladder, and not within 
intrahepatic bile ducts. This observation may reflect a difference in environmental constraints 
affecting proliferation of epithelial cells in each location. Epithelial cells within intrahepatic bile 
ducts are fewer in number, and their proliferation may be physically constrained by surrounding 
connective tissue cells and hepatocytes. In contrast to this, the gall bladder environment is much 
more dynamic, with the gall bladder itself being capable of expanding in size, normally allowing 
storage of bile produced by the liver. Thus, the physical environment of the gall bladder may be 
more permissive for hyperplasia than the intrahepatic bile ducts. This may also permit the rapid 
development and progression of lesions arising within the gall bladder.
In order to examine whether PI3K/Akt and/or Raf-MEK-ERK signalling was driving 
development of the lesions present in the biliary epithelium, I next examined the activation status
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of these pathways in control and Ptenf/f;kRas+/T tissues using IHC. Loss of Pten was confirmed in 
tissues from animals bearing the Ptenf/f alleles, which confirmed that lesions in Ptenf/f;kRas+/T 
animals arose from recombined cells. Anti-pAkt IHC indicated that low levels of activated Akt 
were detectable in epithelial cells of WT, kRas+/T and Ptenf/f control tissues. In contrast, strong 
activation of Akt was detected in lesions of Ptenf/f;kRas+A animals arising in both intrahepatic bile 
ducts and in the gall bladder. In addition, cell surface localisation of pAkt was observed, but this 
was only found to be present in lesions of the gall bladder. As described in Chapter 5, cell surface 
localisation of Akt has previously been associated with an increase in oncogenic potential of the 
protein (Mende et al., 2001). The observations here appear to support this observation; lesions in 
the gall bladder which were previously identified as generally being histologically more severe 
show localisation of pAkt to the cell surface, whereas less severe lesions arising within 
intrahepatic bile ducts do not show this staining pattern. Thus, it appears that more severe lesions 
are characterised by cell surface expression of activated Akt.
Activation of the Raf-MEK-ERK pathway was also assessed in WT, kRas+/T and Ptenf/f 
control and Ptenf/f;kRas+/T tissues by IHC against activated MEK and activated ERK. In control 
tissues, low background activity of MEK and ERK were detected, indicating that the pathway is 
normally relatively dormant within the biliary epithelium. In gall bladder lesions, a slight elevation 
in MEK activity was detected, which was not apparent in small lesions of the bile ducts. However, 
despite these observations, the reported downstream target of MEK, ERK, was found to be 
strongly activated in all lesions of the gall bladder and bile duct epithelia in Ptenf/f;kRas+/T mice. 
This may potentially indicate that, in these lesions, ERK is activated by a MEK-independent 
mechanism. Alternatively, the very low levels of MEK activation detected may be sufficient in 
order for ERK to become activated. In either scenario, it is clear that strong activation and nuclear 
localisation of ERK is characteristic of all types of lesions arising in the biliary epithelium of 
Ptenf/f;kRas+/T animals, but is not observed in normal epithelial cells in Ptenf/f;kRas+/T and WT, 
kRas+/Tand Ptenf/f control animals.
6.3.2 Hyperplasia of the forestomach squamous epithelium is not characterised by increased 
activation of PI3K/Akt signalling, and shows only limited increase in activation of the Raf-MEK- 
ERK pathway
Extensive hyperplasia of the forestomach was also observed to occur with high 
penetrance in Ptenf/f;kRas+/r animals but not in WT, kRas+/T and Ptenf/f controls. Histopathological 
examination of lesions arising within the forestomach revealed them all to be histologically 
similar. Lesions were identified as being diffuse hyperplastic papillomata of the squamous
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epithelium, typified by florid hyperkeratosis of the lumenal surface. In no instance were these 
lesions found to be malignant.
Given that activation of both the PI3K/Akt pathway and the Raf-MEK-ERK pathway are 
both characteristic of the development of lesions of the biliary tract, I next determined whether 
activation of these pathways is responsible for driving development of the lesions observed in this 
tissue. As previously, loss of Pten and hence recombination in lesions was confirmed. Examination 
of pAkt staining patterns immediately indicated that the PI3K/Akt pathway is normally active 
within the squamous epithelium of the forestomach, as indicated by strong staining of normal 
tissues from WT, kRas+/T and Ptenf/f controls. As such, no increase in staining for pAkt was 
observed within hyperproliferative lesions of Ptenf/f;kRas+/T animals, though pAkt was found to 
remain present. No change in localisation of pAkt was observed in forestomach lesions, in 
contrast to lesions arising in the gall bladder epithelium which showed relocalisation of Akt to the 
cell surface. Staining for pMEK and pERK in control animals indicated that, whilst levels of MEK 
were virtually undetectable in all genotypes, strong staining for activated ERK was evident in 
epithelial cells of all genotypes, indicating activation of MAPK signalling in normal cells. In 
hyperproliferative lesions of the forestomach arising in Ptenf/f;kRas+^  animals, no difference in 
staining intensity was generally observed compared to control tissues. However, distinct areas 
were found to show a co-ordinate increase in staining intensity for both pMEK and pERK. These 
areas of tissue were generally found to be located at the lumenal surface of lesions. The relevance 
of strong activation of Raf-MEK-ERK signalling in these small and infrequent areas of tissue with 
respect to the overall hyperplastic phenotype remains unclear. Given that, in general, the 
hyperproliferative cells of the squamous epithelium do not show increased activation of Raf-MEK- 
ERK or PI3K/Akt signalling compared to control tissues, it seems unlikely that these pathways are 
driving the hyperproliferative phenotype. This therefore suggests that loss of Pten and activation 
of k-Ras may co-operate to drive hyperproliferation within the forestomach through an 
alternative pathway. Further investigation needs to be carried out in order to ascertain the exact 
mechanism which is driving this phenotype.
6.3.3 Summary and future directions
In summary, data presented in this chapter indicates for the first time that synergy 
between Pten loss and activation of k-Ras exists within epithelial cells of both the biliary tract and 
the forestomach.
These data also indicate that tissue-specific sensitivity exists within epithelial cells with 
respect to activation of the PI3K/Akt and Raf-MEK-ERK pathways and the subsequent 
tumourigenesis which ensues. In the biliary epithelium, loss of Pten and activation of k-Ras drive
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both activation and membrane localisation of pAkt, and also activation of MEK and ERK in 
epithelial lesions. These phenomena in turn appear to drive rapid tumour development and 
progression.
In contrast, the squamous epithelium of the forestomach is found to have a higher basal 
level of both PI3K/Akt and Raf-MEK-ERK pathway activity in its normal state. As such, activation of 
k-Ras and deletion of Pten does not appear to have a dramatic effect on these signalling 
pathways, despite the fact that a synergistic effect upon tissue phenotype is evident. This implies 
that hyperproliferation may be driven by another pathway, which currently remains elusive and 
warrants further investigation in the future.
In the intestine, tumourigenesis is not apparently initiated in this model. However, the 
very rapid development of hyperplastic disease in other tissues may eclipse the timescale 
required for tumourigenesis in the intestinal epithelium. Thus, it has not been possible to examine 
synergy between Pten loss and k-Ras activation in intestinal tumourigenesis in this model. Given 
the short timescales involved in this study (the average survival time of Ptenf/f;kRas+A animals was 
just 43 days), it seems likely that disease within the intestine might be observed if animals were to 
be aged longer than was possible here. As such, further investigation of the combined role of Pten 
loss and k-Ras activation in the intestinal epithelium is warranted, but a system which does not 
permit recombination either in the biliary epithelium or the squamous epithelium of the 
forestomach must be utilised.
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Chapter 7: Analysis of the short- and long-term consequences of Vil-CreERT- 
mediated activation of k-Ras and loss of Pten in the intestine
7.1 Introduction
Previous work, described both in this thesis and elsewhere, has indicated that combined 
loss of Pten and activation of k-Ras has a synergistic effect upon neoplastic transformation of 
epithelial cells of the lung (Iwanaga et al., 2008), ovary (Dinulescu et al., 2005), biliary system and 
forestomach (Chapter 6). In each of these systems, loss of Pten and activation of k-Ras has been 
found to result in hyperproliferation of epithelial cells. In the ovary (Dinulescu et al., 2005) and 
biliary epithelium (Chapter 6), neoplasia is characterised by an increase in both PI3K/Akt signalling 
and Raf-MEK-ERK pathway activation.
In the intestinal epithelium, the existence of any co-operative effect between Pten loss 
and k-Ras activation remains unconfirmed. In Chapter 6, I attempted to characterise the effects 
upon the intestinal epithelium following conditional loss of Pten and activation of k-Ras driven by 
the AhCreER1 transgene. However, due to the rapid and catastrophic phenotypes occurring within 
epithelial cells of the biliary tree and of the forestomach, it was not possible to analyse any 
synergistic effects in tumourigenesis of the intestinal epithelium.
Thus, in order to examine the effects of combined loss of Pten and activation of k-Ras in 
the intestinal epithelium using this system, recombination within both the epithelium of the 
biliary system and the squamous epithelium of the forestomach must be avoided. One method of 
achieving this is to use an inducible Cre-expressing transgene which drives ere expression more 
specifically within the intestine. An example of such as transgene is Vil-CreERT (el Marjou et al., 
2004). This transgene makes use of the Cre recombinase-estrogen receptor fusion protein as 
described for AhCreER1, which must be exposed to Tamoxifen in order to gain access to the 
nucleus and act on its targets. In the Vil-CreERT transgene, expression of the fusion protein is 
driven by the Villin gene promoter, rather than by the inducible CYP1A1 promoter as was 
described for the AhCreER1 transgene (Kemp et al., 2004). The Villin gene is endogenously 
expressed in an intestine- and kidney-specific manner. In the intestine, its expression is noted to 
be further restricted to the epithelial cell population, within no expression in other cell types 
(Pinto et al., 1999). Reporter analysis of induced Vil-CreERT expression indicates that Cre is 
activated with high efficiency specifically within the epithelial cell population, reflecting the 
endogenous expression pattern of the Villin gene (el Marjou et al., 2004).
In this chapter, I aimed to make use of this Vil-CreERT transgene in order to achieve 
efficient and specific inducible recombination in the intestinal epithelium in order to drive both
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deletion of Pten and activation of the endogenous k-RasV12 (G12V mutant) transgene. As Vil- 
CreER1 is not expressed within the epithelium of the biliary system or in the forestomach, this 
should circumvent previous problems of confounding phenotypes within these tissues, allowing 
analysis of any resulting intestinal phenotypes8.
8 Data presented in this chapter was collected with the assistance of Emma J. Davies. Breeding of 
animals to generate experimental genotypes was conducted by me. Induction, dissection and analysis of 
experimental animals were performed together with Emma, under my direction and supervision.
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7.2 Results
7.2.1 Induction of Vil-CreERT causes recombination in epithelial cells at the LoxP-targeted Pten 
locus and the k-RasV12 transgene
Animals bearing the Vil-CreERT transgene (el Marjou et al., 2004), the LoxP-targeted Pten 
alleles (Suzuki et al., 2001) and the k-RasV12 mutant transgene (Guerra et al., 2003) were 
interbred. This generated experimental animals, of the genotype Vil-CreERT+;Ptenf/f;kRas+/T (herein 
referred to as 'Ptenf/f;kRas+/T'), and controls of genotypes Vil-CreERT+; Ptenf/f;kRas+/+ ('Ptenf/f/), Vil- 
CreERT+;Pten+/+;kRas+/T ('kRas+A') and Vil-CreERT+;Pten+/+;kRas+/+ ('WT'). Animals were induced as 
described (Section 2.1.3.2) and were culled at day 14 post-induction (PI).
I first confirmed that recombination occurred within the intestinal epithelium using this 
system and induction protocol. To do this, samples of tissue were obtained from WT, Ptenf/f and 
kRas+Ar controls and Ptenf/f;kRas+/T experimental animals by scraping of the mucosal surface of the 
intestine as described (Section 2.2.7.5). This allowed crude enrichment of tissue samples for 
epithelial cells, which is the cell type in which recombination is induced in this system (el Marjou 
et al., 2004). Total genomic DNA was extracted from these epithelial-enriched samples and was 
used for multiplex PCR amplification of products specific to the wild-type, LoxP-targeted and 
recombined forms of the Pten allele and k-Ras transgene (See Section 2.6.4 and Figure 2.2). DNA 
samples from animals WT for the Pten locus (Pten+/+;kRas+/+ [WT] and Pten+/+;kRas+/T) were found 
to amplify products of a size corresponding only to the wild-type Pten allele (428bp) (Figure 7.1). 
Samples from induced animals bearing the LoxP-targeted Pten alleles (Ptenf/f;kRas+/+ and 
Ptenf/f;kRas+/T) were found to generate products corresponding to both the LoxP-targeted but 
unrecombined allele (514bp) and to the recombined allele (705bp). As all animals bear at least 
one copy of the wild-type k-Ras allele, a product corresponding to the wild-type k-Ras allele 
(403bp) was detected in tissue samples from all genotypes. In addition to this, samples from 
animals bearing the k-Ras transgene (Pten+/+;kRas+/T and Ptenf/f;kRas+/T) were found to generate 
products corresponding to the LoxP-targeted, unrecombined k-Ras transgene (621bp) and to the 
recombined form of the transgene (669bp) (Figure 7.1). This therefore confirms that, using this 
system, induction results in recombination at both the Pten allele and the k-Ras transgene within 
the intestinal epithelium.
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Figure 7.1: Recombined-specific PCR confirms recombination at the Pten locus and the kRasV12 
transgene in the intestinal epithelium o f experimental animals
PCR reactions designed to specifically detect the wild-type, LoxP-targeted and recombined alleles of the 
Pten (A) and k-Ras (B) genes were performed on genomic DNA extracted from epithelial-enriched 
intestinal tissue samples. Samples from induced animals wild-type for the Pten gene (Pten+/+;kRas+/+ and 
Pten+/+;kRas+/T) were found to generate only the wild-type allele-specific product (c, 428bp). Samples 
from induced animals bearing the LoxP-Targeted Pten alleles (Ptenf/f;kRas+/+ and Ptenf/f;kRas+/fT) were 
found to generate products specific to both the LoxP-Targeted unrecombined allele (b, 514bp) and to 
the recombined allele (a, 705bp), indicating the presence of both recombined and unrecombined cells. 
As all animals bear at lest one copy of the wild-type k-Ras allele, samples from all animals were found to 
produce the wild-type alelle-specific product (c', 403bp), as expected. Samples from induced k-Ras 
transgenic animals (Pten+/+;kRas+/T and Ptenf/f;kRas+A) additionally generated products corresponding to 
the LoxP-targeted but unrecombined allele (b', 621bp) and to the recombined allele (a', 669bp).
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7.2.2 No change in gross intestinal structure associated with Pten loss and k-Ras activation at 
day 14 PI
Experimental Ptenf/f;kRas+A and control (Ptenf/f, kRas+/T and WT) animals were induced 
and culled at day 14 PI. Intestines were removed, fixed and sectioned before being stained with 
H&E for histological assessment (Sections 2.2 and 2.3). Microscopic examination of tissue sections 
revealed no difference in gross histology between Ptenf/f;kRas+/T experimental intestines and 
controls (Figure 7.2). Tissues from Ptenf/f;kRas+/T animals were found to have normal structural 
organisation of the epithelium into crypt and villus units. Crypts and villi appeared to be of 
approximately normal size compared to Ptenf/f, kRas+/T and WT controls. Levels of apoptosis and 
mitosis were noted to not be obviously different in Ptenf/f;kRas+/T tissue compared to controls. 
Thus, combined loss of Pten and activation of k-Ras has no effect upon normal histology of the 
intestinal epithelium at up to day 14 PI.
214
W T  P ten f/f
kRas+/T P ten f/f;kRas+/T
Figure 7.2: No perturbation of gross intestinal histology at 14 days following intestine- 
specific loss of Pten and activation o f k-Ras
Control (W T, P tenf/f and kRas+/T) and experim enta l (P tenf/f;kRas+/T) anim als w ere  induced and 
culled at 14 days PI. Intestines w ere  then  rem oved, fixed and processed before being 
sectioned and H&E stained. Histological exam ination o f intestinal tissues from  experim ental 
anim als revealed no obvious pertu rbation  in gross structure or histology of the  intestine at 
this tim ep o in t com pared to  control genotypes. Scale bar indicates 100pm .
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7.2.3 Increase In mitosis, but not apoptosis, in Pten-deficient k-Ras-activated intestinal 
epithelium
In order to more closely investigate more subtle perturbations of intestinal homeostasis 
following loss of Pten and activation of k-Ras, I quantitatively examined levels of apoptosis and 
mitosis in H&E-stained sections of Ptenf/f;kRas+/T tissues compared to Ptenf/f, kRas+/T and WT 
controls. Mitoses and apoptoses were identified based on their morphological appearance, and 
the number of figures per crypt was counted (Figure 7.3). Scoring for apoptosis revealed that 
there was no significant difference in the average frequency of apoptosis scored in Ptenf/f;kRas+/T 
experimental tissues (Average number ±Standard deviation of 0.22±0.06) compared to Ptenf/f 
(0.23±0.16), kRas+/T (0.26±0.04) or WT 0.29±0.11) controls (Mann-Whitney U test for the 
comparison Ptenf/f;kRas+/T Vs. WT, p=0.63). In contrast, levels of mitosis were found to vary 
between genotypes. Whilst no difference in mitotic index was observed between WT (1.02±0.15) 
and Ptenf/f (1.26±0.20) controls, kRas+/T controls were found to have a significant increase in the 
number of mitoses per crypt (at 1.46±0.19) compared to WT controls (Mann-Whitney U test, 
p<0.001). Similarly, experimental Ptenf/f;kRas+/T tissues were found to show an elevation in levels 
of mitosis (1.33±0.23) compared to WT controls (Mann-Whitney U test, p<0.1), though this 
difference was not as highly statistically significant as that between WT and kRas+/r controls. No 
significant difference in mitotic index was observed between Ptenf/f;kRas+/T experimental tissues 
and kRas+/T control tissues (Mann-Whitney U test, p=0.63).
These data therefore indicate that activation of k-Ras within the intestinal epithelium 
results in a significant increase in mitosis compared to tissues lacking activated k-Ras, however 
additional loss of Pten does not further modulate this phenotype. Neither activation of k-Ras or 
deletion of Pten alone, nor combined activation of k-Ras and deletion of Pten has an effect upon 
levels of apoptosis within the intestinal epithelium.
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Figure 7.3: Increase in m itosis w ith  no change in apoptosis fo llo w in g  loss o f  Pten and  
activation o f  kRas
Apoptoses and mitoses within intestinal crypts was scored from H&E-stained tissue 
sections based on morphological appearance. Scoring of apoptosis revealed no 
difference in number of apoptotic cells per crypt between WT (dark grey bar), kRas+/T 
(medium grey bar) and Ptenf/f (light grey bar) controls and experimental (Ptenf/f;kRas+/T- 
white bar) tissues samples. In contrast, scoring of the number of mitoses per crypt 
revealed a significant alteration in the number of mitotic figures present. kRas+y/T 
controls (medium grey bar) were found to have a significant increase in levels of mitosis 
compared to WT controls (dark grey bar) (*, Mann-Whitney U test, significant at 
p<0.01), and also apparently showed an increase in mitosis compared to Ptenf/f controls 
(light grey bar), though this was not statistically significant. In addition, experimental 
tissues (white bar) showed a significant increase in number of mitoses per crypt 
compared to WT controls (**, Mann-Whitney test, significant at p<0.1), though this 
difference was not significant compared to Ptenf/f controls. Error bars indicate standard 
deviation.
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7.2.4 Increase in size of crypts and villi in Ptenf/f;kRas+/T intestines compared to controls
Having determined that activation of k-Ras within the intestinal epithelium results in an 
increase in mitosis with no change in levels of apoptosis, I next examined whether this had any 
effect on the overall size of the crypt and villus within kRas+^  or Ptenf/f;kRas+/T tissues. Average 
sizes of crypts and villi were scored from H&E-stained tissue sections by counting the number of 
epithelial cells present from base to tip of the structure in comparable regions of tissue.
Scoring of crypt size revealed that the average number of epithelial cells comprising each 
half crypt was increased in Ptenf/f;kRas+/T tissues (average number of cells ±Standard deviation 
was 30.48±3.49) compared to Ptenf/f (22.0±1.19), kRas+/T (25.4712.91) and WT (24.2613.38) 
controls (Figure 7.4A). Despite the previously noted increase in mitosis, crypts of kRas+/T control 
tissue were not found to be significantly larger than those in WT tissues (Mann-Whitney U test, 
P=0.7). The observed increase in crypt size in Ptenf/f;kRas+/T experimental tissue was statistically 
significant compared to WT controls (Mann-Whitney U test, p=0.057) and compared to kRas+/T 
controls (Mann-Whitney U test, p=0.057).
A similar pattern was observed upon analysis of villus size. The average number of 
epithelial cells comprising each half villus was found to be increased in Ptenf/f;kRas+/T tissue 
(average number of cells iStandard deviation was 114.1917.97) compared to Ptenf/f (79.7219.05), 
kRas+A (93.6318.16) and WT (65.2719.04) controls (Figure 7.4B). In contrast to the observed lack 
of increase in size of the crypt in kRas+/T compared to WT controls, the previously reported 
increase in mitotic index was found to be translated into a significant increase in villus size (Mann- 
Whitney U test, p<0.001) in this control group. However, villus size in Ptenf/f;kRas+/T tissues was 
further found to be significantly increased compared to both kRas+/r controls, as well as compared 
to WT controls (Mann-Whitney U test, p<0.001 for both comparisons).
In summary, combined loss of Pten and activation of kRas within the intestinal epithelium 
causes an increase in size of both the crypt and villus compared to Ptenf/f, kRas+/T or WT controls, 
whereas activation of k-Ras alone causes an increase in villus size, but not in crypt size, compared 
to WT controls.
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A v e ra g e  n u m b e r  o f  ce lls  p e r  h a lf  c ry p t
Average n u m b e r o f cells per h a lf villus
F ig u re  7 .4 :  Significant increase in size o f crypts and villi in Ptenf/f;kRas+/T intestines a t day 14 PI
Size of both crypts (A) and villi (B) in WT, kRas+/T and Ptenf/f control and Ptenf/f;kRas+/T 
experimental tissue samples was scored by counting the number of epithelial cells present from 
base to top of the structure in comparable areas of tissue sections. A significant increase in the 
number of cells within the crypt (A) was observed in Ptenf/f;kRas+/T animals (white bar) compared 
to all controls (WT: dark grey bar, kRas+/T: medium grey bar, Ptenf/f: light grey bar) (*, Mann- 
Whitney U test, significant at p<0.1). A similar pattern of villus size was observed (B), with 
Ptenf/f;kRas+/T animals (white bar) showing a significant increase in the number of epithelial cells 
comprising the villus compared to controls (WT: dark grey bar, kRas+/T: medium grey bar, Ptenf/f: 
light grey b ar). Additionally, kRas+/Tcontrols were noted to show a significant increase in villus size 
compared to WT controls. (* * , Mann-Whitney U test, significant at p<0.001). Error bars indicate 
standard deviation.
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7.2.5 No change in number or location of Ki67-positive proliferative cells in Ptenf/f;kRas+/T tissue
In order to further investigate differences in proliferation between Ptenf/f;kRas+/T and 
Ptenf/f, kRas+/T and WT control tissues at day 14 PI, I next performed anti-Ki67 IHC in order to 
visualise proliferating cells. This revealed normal localisation, and approximately normal numbers, 
of Ki67-positive cells in experimental Ptenf/f;kRas+/T tissues compared to Ptenf/f, kRas+A and WT 
controls (Figure 7.5A). To quantify this, I next scored the average number of Ki67-positive cells per 
crypt in Ptenf/f;kRas+/T tissue compared to Ptenf/f, kRas+/T and WT tissues. The average number of 
Ki67-positive cells in Ptenf/f;kRas+/T intestinal crypts (iStandard deviation) was found to be 
22.88±3.77, and in Ptenf/f, kRas+/T and WT control crypts was 17.8412.05, 24.7910.85 and 
18.5310.64 respectively (Figure 7.5B). This apparently indicated an increase in proliferation in 
kRas+A and Ptenf/f;kRas+/T tissues compared to WT tissue, concurring with previous scoring of 
mitotic index from H&E-stained tissues (Section 7.2.3). However, despite the fact that the 
increase in Ki67-positive cells in kRas+/T tissue compared to WT controls was significant (Mann- 
Whitney U test, p<0.001), the observed increase in positively-stained cells in Ptenf/f;kRas+/T 
experimental tissue compared to WT tissue was found not to be statistically significant (Mann- 
Whitney U test, p=Q.ll). In addition, no significant difference in average numbers of positively- 
labelled cells was observed between kRas+/T controls and Ptenf/f;kRas+^  experimental tissues 
(Mann-Whitney U test, p=0.86).
From these data, it is therefore apparent that activation of k-Ras alone results in an 
increase in Ki67 positively-labelled cells within intestinal crypts compared to WT samples, but 
combined loss of Pten and activation of k-Ras does not cause a significant change in numbers of 
proliferative cells in the intestinal epithelium.
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Figure 7 .5 : No significant alteration in number ofK i67 antigen-positive cells in Ptenf/f;kRas+/T intestines 
at day 14 PI
In order to visualise proliferative cells and the proliferative zone in control and experimetnal tissues, 
anti-Ki67 IHC was performed (A). This revealed that the proliferation com partm ent is normally localised 
in experimental tissues compared to controls, and that there is no obvious change in numbers of Ki67- 
positive cells. Scale bars indicate 100pm . In order to quantify this observation, the number of Ki67- 
positively stained cells was scored from these sections in control and experimental tissues (B). A 
significant increase in the number of positively labelled cells was observed in kRas+/T controls (medium  
grey bar) compared to WT controls (dark grey bar) (* , Mann-W hitney U test, p<0.001). No difference was 
observed between WT controls and Ptenf/f controls (light grey bar). Despite an average increase in the 
number of Ki-67-positive cells present in Ptenf/f;kRas+/T tissues (white bar) compared to W T tissues, this 
change was not statistically significant (# ,Mann-W hitney U test, p=0.11). Error bars indicate standard 
deviation.
Ptenf/f
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7.2.6 No impairment in differentiation of epithelial cells associated with combined Pten loss and 
activation of k-Ras
In order to examine any further effects upon intestinal homeostasis caused by combined 
loss of Pten and activation of k-Ras, I next examined the differentiation program of epithelial cell 
types in this context. Tissue sections of experimental Ptenf/f;kRas+/T and Ptenf/f, kRas+/T and WT 
control intestines at day 14 PI were subjected to IHC or special stains in order to visualise the four 
differentiated cell types of the epithelium; Paneth cells, goblet cells, enterocytes and 
enteroendocrine cells.
IHC against lysozyme was used to identify paneth cells within intestinal tissue samples. 
This revealed that paneth cells were present at approximately the expected frequency and were 
correctly localised at the base of the crypt in tissue sections of all genotypes (WT, Ptenf/f, kRas+/T 
and Ptenf/f;kRas+/T) (Figure 7.6A). In experimental Ptenf/f;kRas+/T tissues, some weak anti-lysozyme 
staining of epithelial cells in both the crypt and villus, which were histologically similar to goblet 
cells, was also apparent. This phenomenon was not observed in intestinal tissue sections of 
Ptenf/f, kRas+A or WT genotypes.
Mucin-secreting goblet cells were identified in tissue sections of all genotypes by staining 
with Alcian blue. This indicated that goblet cells were present and were normally distributed in 
both experimental (Ptenf/f;kRas+/T) and control (Ptenf/f, kRas+/T and WT) tissues (Figure 7.6B). No 
alterations in staining pattern were observed between tissue samples of any genotype.
Colourimetric detection of alkaline phosphatase activity, characteristic of brush border 
absorptive enterocytes, was next performed upon tissue sections of all genotypes in order to 
visualise cells of the enteroctye lineage. Enterocytes were found to be present, and formed a 
continuous brush border, in tissues of all genotypes (Figure 1.1k). No differences in staining 
pattern in Ptenf/f;kRas+/T tissue was observed compared to Ptenf/f, kRas+/T or WT tissues.
Finally, the Grimelius silver staining method was used to visualise enteroendocrine cells 
within the epithelium. Staining revealed that enteroendocrine cells were present, and correctly 
localised on the villus, in tissues of all genotypes (Figure 7.7B). No obvious differences in staining 
patterns were apparent in Ptenf/f;kRas+/T tissue compared to Ptenf/f, kRas+/T or WT controls.
In summary, combined activation of k-Ras and deletion of Pten has no apparent effect 
upon the presence or localisation of mature, differentiated cell types within the intestinal 
epithelium at day 14 PI. A mild perturbation in differentiation is observed in that Ptenf/f;kRas+/T 
goblet cells seem to express low levels of lysozyme, which is normally only characteristic of 
paneth cells, however this does not seem to have any effect upon the number or location of 
normal, mucin-secreting goblet cells.
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F ig u re  7 .6 :  No alteration in presence or localisation o f Paneth cells and Goblet cells in 
Pten}/f;kRas+/T intestines a t day 14 PI
Anti-Lysozyme IHC (A) and Alcian blue staining (B) were used to visualise mature paneth cells 
and goblet cells respectively within WT, Ptenf/f and kRas+/T control and Ptenf/f;kRas+/T tissues at 
day 14 PI. Anti-Lysozyme IHC revealed presence and normal localisation of paneth cells in 
experimental (Ptenf/f;kRas+/T) and control (WT, Ptenf/f and kRas+/T) tissues. A number of 
epithelial cells in Ptenf/f;kRas+/T tissues, which appeared morphologically to resemble goblet 
cells, were noted to stain positively for anti-lysozyme (Arrows). Alcian blue staining revealed 
presence and normal distribution of mucin-secreting goblet cells in Ptenf/f;kRas+/T tissues 
compared to controls (arrows indicate examples of positively-labelled cells). Scale bars 
indicate 100pm.
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Figure 7.7: No alteration in differentiation or localisation of Enterocytes and Enteroendocrine 
cells in Ptenf/f;kRas+/T intestines at day 14 PI
Alkaline phosphatase staining (A) and the grimelius method (B) were used to visualise enterocytes 
and enteroendocrine cells (B) in WT, Ptenf/fand kRas+/T control and Ptenf/f;kRas+/T tissues. No 
obvious difference in the location or differentiation of enterocytes was apparent in experimental 
Ptenf/f;kRas+/T tissues compared to control (WT, Ptenf/f and kRas+/T) tissues (A). Enteroendocrine 
cells were also found to be present and normally localised in Ptenf/f;kRas+/T tissues compared to 
controls (Arrows indicate examples of positively-stained cells). Scale bars indicate 100pm.
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7.2.7 Increase in activation of Akt at day 14 following induction of Pten deficiency and 
activation of k-Ras
Previously, combined deletion of Pten and activation of k-Ras has been noted to have a 
synergistic effect upon activation of the PI3K/Akt pathway in tissues outside the intestine 
(Chapter 6). In order to determine if Pten loss and k-Ras activation synergise in the intestinal 
epithelium to activate PI3K/Akt signalling, I next examined the activation status of this pathway 
using anti-phospho-AktSer473 IHC.
I first confirmed that the intestinal epithelium of induced animals bearing the LoxP- 
targeted Pten alleles was indeed deficient for Pten protein at day 14 PI. To do this, anti-Pten IHC 
was performed on intestinal tissue samples of all genotypes. This revealed that almost 100% of 
the epithelium of induced Ptenf/f and Ptenf/f;kRas+/T animals was negative for anti-Pten staining, 
whist underlying stromal cells and smooth muscle cells retained expression of Pten (Figure 7.8A). 
In comparison, epithelial cells of WT and kRas+/a tissues were found to retain strong positivity for 
anti-Pten staining, indicating that epithelial cells within these genotypes remained Pten proficient 
following induction.
These data therefore confirm that recombination in this system occurs specifically within 
epithelial cells of the intestine, resulting in loss of Pten protein from epithelial cells (but not other 
intestinal cell types) in animals bearing the Ptenf/f alleles.
Next, Anti-phospho-AktSer473 (pAktSer473) IHC was performed on intestinal tissue sections of 
all genotypes in order to visualise activation of the PI3K/Akt pathway (Figure 7.8B). Staining 
patterns revealed that cytoplasmic pAktSer473 staining was detected in epithelial cells of all 
genotypes. However, staining intensity of Ptenf/f;kRas+/T epithelial cells was noted to be higher 
than that of epithelial cells within Ptenf/f, kRasf/+ or WT controls, indicating an increase in 
activation of Akt. Despite this increase in staining intensity, no change in subcellular localisation of 
pAkt was detected, as has previously been described in Pten-deficient k-Ras-activated cells of 
different epithelial origins (Chapter 6).
In summary, these data therefore indicate that combined loss of Pten and activation of k- 
Ras causes activation of Akt, but no change in localisation of pAkt is reported. Levels of activated 
Akt in Pten-deficient, k-Ras activated epithelial cells are found to be greater than that found in 
wild-type epithelial cells, or in epithelial cells in which deletion of Pten or activation of k-Ras alone 
has been induced.
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F ig u re  7 .8 :  IHC analysis o f A kt activation in Ptenf/f;kRas+/T intestines
A nti-P ten IHC (A) was used to  confirm  recom bination in epithelial cells at day 14 fo llow ing induction 
of the Villin-CreERT transgene. Anim als w ild -type fo r the  Pten gene (W T and kRas+/T controls) were  
found to  retain expression o f Pten protein  in the epithelium , as indicated by strong staining of 
epithelia l cells. P tenf/f controls and Ptenf/f;kRas+/T experim ental tissues w ere found to  show  
epithelial-specific loss o f Pten protein  in virtually 100%  of all cells but not from  strom al cells, 
indicating high-frequency recom bination  w ith in  the  epithelium . To exam ine activation of the  
PI3K/Akt pathw ay in Ptenf/f;kRas+/T com pared to  W T, Ptenf/f and kRas+/T control tissues, anti- 
phospho-AktSer473 IHC was perfo rm ed. This revealed an increase in staining intensity in Ptenf/f;kRas+/T 
tissue com pared to  all controls. The staining pattern in Ptenf/f;kRas+/T tissue was observed to  be 
hom ogeneously cytoplasmic, indicating no alteration in subcellular localisation o f pAkt. Scale bars 
indicate 100pm .
Ptenf/f;kRas+/T
Ptenf/f
kRas+/T Ptenf/f;kRas+/T
P tenf/f
226
7.2.8 Preliminary data indicates a reduction in survival time in double-mutant animals
The above data establish that, in the short-term (at day 14 PI), combined loss of Pten and 
activation of k-Ras results in an increase in proliferation of epithelial cells characterised by 
activation of the PI3K/Akt pathway. Based on these data, I next examined the long-term 
consequences of combined loss of Pten and activation of k-Ras within the intestinal epithelium.
In order to do this, cohorts of experimental Ptenf/f;kRas+^  (n=20) and control kRas+/T 
(n=10) mice were generated and induced. After induction, animals were aged whilst being 
monitored for signs of disease. Animals were culled when showing signs of illness, and tissues 
removed for analysis.
Whilst this experiment is currently on-going, preliminary Kaplan-Meier survival analysis 
has been performed on early survival data from these cohorts (Figure 7.9). The current trend in 
survival of the two cohorts of animals indicates that Ptenf/f;kRas+/T animals show a reduction in 
survival compared to kRas+/T controls, however this trend is not currently statistically significant 
(p=0.14, x2= 2.13, DF = 1). At the time of writing this thesis, 9 of 20 animals in the Ptenf/f;kRas+/T 
cohort (45%) had had to be culled due to illness, with the average time after induction at culling 
being 148 days PI. The oldest animal in the cohort was found to remain healthy at 422 days PI. In 
contrast, just one of 10 animals in the control kRas+/T cohort had been culled, which occurred at 
day 7 PI. The oldest animal in this cohort also remained alive and healthy at 422 days PI. Thus, 
these preliminary data and observations indicate that combined loss of Pten and activation of k- 
Ras in the intestinal epithelium results in a reduction in lifespan.
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Figure 7.9: Survival o f Ptenf/f;kRas+/T mice compared to kRas+/Tcontrols
Cohorts of experimental animals (Ptenf/f;kRas+/T) and controls ( kRas+/T) were induced and 
aged whilst being monitored for signs of disease. Animals were culled when symptomatic of 
disease, and Kaplan-Meier survival analysis performed. This indicates a reduction in survival 
time of experimental animals compared to controls, however this difference is not 
statistically significant (p=0.14, x2= 2.13, DF = 1). Median survival times of each cohort were 
not calculated, as this experiment is not currently complete, and more than 50% of each 
cohort currently remain healthy. However, the current trend of these data indicates that 
experimental animals are likely to show a significant reduction in median survival time 
compared to controls.
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7.2.9 Decrease in survival of Ptenf/f;kRas+/T animals is caused by intestinal pathologies
Ptenf/f;kRas+/T animals were culled when symptomatic of disease and dissected. At 
dissection, a number of animals were found to bear intussusception of the large bowel 
(longitudinal folding of the bowel into itself), which had caused blockage of the colon and 
haemorrhaging into the lumen of the gut. In these cases, this was the presumed cause of 
morbidity. In all animals dissected, removal and opening of the small intestine revealed notable 
thickening of the mucosa, particularly at the end proximal to the stomach. No abnormalities of 
any other tissues were noted at dissection.
Organs and intestines were subsequently fixed, processed and sectioned as previously 
described. H&E-stained sections of all tissues were examined in order to detect any microscopic 
histological abnormalities. No microscopic abnormalities were detected in tissues other than the 
intestine. In particular, no abnormalities of the kidney were noted, which is the only reported 
location of Vil-CreERT activity outside of the intestine (el Marjou et al., 2004).
In the intestine, the macroscopically visible thickening of the mucosa of Ptenf/f;kRas+/T 
animals was clearly evident microscopically. The epithelium of all Ptenf/f;kRas+/T animals analysed 
was found to be hyperproliferative, with numerous obvious mitotic figures present in each crypt 
(Figure 7.10A). Levels of mitosis were noted to be greater than that observed in tissue of the same 
genotype at day 14 PI. The hyperproliferative phenotype of the intestine was noted to show a 
clear decrease in severity along the longitudinal axis of the intestine, with hyperproliferation 
being most pronounced at the stomach end of the small intestine.
Along the length of the intestine in aged Ptenf/f;kRas+/T animals, villi were noted to be 
abnormal in structure compared to Ptenf/f;kRas+/r tissue at day 14 PI (Figure 7.10B). Frequent 
branching of the villus tip was noted, which was not observed in tissues of the same genotype 
harvested at day 14 PI. Gross invaginations of the epithelium along the crypt-villus axis were also 
noted to be very common, giving the epithelium of the villus a 'crinkled' appearance. Again, such 
abnormalities of the gross appearance of the epithelium were not observed in Ptenf/f;kRas+/T 
intestines at day 14 PI.
In one case, an aged Ptenf/f;kRas+/T animal (which was culled at day 166 PI) was noted to 
have developed a large tumour of the small intestine, proximal to the stomach. Microscopic 
assessment of this lesion revealed it to be an aggressive adenocarcinoma, which displayed clear 
invasion of epithelial cells into the underlying submucosa, and generated an obvious desmoplastic 
response. However, this preliminarily remains the only example of overt malignant disease 
observed in this cohort.
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Ptenf/f;kRas+/T, Day 14 PI Aged Ptenf/f;kRas+/T
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Figure 7 .1 0 : Intestinal histology o f aged Pteri/f;kRas+/T mice reveals hyperproliferation o f epithelial 
cells, abnormal villus structure and adenocarcinoma.
H&E-stained tissue sections of intestines from aged Ptenf/f;kRas+/T animals were examined for the 
presence of any histological abnormalities. An increase in proliferation within crypts of aged 
Ptenf/f;kRas+/T animals was apparent (A, Right hand panel, arrows indicate mitoses) compared to tissue 
of the same genotype at day 14 PI (Left panel), particularly at the end of the small intestine proximal to 
the stomach. Levels of mitosis appeared further elevated in aged Ptenf/f;kRas+/fT animals in comparison to 
the previously characterised increase in mitosis at day 14 PI in animals of the same genotype. Along the 
length of the intestine, gross abnormalities in villus structure were apparent in aged Ptenf/f;kRas+/T 
animals, including branching of villi (B, right hand panel, dashed lines indicate outline of a single villus). 
Such abnormalities w ere not noted in tissue of the same genotype at day 14 PI (left hand panel). In one 
instance a Ptenf/f;kRas+/T animal, culled at day 166 PI, was found to have developed invasive 
adenocarcinoma of the proximal small intestine (C, arrows indicate epithelial cells invading into the 
submucosa). Scale bars indicate 100pm.
Pten,/f;kRas^, Day 14 PI Aged Pten,/f;kRas+/T
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7.3 Discussion
In Chapter 6, I described work indicating that loss of Pten and activation of k-Ras is 
strongly synergistic in promoting neoplasia in the epithelial lining of the biliary system and in the 
squamous epithelium of the forestomach. Data published in the literature also indicates that 
synergy exists between Pten loss and k-Ras activation in promoting tumourigenesis both of the 
lung (Iwanaga et al., 2008) and of the ovary (Dinulescu et al., 2005). However, the combined 
effect of deletion of Pten and activation of k-Ras upon the intestinal epithelium remains 
uncharacterised.
In this chapter, I aimed to examine the effects of co-ordinate loss of Pten and activation of 
the k-Rasv12 transgene in the intestinal epithelium. In order to circumvent previous problems, this 
required expression of Cre in a highly intestinal-specific manner. To do this, I made use of the 
Villin-CreERT Cre-expressing transgene, which drives recombination specifically within the 
intestinal epithelium and the kidney following induction by administration of Tamoxifen (el 
Marjou et al., 2004).
I first confirmed that cre activity is induced in experimental mice, and that recombination 
occurs at the LoxP-targeted Pten allele and/or the k-Ras transgene, using PCR reactions designed 
specifically to detect the wild-type, LoxP-targeted and recombined forms of each gene. Tissue 
samples wild-type for the Pten allele were found to generate a product specifically corresponding 
to the wild-type product only. In contrast, samples from induced animals bearing the LoxP- 
targeted Pten alleles were found to generate products corresponding to both the LoxP-targeted 
unrecombined allele and to the recombined allele. Similarly, samples from animals not bearing 
the kRasV12 transgene were found to generate a single product, the size of which corresponded to 
the wild-type-specific product. Samples from induced animals bearing the k-Ras transgene were 
found to generate all three types of product, corresponding to the wild-type allele, the LoxP- 
targeted but unrecombined transgene and to the recombined form of the transgene. In both 
cases, transgenic animals were found to generate products corresponding to both the 
unrecombined and the recombined forms of the targeted alleles. This indicates that 
recombination has not occurred in all copes of genomic DNA present in the sample. This can be 
explained by two possible scenarios. Recombination may not have occurred with 100% efficiency 
in all epithelial cell types. Alternatively, or indeed additionally, non-epithelial cell types would 
almost certainly have been present in tissue samples. Thus, cell types in which Cre activity is not 
induced, such as stromal cells, would not have recombined, explaining detection of the non­
recombined allele.
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7.3.1 Combined loss of Pten and activation of k-Ras results in an increase in proliferation and 
expansion in crypt and villus size in the intestinal epithelium at day 14 PI
Having established that treatm ent with Tamoxifen results in recombination at both the 
Pten allele and the k-Ras transgene, I next examined the effect of Pten loss and k-Ras activation 
upon homeostasis of the intestinal epithelium. Scoring for apoptosis in Ptenf/f;kRas+/T tissue at day 
14 PI revealed that there was no difference compared to Ptenf/f, kRas+A and WT controls, 
indicating that combined loss of Pten and activation of k-Ras has no effect upon cell death within 
the crypt. In contrast to this, scoring for mitosis revealed an increase in proliferation in both 
Ptenf/f;kRas+/T and kRas+/T tissues compared to WT tissues. These data therefore indicate that the 
observed increase in mitosis in these tissues is driven by activation of k-Ras, and occurs 
independently of Pten status. To examine the effect of this increase in cell division upon 
homeostasis of the epithelium, average sizes of crypts and villi were scored in tissue of all 
genoytpes. A significant increase in crypt size (as scored by numbers of cells per crypt) was 
observed in Ptenf/f;kRas+/T tissues compared to WT, Ptenf/f and kRas+/T tissues. This is probably 
reflective of the observed increase in levels of mitosis in the crypt, which is presumably driving an 
increase in the number of cells comprising the crypt. However, despite the fact that a similar 
increase in mitosis was observed in kRas+/T tissues, this was not found to be translated into an 
increase in crypt size compared to wild-type tissue. These data therefore suggest that whilst 
activation of k-Ras drives proliferation within the crypt, additional loss of Pten is required in order 
for this perturbation in cell division to become manifest as an increase in crypt size.
In contrast to this, scoring of villus size revealed a significant increase in the number of 
cells comprising the villus in both Ptenf/f;kRas+/T and kRas+/T tissues compared to WT and Ptenf/f 
controls. Villi from Ptenf/f;kRas+/T tissues were also noted to be significantly larger than those in 
kRas+A tissues. Thus, these data indicate that whilst activation of k-Ras alone results in a 
significant increase in villus size, additional inactivation of Pten causes exacerbation of this 
phenotype. This indicates that the observed increase in mitosis has a moderate impact upon villus 
size in kRas+/T tissue, but similar to the situation in the crypt, additional loss of Pten is required for 
this to become fully manifest.
In order to further investigate the phenotype of increased proliferation in the crypt 
following activation of k-Ras, analysis of Ki67-positive cells in tissues of all genotypes was next 
performed. Anti-Ki67 IHC revealed that the approximate size and location of the proliferative zone 
was constant between WT, Ptenf/f, kRas+/T and Ptenf/f;kRas+/T tissues. Scoring of the number of 
Ki67-positive cells within the epithelium confirmed previous observations indicating an increase in 
proliferative cells in response to activation of k-Ras. The number of Ki67-positive cells present in 
kRas+/T tissues was found to be significantly increased compared to WT controls. However, a 
similar increase in Ptenf/f;kRas+/T tissues was found not to be statistically significant. This is
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probably due to high variability between samples, as indicated by a large standard deviation of 
the data. Future scoring of a larger sample size may allow determination as to whether this 
change is truly significant or not.
I next investigated the effect of combined loss of Pten and activation of k-Ras upon 
intestinal homeostasis by examining the presence and localisation of differentiated epithelial cell 
types. Special stains or IHC to detect specific markers of each cell type revealed the presence and 
normal localisation of Paneth cells, goblet cells, enterocytes and enteroendocrine cells in 
Ptenf/f;kRas+^  tissues compared to Ptenf/f, kRas+/7T and WT controls. This indicates that combined 
loss of Pten and activation of k-Ras has no dramatic effect upon the differentiation program of 
mature cells types, or on their location within the epithelium. One subtle phenotype was 
observed in Ptenf/f;kRas+/T tissues however, which was that a number of cells which appeared 
morphologically to be goblet cells were noted to stain weakly positively for anti-lysozyme, which 
is normally only expressed by paneth cells. This may imply that the differentiation program of 
secretory cell lineages may be perturbed in the context of Pten loss and k-Ras activation. 
However, these data are currently only preliminary observations, and further characterisation of 
the phenotype is necessary in order to confirm this notion.
7.3.2 Increase in activation of Akt following co-ordinate loss of Pten and activation of k-Ras
Combined loss of Pten and activation of k-Ras has previously been noted to have varying 
effects upon activation of Akt, depending upon the exact tissue type. In the gall bladder 
epithelium Pten loss and k-Ras activation has been found to result in strong activation of Akt 
together with its membrane localisation. In bile duct epithelium, activation of Akt was noted, but 
its subcellular localisation was not changed. In the forestomach, no increase in activation of Akt 
compared to controls was noted (Chapter 6). Given that tissue-specific differences exist with 
respect to activation of PI3K/Akt signalling following loss of Pten and activation of k-Ras, I next 
examined the effects of these mutations upon Akt activation within the intestinal epithelium.
As in previous chapters, anti-Pten IHC was first used to confirm that induced animals 
bearing the Ptenf/f alleles were deficient for Pten protein. This revealed that Pten was lost from 
the epithelium in Ptenf/f and Ptenf/f;kRas+/T animals with high efficiency. No loss of Pten staining 
was observed from the underlying stroma or from smooth muscle cells. In contrast, WT and 
kRas+/T animals (both of which are Pten+/+) were shown to retain Pten positivity in the epithelial 
cell layer.
Anti-phospho-AktSer473 (pAkt) IHC was then performed upon intestinal tissue sections of all 
genotypes. In tissues sections of WT, Ptenf/f and kRas+/r animals, staining for pAkt was detected, 
but was fairly low and was consistent between all three genotypes. In contrast, pAkt staining of
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Ptenf/f;kRas+/T tissues showed an increase in staining intensity, indicating an increase in activation 
of Akt. However, no change in localisation of pAkt was observed, with staining found to be 
uniform across the cytoplasm of epithelial cells. Thus, from these data I conclude that a 
synergistic effect of activation of k-Ras and loss of Pten results in activation of Akt, which is not 
seen in WT or single-mutant tissues. Whilst synergistic activation of Akt is observed however, in 
this tissue, change in subcellular localisation of the activated protein is not.
7.3.3 Hyperplasia of the intestinal epithelium following prolonged loss of Pten and activation of 
k-Ras
At day 14 PI, it was apparent that a phenotype of increased proliferation, in turn resulting 
in an increase in epithelial cell number in the crypt and villus, was driven by combined loss of Pten 
and activation of k-Ras in the short term. In order to investigate the consequences of this 
phenotype upon intestinal homeostasis over the longer term, I next conducted an aging study of 
induced Ptenf/f;kRas+yrT mice. Whilst preliminary data has been collected from this experiment and 
is reported here, full analysis of this study falls outside the scope of this thesis.
Survival analysis of induced Ptenf/f;kRas+/fT animals indicated a reduction in survival time 
compared to kRas+/T controls. This trend is currently not significant, however the fact that at the 
time of analysis, almost half of all Ptenf/f;kRas+/T animals had been culled due to sickness whereas 
the vast majority of kRas+/T animals remained healthy, suggests that this trend is likely to 
continue. This therefore indicates that synergy within the intestinal epithelium between loss of 
Pten and activation of k-Ras may cause a reduction in lifespan.
Histopathological assessment of tissues from aged Ptenf/f;kRas+/T animals was then 
performed in order to confirm that intestinal pathologies were the cause of death of these 
animals, rather than phenotypes occurring on tissues outside of the intestine. The discovery that 
no abnormalities of any tissues other than the intestine were found indicated that this was indeed 
the case. Examination of intestinal tissues revealed that gross abnormalities were apparent. 
Extensive hyperproliferation of the epithelium was noted, which was found to be much more 
marked than that observed at day 14 PI. An obvious variation in severity of the hyperproliferative 
phenotype was noted along the longitudinal axis of the small intestine, with hyperproliferation 
most obvious at the end of the intestine proximal to the stomach. This variation in phenotype can 
potentially be explained in two ways; firstly, levels of Cre expression (and thus levels of 
recombination) may vary along the length of the intestine. This has previously reported as a 
characteristic of other Cre-expressing transgenes such as AhCre (Ireland et al., 2004), but has not 
been noted for the Villin-CreERT transgene in use here (el Marjou et al., 2004), and therefore 
seems unlikely. Alternatively, differences in biology of the intestine along its length may mean
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that some regions are more susceptible to stimulation of proliferation by combined loss of Pten 
and activation of k-Ras. This however, has not been proven here, and requires further 
investigation in order to fully characterise the observed effects. Another obvious abnormality of 
the intestinal epithelium in aged Ptenf/f;kRas+/T mice was that of perturbation of villus structure. 
Along the entire length of the intestine, villi were observed to show an unusual arrangement of 
the epithelial cells of which they were comprised. Epithelial cells were observed to form frequent 
invaginations into the underlying stromal core of the villus, giving the epithelium a 'wrinkled' 
appearance. Furthermore, branching of villi was also frequently observed, which occurred both at 
the tip of the villus and lower down on the structure. These phenotypes were not observed in 
Ptenf/f;kRas+/T animals at day 14 PI. Thus, it is clear that long-term combined activation of k-Ras 
and deletion of Pten causes alteration in the normal structure of villi. This phenotype could 
possibly be explained by a failure of cells at the villus tip to undergo apoptosis and/or be shed into 
the intestinal lumen, as would normally occur. It is conceivable that a block in shedding of cells 
from the villus tip combined with increased proliferation and crypt-villus migration of epithelial 
cells could result in abnormal patterning of the epithelium, as seen here. However, as these data 
remain preliminary, this is pure speculation. Further investigation of the kinetics of cell migration 
and shedding within the epithelium in the future may allow confirmation of this hypothesis.
Finally, the most severe intestinal pathology observed in an aged Ptenf/f;kRas+/T animal 
was that of the development of adenocarcinoma, which has so far only been noted in one 
individual, at day 166 PI. This lesion was noted to be large and aggressive, and occurred proximal 
to the stomach. Clear invasiveness of epithelial cells into the underlying stroma was noted in this 
lesion. This therefore indicates that, in the context of combined loss of Pten and activation of k- 
Ras, tumour initiation and rapid tumour progression is possible. However, the penetrance of this 
phenotype, and determination of whether it is truly driven by Pten-deficient, k-Ras activated cells, 
remains to be fully determined.
7.3.4 Summary and future directions
In summary, the data presented in this chapter indicate that in the short term, k-Ras 
activation and Pten loss within the intestinal epithelium results in an increase in proliferation and 
a consequent increase in crypt and villus size within the intestine. Pten deletion and activation of 
k-Ras have been found to synergise with respect to activation of the PI3K/Akt pathway, but 
change in subcellular localisation of activated Akt is not observed. In the longer term, double­
mutant animals show a reduction of lifespan, with morbidity being directly caused by intestinal 
pathologies. Dramatic hyperplasia, abnormalities of villus structure and the development of
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adenocarcinoma have all been observed in the intestine following long-term activation of k-Ras 
and deletion of Pten.
The data presented here represent only the preliminary findings of this study, and there is 
therefore scope for this investigation to continue. Firstly, I described in Chapter 6 that biliary tract 
lesions in tissues with combined loss of Pten and activation of k-Ras are driven by activation of 
both PI3K/Akt signalling and the Raf-MEK-ERK pathway. Contribution of activation of the Raf- 
MEK-ERK pathway in the phenotypes observed here in the intestinal epithelium have not yet been 
characterised, and this should be addressed. Furthermore, the observed increase in number of 
cells present in both the crypt and villus implies that there may be some form of block in 
migration of epithelial cells occurring following combined loss of Pten and activation of k-Ras. This 
therefore warrants further characterisation.
The data reported here analysing the long-term effects of Pten loss and k-Ras activation 
on the intestinal epithelium are currently poorly characterised. This needs to be addressed in 
order to confirm that the phenotypes reported here are truly synergistic consequences of loss of 
Pten and activation of k-Ras. The fact that the development of adenocarcinoma has been 
reported here represents the first evidence that Pten and k-Ras synergise to initiate and drive 
intestinal tumourigenesis. However, as this has currently only been described in one cohort 
animal, the penetrance of this phenotype remains undetermined. One potential reason explaining 
why malignancy has developed in so few cases is that the widespread hyperproliferative 
phenotype of the epithelium observed may be causing morbidity of animals before 
tumourigenesis ensues. Thus, it would be worthwhile in future experiments to aim to achieve 
lower levels of recombination directed towards the intestinal epithelium. This should generate a 
more restricted hyperproliferative phenotype within the intestine, which may then allow longer 
survival of animals, providing a longer time-frame for bona fide intestinal tumours to develop.
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Chapter 8: General Discussion
Colorectal cancer (CRC) is a significant cause of human mortality in the UK, being the third 
most common form of cancer (Cancer Research UK, 2007). Despite an increasing incidence of CRC, 
mortality rates for colorectal disease are actually steadily falling (Cancer Research UK, 2007); this 
is probably due to improved awareness of the disease and better detection methods, as well as 
significantly improved treatm ent methods (NICE Guidelines, 2004).
The step-wise model of colorectal cancer initiation and progression hypothesises that a 
series of genetic mutations must be acquired in order for malignant disease to become manifest 
(Fearon and Vogelstein, 1990). These mutations include both inactivation of tumour suppressor 
genes, such as Ape and p53, and activation of oncogenes, such as k-Ras.
Up to 40% of sporadic human colorectal cancers are reported to bear mutations within 
components of the PI3K/Akt signalling pathway, resulting in its activation (Parsons et al., 2005). 
The tumour suppressor PTEN is one of the principal antagonists of this pathway, functioning as a 
lipid phosphatase, which dephosphorylates phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) at 
the 3 position of the inositol ring (Maehama and Dixon, 1998). As such, mutational inactivation of 
Pten results in activation of the Akt signalling cascade.
PTEN is well characterised as a suppressor of tumourigenesis, and in humans is commonly 
reported to be mutated in cancers of the breast (Saal et al., 2008), prostate (Cairns et al., 1997), 
endometrium (Tashiro et al., 1997), cervix (Kurose et al., 2000) and skin (Birck et al., 2000). 
Furthermore, Germline mutation of Pten leads to a spectrum of hamartoma predisposition 
syndromes (PTEN Hamartoma Tumour Syndromes; PHTS), the most common form of which is 
Cowden's disease (Nelen et al., 1999). Lesions of the gastrointestinal mucosa are thought to occur 
in between 35-75% of individuals with Cowden's disease (Carlson et al., 1984, Merg and Howe, 
2004).
Evidence from mouse-based studies has further indicated that PTEN plays an important 
role in suppressing neoplasia of the intestine. Mice constitutively heterozygous for Pten have 
been noted to develop neoplasia of multiple tissues, including the intestine (Di Cristofano et al., 
1998, Podsypanina et al., 1999, Suzuki et al., 1998). Widespread conditional deletion of Pten in 
the mouse has also been shown to result in susceptibility to intestinal cancer (Lu et al., 2007). 
More restricted conditional deletion of both copies of Pten within both stromal and epithelial 
cells of the intestine is reported to result in rapid tumourigenesis, which is attributed to an 
expansion of the stem cell compartment (He et al., 2007). Previous data from the same laboratory 
has also indicated that inactivation of Pten by phosphorylation is a characteristic of the intestinal 
stem cell, playing a role in modulating interaction of the Wnt and BMP signalling pathways (He et
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al., 2004). Together, these data provide compelling evidence indicating a role for Pten in 
regulation of the intestinal stem cell, and in suppressing intestinal tumourigenesis.
In this thesis, I set about investigating the effects of homozygous deletion of Pten 
specifically from the epithelial cell compartment of the intestine using a Cre-LoxP-based 
approach. I aimed to examine the effects of Pten deletion upon normal homeostasis of the 
intestine, with particular emphasis on the stem cell. Further, I wished to examine the effects of 
Pten deletion upon tumourigenesis of the intestine, both in otherwise normal intestinal 
epithelium, and also in the context of genetic activation of signalling pathways known to play a 
role in homeostasis of the intestine.
8 .1  Pten, th e  in testinal stem  cell and ep ithe lia l-s trom al interactions
In Chapter 3, I describe work investigating the short-term effects of epithelial-specific 
deletion of Pten from the murine small intestine. My investigations revealed that up to 50 days 
following Pten loss, no perturbations in intestinal homeostasis occur. No changes to the gross 
histology or structure of the intestine were observed, and no effects upon proliferation, 
apoptosis, migration or differentiation of epithelial cells were noted in the context of Pten 
deficiency. These findings were surprising considering that loss of Pten was confirmed, and that 
increased levels of activated Akt were detected in the intestinal epithelium. This therefore 
indicated that Pten is redundant with respect to normal homeostasis of the intestine, at least at 
short timepoints following its loss.
Given that recent data in the literature has indicated that Pten loss may play a role in 
regulation of the ISC (He et al., 2007), I set about examining any changes to the stem cell 
compartment in the Pten-deficient model I was using. Indirect examination of the clonogen 
content of the intestine indicated no increase in putative stem cells in Pten-deficient intestines. 
Furthermore, I examined the expression of previously proposed markers of the intestinal stem 
cell, DCAMKL-1 (May et al., 2008), Musashi-1 (Potten et al., 2003), Bmil (Sangiorgi and Capecchi, 
2008) and Lgr5 (Barker et al., 2007). This analysis indicated no increase in expression of any of 
these markers in Pten deficient tissues, as would be expected if the number of stem cells had 
increased following Pten deletion. Thus, from my data, I conclude that epithelial-specific deletion 
of Pten does not affect multiplicity of intestinal stem cells up to day 50 following Pten loss.
Clearly, there is some discrepancy between the data I report here, and that of the 
recently published data of He et al. (2007). In their study, He et al. used an inducible form of Cre 
transgene which has previously been described as being expressed in both the epithelial and 
stromal cell compartments of the intestine following induction (Schneider et al., 2003). Here, I 
have used a form of Cre recombinase which shows a pattern of expression which is tightly 
restricted to the epithelial cell layer (Ireland et al., 2004). Thus, the difference in phenotype
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observed between these studies may be attributed to differing patterns of recombination in each 
system used. My data indicate that epithelial-specific deletion has little effect upon intestinal 
homeostasis, whereas He et al. (2007) report that combined epithelial and stromal deletion of 
Pten causes rapid expansion of stem cell multiplicity, which in turn results in tumourigenesis. This 
therefore suggests that Pten and PI3K/Akt signalling may play an important role in epithelial- 
stromal interactions within the stem cell niche in order to control stem cell multiplicity.
Thorough analysis of this hypothesis is currently precluded by the present failure to 
definitively characterise the intestinal stem cell, and consequently the lack of specific markers 
allowing identification and visualisation of ISCs. Until this information is available, direct analysis 
of the role of Pten and PI3K/Akt signalling and interaction within the intestinal stem cell niche will 
not be possible.
Additionally, these studies do not address the question of whether stromal Pten 
deficiency alone is sufficient for expansion of the stem cell compartment, or whether the stem 
cell itself (and/or its surrounding epithelial cells) also has to be Pten-deficient in order for this to 
occur. One experiment which could potentially resolve this issue would be to examine the effects 
of deleting Pten specifically from the stromal cell compartment. A potential method for achieving 
this would be to use a form of Cre recombinase transgene which is expressed specifically within 
fibroblasts of the stromal cell population, such as that driven by the pro-alpha2-collagen (Colla2) 
gene promoter, which has been described by Zheng et al. (2002). This line of analysis is currently 
being pursued within our laboratory, and currently mice bearing both the Colla2-Cre transgene 
and LoxP-targeted Pten alleles have been generated, but not yet analysed.
The major caveat of the work I first described analysing the role of Pten in the intestinal 
epithelium was that only short-term analysis of the effects of Pten deletion were possible. This 
was due to the presence of over-riding phenotypes within other tissues, which precluded analysis 
of Pten deficiency in the intestine at more extended timepoints. In order to circumvent these 
problems, I next crossed animals bearing LoxP-targeted Pten alleles to animals bearing a more 
tightly regulated inducible form of Cre recombinase, AhCreER1. This transgene has previously 
been reported to drive recombination within the intestinal epithelium after induction, but 
minimises levels of background recombination previously found to be problematic with AhCre 
(Kemp et al., 2004). Indeed, analysis of Pten deletion at greatly extended timepoints after 
induction was possible in this study. Notably, these animals were found to develop intestinal 
hamartomas at a low frequency, and may therefore provide a useful model of intestinal lesions of 
a similar histopathology to that observed in human Cowden's syndrome. Additionally, intestinal 
lesions of a more severe, adenomatous histology were noted to be present in these animals. 
However, evidence of these types of lesions being a progression of hamartomatous lesions was
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not detected. Thus, further analysis of the timecourse of development of intestinal lesions is 
warranted in order to ascertain whether this is truly the case.
Based on the data of He et al. (2007), it could be predicted that the development of 
intestinal lesions may be initiated by an increase in stem cell number following Pten loss. This 
hypothesis has not yet been addressed here, but further analysis may allow confirmation of this 
proposed mechanism of tumour initiation. Alternatively, the delay in onset of tumourigenesis in 
these mice may suggest that an initiating mutation must be acquired in order for tumour 
formation to ensue. Again, this has not been analysed here, but mutational analysis of DNA 
extracted from tumour samples would allow confirmation of this notion.
8 .2  Pten suppresses tu m o u r progression
8.2.1 In the context o f activated Wnt signalling
Having established that deletion of Pten alone from the intestinal epithelium has no 
immediate effect upon intestinal homeostasis, but results in delayed intestinal tumourigenesis, I 
next investigated the role of Pten as a suppressor of tumour progression in the context of 
activation of other regulatory pathways.
As the Wnt signalling pathway is known to be critical for intestinal homeostasis and has a 
well characterised role in intestinal tumourigenesis (Reviewed by Clevers, 2006), I first chose to 
examine the effects of Pten deletion in the context of activated Wnt signalling. This was achieved 
by additional conditional deletion of one copy of the Ape gene within the intestinal epithelium, 
which has previously been reported as an intestinal tumour-prone model (Shibata et al., 1997).
My data indicated that deletion of Pten in the context of activated Wnt signalling causes a 
rapid progression of disease, with resulting formation of adenocarcinomas. This is significant for 
two reasons. Firstly, there is a paucity of mouse models which show robust development of more 
advanced intestinal disease. Secondly, it places Pten among the few tumour suppressor genes 
which have been found to have a clear role in progression, rather than initiation, of intestinal 
tumourigenesis.
Advanced tumours arising in Apcf/+;Ptenf/f animals were also noted to show a 
characteristic pattern of increased activation of Akt, which was coupled with relocalisation of the 
protein to the cell surface. This phenomenon was also observed following both acute activation of 
Wnt signalling and deletion of Pten (in Apcf/f;Ptenf/f animals). This finding was significant given 
that experiments targeting Akt isoforms to the cell membrane have previously been performed, 
which was found to result in an increase in oncogenic potential both in cell lines and in vivo
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(Mende et al., 2001). The potential implications of this observation are discussed in more detail 
below.
8.2.2 In the context of k-Ras activation
Pten is well characterised as a suppressor of tumourigenesis in multiple tissues, 
functioning as a negative regulator of Akt activation (For review, see Dahia, 2000). However, my 
observations described in Chapter 3 indicate that Pten has little tum our suppressive effect in the 
intestinal epithelium, at least in the short term following its deletion, despite an observed 
increase in levels of activated Akt. Additionally, data described in Chapter 5 indicate that hyper­
activation of Akt, following combined loss of Pten and activation o f the Wnt pathway, results in 
rapid intestinal tumourigenesis. These observations therefore raise two hypotheses. First, the 
notion that Pten is a 'permissive' tumour suppressor gene (in that its deletion passively permits, 
rather than actively stimulates, the PI3K/Akt pathway) is raised; suggesting that loss of Pten will 
only become relevant in the context of activated PI3K/Akt signalling. Second, these data allude to 
the possibility of a 'threshold' of Akt activation in the intestine, w ith low levels of Akt having little 
effect upon intestinal homeostasis, whereas increased activation of Akt is associated with 
tumourigenesis.
To examine these notions, I next investigated the effects of Pten deletion in the context of 
activation of both the PI3K/Akt pathway and of the Raf-MEK-ERK MAPK pathway. This was 
achieved using a conditionally inducible form of activated Kirsten-Ras. Previous studies have 
indicated that deletion of Pten and activation of k-Ras co-operate to  promote tumourigenesis of 
both the lung (Iwanaga et al., 2008) and the ovary (Dinulescu et al., 2005). In the ovary, this was 
found to be driven by activation of both the PI3K/Akt pathway and of the Raf-MEK-ERK signalling 
pathway (Dinulescu et al., 2005).
When driven by AhCreER1, I found combined deletion of Pten and activation of k-Ras to 
have a synergistic effect in promoting rapid neoplasia of both the epithelium of the biliary system 
and hyperplasia of the squamous epithelium of the forestomach. Lesions were found to be most 
advanced within the gall bladder of Ptenf/f;kRas+/T mice. These lesions were noted to show strong 
activation of both Akt, and of MEK and ERK. Furthermore, the phenomenon of membrane 
association of Akt was observed once again. In bile ducts, lesions were found to generally be 
smaller and less severe. They too exhibited an increase in activated Akt and ERK expression, but 
did not show the strong cell surface localisation of phospho-Akt which was noted in lesions of the 
gall bladder. Finally, hyperplasia of the forestomach was not noted to show increased activation 
of Akt compared to normal control tissues, and only showed limited activation of MEK and ERK.
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These data therefore represent the first evidence indicating that Pten loss and activation 
of k-Ras act synergistically to promote neoplasia of the biliary epithelium and hyperplasia of the 
squamous forestomach epithelium. These data also indicate that the mechanism by which this is 
achieved is highly tissue-dependent. In the biliary epithelium, the resultant phenotype is 
apparently driven by strong activation of both PI3K/Akt signalling and Raf-MEK-ERK signalling, 
whereas in the forestomach the observed phenotype is apparently largely PI3K/Akt- and Raf-MEK- 
ERK-independent. Similar phenotypes to those reported here have also been noted following 
combined deletion of both Pten and the transducer of TGF-beta/BMP signalling, SMAD4. Separate 
studies have indicated that combined deletion of both these tumour suppressor genes results in 
squamous forestomach carcinoma (Teng et al., 2006) and cholangiocellular carcinoma (Xu et al., 
2006). In these studies, similar phenotypes to those reported here following combined deletion of 
Pten and activation of k-Ras were observed, though in both cases the phenotypes reported were 
more severe than those described here. The similarity between these phenotypes may suggest 
that, despite perturbations of different pathways at a molecular level, the effects of these 
mutations may converge on a cellular level to drive tumourigenesis. However, this is purely 
speculative, and further investigation is needed in order to examine this hypothesis.
In the intestine, combined deletion of Pten and activation of k-Ras driven by the Villin- 
CreERT transgene has further indicated a co-operative effect of these mutations (Chapter 7). 
Despite the fact that the results of this study are preliminary, current data indicates that 
combined loss of Pten and activation of k-Ras within the intestinal epithelium results in a marked 
hyperproliferative phenotype. In the short term, this is characterised by an increase in mitosis and 
increase in crypt and villus size compared to controls. This is found to also be associated with an 
increase in activation of Akt. Over longer periods of time, the hyperproliferative phenotype 
becomes more marked, with gross defects in villus structure apparent. The development of 
adenocarcinoma has also been noted. Thus, although analysis of this data is not yet complete, the 
current indication is that Pten loss and k-Ras activation act synergistically to promote hyperplasia 
and tumourigenesis in the intestinal epithelium. Again, this is significant as it represents the first 
evidence of synergy between these two mutations in this tissue type.
8 .3  Potential significance o f m em brane-localised activated Akt
It has been noted throughout this thesis that cell-surface localisation of phospho-AktSer473 
is a recurring phenomenon in Pten-deficient tissues showing strong activation of Akt. This 
phenomenon also appears to be more commonly associated with advanced states of disease. 
Based on these observations, it would seem reasonable to suggest that cell-surface localisation of 
activated Akt may not simply be a passing observation, but could actually be closely linked to 
progression of disease.
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There is currently no evidence in the literature to suggest that membrane localisation of 
phospho-Akt is a particular feature of human cancer, or that it is associated with increased 
severity of disease. Thus, before this phenomenon is investigated further, it must first be 
confirmed that it is indeed relevant to tumourigenesis in humans. To this end, a tissue microarray 
study of biopsies taken from human colorectal cancers is currently being pursued9 in order to 
ascertain whether membrane localisation of Akt can be detected, and whether it is associated 
with advancement of disease or clinical outcome. The detection of cell surface activated Akt in 
human cancers would potentially have two significant applications; first, it could be used as a 
prognostic marker of disease, and second, it could be an appropriate target for therapy. 
However, each of these potential applications requires further investigation before potentially 
being implemented.
The use of membranous Akt as a prognostic marker in human disease would first require 
examination of a large number of human cancers of different tissue origins in order to ascertain a 
clear relationship between subcellular localisation of Akt and stage of disease.
If membrane-localised Akt were to be explored as a potential target for therapy, a 
mechanistic link between location of Akt at the cell surface and progression of disease would 
need to be established. This could involve expressing membrane-targeted forms of Akt in the 
context of activation of W nt signalling or PI3K/Akt and Raf-MEK-ERK signalling, and examining 
whether the resulting phenotypes are comparable to that achieved following deletion of Pten. 
This would provide convincing evidence that tumourigenesis resulting from Pten deletion is driven 
principally through cell surface localisation of Akt. If this notion were to be proven, then activated 
and membrane-localised Akt may provide a good potential therapeutic target for the 
malignancies described here. Indeed, inhibitors of Akt are already in use as chemotherapeutics, 
but often show problems with off-target effects. One such inhibitor of Akt, Perifosine, is a 
synthetic phospholipid analog known to elicit its anti-tumourigenic effects by decreasing 
association of Akt to the membrane (Kondapaka et al., 2003). Thus, agents such as this would 
probably be highly effective if specifically selected to treat lesions which show strong membrane 
localisation of activated Akt. However, as with many cancer therapies, the challenge of specifically 
targeting therapeutic agents to cancer cells whilst sparing normal cells remains.
8 .4  Developing a fa ith fu l m ouse m odel o f step-w ise colorectal cancer progression
A secondary aim of the work described here was to generate a good, faithful mouse 
model of step-wise colorectal cancer progression.
9 The tissue microarray study is currently being performed in collaboration with Dr Marnix Jansen, 
Hubrecht Institute, The Netherlands.
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Mouse models of human disease have undoubtedly been massively beneficial in the field 
of cancer research. They provide a mammalian model of disease, which is easy to use and 
relatively easy to genetically manipulate, which has allowed basic research into the biology of 
disease. Furthermore, they provide an excellent platform in which to test novel and potential 
therapeutic agents in vivo. However, particularly with respect in intestinal tumourigenesis, the 
current mouse models available do leave some scope for improvement. For instance, one of the 
most commonly used mouse models of intestinal disease is the ApcMIN mouse (Moser et al., 1990). 
The ApcMIN mouse tends to develop a large number of polyps of both the small and large intestine, 
the vast majority of which are adenomatous polyps. Morbidity is usually caused by tumour 
burden, rather than by advancement of disease. In contrast to this, most humans with sporadic 
CRC will develop a single lesion, usually located within the lower colon or rectum. In humans, 
disease is currently often much more advanced before it is detected and treated (NICE Guidelines, 
2004). Thus, there are three clear discrepancies between the ApcMIN model and the actual human 
disease situation. First, lesion development in the ApcMIN mouse is too prolific compared to the 
usual situation in humans. Second, those lesions generally develop along the entire length of the 
small and large intestine, and do not show preferential development in the distal colon, as is 
commonly the case in humans. Finally, the polyps which develop in ApcMIN mice do not show 
advancement of disease. Invasiveness and metastasis of tumours arising in ApcMIN mice is not 
reported.
Here, I have addressed the final point of these discrepancies in that I have developed a 
robust model of disease progression in the Apcf/+;Ptenf/f mouse. Thus, between the Apcf/+ and 
Apcf/+;Ptenf/f models, the first few stages of intestinal cancer initiation and progression have been 
modelled. In order for mouse models of CRC to completely come to fruition, future work must 
focus on targeting tumour development to the colon, on reducing the numbers of tumours which 
develop in these models, and on generating a model of metastatic disease.
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Epithelial Pten is dispensable for intestinal homeostasis 
but suppresses adenoma development and progression 
after Ape mutation
Victoria Marsh1, Douglas J Winton2, Geraint T  Williams3, Nicole Dubois4,6, Andreas Trumpp4,6,
Owen J Sansom5 & Alan R Clarke1
PTEN acts as a tumor suppressor in a range of tissue types and has been implicated in the regulation of intestinal stem cells. To 
study Pten function in the intestine, we used various conditional transgenic strategies to specifically delete Pten from the mouse 
intestinal epithelium. We show that Pten loss specifically within the adult or embryonic epithelial cell population does not affect 
the normal architecture or homeostasis of the epithelium. However, loss of Pten in the context of Ape deficiency accelerates 
tumorigenesis through increased activation of Akt, leading to rapid development of adenocarcinoma. We conclude that Pten is 
redundant in otherwise normal intestinal epithelium and epithelial stem cells but, in the context of activated Wnt signaling, 
suppresses progression to adenocarcinoma through modulation of activated Akt levels.
Phosphatase and tensin homolog mutated on chrom osom e 10 
(PTEN) acts as a potent tumor suppressor in a range o f  tissue types 
and is commonly mutated in sporadic cancers o f  multiple origins1-3. 
PTEN elicits its antitumorigenic effects through antagonism o f  the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway4, which normally 
promotes proliferation and cell survival and stimulates progression o f  
the cell cycle (reviewed extensively, including in ref. 5). Activating 
mutations o f PI3K pathway components have been reported in almost 
40% o f all human colorectal cancers6. Germline mutation o f PTEN in 
! ■  humans leads to multiple hamartoma syndromes, o f which Cowden’s 
W syndrome is the most common. Individuals with Cowden’s syndrome 
show susceptibility to hamartoma development in various organ 
systems, including the gastrointestinal tract ’8. Mouse studies have 
shown that, whereas constitutive Ptett deletion causes embryonic letha­
lity, heterozygous inactivation of Pten predisposes to neoplasia in a 
range of tissues, including skin, thyroid and genitourinary and gastro­
intestinal tracts9-11. Pten heterozygotes have been reported to develop 
dysplasia o f the colonic epithelium accompanied by invasion into the 
lamina propria, described as being consistent with adenocarcinoma9.
Inactive, phosphorylated Pten has been identified as a potential 
marker o f intestinal stem cells (ISCs)12, although there has been some 
debate over this interpretation13. Previous studies also showed that 
inactivation o f Pten and increased activation o f  Akt correlate with 
accumulation o f nuclear P-catenin14. This suggests that Pten inactiva­
tion confers stem-like properties to cells within the intestinal epithelium.
Recently, a conditional transgenic approach was used to delete Pten 
from a number o f intestinal cell types, resulting in rapid tumori­
genesis that was attributed to an expansion of the ISC population15.
To determine the role o f Pten in homeostasis and tumorigenesis, 
specifically within the epithelial cell compartment o f the adult small 
intestine, we used a conditional strategy to delete Pten in a temporally 
and spatially controlled manner.
RESULTS
A/iCre-mediated deletion of Pten
We achieved conditional deletion o f Pten in the mouse small intestine 
by crossing mice carrying loxP-flanked Pten alleles16 with mice 
carrying Cre recombinase under control o f  the Cyplal aryl hydro­
carbon-responsive promoter ( Tg(Cyplal-cre)lDwi transgene, abbre­
viated here as AhCre)1' . We induced Cre-mediated excision o f  exons 
4 and 5 o f the Pten allele by intraperitoneal injection o f P-naphtho- 
flavone, which induces Cre expression within the small intestinal 
crypt17,18. After maximal recombination (achieved by daily injection 
o f 80 mg/kg for four consecutive days), nearly 100% recombination is 
achieved in Cre+ mice17, as scored using the Gt(ROSA)26Sor marker 
allele (referred to here as Rosa26R) for recombination19.
To determine the consequences o f  deletion o f Pten from the 
intestinal epithelium, we induced adult experimental (cre+;Ptenflf) 
and control (cre-; Pten(l{, cre+; Pten+/+, cre+; Pten(l+ or cre~; Pten{,+) 
mice and killed them at defined time points after induction. Total
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numbers of control versus experimental mice, respectively, analyzed in 
W this study were 38 versus 22 on day 5 after induction, 3 versus 5 on 
day 30 and 33 versus 35 on day 50. Not all analyses were conducted on 
every sample. No mice were observed to develop hamartomatous 
lesions o f the intestine over the course o f the study.
On day 5 after induction, we stained intestines for activity o f  the 
LacZ recombination reporter transgene, which showed nearly 100% 
recombination in Cre+ mice regardless o f Pten status; this level of 
recombination remained stable for over 100 d after induction (Fig. la). 
To examine the kinetics of Pten loss from the epithelium after re­
combination, we analyzed Pten by immunohistochemistry and western 
blotting. Immunohistochemistry revealed that Pten levels were greatly 
reduced in experimental mice compared to control mice (Fig. lb). 
Occasional crypts retaining Pten were detected in experimental mice 
(Fig. lb), consistent with recombination occurring at less than 100% 
efficiency. Western blot analysis of epithelium-enriched tissue samples 
supported our immunohistochemistry results, showing very little Pten 
on day 5 after induction (Fig. lc) and no appreciable Pten on days 30 
and 50. Quantitative real-time PCR on RNA extracted from epithelial- 
enriched tissue samples showed that experimental mice had a 99.8% 
and 99.95% reduction in Pten expression on days 5 and 50, respectively.
The AhCre transgene drives low-level recombination in a number 
of other tissues17,18. This allowed us to confirm Cre-mediated
inactivation of Pten in our model, as we recapitulated multiple 
phenotypes o f Pten deficiency outside the intestine. In the liver, 
Pten deficiency led to steatosis (Fig. Id) and hepatomegaly 
(Fig. le), which in one case progressed to hepatocellular carcinoma 
(Fig. If). Recombination in the midbrain caused behavioral defects of 
varying severity, which in many cases forced us to kill the mouse 
prematurely. Other phenotypes observed included predisposition to 
lymphoma (Fig. lg) and complex atypical hyperplasia of the endo­
metrium (Fig. lh). These phenotypes have all been reported as 
consequences of Pten deficiency20-22.
We next characterized the consequences o f Pten loss in the small 
intestine. Histological analysis revealed no major alterations in crypt- 
villus architecture after Pten loss (Fig. 2a). Crypt size, mitotic index 
and levels o f apoptosis were scored from these sections and did not 
vary significantly between experimental and control tissue on days 5 
or 50 after induction (for all comparisons, n > 3 and Mann-Whitney 
U-test P >  0.39). Immunohistochemical analysis of the proliferation 
marker Ki67 showed that Pten-deficient cells were permissive for cell 
division and that the location and size of the proliferative compart­
ment in the crypt were comparable to controls (Fig. 2a). We 
confirmed the presence and correct localization of all differentiated 
intestinal cell lineages in Pten-deficient tissue using specific stains or 
immunohistochemical analysis of markers of the differentiated cell
Control
Day 5 Day 30 Day 50
I f 3.0 i
1 2.5 ■ cn% 20 ■ 
S 15' rTif\
Liv
en
 
o 
—
6i 
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Ar\ I
Day 14
Control e*; Pten11
Control cre*;PterP
Figure 1 Induction w ith (1-naphthoflavone causes 
recombination in the intestine, leading to loss of 
Pten protein from the epithelium , (a) The Rosa26R 
reporter allele was used to  assess levels of 
recombination in the intestinal epithelium  after 
induction. Whole-mounts of small intestine from 
cre*; Pten*'* (leftm ost panel) and cre*; Pterf11 
(second from left) mice on day 5 after induction 
showed nearly 100%  recombination, regardless of 
Pten status. Cre' tissue (second from right) showed
no recombination. Recombination was seen in tissue from cre*; Pterfn mice more than 100  d after induction (right panel), indicating that recombination in 
the intestine was stable, (b) Loss of Pten protein from the intestinal ep ithe lium  was shown by immunohistochemistry. On days 5. 30  and 50 after induction, 
levels of Pten protein in the epithelial layer were much lower in cre*; Pterfn tissue than in controls (top panel), cre*; Pterfn tissue on day 50 after induction 
(bottom panel) revealed occasional crypts that retained Pten (filled arrows), surrounded by crypts deficient for Pten (open arrows), reflecting the sub-100% 
recombination efficiency delivered by th is system, (c) Pten protein loss from the intestinal epithelium  was confirmed by western blot analysis of epithelium- 
enriched tissue samples. Samples from cre*; Pterin mice on days 5, 3 0  and 50 after induction had markedly lower Pten protein than did controls. Western 
blot membranes were reprobed with antibody to fl-actin to confirm  equal loading of protein samples, (d-h) Recombination in tissues outside the intestine 
led to additional phenotypes, which were previously reported, (d) In the liver, areas of steatosis were observed in experimental mice, but not in controls.
(e) Development of hepatomegaly in experimental mice (open bars) compared to  control mice (gray bars) was evident on days 5 and 14 after induction.
Error bars indicate s.d. (f) A single cre*; Pterfn mouse also developed hepatocellular carcinoma, (g) Experimental mice were highly susceptible to lymphoma, 
(h) Female experimental mice commonly developed complex atypical hyperplasia of the endometrium, which was never observed in control mice. Inset shows 
boxed area, magnified x2 .
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types (Fig. 2b). Numbers of goblet cells and enteroendocrine cells in 
the crypt and villus were comparable with controls (for all compar­
isons, n 2; 3 and Mann-Whitney U-test P ^  0.19). Finally, we 
determined whether Pten-deficient epithelial cells are able to migrate 
normally up the crypt-villus axis. On day 5 after induction, we 
injected mice with bromodeoxyuridine (BrdU) and killed them after 
2 or 24 h. Immunohistochemical analysis o f BrdU (Fig. 2c) and 
quantification o f the position of labeled cells (Fig. 2d) revealed that 
Pten-deficient cells showed a normal migration pattern between 2 and 
24 h after labeling compared to controls (Kolmogorov-Smimov 
test for difference in cumulative distribution o f data was not sig­
nificant at a 99% confidence level). These data are therefore in stark 
contrast to the prediction that Pten loss should lead to a crypt 
progenitor cell phenotype.
As Pten is well documented to elicit its tumor suppressive pro­
perties through negative regulation of the PI3K/Akt pathway, we
determined the activation status o f this pathway. Western blot analysis 
of epithelial-enriched tissue samples (F ig . 3 ) revealed increased levels 
of Thr308-phosphorylated Akt— indicating activation of Akt— in 
Pten-deficient tissue compared to controls. No change in levels of 
total Akt was observed.
PTEN has been shown to promote stability o f p53, and loss of 
PTEN has been shown to lead to p53 degradation and blocking of 
apoptosis23. We therefore determined whether loss of Pten in the 
intestine protects cells against p53-mediated apoptosis. We exposed 
experimental and control mice on day 50 after induction to 5 Gy of 
gamma irradiation and killed them 6 h after exposure. Scoring of 
apoptosis revealed no impairment in the ability o f Pten-deficient 
tissue to engage apoptosis compared to controls (w =  3, Mann- 
Whitney U-test P — 1.00).
It has recently been postulated that Pten is inactivated by phos­
phorylation specifically in dividing ISCs12, and Pten inactivation has
C
i
Figure 2  Loss of R en does not cause gross phenotypic changes in the small intestine, (a) Left, H&E-stained intestinal tissue from control and experimental 
mice on days 5 or 50 after induction revealed no alterations to  the  architecture of the crypt-villus axis or to levels of apoptosis and mitosis. Right, 
immunohistochemical analysis of K i67 in control and experimental m ice 50 d after induction showed that Pten-deficient cells were capable of division 
and that the location of the proliferative compartment was unchanged, (b) Visualization of the four differentiated cell types of the epithelium. Immuno­
histochemical analysis o f lysozyme and v illin  and sta in ing w ith  periodic a c id -S ch iff stain (PAS) and Grimelius stain revealed Paneth cells, enterocytes, 
goblet cells and enteroendocrine cells, respectively (examples of positively stained cells are indicated w ith arrowheads). All cell types were present at the 
expected frequency and location in Ren-deficient tissue, compared to  control tissue on day 50 after induction, (c) Cell migration was assessed by labeling 
cells on day 5 after induction with BrdU and k illing  m ice 2 or 2 4  h after labeling. Immunohistochemical analysis of BrdU revealed that control and Ren- 
deficient cells at 2 h incorporated the label at s im ilar frequencies and positions and by 24  h had migrated to sim ilar positions on the crypt-villus axis.
(d) Migration of BrdU-labeled cells was quantified, and a cum ulative frequency plot was generated. Control (red lines) and experimental (blue lines) tissues 
had distributions of labeled cells at both 2 h (solid lines) and 24  h (dashed lines) that were not significantly different from each other (Kolmogorov-Smirnov, 
not significant at a 99%  confidence level).
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Figure 3 Pten deletion results in increased levels of activated Akt. 
Activation status of Akt in response to Pten deficiency was assessed by 
western b lo t analysis o f protein samples extracted from a population of 
epithelial-enriched intestinal ce lls from both control and experimental m ice 
on days 5 and 50 after induction. Membranes were probed w ith  antibody 
to  Pten to ensure tha t Pten protein was lost from the samples and w ith  
antibody to  p-actm to  ensure equal protein loading. Replicate membranes 
were probed w ith  antibody to Thr308-phosphorylated Akt (pAktThf308) and 
pan-Akt, revealing that Pten-deficient tissue showed increased levels of 
activated Akt (pAktThr308) at days 5 and 50 after induction, w ith  no change 
in total Akt levels.
been shown to lead to accumulation of nuclear P-catenin through Akt 
activation in cell lines14. Given these observations, one prediction is 
that inactivation o f Pten confers stem-like properties on intestinal cells 
and may increase the number o f clonogens in the intestinal crypt. To 
investigate this, we scored clonogenic survival in the intestine 72 h 
after exposure to various doses o f gamma irradiation (10, 12.5 or
15 Gy), as previously described24. No significant difference (for all 
comparisons, n ^  4 and Mann-Whitney U-test P ^  0.31) in crypt 
survival was observed in the absence o f Pten, indicating no increase in 
clonogen numbers in the crypt (Fig. 4a).
We also analyzed expression o f recently proposed stem cell markers 
by quantitative real-time PCR in Pten-proficient and Pten-deficient 
tissue. We observed no significant differences between control and 
experimental genotypes on day 50 after induction (for all compar­
isons, n =  3 and Mann-Whitney U-test P > 0.05) in expression of  
Msil, Bmil or Lgr5 (adjusted average cycle times ± s.d. for control 
versus experimental samples were as follows: Msil, 14.89 ± 1.69 versus 
16.52 ± 0.86; Bmil, 11.13 ± 1.17 versus 11.29 ±  0.16; Lgr5, 14.22 ±  
0.50 versus 15.25 ± 1.23).
A second prediction is that Pten loss results in increased numbers o f  
cells with nuclear-localized P-catenin and that these cells should have a 
stem-like phenotype14, as has been observed after deletion o f Ape. 
However, we observed no such differences by immunohistochemistry 
(Fig. 4b). We also used quantitative real-time PCR on epithelial- 
enriched control and experimental tissue samples to examine expres­
sion of well-characterized Wnt signaling pathway targets. Expression 
of Cd44, Tcf4, Axin2 and Myc was not significantly different (for all 
comparisons, n — 3 and Mann-Whitney (7-test P >  0.05) between 
control and experimental samples on day 50 after induction (adjusted 
average cycle times ± s.d. for control versus experimental samples were 
as follows: Cd44, 15.42 ± 0.73 versus 14.48 ± 0.31; Tcf4, 9.57 ± 0.02 
versus 9.48 ± 0.38; Axin2, 8.23 ± 0.90 versus 8.57 ± 0.67; Myc, 7.46 ±  
0.98 versus 7.64 ± 0.37). Thus, Pten inactivation does not activate Wnt 
signaling or confer stem-like properties on intestinal epithelial cells.
W///n-OefffT2-mediated Pten deletion
To validate our observations from A/iCre-mediated loss o f Pten from 
the adult intestinal epithelium, we used a different genetic system 
to achieve epithelial Pten loss. In this case, we used tamoxifen- 
inducible Cre under the control of the villin 1 (Vi/1) promoter
(Tg( Vil-cre/ESR 1 )23Syr, abbreviated here as Villin-CreERn ) to direct 
recombination specifically to the intestinal epithelium25. We induced 
6- to 8-week-old adult mice with tamoxifen (five consecutive daily 
doses at 50 mg/kg), killed them 12 weeks after induction, and assessed 
their intestines for any gross changes in architecture or homeostasis 
using histology and immunohistochemistry. No hamartomas were 
observed in any genotype. Loss of Pten from the intestine was 
confirmed by Southern blot analysis (Supplementary Fig. la  online) 
and immunohistochemical analysis (Supplementary Fig. lb). Assess­
ment o f  hematoxylin and eosin (H8cE)-stained intestinal sections 
revealed no changes in crypt-villus architecture and no obvious 
perturbation in apoptotic or mitotic levels after Pten loss (Supple­
mentary Fig. lc). Specific stains or immunohistochemical analyses for 
differentiated cell types in the epithelium revealed that all were present 
and correctly localized after Pten loss (Supplementary Fig. lc). The 
proliferation zone within the crypt was visualized by immunohisto­
chemistry against the proliferation marker Ki67 and by labeling of 
replicating cells using BrdU. Both methods revealed that loss of Pten 
does not perturb the size or location o f the proliferation zone 
(Supplementary Fig. Id).
In utero deletion of Pten
Pten deletion in embryonic intestinal epithelium allowed us to assess 
the role o f  Pten during development. We induced experimental and 
control mice in utero on embryonic day 12.5. Mice treated in this way 
were viable and were obtained at the expected Mendelian ratio. This 
procedure delivered ~  50% recombination at the proximal end of the 
small intestine, as assessed by LacZ expression in mice transgenic for 
the Rosa26R allele (Fig. 5a). When allowed to age, in u/ero-induced 
cre+; Ptenf,f mice developed many o f the symptoms previously 
described in uninduced and induced cre+; Pten{,{ mice. In utero- 
induced cre+; Pten{/{ mice also showed recombination in the skin, 
resulting in an abnormally shaggy coat (Fig. 5b), which is again 
consistent with previous reports26. Examination o f Pten loss in the
5  120
&
cre'; PtenC on tro l
Figure 4  R en deficiency does not alter the number of crypt clonogens or 
P-catenin localization, (a) Clonogenic microcolony assay was used to 
determine the number of clonogens present in the crypt. Control and 
experimental mice were exposed to  15 Gy of gamma irradiation and killed 
after 72  h. The number of surviving crypts per circum ference of the 
intestine was then scored from H&E-stained sections. There was no 
significant difference in the number of surviving crypts in Pterf* tissue 
(open bars) compared to control tissue (gray bars; n =  5; Mann-Whitney 
U-test, P = 0 .63 ). Error bars indicate s.d. (b) Immunohistochemical 
analysis o f p-catenin was done on control and experimental tissue on day 5 
after induction. R en-deficient tissue showed a p-catenin d istribution pattern 
comparable to  control tissue— that is, predominantly membrane associated 
in cells o f the crypt, w ith occasional nuclear sta ining (examples indicated by 
arrowheads) of long-lived cells in the base o f the crypt, presumably Paneth 
cells and stem cells.
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Figure 5 Loss of Pten in utero does not affect the normal development of the mouse small intestine, (a) Induction of recombination in utero at embryonic 
day 12.5 resulted in ~  50%  recombination in experimental and control mice in the proximal region of the intestine, as assessed by LacZ staining.
(b) In utero-induced cre*; Pterf77 mice showed recombination in the skin, resulting in a ruffled coat compared to that of control mice, consistent with 
previous reports, (c) Pten deficiency in the intestine of in ufe/o-induced mice was assessed by immunohistochemistry. Control mice showed strong Pten 
staining in the epithe lium , whereas ~ 5 0 %  of crypts in cre*; Pten/77 m ice retained Pten protein (indicated by filled arrowheads) and the remaining crypts 
were deficient for Pten (open arrowheads), (d) Ki67 immunohistochemistry revealed no difference in the ability of Pten-deficient cells to proliferate or in the 
size and location of the proliferative compartment compared to controls.
proximal small intestine by immunohistochemistry revealed that 
~  50% o f intestinal crypts lacked Pten, consistent with the estimate 
of recombination derived from the Rosa26R allele (Fig. 5c). Histo­
logical analysis revealed no gross differences in crypt size, apoptosis or 
differentiation status in the absence of Pten. Immunohistochemical 
analysis o f Ki67 showed no differences in staining (Fig. 5d). Our data 
therefore indicate that Pten is not required for normal development of 
the small intestinal epithelium, and its deficiency does not result in 
overgrowth as might be predicted from its proposed role in ISCs.
Combined deletion of Ape and Pten
Despite the above observations, PTEN loss remains implicated in 
intestinal neoplasia, raising the hypothesis that its status only becomes 
relevant in the context o f activated Wnt signaling. To test this 
hypothesis, we crossed the loxP- flanked Pten allele onto a conditional 
Ape background27. We circumvented problems caused by recombina- 
H  tion of the AhCre transgene in tissues other than the intestine by use of 
0 F  the Tg(Cyplal-cre/ESRl)lDwi transgene (abbreviated here as 
AhCreER1), a more tightly regulated form of aryl hydrocarbon- 
responsive Cre that requires binding of tamoxifen for activity28.
Figure 6  Deficiency of both Pten and Ape leads to  activation of Akt. Serial 
sections of tissue from WT (AhCreER7*; Ape*1*; Pten*1*), Ape/77; Pten*1* 
(AhCreER7*; Ape/'1; Pten*'*), Ape*'*; Pten777 (AhCreER7*; Ape*'*; PterP7) and 
Ape/*; Pten/77 (AhCreER7*; Ape/77; Pten/17) mice killed 7 d after induction 
were assessed for loss of Ape and Pten protein and activation of Akt by 
immunohistochemistry. Pten was lost from ~ 5 0 %  of epithelial cells in 
PterP7 genotypes, w ith Pten*1* genotypes retaining 100%  staining for Pten. 
P-catenin was used as a surrogate marker of Ape loss, and nuclear 
localization of P-catenin was seen in the majority of epithelial cells in Ape/77 
genotypes. To assess differences between recombined and nonrecombined 
tissue, areas of tissue showing a lower than usual level o f recombination 
were selectively photographed. Nuclear localization of P-catenin was 
not seen in Ape*7* genotypes. Activation of Akt was assessed by 
immunohistochemical analysis of Ser473-phosphorylated Akt (pAktSer473). 
Wild-type tissue had no detectable activation of Akt w ithin the epithelium . 
Tissue deficient for either Pten or Ape alone had slightly elevated levels of 
activated Akt, which was distributed evenly w ith in  the cytoplasm. Tissue 
deficient for both Pten and Ape had a large increase in activation of Akt; 
areas of tissue w ith high activation of Akt also showed increased association 
of activated Akt w ithin the plasma membrane (insets magnified x3 ).
We induced Cre recombinase activity in experimental mice 
(AhCreERT+; Pten{,{; Ap<^ {) and control mice (AhCreERIT+; Pten{,{; 
Ape*7*, AhCreERr+; Pten*7*; Apef/f and AhCreER1*; Pten*7*; Ape*7*) 
using both P-naphthoflavone and tamoxifen. After induction, we
t
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Figure 7 Pten deficiency causes rapid |  
progression to adenocarcinoma, associated , - 
w ith increased activation of Akt. (a) Kaplan ^
-Meier survival analysis of cohorts of 
Apcf*; Pterf* (AhCreER**; Apr7'* ; Pterf'*),
Ape"* (AhCreER**; Ape"*; Pten*1*),
Pterf* (AhCreER'**; Ape*'*; Pterf*) and =t 
WT (AhCreER1*; Ape*1*; Pten*'*) mice I  
revealed that the experimental cohort » '
(AhCreER**; Ape"*; Pterf*) had a reduced £  
lifespan compared to any of the control 
cohorts, (b) Histological examination of
small intestinal tum ors from AhCreER1*; Anti-Pten Anti-p-catenm
Apef*; P te rf * m ice revealed advanced, 
ulcerating, invasive adenocarcinomas that penetrated the fu ll thickness of the sm all intestinal wall, destroying the muscularis propria and leading to a 
localized periton itis (right). Tumors in AhCreER1*; Apr}'*; Pten*'* mice, by contrast, were mostly nonulcerated, noninvasive, benign intramucosal adenomas 
(le ft), (c) Immunohistochemistry of small intestinal tumors confirmed tha t they were deficient for R en and showed strong nuclear localization of p-catenin, 
ind icating loss of Ape. Ape and Pten double-deficient adenocarcinomas also had elevated activated Akt (pAktSer473), particularly at the lumenal surface of 
the tumor. As seen previously, areas w ith strong expression of activated Akt also showed association of activated Akt w ith in  the cell membrane (insets 
magnified x8 ).
100 200 300 400 500 600
Tim e (d) Q
Genotype
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observed recombination in ~  50% of intestinal epithelial cells. On day 
7 after induction, we identified tissue deficient for Pten and Ape by 
immunohistochemical analysis o f Pten and P-catenin (P-catenin 
served as a surrogate marker of Ape loss, as specific nuclear localiza­
tion o f P-catenin is a well-recognized immediate effect o f dysregulated 
»2j4 Wnt signaling29). Immunohistochemical analysis o f serial sections o f  
intestine from experimental and control mice (Fig. 6) revealed that 
~  50% of epithelial cells were deficient for Pten in Pten{,( mice 
compared to Pten*'* mice, where the entire epithelium retained 
positivity for Pten. The majority of epithelial cells in Ap?7 mice 
showed strong nuclear localization o f P-catenin, indicating loss o f Ape 
protein, compared to Ape*'* control mice, where P-catenin was 
predominantly cytoplasmic or membrane associated.
To examine the effect o f Ape and Pten loss on pathways down­
stream of Pten, we carried out immunohistochemical analysis of 
activated (Ser473-phosphorylated) Akt on adjacent tissue sections 
(Fig. 6). Consistent with previous western blot analysis o f Thr308- 
phosphorylated Akt, there was a small increase in levels o f activated 
Akt in tissues deficient for Pten or Ape alone. This level was lower than 
that seen in tissue deficient for both Ape and Pten. In addition, 
activated Akt was membrane associated in cells deficient for both Pten 
and Ape, but not in tissue deficient for Ape or Pten alone. These 
phenomena were generally observed in epithelial cells o f the villus, not 
within the crypt (Supplementary Fig. 2 online). Previous work has 
shown that targeting o f Akt isoforms to the cell membrane both 
in vitro and in vivo increases its oncogenic potential30. Here we 
showed that loss o f both Pten and Ape synergistically increases overall 
levels o f activated Akt and increases its membrane association.
Pten loss in the context o f Ape deficiency
To investigate whether the activation and change in localization of Akt 
we observed at this early stage could lead to a change in intestinal 
tumor phenotype, we generated AhCreER7*; Pten717; Ap?* mice. We 
induced cohorts o f more than 25 experimental (AhCreER7+; Pten717; 
Ap?*) and control (AhCreER7*; Pten*'*; Ap?*, AhCreER7*; Pten7'7; 
Ape*'* and AhCreER7*; Pten+/*; Ape*1*) mice, allowed them to age 
and monitored them for signs of intestinal tumors (rectal bleeding, 
prolapse and anemia) or other illness. We killed the mice when they 
became symptomatic of disease and retained their tissue for histo­
logical analysis.
Experimental AhCreER7*; Pten717; Apt?* mice had a median survival 
of 99 d, a significant reduction compared to AhCreER7*; Pten*'*; 
Apt?* and AhCreER7*; Pten{,{; Ape*'* control mice, which had a 
median survival of 405 and 409 d, respectively (x2 =  45.16, d.f. =  1, 
P <  0.0001 for AhCreER7*; Pten{,{; Ap?* versus AhCreER7*; Pten*'*; 
Ap?*; Fig. 7a). Ninety-five percent o f experimental mice analyzed 
(n = 19) had large, flattened, ulcerated lesions within the small 
intestine, with an average of 6.9 lesions per mouse (n =  14). By 
contrast, a cohort of 30 AhCreER7*; Pten*'*; Ap?* mice remained 
healthy up to 200 d after induction. We killed groups of control 
AhCreER7*; Pten*'*; Ap?* mice 180 or 250 d after induction (±10%) 
to assess intestinal tumor burden. At 180 d after induction, 33% of 
control mice analyzed bore polyp-like lesions within the small intes­
tine, with an average of 1.0 lesions per mouse (« =  6). At 250 d after 
induction, 58% of control mice had small intestinal polyps, and the 
average number of lesions increased to 1.8 per mouse (n =  12). 
Despite these increases, the frequency of lesions remained less than
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that seen in experimental mice. Both AhCreERJ+; Pten+/+; Apc+/+ and 
AhCreER1 *; Pten(/{; Apcin control cohorts remained free o f symptoms 
of intestinal disease more than 200 d after induction, with no evidence 
of hamartoma formation, supporting our earlier conclusions regard­
ing epithelial Pten redundancy.
Histological examination o f the small intestinal lesions o f experi­
mental mice revealed the majority to be invasive adenocarcinomas 
arising in severely dysplastic adenomas. Malignant invasion into the 
submucosa was evident, accompanied by luminal ulceration and the 
presence o f a desmoplastic stroma rich in fibroblasts, often associated 
with a mixed acute and chronic inflammatory cell reaction. Many 
adenocarcinomas showed destructive invasion through the muscularis 
propria o f the small intestinal wall and into the peritoneal serosa, 
resulting in localized peritonitis (Fig. 7b). This is in direct contrast to 
lesions observed in AhCreERJi; Pten+n; Ap<?l+ control mice in this 
and previous studies, where the great majority o f small intestinal 
neoplasms were benign, nonulcerating and noninvasive intramucosal 
adenomas. We examined and classified lesions as adenomas or 
microadenomas confined to the mucosa, early invasive adenocarcino­
mas infiltrating the submucosa only or advanced invasive adenocarci­
nomas that infiltrated into or through the muscularis propria o f the 
intestinal wall. In control mice, 85.7% o f  tumors identified were 
characterized as microadenomas or adenomas and 14.3% were char­
acterized as early invasive adenocarcinomas. In contrast, 46.4% of  
tumors in experimental mice were adenomas or microadenomas, 
32.1% were classified as early invasive adenocarcinomas and 21.5% 
were advanced adenocarcinomas showing invasion through the mus­
cularis propria, which were never found in control mice.
We analyzed small intestinal tumors of control AhCreERT+; Pten+/+; 
Apc*M and experimental AhCreERn ; Ptcn(/{; Apci/+ mice using 
immunohistochemistry. Analysis o f  Pten P-catenin (Fig. 7c) con­
firmed Pten and Ape status. Analysis o f  Ser473-phosphorylated Akt 
(Fig. 7c) revealed that tumors arising in AhCreERJ+; Pten{l{; Apc*l+ and 
AhCreERJi; Pten+/+; Apcf/* mice showed activation o f Akt, particularly 
at the lumenal surface o f the tumor. Activated Akt was also commonly 
localized to the cell membrane in tumor cells from AhCreERT+; Ptenil{; 
Apcih mice, although this was not seen in tumors from AhCreER1+; 
Pten+/+; Ap/ /+ mice. These observations are consistent with our
§ observations after immediate loss o f Ape and/or Pten, where mem­brane localization o f activated Akt was only observed after loss o f  both Ape and Pten. This suggests that activation and relocalization o f  Akt 
to the membrane, which arises through deficiency o f both Pten and 
Ape but not Pten or Ape alone, allows the progression o f  a tumor 
from adenoma to adenocarcinoma.
DISCUSSION
It has been repeatedly shown through mutational analysis that PTEN 
functions as a tumor suppressor and is lost or mutated in a variety o f  
different tumor types in humans (reviewed in ref. 31). Inherited 
mutation in one copy o f PTEN causes Cowden’s syndrome, which is 
characterized by the development o f hamartomatous tumors o f  
various origins, including the gastrointestinal tract7,8.
Extensive mouse studies have shown that constitutive Pten defi­
ciency is incompatible with life9-11. However, Pten heterozygotes 
model some features o f  Cowden’s disease, including predisposition 
to papillary thyroid carcinoma and skin hyperkeratosis9, endometrial 
neoplasia10 and intestinal polyposis11. In addition, studies using 
conditional deletion strategies have shown that Pten loss in tissues 
as diverse as the liver20,21, skin26, prostate26 and breast32 leads to 
neoplasia or carcinoma, or both. Here we report recapitulation of  
several o f these phenotypes as a consequence o f low-level expression of
Cre recombinase in a number of tissues. These findings confirm that 
the recombined Pten allele is truly a null allele.
It is clear that Pten functions as a major tumor suppressor, and 
evidence in the literature suggests that Pten deletion in the intestine 
leads to deregulation of growth control and the subsequent develop­
ment of hamartomatous polyps. In direct contrast to these predic­
tions, however, we found in two independent genetic models that 
deletion o f Pten specifically within the epithelium has no adverse effect 
on intestinal development or homeostasis, nor does it lead to 
hamartoma formation over 200 d after Pten deletion. We also showed 
that Pten deficiency does not impose a ‘crypt progenitor’ phenotype, 
nor does it perturb the Wnt signaling pathway. Furthermore, Pten 
deficiency does not confer an increase in clonogens after gamma 
irradiation, as might have been predicted from the literature. Taken 
together, our data argue that Pten is normally redundant in the mouse 
small intestinal epithelium.
These conclusions contrast with the findings o f He et al, who 
reported rapid tumorigenesis after conditional deletion o f Pten in the 
intestine15. However, that strategy differed from the one used here in 
that the former used an inducible cre construct driven by the Mxl 
promoter to drive Pten deficiency in epithelial and stromal cells of the 
small intestine33. Here, we drove Pten deletion using either AhCre or 
Villin-CreERT2, both of which are restricted to the epithelium within 
the intestine25,28. The difference in phenotype observed may therefore 
be a result of Pten loss in different cell types. Our data implying 
redundancy o f Pten within normal intestinal epithelium, together with 
the data o f  He et al., suggest that tumor formation is initiated by loss 
of Pten in another cell compartment within the intestine, probably 
within the underlying stroma. The findings o f He et al. are also 
consistent with the increased predisposition to intestinal tumors of 
humans with Cowden’s syndrome and mice with a constitutive Pten 
deletion, where all cell types o f the tissue are effectively heterozygous 
for Pten. Tumor formation in this case may actually be initiated by loss 
o f Pten within a stromal cell, rather than in the epithelial compart­
ment. These data highlight the importance o f interaction between 
epithelial cells and other cell types in their neighboring environment 
in the development and progression o f intestinal tumors. Indeed, the 
importance o f this interaction for suppression o f tumorigenesis has 
very recently been shown in two studies. First, deletion o f the bone 
morphogenetic protein type II receptor specifically in the stroma was 
shown to have a marked effect on epithelial homeostasis, ultimately 
resulting in hamartoma development34. Second, mesenchymal-specific 
deletion o f the tumor suppressor Stkll (also known as Lkbl) was 
shown to result in polyposis, which recapitulates that seen in con­
stitutive Stkl 1 -heterozygous animals35. These data, together with 
those o f  He et al.15 and the observations we report here, provide 
evidence supporting the notion that the initiating event for hamar­
toma formation occurs outside o f the epithelial cell population36.
To further investigate the role o f  Pten within the intestinal epithe­
lium, we characterized the effects o f Pten loss in the context of 
activated Wnt signaling, achieved by combined deletion o f both 
Pten and Ape. In epithelium deficient for Pten or Ape alone, we 
observed a small increase in activated Akt levels. In tissues deficient for 
both genes, we observed higher levels o f activated Akt in the 
epithelium coupled with strong membrane localization, a phenom­
enon previously associated with increased oncogenic potential30. Pten- 
deficient tumors arising in Ape-heterozygous mice also showed 
increased levels o f activated Akt, which was again localized to the 
cell periphery. In these mice, the majority o f lesions showed clear 
evidence o f progression to adenocarcinoma, in direct contrast to 
Ape-heterozygous mice, which only develop adenomas. These data
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therefore show that Pten loss increases the levels of activated Akt and 
alters its cellular localization, the consequences o f which are increased 
adenoma predisposition and progression. Within the prostate, neo­
plasia driven by Pten loss has been found to be absolutely dependent 
upon functional Akt3'. Our data support the notion that activation o f  
Akt is the key tumor-promoting event after Pten loss. When Akt 
activation is weak, as in the context o f  Pten loss alone, no tumor 
suppressor function is seen. However, when Akt activation is high, 
such as when both Pten and Ape are deleted, rapid tumor onset and 
progression ensue. Our data therefore add Pten to the relatively short 
list o f genes that have been directly implicated in adenoma progression. 
This, along with the observation that the PI3K pathway is activated in a 
large percentage o f colorectal cancers6, argues for the therapeutic 
targeting o f Akt in intestinal adenomas and adenocarcinomas.
METHODS
Mice. All procedures were conducted  in accordance w ith local and  national 
regulations as appropriate. Mice were m aintained on  an o u tb red  background, 
and all mice were genotyped as previously described for the  targeted Pten 
allele1*, the targeted Ape allele2 , the Rosa26R allele19 and the  cre transgene29. 
C ontrol mice were derived from  the sam e colony as the  experim ental mice, but 
they were not always litterm ates. Cre activity was induced in contro l and 
experim ental AhCre mice by in traperitoneal injection w ith 80 m g/kg 
(3-naphthoflavone (Sigma) dissolved in com  oil for four consecutive days29. 
Mice bearing the AhCreER' transgene received a com bined  in traperitoneal 
injection o f  80 m g/kg (3-naphthoflavone and tam oxifen (S igm a), dissolved 
together in corn oil, for four consecutive days. Mice bearing the  Villin-CreER12 
transgene2  ^ were induced by intraperitoneal injection o f  tam oxifen at a dose o f  
30 m g/kg for five con.secutive days.
To exam ine S phase labeling in vivo, selected mice were injected w ith  100 pg 
o f  BrdU (Sigma) and killed at indicated tim e po in ts after labeling. For the 
clonogenic m icrocolony assay, control and experim ental m ice were exposed to  
13 Gy o f  gam m a irradiation  and killed 72 h later. K aplan-M eier survival 
analysis was done using M edCalc software (version 8.2.1.0; available at h ttp :// 
www.medcalc.be).
W hole intestines were rem oved and flushed well w ith water. As recom bina­
tion levels decrease along the proxim al-distal axis o f  the  in te s tin e1', small 
intestinal tissue was consistently collected from  defined po in ts  a long the 
intestine. The first 5 cm of the intestine was fixed in m ethacarn  (4:2:1 ratio  
o f m ethanol:chloroform :acetic acid) for histological analysis. T he next 3 cm  was
& bundled  using surgical tape and fixed in ice-cold 10% neutra l buffered form alin overnight to  be used for im m unohistochem istry. T he following 10 cm  was used fresh for enrichm ent o f  epithelial cells (see below).
p-galactosidase analysis. Assessment o f  (3-galactosidase activity  was used to  
exam ine the efficiency o f recom bination  at the Rosa26R reporte r allele after 
induction  o f Cre activity. Intestinal w hole-m ounts were prepared , fixed and 
exposed to  X-gal substrate using a m ethod  previously repo rted29.
Histology and immunohistochemistry. Intestinal tissue was fixed in  ice-cold 
10% neutral buffered form alin (Sigma) for no longer than  24 h before being 
processed in to  paraffin blocks according to  s tandard  procedures. Tissue 
sections (5 pm ) were e ither stained w ith H&E for histological analysis o r 
used for im m unohistochem istry . T he following p rim ary  antibodies were 
used for im m unohistochem istry : Ab-2 rabbit an tibody  to  Pten (1:25; Lab 
Vision), rabbit an tibody  to  Pten (1:100, Cell Signaling Technology), m ouse 
antibody to  Ki67 (1:100; Novacastra), rabbit an tibody  to lysozyme (1:100; 
N eom arkers), rabbit an tibody  to  villin (1:100; Santa C ruz), m ouse antibody to 
BrdU (1:100; Becton D ickinson), m ouse an tibody  to  P-catenin (1:200; Trans­
duction  Labs) and rabbit an tibody  to  Ser473-phosphorylated Akt (1:50; Cell 
Signaling Technology). Periodic acid-Schiff (PAS) staining and Grim elius 
staining were done according to  standard  protocols^9.
Enrichment for epithelial cells. To obtain  a population  o f  cells enriched for 
epithelial cells, we used an epithelial extraction protocol based on  one 
previously described '*  on freshly collected intestine. Briefly, a 10-cm section
o f small intestine was flushed well w ith w ater before being tied off at one end 
and inverted over a 4 -m m  glass rod. V ibration was then applied to the glass 
rod, and  the intestine was placed in 10 m M  EDTA in H ank’s balanced salt 
solution (Gibco) at 37 C for 15 m in. The intestine was then  m oved into a clean 
tube o f 10 m M  EDTA in H ank’s balanced salt solution and incubated in the 
same fashion for a further 15 min. Centrifugation (2,700 g, 4 °C, 15 min) 
yielded a pellet containing predom inantly  epithelial cells.
Quantitative real-time PCR. RNA was isolated from  cells obtained by epithelial 
extraction using a standard phenol-chloroform  protocol. RNA was purified 
using the RNeasy kit (Qiagen) and treated w ith R Q l RNase-free DNase 
(Prom ega) according to  the m anufacturer’s instructions to  remove genomic 
DNA. Reverse transcription was done using the SuperScriptll reverse tra n ­
scriptase kit (Invitrogen) and random  hexam ers (Invitrogen) according to  the 
m anufacturer’s instructions. Q uantitative real-tim e PCR was done to  assess 
expression o f  Pten, CD44, Tcf4, Axin2, Myc, M sil, B m il and  Lgr5. Prim er 
sequences are provided in Supplementary Table 1 online.
DyNAmo HS SYBR Green (Finnzymes) was added to  appropria te  cDNA 
sam ples and prim ers. (3-actin was used as a loading control. Reactions were run 
on a PTC-200 therm al cycler and a Chrom o4 continuous fluorescence detector 
(bo th  from  MJ Research), which were used in conjunction w ith O pticon 
M onito r analysis software (version 2.03, MJ Research) to  calibrate and run  the 
reaction. Data were analyzed using the 2 AAQ m e th o d '9.
Western blot analysis. Protein was extracted from  epithelial-enriched samples 
by standard  m ethods using lysis buffer (20 mM  Tris-HCl (pH  8.0), 2 mM  
EDTA (pH  8.0) and 0.5%  (vol/vol) NP-40) containing protease inhibitors 
(C om plete, M ini protease inhib itor tablets, Roche) and phosphatase inhibitors 
(25 m M  sodium  (3-glycerophosphate, 100 mM  sodium  fluoride, 20 nM 
calyculin A and 10 m M  sodium  pyrophosphate). Solubilized proteins 
(30 pg) were separated by standard SDS-PAGE on a 10% polyacrylamide 
separating gel w ith 5% stacking gel and  then transferred to polyvinylidene 
fluoride m em brane (Hybond-P, Am ersham  Biosciences) by standard m ethods.
The following prim ary  antibodies were used to  probe blots: Ab-2 rabbit 
an tibody  to Pten (1:500; Lab Vision), rabbit an tibody to  Akt (1:1,000; Cell 
Signaling), rabbit antibody to Thr308-phosphorylated Akt (1:300; Cell Signal­
ing) and  m ouse antibody to (3-actin (1:5,000; Sigma). A ppropriate horseradish 
peroxidase-conjugated secondary antibodies were used (Am ersham  Bios­
ciences). Blots were developed using ECL, ECL Plus o r ECL Advance reagents 
(A m ersham  Biosciences) according to the m anufacturer’s instructions.
Note: Supplementary information is available on the Nature Genetics website.
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Intestinal homeostasis and 
neoplasia studied using 
conditional transgenesis
Victoria Marsh and Alan Clarkef
Constitutive mouse models of intestinal neoplasia, such as the Apcmin/+ (multiple intestinal 
neoplasia) mouse have proven valuable tools both for furthering our understanding of 
tumorigenesis and for the development of therapeutic strategies. However, the in vivo 
study of a number of genes has been precluded by their absolute requirement during 
embryonic development. This has led to the development of conditional strategies that 
allow gene regulation in vivo. This review describes the principal techniques used to 
achieve conditional transgenesis within the mouse intestine, with a particular focus upon 
the Cre-Lox and Tet-regulable systems. Further, we discuss how these techniques are 
being used to dissect the mechanisms governing both normal homeostasis and neoplastic 
development within the intestine.
Expert Rev. Anticancer Ther. 7 (4 ), 519 -5 3 1  (2007)
The ab ility  to model intestinal neoplasia in  the 
mouse has proven a crucial factor in increasing 
our understanding o f  the complex processes 
that underlie neoplasia. M odeling has also 
facilitated the identification o f  novel potential 
therapeutic targets, as well as provid ing an 
in vivo setting for testing existing and novel 
therapeutic agents. The models currently avail­
able to us have been developed through the 
constitutive overexpression o f  known onco­
genes, as randomly generated mutants or as 
specific knockouts o f known tumor-suppressor 
genes. One o f the best characterized and most 
extensively used models o f  intestinal tum or 
development is the Ap(f"nl* (m ultip le  intesti­
nal neoplasia) mouse. The Apff""'* strain was 
generated by random mutagenesis follow ing 
exposure to ethylnitrosourea, creating a line 
that spontaneously developed polyps w ith in  
both the large and small intestine [1). Subse­
quent sequencing o f  this m utant revealed a 
po in t m utation w ith in  the Ape gene at 
codon 850 [2], Since its development and char­
acterization, the Ap<ff'nl* mouse has been used 
as an accurate model o f  the human disease 
fam ilial adenomatous polyposis (FAP), 
although it  should be noted that some differ­
ences do exist between the Aptff'nl* model and
human FAP patients: FAP patients tend to 
develop tumors w ith in  the colon and rectum, 
whereas ApcFnin/* mice predominantly develop 
small intestinal tumors. This model has been 
particularly valuable for expanding our know­
ledge o f the neoplastic process in the intestine [3] 
and has also been a useful tool for the screening 
and development o f chemotherapeutic and 
chemopreventative agents. For example, the 
efficacy o f nonsteroidal anti-inflammatory 
drugs in the prevention and treatment o f intes­
tinal tumors has been widely tested in the 
Apc-min,+ model. Examples o f specific studies 
include Sansom and colleagues, who showed 
that treatment o f Apff1 mice w ith aspirin from
conception onwards results in dramatic suppres­
sion o f intestinal adenoma development [41, and 
Boolbol and colleagues who showed that the 
administration o f sulindac to Ap<ffinl* mice 
results in reduced tum or incidence [51. Encour­
agingly, the findings o f  the latter study have 
been recapitulated in human FAP patients 
treated w ith  the same agent [6].
Constitutive knockout models have also been 
used to provide insight into factors contributing 
to neoplasia w ith in  the intestine. One example 
o f this is deletion o f the tumor-suppressor gene 
p53, which has been widely studied in a range
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of tissues in the mouse. We have previously examined the role o f  
p 53 in the D N A  damage response o f the intestine 2 ]. T h is  study 
found that deficiency of p53  allowed cells bearing rad ia tion- 
induced D N A  damage to evade apoptosis. A t the tim e, this sup­
ported the no tion  that p53  deficiency may con tribu te  to 
tumorigenesis by a llow ing m utan t cells to persist. T h is  no tion  
has now been d irectly  tested using a mouse model in w h ich  p53  
status can be reversibly switched in vivo between functiona l and 
inactive states, to demonstrate that that the />53-mediated pa th­
ological response to w hole -body irradia tion is actually irrele­
vant, at least for the suppression o f  rad iation-induced ly m ­
phoma s;. W hether this remains true fo r all tissues, inc lud ing  
the intestine, remains unclear.
Despite the ir obvious successes, the extensive use o f  cons titu ­
tive knockouts has been hampered by the fact that many onco­
genes and tum or-suppressor genes are required fo r em bryon ic 
development. Furtherm ore, analysis o f  gene function  w ith in  a 
given tissue has often been precluded or compromised by over­
rid ing  phenotypes w ith in  other tissues. It has also been argued 
that constitu tive  knockou t models may not fa ith fu lly  represent 
the norm al process of neoplasia, as this is norm ally character­
ized by sequential m uta tions occurring w ith in  a subset o f  cells 
(usually) w ith in  an adu lt organism in the context o f  genetically 
norm al ne ighboring  cells. T his s ituation contrasts w ith  that in 
constitu tive  models in two s ignificant ways:
• The cells in a constitu tive lv  m utan t animal all possess the
m uta tion  of interest
• C onstitutive mutants provide an opportun ity  for compensation
by other genes to occur during the process o f development
In order to c ircum vent these issues, cond itiona l transgenic 
strategies have been developed that a llow  a gene to be deleted 
specifically w ith in  a single cell type or at a pa rticu la r stage of 
development. Th is  review aims to deal w ith  how  cond itiona l 
transgenesis can be achieved w ith in  the m urine in testine and 
also to examine recent studies that have used con d itiona l tech­
nology to investigate the c o n trib u tio n  o f  various regulatory 
pathways to intestinal neoplasia.
Conditional transgenic technology
Systems that perm it sw itching o f  gene expression are designed such 
that transgenesis occurs on ly once defined conditions are met. 
Such conditions may include cell or tissue specificity, develop­
mental stage, exposure to xenobiotics or indeed a com bination o f  
these factors. Here, we brie fly  review the methods o f  achieving 
conditional transgenesis in the intestine, although it should be 
noted that more extensive reviews can be found elsewhere [9-i2]. 
In its very simplest form , conditiona l transgenesis involves the 
use o f  a tissue-specific promoter, which drives expression o f  a 
chosen transgene. For instance, the prom oter o f  the Villin gene 
has been used to drive transgene expression specifically and 
effic iently in the small and large intestinal ep ithe lium  : 13|.
Early attempts to develop tru ly  switchable systems used exo­
genous agents, such as steroids, heat-shock or heavy metals, to 
induce promoters that w ou ld  d irectly  drive transgene expression
in a tem porally contro lled manner ' 14,15). However, such 
approaches were found to be somewhat problematic, w ith  
inducing agents often being toxic to cells and w ith  poor levels o f  
gene expression being achieved. M ore sophisticated conditional 
systems have now been developed, many o f  w hich are b ipartite 
in  mechanism, invo lv ing both an ‘effector’ and a ‘targeted’ trans­
gene, upon which the effector acts to switch the gene on or off. 
Such binary approaches include the causes recom bination 
(C re)-locus o f  crossover (Lox), Flp—Flp recognition target (Frt) 
and tetracycline (Tet)-regulable sysms.
Probably the most popular method o f  achieving cond itiona l 
transgenesis w ith in  the intestine is the C re -Lox  approach. The 
effector, Cre recombinase, was in it ia lly  isolated from  the bacte­
riophage P I ,16) and catalyzes recom bination between pairs o f  
recogn ition sequences, termed LoxP (locus o f  crossover P i)  
sites ; 17.18]. I f  a target gene or one or more o f  its essential coding 
regions, is placed between a pair o f LoxP sites and exposed to 
Cre recombinase, the region o f D N A  between the two LoxP 
sites is com plete ly excised (or ‘floxed’ out), resulting in inactiva­
tion  o f  the gene. It is also possible to activate transgenes using 
this system, by engineering the transgene so that it contains a 
‘S T O P ’ cassette flanked by a pair o f  LoxP sites. W hen Cre is 
expressed, the STO P cassette is then removed, pe rm itting  
expression o f  the transgene ; i9 |.
C o n tro l o f  the C re -LoxP  system is achieved p rinc ip a lly  
th rough  careful selection o f  the p rom oter to drive expression 
o f  Cre recombinase. Examples o f  p rom oter-C re  constructs 
com m o n ly  used to drive recom bination w ith in  the intestine 
inc lude V il l in -C re  [20,211, Fabp-C re [22], M x l- C r e  [23] and 
A h -C re  [24], Both the V il l in -  and fa tty  ac id -b ind ing  pro te in  
prom oters are active specifically in  the in testine by em bryon ic 
day (E) 12.5 [2 i ) and E 13.5 [22], respectively, and Cre recom ­
binase is therefore constitu tive ly  bu t specifica lly expressed 
w ith in  the in testine th roughou t developm ent and in to  ad u lt­
hood. M x l- C r e  requires exposure to in te rfe ron or po lyinos- 
in ic -p o ly c y tid y lic  acid (p I-p C ; w h ich  stim ulates host in te r­
feron p ro du c tion ) in  order fo r Cre to be expressed [23]. The 
p rom ote r o f  the cytochrom e P450 1A1 sub fam ily  is used to 
d rive Cre expression in the A h -C re  transgene, thus exposure 
to  aryl hydrocarbons, such as p-naphthoflavone, is required to 
induce ac tiv ity  [24,25]. Each o f  these constructs show d iffe r­
ences in  the patterns o f  recom bination w ith in  the intestine, 
w ith  V il l in -C re  and A h -C re  show ing recom bination 
restricted to ep ithe lia l cells [20,21,24], whereas M x l- C r e  also 
drives recom bination  more w ide ly  [26]. Furtherm ore, recom bi­
na tion  patterns can d iffe r even w ith in  a single cell type. For 
example, a lthough V il l in -C re  and A h -C re  bo th drive recom­
b in a tio n  w ith in  the ep ithe lia l com partm ent, there are d iffe r­
ences in  the exact location o f  the ir activity. V il l in -C re  is 
expressed in  ep ithe lia l cells along the en tire ty  o f  the c ry p t-v il­
lus axis, d r iv in g  recom bination in  bo th m ature d iffe rentia ted 
cells and im m ature precursor cells [ 13]. T h is  is in  contrast to 
A h -C re , w h ich  is p rinc ip a lly  expressed w ith in  the stem and 
precursor cell com partm ent located towards the base o f  the 
cryp t [24].
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Systems that em ploy post-translational con tro l over Cre 
recombinase activ ity  through dependence on ligand b ind ing  
have also been developed. For instance, fusion proteins o f  Cre 
recombinase and a m od ified  estrogen receptor (ER) have been 
generated (e.g., C re E R 1, C reER 12 and C re E R 1 M) [21,27- 29]. 
Once translated, the ER dom ain o f  the pro te in  sequesters the 
recombinase in the cytoplasm, preventing it  from  acting on its 
target sequences contained w ith in  the nucleus. O n  b ind ing  o f  
the estrogen analog tam oxifen, the nuclear localization signal o f  
the receptor is exposed and the fusion pro te in  is able to trans­
locate to the nucleus, where it can act on its target. Such fusion 
proteins can also be placed under the con tro l o f  the promoters 
described previously, w hich provides m uch tigh te r con tro l o f  
Cre expression. One example o f  this is the A h -C re E R T con­
struct, which requires both exposure to an aryl hydrocarbon to 
induce transcription o f  the transgene, plus add itiona l b in d in g  o f  
tamoxifen to allow activation o f  the recombinase ( f i g u r e  d  [3 0 ].
O ne o f  the main advantages o f  the C re -L o x  approach is its 
popu larity: this has meant that a large num ber o f  bo th the ta r­
geted transgenes and Cre-expressing transgenes have been 
developed [ i o n .  However, this approach also has several dis­
advantages. These include aberrant Cre expression o r ‘ leakiness’ 
in other tissues, although it has been argued that th is is a bene­
f it  o f  some systems. Also, the discovery o f  pseudo-LoxP recog­
n itio n  sites w ith in  mammalian genomes, w h ich  can be acted 
upon by Cre recombinase 3 1 ], has prom pted the suggestion 
that Cre expression in m am m alian cells may cause doub le­
stranded D N A  breaks and perhaps prom ote genom ic ins tab il­
ity. Finally, w ith  respect to genetic m an ipu la tion  one o f  the 
m ajor drawbacks of this system is that it  is irreversible: once the 
targeted region has been excised there is no way o f  restoring it.
F lp -F rt systems w ork on very s im ila r princ ip les to those o f  
C re -LoxP  systems. Flp recombinase, isolated from  the yeast 
Saccharomyces cerevisiae, is another site-specific recombinase 
that acts to cause recom bination between pairs o f  Flp recom bi­
nation target (Frt) sites [32]. However, Flp—Frt is no t com m only  
used w ith in  the intestine, therefore its use is no t dealt w ith  in 
detail here. The final b inary system o f  cond itiona l transgenesis 
that w ill be discussed here, and w h ich  has been used in  the 
intestine to some extent, is the Tet-regulable approach. Tet- 
dependent systems were o rig in a lly  adapted from  the ir 
Escherichia coli origins and m od ified  fo r use in  m am m alian sys­
tems by Gossen and Bujard [33]. T hey d iffe r from  the recom bi­
nation-based C re -LoxP  and Flp—Frt systems described previ­
ously in that the effector transgene acts to transactivate the 
target transgene. The effector transgene typ ica lly  consists o f  a 
tissue-specific prom oter that drives the expression o f  a fusion 
prote in consisting o f  the E. coli tetracycline-resistance (TetR) 
D N A -b in d in g  dom ain and the VP 16 transactivation dom ain 
derived from  the herpes simplex virus. T h is  product can then 
act on the second com ponent o f  the system. The target con­
struct consists o f  the human cytomegalovirus prom oter under 
the con tro l o f  the E. coli Tet operator (TetO ), w h ich  together 
drive the expression o f  the gene o f  interest. In  the case o f  the 
tetracycline-contro lled transactivator (tTA ), or ‘T e t-o ff ’ system,
when doxycycline is present, it  is bound by the TetR domain o f 
the fusion protein, inactivating it  and preventing expression o f 
the target gene [34], An adaptation o f  this system, known as the 
reverse-tTA (rtTA ), or ‘Tet-on’ system, employs use o f  a m utant 
TetR protein, which is only active when bound to doxycycline, 
and therefore is required fo r target gene expression [35]. The 
main advantage o f  the Tet-regulable systems over the systems 
described previously, which require recom bination, is undoubt­
edly that it  is completely reversible and allows gene expression to 
be turned on and o ff  at w ill. However, the system also has sev­
eral drawbacks, includ ing a lack o f  responsiveness to doxycycline 
in certain tissues and ‘ leaky’ expression o f  transgenes 112].
C ond itiona l transgenesis has undoubtedly revolutionized the 
way in  w hich gene function can be studied in  the mouse. Exam­
ples o f  uses o f  the technology, employed specifically to investi­
gate homeostasis and neoplasia w ith in  the intestine, are 
described later and are grouped according to regulatory pathway. 
The examples described here are summarized in t a b l e  1.
Wnt signaling
By v irtue  o f  its frequent association w ith  intestinal cancer in 
humans, the W n t signaling pathway is probably the best stud­
ied o f  the regulatory pathways in the mouse intestine (further 
W n t pathway reviews can also be found [36,37]). A  num ber o f 
W n t pathway components have been cond itiona lly  m odified 
w ith in  the intestine and these studies are described below.
Ape
O ften  referred to as the ‘gatekeeper’ o f  in testinal tum origene­
sis, the adenomatous polyposis co li gene product, o r Ape, is 
central to the W n t signaling pathway, fo rm in g  part o f  the 
P-catenin destruction complex along w ith  glycogen synthase 
kinase (GSK)-3P and Axin . Study o f  complete inactivation o f 
Ape in vivo has previously been precluded by the fact that 
b ia lle lic  m uta tion  causes em bryonic le tha lity  [38]. Ape was first 
deleted from  the adult in testinal ep ithe lium  by Sansom and 
colleagues in  2004 [39]. In  this study, a C re -Lox  approach was 
employed, w ith  Cre expressed from  the A h -C re  transgene fo l­
low ing  induc tion  using P-naphthoflavone and both copies o f 
the Ape gene targeted for recom bination w ith  LoxP sites. This 
approach allowed characterization o f  the very early effects o f 
Ape loss in vivo p rio r to adenoma form ation , w h ich  had not 
previously been achieved using any other model system. Loss 
o f  Ape was found to rap id ly  lead to overexpression and nuclear 
localization o f  P-catenin, w h ich  was coincident w ith  perturba­
tion  o f  the norm al c ryp t-v illu s  architecture o f  the epithe lium . 
The pro life ra tive com partm ent o f  the ep ithe lium  was found to 
dram atica lly expand fo llow ing  Ape deletion, resulting in  abnor­
m ally large, aberrant cryp t-like  structures and a greatly 
increased num ber o f  cells in  S-phase. D iffe ren tia tion  o f  epithe­
lia l precursor cells in to  the fou r mature cell types o f  the epithe­
lium  was found to be perturbed, w ith  failure o f  zl/>f-deficient 
cells to express V il l in  (a marker o f  the brush border), and a lack 
o f  goblet cells and enteroendocrine cells. Paneth cells were 
found to be present, although the ir localization was grossly
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Figure 1. Overview of conditional Cre-Lox-based experimental strategies. (A) Cre expression can be targeted to selected cell types by use o f a tissue-specific 
promoter. Activation o f the tissue-specific promoter drives expression o f the Cre transgene, which is translated in the cytosol. Cre recombinase can then translocate 
to the nucleus, where it catalyzes recombination between pairs o f LoxP sites. Examples o f this type o f regulation in the intestine include Villin-Cre, fa tty  acid-binding 
protein (liver)-Cre and Ck19-Cre. (B) Transcriptional contro l o f Cre expression can be achieved through the use o f inducible promoters. The Cre transgene is 
transcriptionally silent in the absence o f an appropriate inducer. On adm inistration o f the inducer, the inducible promoter is activated and the Cre transgene 
expressed. Cre is translated in the cytosol and translocates to  the nucleus as described for (A). Inducible expression o f Cre in the intestine can be achieved through 
use o f constructs such as Ah-Cre (which requires induction using p-naphthoflavone) and M xl-C re  (which requires induction using interferon or poly(l) poly(C) 
motifs). (C) Cre activity can be modulated in a post-translational manner through use o f a fusion protein composed o f Cre recombinase and a modified ER. The 
CreER fusion protein is usually expressed from  a tissue-specific promoter as described for (A). However, as a consequence o f heat-shock protein-ER domain 
interaction, the fusion protein is sequestered in the cytosol until adm inistration o f Tam. This synthetic estrogen binds to the ER domain o f the fusion protein and 
allows exposure o f the nuclear localization signal. The fusion protein is then able to translocate to the nucleus, where Cre can act on target sequences as described in 
(A). (D) Both transcriptional and post-translational control o f Cre activity can be achieved through use o f inducible promoters coupled w ith CreER fusion proteins. 
Transcription o f the CreER fusion protein is regulated as described fo r (B). Post-translational control o f the fusion protein is achieved as described in (C). An example 
o f use o f this tightly  regulated Cre in the intestine is the Ah-CreER construct, which requires both p-naphthoflavone administration to stimulate CreER expression 
and Tam binding to  allow Cre to  access the nucleus.
Cre: Causes recombination; ER: Estrogen receptor; IP: Inducible promoter; LoxP: Locus o f crossover in P1; NLS: Nuclear localization signal; Tam: Tamoxifen;
TSP: Tissue-specific promoter.
abnormal, and this was attribu ted to d isruption o f  the erythro­
poietin-producing hepatocellular (Eph)B gradient on the 
c ryp t-v illus  axis, which w ould norm ally provide positional cues 
for differentiated cells.
In  2005, Andreu and colleagues conducted a separate study 
to address the same question as Sansom and coworkers, again 
using a Cre—Lox approach to inactivate Ape [40]. In this case 
however, Cre was expressed under the contro l o f  the V il lin  pro­
moter in the form  o f  a CreER72 fusion protein, requiring expo­
sure to tamoxifen fo r Cre to become active. This study largely 
recapitulated the results o f  Sansom and colleagues, w ith  the
description o f  sim ilar phenotypes o f  gross expansion o f the 
crypt compartment, m igration failure and perturbed differenti­
ation. By using the V illin  promoter to drive Cre expression, 
Andreu and colleagues were additionally able to address the role 
o f  Ape in  mature, differentiated cells o f  the villus, which was 
not possible in the Sansom and colleagues study due to the fact 
that A h—Cre induces principally w ith in  the proliferative com­
partment. Andreu and colleagues found that differentiated cells 
were not susceptible to the effects o f  increased P-catenin signal­
ing, w ith  no change in  morphology and failure to re-enter the 
cell cycle. The authors concluded that their observations (and
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Table 1. Summary of conditional models used to study homeostasis and neoplasia in the intestine.
Pathway Target Experimental approach(es) Major intestinal phenotype(s)
W nt Ape
p -c a te r in
Noggin
Inducib le inac tiva tion  o f ta rge t gene mediated by D isruption o f normal intestinal arch itectu re ; expansion o f 
A h-C re  prolifera tive com partm ent; perturbed d iffe ren tia tion  o f
ep ithelia l cell types; failed m igration 
Inducib le inac tiva tion  o f ta rge t gene mediated by Expansion o f pro lifera tive com partm ent; perturbed
V illin -C reER  2 d iffe ren tia tion ; failed m igration ; no phenotype observed
w ith in  the postm ito tic  cell population o f the villus
C ond itiona l inac tiva tion  o f targe t gene mediated Colorectal adenoma developm ent w ith in  3 m onths;
by local in fec tion  w ith  C re-encoding adenovirus eventual progression to adenocarcinoma
Inducib le inactiva tion  o f ta rge t gene mediated by Ablation o f crypts; detachm ent o f ep ithe lium  from
underlying stromaA h-C re
Expression o f a stable trunca tion  m u tan t 
transgene driven by the Fabpl p rom oter 
Expression o f a stable tru nca tio n  m u tan t 
transgene driven by the Calbindin p rom oter
Inducible stab iliza tion by exon de le tion mediated 
by Ck 19-C re and Fabpl-Cre
c-M yc
O c t - 4
Notch CSL/RBP-J
N o tc h -1 
receptor
TGFp/BMP TGF-p type 
II receptor
BM PRla
C ond itiona l inac tiva tion  o f targe t gene mediated 
by V illin -C reER 12
Ectopic expression mediated by a Tet-regulable 
system
Dysplasia; expansion o f pro lifera tive com partm ent; 
fa iled d iffe ren tia tion
Inducible inactiva tion  o f ta rge t gene mediated by Replacement o f cells in transit am plify ing  zone w ith  
A h-C re  and V illin -C reER 12 mature, d iffe ren tia ted  goblet cells; com plete loss o f
C ond itiona l overexpression o f active in trace llu la r 
dom ain mediated by V illin -C re
Inducib le overexpression o f active in trace llu la r 
dom ain m ediated by A h-C re
Overexpression o f do m in a n t negative m u tan t 
driven by ITF prom oter
Inducible inactiva tion  o f ta rge t gene mediated by 
M x l-C re
Overexpression o f transgene driven by 
V illin  prom oter
Overexpression o f transgene driven by 
Fabpl prom oter
PI3K/Akt PTEN
Ras k-Ras
SMAD4 C ond itiona l inactiva tion  mediated by m m tv)-C re  No phenotype when deleted from  ep ithelia l cells. T-cell
and ttr -C re  in ep ithelia and Lck-Cre and CD4-Cre specific deletion leads to fo rm ation  o f polyps
in T cells h isto log ica lly s im ilar to  those seen in human JPS
Inducib le inac tiva tion  o f ta rge t gene mediated by Development o f polyps in small in testine; altered W nt
M x l-C re
Overexpression o f activated m u tan t driven by 
V illin  prom oter
C ond itiona l expression o f activated m u tan t from  
endogenous prom oter mediated by Fabpl-Cre 
Inducible expression o f activated m u tan t from  
endogenous prom oter mediated by A h-C re
signaling in stem cells, leading to  an increase in 
pro life ra tive intestinal stem cells
Rapid developm ent o f neoplastic lesions 
Hyperplasia and dysplasia; increased pro life ra tion 
No phenotype in adult tissue
Ref.
Abnormal v illus branching; increase in apoptosis and 
m itosis; impaired m igration 
Rapid developm ent o f numerous dysplastic lesions 
along the length o f the intestine; increased pro life ra tion  
and apoptosis
Rapid developm ent o f large numbers o f polyps w ith in  the 
small intestine, but not the colon
Defective crypt form ation during developm ent fo llow ed 
by recovery; no phenotype seen in adult tissue 
Inducible inac tiva tion  o f ta rge t gene m ediated by Deletion not tolerated in the adult crypt; crypts are greatly 
A h-C re reduced in size and show decreased m etabolic ac tiv ity ;
ep ithe lium  is repopulated w ith  w ild -typ e  cells
p ro life ra tive  zone
Lack o f secretory cell lineages w ith in  the mucosa; 
expansion o f pro life ra tive zone; increased apoptosis; 
defects in apical surface o f enterocytes 
Increase in numbers o f goblet cells present on villus; 
increased apoptosis
Increased susceptib ility  to  colon tum ours in response to  
carcinogen trea tm ent
Increase in pro life ra tive cells, developm ent o f 
intestinal polyps
Abnorm al v illus structure; developm ent o f mislocalised 
c ryp t-v illu s  structures; fo rm ation  o f polyps histo logically 
s im ilar to  those seen in human JPS 
Formation o f polyps histo logically sim ilar to  those seen in 
human JPS
[39]
[40]
[42]
[24]
[46]
[47]
[48]
[50]
[51]
[57]
[59]
[60]
[61]
[63]
[6 6 ]
[69]
[70]
[71]
[72]
[74]
[75]
[76]
B M P Bone m orp ho ge n ic  prote in ; BMPR: Bone m orphogenic  protein  receptor; Cre: Causes recom bination; ER: Estrogen receptor; Fabpl: Fatty acid-binding  protein, liver; 
ITF k te s t .n a i tre fo il facto r; JPS: Juvenile polyposis syndrom e; Lck: Src fa m ily  protein  tyrosine kinase; m m tv: M urine  m am m ary tu m o r virus; PTEN: Phosphatase and Tensin 
hom o og m u ta te d  on ch rom osom e 10; RBP-J: R ecom bination  signal b inding protein for im m unog lobulin  k:J region; SMAD: M others  against decapentaplegic;
Tet Tetracycline, TGF: Transform ing g ro w th  facto r; ttr: T ransthyretin .
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indeed rhose o f Sansom and colleagues) support the ‘bo ttom -up ’ 
hypothesis o f in testinal tumorigenesis, which proposes that early 
adenoma in it ia tio n  occurs w ith in  the crypt, w ith  spreading o f 
the adenoma in an upwards manner [4 i|.
In order to address the fact that most mouse models o f  Ape 
deficiency p redom inan tly  develop small intestinal tum ors 
rather than the colorectal lesions more com m only seen in 
humans, attem pts have been made to generate models that 
more accurately recapitulate the human tum or d is tribu tion . 
Shibata and colleagues used a C re -Lox  approach to delete 
exon 14 o f  the Ape gene specifica lly from  the colon and rectum 
by local in fection  w ith  a recom binant adenovirus encoding the 
Cre recombinase 4 2 ! .  A ltho ug h  the incidence o f  adenoma fo r­
m ation was somewhat low  using this approach, this strategy 
modeled the tum or d is tr ib u tio n  observed in human colorectal 
FAP more accurately, w ith  recom bination leading to colorectal 
adenoma form ation w ith in  3 m onths and progression to adeno­
carcinoma at later tim e points. The findings o f  this study have 
also been recapitulated more recently using a s im ilar model [43 ].
(\-catonin
P-catenin is a m u ltifu nc tio na l prote in , playing m ultip le  cellular 
roles. It is involved in cell adhesion through interaction w ith  
a-catenin and the cadherins > *4 j. Im portan tly  fo r intestinal 
homeostasis, it is also one o f  the m ajor effectors o f  the W n t path­
way. acting in a complex w ith  T c f-4  to prom ote transcription o f 
W n t target genes 44.
A num ber o f  c o n d itiona l strategies have been used to  study 
the role o f  fi-caten in in  the in testine . Ire land and colleagues 
con d itio n a lly  deleted p-catenin from  the ep ith e liu m  using the 
A h -C re -L o x  approach described previously 2 4 ] ,  T h is  study 
dem onstrated tha t deficiency in P-catenin results in  a loss o f  
c ryp t structures and detachm ent o f  enterocytes fro m  the v i l­
lus. T h is  confirm s an absolute requ irem ent o f  P-catenin fo r 
maintenance o f  the c ryp t p ro life ra tive  com p artm en t and 
shows that it  is also required fo r adequate cell adhesion w ith in  
the in testina l ep ithe lium .
In other earlier studies, P-catenin was stabilized by either 
truncation o f  the prote in 4 6 4 4  or exon deletion [4 8 ], both result­
ing in loss o f  phosphorylation sites that w ou ld  norm ally  target 
the prote in for degradation, a llow ing the pro te in  to accumulate 
in the cytoplasm and translocate to the nucleus. W ong and cow­
orkers generated a line expressing an N -te rm ina l truncation 
m utan t o f  P-catenin (A N 89) as a transgene from  the rat fa tty- 
acid b ind ing  prote in , liver (Fabpl) prom oter, a llow ing intestinal- 
specific expression ;4 6 |. Expression o f  p-cateninAN89 had previ­
ously been shown to sim ulate W n t pathway activation in  bo th 
Drosophila and Xenopus. T h is  truncated form  o f  P-catenin lacks 
a num ber o f  residues that are norm ally  phosphorylated by GSK- 
3P to target the pro te in  fo r ub iq u itin a tio n  and subsequent pro- 
teasomal degradation. As the m utant prote in cannot be phos­
phorylated by G SK-3P, it is not degraded and accumulates 
w ith in  the cell. The intestinal phenotype o f  expression o f  this 
construct was found to be rather subtle. Intestinal defects 
included abnorm al branching o f  v illus structures, along w ith  an
increase in both m ito tic  index and apoptosis w ith in  the 
mucosa. A lthough no changes in the d iffe rentia tion  program o f  
precursor cells were observed, the m igration o f  epithelia l cells 
was found to be impaired in areas o f  transgene expression, a 
phenotype sim ilar to that seen in cond itiona l zl/>c-deficient 
adult tissue [3 9 ,4 0 |. Surprisingly, neoplastic development w ith in  
the ep ithe lium  was not observed in  the course o f  this study. 
The authors suggest that this may be a ttribu ted to the fact that 
epithelia l cells retain normal levels o f  Ape expression.
A  further study by Romagnolo and colleagues used a strain 
expressing a sim ilar N -term inal truncated form  o f  P-catenin 
(AN131); however, in this case expression was driven from  the 
prom oter o f  the calbindin gene, w ith  additional enhancer ele­
ments derived from  the aldolase B prom oter sequence [471 • The 
m utant rorm o f  P-catenin was found to be strongly expressed 
along the length o f  the small and large intestine, and also in the 
cecum and kidney. M ice were sacrificed at 4 weeks o f  age ow ing 
to m o rb id ity  and, in dramatic contrast to the previous study, 
necropsy revealed numerous dysplastic lesions in the small intes­
tine. The d is tribu tion  and histological appearance o f lesions 
w ith in  the small intestine were described as being reminiscent o f 
early intestinal lesions found in Ape heterozygous mice and were 
found to display increased proliferation and increased apoptosis, 
again s im ilar to /4/xr-deficient lesions. I t  was concluded that the 
contrasting phenotypes observed between this study and that o f  
W ong and colleagues may be attributed to a number o f  d iffe r­
ences in experimental approach, includ ing different expression 
patterns o f the relative transgenes w ith in  the intestine, as well as 
differences in the exact forms o f truncated P-catenin used.
In one further study, Flarada and colleagues generated a novel 
P-catenin allele that bears LoxP sites flanking exon 3 o f  the 
endogenous gene [481. Recombination between LoxP sites causes 
deletion o f  exon 3, leading to the generation o f  messenger 
(m )R N A  in which exon 4 directly follows exon 2, although the 
reading frame o f the transcript is maintained. Translation o f this 
m R N A  produces a m utant form o f  P-catenin protein lacking 
76 am ino acids, four o f  which are phosphorylation target sites o f 
GSK-3p. Mouse lines bearing the m utant form  o f  P-catenin were 
generated and crossed to lines expressing Cre constitutively in the 
intestine either under the control o f  the cytokeratin (Ck)19 or 
Fabpl promoters. Both types o f compound mutants were found 
to develop large numbers o f  small intestinal polyps at a young 
age, w ith  polyp density being highest at the proxim al (stomach) 
end, gradually decreasing along the length o f  the small intestine. 
In both strains, v irtua lly no lesions were found in the colon, con­
curring w ith  previous observations [471. Polyps were found to 
strongly express the mutant form  o f P-catenin, whereas adjacent 
normal tissue d id  not, suggesting that polyp form ation occurred 
in v irtua lly  every location where the m utant protein was 
expressed in the small intestine. This was in  contrast to the large 
intestine where, even though m utant P-catenin expression was 
detected, essentially no lesions were found. Polyps from 
Fabpl-Cre-mediated mutants were further analyzed and again 
found to be histologically sim ilar to polyps observed previously in 
Ape m utant mice. Immunohistochemistry against cyclooxygenase
524 Expert Rev. Anticancer Ther. 7(4), (2007)
Conditional transgenesis in the murine intestine
(C O X )-2  also revealed stromal staining patterns comparable w ith  
those seen in y4/>r-deficient adenomas. The authors compare their 
contrasting phenotype w ith  that o f W ong and colleagues, and 
explain that the differences in phenotype observed are probably 
due to lower expression levels o f m utant P-catenin in the W ong 
and colleagues’ study compared w ith  this study, which allows 
m utant p-catenin to be expressed from its endogenous promoter.
T he  sim ilarities in  phenotype observed among the studies o f 
stable m utants of P-catenin and those o f  cond itiona l deletion o f  
Ape clearly im p ly  tha t P-carenin is one of, i f  no t the only, key 
downstream effector o f  y4/>c-mediated tum or suppression. I t  
could be argued tha t loss o f  Ape and stabilization o f  P-catenin 
are equivalent in the intestine, w ith  both resulting in nuclear 
accum ulation o f  p-catenin and increased transcrip tion o f  W n t 
target genes. However, we see from  the aforem entioned exam­
ples that some differences in phenotype do exist. I t  remains to 
be clarified whether these differences observed are due to non­
equivalence of Ape de le tion and p-catenin stabilization or 
whether the differences are due to non-W nt-re la ted  roles 
played by each p ro te in  in tumorigenesis.
C-Myc
c-Myc has been shown to be an in vivo target o f  the W n t signal­
ing pathway through analysis o f  both norm al crypts [49| and o f  
/l/>r-deficient tissue v>:. Studies in colorectal cancer cell lines 
have shown that c-Myc plays a vita l role in maintenance o f  p ro­
liferative precursor cells [49], Based on these observations, it 
could be predicted that c-Myc m ig h t play a c ritica l role in m ain­
tenance o f  the in testina l ep ithe lium . Two recent studies have 
aimed to address this hypothesis through cond itiona l deletion 
o f  c-Myc using a C re -L o x  approach.
Bettess and colleagues con d itiona lly  deleted c-Myc from  both 
the developing and the adult in testina l ep ithe liu m  using a V i l­
lin -C re E R  ^  system, where treatm ent w ith  tam oxifen allows 
Cre activation and excision o f  exons 2 and 3 o f  targeted c-Myc 
alleles so . Loss of c-Myc was induced before com plete intestinal 
architecture had developed, at postnatal day (P) 7. H isto log ica l 
analysis o f  intestines from  these animals culled at day 6 after 
induction  revealed areas showing widespread defects in crypt 
structure fo rm ation  compared w ith  contro ls, suggesting that 
c-Myc is absolutely required fo r c ryp t invagination. However, 
this effect was found  to  be transient and mice were able to 
recover and showed norm al intestinal h isto logy by day 10 after 
induc tion . A d u lt m ice w ith  induced c-Myc deficiency were also 
assessed. In  stark contrast to its predicted role in  the intestine, it 
was found that c-Myc deficiency does not affect p ro life ra tion , 
d iffe ren tia tion  o r the apopto tic response o f  the ep ithe lium . It  
was therefore argued tha t there may be a compensatory mecha­
nism invo lv ing  o ther Myc fam ily  members tha t operates fo llo w ­
ing c-Myc de le tion or that a r-A /yr-independent homeostatic 
program  m ust exist w ith in  the intestine.
T he  requirem ent fo r c-Myc has been fu rthe r studied by 
M uncan and colleagues, w ho used the A h -C re  system to delete 
c-Myc w ith  high effic iency w ith in  adu lt crypts :si|. In  marked 
contrast to  the study o f  Bettess and colleagues, this study
found that deletion o f  c-Myc in the adult c ryp t was not to le r­
ated, resulting in replacement o f  m utan t crypts w ith  w ild -type 
crypts by day 28 post induc tion . Early analysis o f  c-Myc-defi- 
cient crypts (before replacement o f  m utan t crypts) revealed 
them to be m uch smaller than the ir w ild -type  counterparts, 
w ith  a fou rfo ld  reduction in cell num ber per crypt. The size o f 
c-A/yc-deficient cells was also found  to be smaller and cells 
showed reduced metabolic ac tiv ity  compared w ith  controls. 
N o  changes in apoptotic levels were found  fo llow ing  c-Myc 
deletion. Finally, although loss o f  c-Myc was no t found to alter 
the pro life ra tion  state o f  cells w ith in  the cryp t, the cell-cycle 
rate was slower, leading to slowed m ig ra tion  o f  cells ou t o f  the 
cryp t com partm ent. These find ings clearly contrast those o f  
Bettess and colleagues, suggesting that c-Myc is indeed 
required fo r the maintenance o f  pro life ra tive cells w ith in  the 
crypt. The most like ly  explanation offered by the authors for 
this contrast in phenotype is that the differences relate to the 
effic iency w ith  w hich c-Myc is deleted from  the ep ithe lium , 
w h ich  is a d irect result o f the contrasting expression patterns o f  
the Cre transgenes used.
A recent study has addressed the role o f  c-Myc in tum origene­
sis w ith in  the ApcmmU mouse [52]. T his  study constitutively 
deleted c-Myc from  the intestinal ep ithe lium  o f  v4/>rm‘n/+ mice 
through use o f  Fabpl-Cre. The find in g  that c-A/yc-deficient 
intestines were m orpholog ica lly normal in this study corrobo­
rates the data o f  Bettess and colleagues; however, this study also 
found an increase in apoptosis in c-A/yc-deficient regions, 
wh ich is in contrast to both previous studies. Small intestinal 
tumorigenesis o f  Apcm'nU mice was found to be significantly 
reduced in mice additiona lly deficient fo r c-Myc compared w ith  
controls. Th is observation most like ly  concurs w ith  those o f  
M uncan and colleagues, and suggests that c-A/yc-deficient cells 
have a reduced proliferative capacity compared w ith  w ild-type 
controls. Finally, Sansom and colleagues have used the A h -C re  
system to simultaneously delete both Ape and c-Myc from  the 
ep ithe lium  [53]. Th is  study confirm s an absolutely critica l role 
fo r c-Myc in W nt-m ediated tumorignenesis, as the immediate 
phenotype o f  Ape deficiency is com pletely repressed in  the 
absence o f  c-Myc.
These studies confirm  c-Myc as a key player in  intestinal 
tumorigenesis. However, its role in  norm al intestinal homeo­
stasis is less clear, w ith  con flic ting  data emerging from  the d if­
ferent models used. Such differences in  phenotype may well 
reflect differences in the experimental systems used, an issue 
that clearly now needs to be addressed w ith in  the field.
Oct-4
The Pit-1, O c t-1/2 and Unc-86 domain transcription factor 
Octamer (O ct)-4 has previously been shown to be necessary for 
the maintenance o f stem cell pluripotency [54]. Given the im por­
tance o f  the W n t pathway in maintenance o f  the stem cell com­
partment, it seems likely that the effects o f  O ct-4 and the W n t 
pathway may be linked. Evidence in both zebrafish [55] and mouse 
and human embryonic stem cells [56] has further suggested that 
Oct-4 may be a regulatory factor upstream o f  the W n t pathway.
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In the intestine, recent w ork  has suggested support for this 
hypothesis in m am m alian systems. Hochedlinger and colleagues 
have generated a Tet-regulable system to ectopically express 
O ct-4 in epithelia l cells upon adm inistration o f  doxycycline [S7 |. 
This resulted in a phenotype o f  strik ing s im ila rity  to that 
observed by Sansom and colleagues fo llow ing deletion o f  Ape '39|. 
Areas of dysplasia were found to contain abnormal crypts w ith  a 
greatly expanded pro life ra tive cell com partm ent coupled w ith  
failure o f  p rogenitor cells to differentiate normally. O ct-4  
expression was also strongly associated w ith  nuclear localization 
of [i-catenin. The observed phenotypes were found to be com ­
pletely reversible fo llow ing  w ithdraw al o f  doxycycline treatment, 
ind ica ting dependence o f  these phenotypes on continued O ct-4  
expression. The authors therefore tentatively hypothesize that in 
adult pro liferative progenitor cells, O ct-4  acts to m aintain the 
im m ature progenitor state through upregulation o f  P-catenin. 
Fxtopic expression o f  O ct-4  or activation o f  the W n t pathway 
w ould therefore lead to both the cryp t progenitor phenotype 
described here and previously :.v>i.
Notch pathway
The Notch pathway has been shown to play an im portant role in 
both embryonic development and the adult homeostasis o f  a 
number o f  different organ systems. It has been implicated in the 
regulation o f  processes such as proliferation, stem cell maintenance, 
cell fate specification and differentiation programs, and therefore 
plays a particularly pertinent role in self-renewing tissues ;ssi.
O ne of the first studies that demonstrated an absolute require­
ment o f Notch signaling fo r in vivo intestinal homeostasis was 
that o f  van Es and colleagues ;s9|. The critica l N o tch  pathway 
transcription factor CSL7recombination signal b in d in g  protein 
for im m unog lobu lin  k J region was targeted w ith  LoxP sites and 
deleted in adult intestinal ep ithe lium  using bo th A h—Cre and 
V illin -C re E R 12. Deletion mediated by either Cre-expressing 
transgene resulted in identical, h igh ly penetrant phenotypes o f  
the replacement o f  transit am p lify ing  cells w ith  mature, fu lly  d if­
ferentiated goblet cells. Loss o f  the transit am p lify ing  com part­
ment was confirm ed by K i-67  stain ing and brom odeoxyurid ine 
incorporation, which both revealed a marked deficiency in rep li­
cating cells. Paneth cell and enteroendocrine cell frequency was 
found to be unchanged, suggesting a skew in the d ifferentia tion 
program towards the secretory cell lineages o f  the ep ithe lium . 
Therefore, these observations indicate that N otch signaling is 
required fo r both maintenance o f  the transit am p lify ing  com part­
ment in an undifferentiated state, and also for m aturation o f  the 
absorptive cell lineage. T h is  study also went on to treat adenomas 
arising in Ap<?n'nl* mice w ith  a y-secretase inh ib ito r, dibenz- 
azepine, w hich blocks N o tch  pathway signaling. Dibenzazepine 
treatment led to goblet cell conversion o f  a subset o f  cells w ith in  
the adenoma, forc ing them  in to  a postm ito tic  state. However, 
sim ilar changes were also observed w ith in  surrounding normal 
intestinal ep ithe lium , w h ich  lim ited  treatm ent studies. There­
fore, i f  N o tch  in h ib it io n  were to be pursued as a potential thera­
peutic strategy, a method o f  targeting it  specifically to tumors 
and not norm al ep ithe lium  w ould need to be devised.
In  a reverse approach, Fre and colleagues examined the 
effect o f  increased N o tch  signaling by overexpression o f  a con- 
s titu tive ly  active in trace llu lar dom ain o f  the N o tc h -1 receptor 
(n l ic )  specifically in  the intestine, by use o f  V il l in -C re  and a 
Rosa26—n l ic  construct 160]. The Rosa26 prom oter is strongly 
expressed in all tissues o f  the mouse; however, in this case a 
LoxP-flanked STOP cassette was present in the transgene, 
preventing expression o f  n l ic  in tissues lacking active Cre 
recombinase. As w ou ld  be expected, this study essentially 
observed a reciprocal phenotype to tha t seen by van Es and 
colleagues; transgenic mice became m oribun d  at the very early 
stage o f  day 3 post Cre induction . Exam ination o f  intestines 
fo r d iffe rentia ted cell types revealed a com plete lack o f  secre­
to ry  cell lineages, w ith  no staining fo r markers o f  goblet cells 
or enteroendocrine cells, and no expression o f  Paneth cell 
markers. The pro liferative com partm ent o f  the ep ithe lium  was 
also found to expand significantly and an increase in  apoptosis 
w ith in  the v illus was observed. In add ition , this study 
observed defects in the apical surface o f  absorptive cells, w ith  
poor organization and lower frequency o f  m ic ro v illi com pris­
ing the brush border. In  summary, the results reported in  this 
study support those o f  van Es and colleagues, w ith  opposing 
genetic m an ipu la tion  o f  the N otch  pathway resulting in an 
almost exact reversal o f  phenotype.
O ne fu rther study used a sim ilar Rosa26 prom oter construct 
to cond itiona lly  overexpress a form  o f  activated N o tc h -1 recep­
tor, again consisting o f  on ly the intracellu lar dom ain o f  the pro­
tein ;6i|. In this case, recom bination and expression o f  the 
transgene was achieved by induction  o f  A h -C re . Surprisingly, 
the phenotype observed more closely resembled that o f  van Es 
and colleagues, and not Fre and colleagues as w ould be 
expected. A  dram atic increase in the numbers o f  goblet cells 
was observed; however, in this case the location o f  these cells 
was w ith in  the postm ito tic  cells o f  the villus, as opposed to the 
transit am p lify ing  cells o f  the crypt, as seen in the previous 
study. Some aspects o f  the phenotype d id  resemble that 
observed by Fre and colleagues, such as an increase in  levels o f  
apoptosis fo llow ing  N o tc h -1 overexpression. In  contrast to 
both previous studies, no changes in the frequency o f  entero­
endocrine cells or Paneth cells, or in the size or location o f  the 
pro liferative zone w ith in  the crypt were reported. The d iffe r­
ences between this study and that o f  Fre and colleagues were 
most probably due to two differences in experimental 
approach; first, in this study recom bination (and therefore 
overexpression o f  m utant N o tc h -1) was achieved in  a much 
more effic ient manner than that o f  Fre and colleagues, and sec­
ond, this study overexpressed N o tc h -1 in  adult, fu lly  developed 
ep ithe lium , compared w ith  the previous study where expression 
was induced at very early stages o f  intestinal development.
T h is  study, com bined w ith  the find ings o f  van Es and co l­
leagues, suggests a dose dependency o f  N o tch  signaling fo r 
norm al d iffe re n tia tion  patterns w ith in  the adu lt in testine, 
w ith  bo th  too m uch and too litt le  N o tch  signaling resu lting 
in  a defau lt d iffe re n tia tion  program  o f  precursor cells in to  
goblet cells.
526 Expert Rev. Anticancer Ther. 7(4), (2007)
Conditional transgenesis in the murine intestine
Transforming growth factor-fi & bone morphogenic 
protein signaling
Transform ing grow th factor (TG F)-(I signaling is involved in the 
regulation o f  a num ber o f  diverse processes, inc lud ing prolifera­
tion  and cell d iffe rentia tion . D isruption o f  TG F-P  signaling has 
been im plicated in human colorectal cancers, particularly in the 
progression o f  tum ors from  benign growths to invasive 
cancers ]62 |. O ne study has examined the effect o f  loss o f  TGF-P 
signaling on carcinogenesis in the mouse intestine. Hahm  and 
colleagues achieved this by generating a dom inant negative 
m utant o f  the T G F -P  Type I I  receptor ;63 ). T his  was then 
expressed specifically in the intestine under the contro l o f  the 
intestinal trefo il factor promoter, which constitutively expresses 
w ith in  the epithelia l com partm ent. As TGF-P signaling is im p li­
cated in tum or progression rather than in itia tion , mice were 
treated w ith  a low  dose o f  the carcinogen azoxymethane in order 
to prom ote intestinal tum or form ation. It was found that mice 
lacking TG F-P  signaling were much more susceptible to colon 
tum or form ation compared w ith  contro l littermates, showing an 
increase in both the fo rm ation  o f  aberrant crypt foci as well as 
colon carcinoma. These data therefore demonstrate the clear role 
o f  TG F-P signaling in cancer progression and suggest that this 
pathway must be m aintained in order to prevent carcinogenesis.
Bone m orphogenic proteins (BMPs) are members o f  the 
TG F-P  fam ily o f prote ins and B M P  signaling is though t to play 
a role in maintenance o f  the intestinal ep ithe lium  through 
interaction w ith  the underly ing  mesenchyme 6 4 |.  The role o f  
this pathway in the regulation o f in testinal homeostasis is 
exem plified by the human disease juvenile polyposis syndrome 
(JPS), characterized by the developm ent o f  num erous intestinal 
polyps at a very young age, w h ich  has in m any cases been asso­
ciated w ith  m utation o f  B M P  receptor (B m p r ) lA  subtype or o f  
a downstream transcrip tion factor o f  the pathway, S M A D 4  ;6 5 |.
C ond itiona l d is rup tion  o f  the B M P  pathway in adult mice 
has gone some way to m odeling hum an JPS. He and colleagues 
generated a LoxP-targeted Bm prla  allele, w h ich  was inactivated 
specifically in the intestine fo llow ing  p I -p C  adm in is tra tion  
causing induction  o f  M x l- C r e  .66]. D is rup tio n  o f  B M P  signal­
ing was found to cause an increase in the num ber o f  p ro life ra­
tive cells w ith in  the ep ithe lium , and all m u tan t mice subse­
quen tly  developed in testina l polyps, w h ich  showed sim ilar 
h isto logy to hum an JPS polyps. An increased num ber o f  cells 
expressing stem cell markers were also found in Bm prla  m utan t 
crypts. Further analysis o f  m utan t in testina l ep ithe lium  led the 
authors to hypothesize that B M P  signaling plays a role in  sup­
pressing in testina l stem cell replication and that attenuation o f  
B M P  signaling is necessary fo r fu ll activation o f  W n t signaling 
and thus renewal o f  the stem cell. T h is  hypothesis has, however, 
been the subject o f  some debate '6 7 ,6 8 ) .
A further study investigating the effect o f  B M P  signal abroga­
tion on the intestinal epithelium  made use o f  a gut-specific trans- 
gene constitutively expressing the BM P  inh ib ito r, noggin ’6 9 ],  A 
transgene consisting o f  the Xenopus noggin com plem entary 
D N A  under the con tro l o f  the mouse V il lin  p rom oter was gen­
erated. M ice bearing the transgene were found to have marked
abnormalities o f  the intestinal ep ithe lium  at a young age. A t 
4 weeks o f  age, transgenic intestines were found to contain v il li 
that were abnorm ally broad at the base o f  the structure and had 
abnormal invaginations o f  proliferative epithelia l cells. A t 
12 weeks after b irth , these abnormal invaginations had devel­
oped in to  complete c ryp t-v illu s  units, w h ich had grown per­
pendicular to the original c ryp t-v illu s  axis and contained a pro­
liferative zone and differentiated cell types, comparable w ith  
that o f  normal crypt structures. W hen allowed to age to 
6—8 months, transgenic mice developed polyps that were char­
acterized by a complex arrangement o f  branched epithe lium  
interspersed w ith  dilated cystic structures. The authors describe 
the histological appearance o f  these polyps as being typical o f  
that observed in human JPS lesions. Based on the observation 
that ep ithe lium  lacking BM P signaling develops norm ally bu t 
ectopically, it  is proposed that BM P  signaling mediates in te r­
action between the epithelium  and underly ing mesenchyme to 
ensure that c ryp t-v illu s  structures on ly develop w ith in  the cor­
rect context. A  separate study, in this case o f  Xenopus noggin 
under the contro l o f  the Fabpl promoter, has supported these 
find ings ;7 0 ].
The BM P pathway downstream transcription factor SM AD 4 
is also implicated in human JPS. A  recent study has detailed the 
consequences o f  Cre-mediated inactivation o f Smad4 in both the 
gastrointestinal (G I) tract epithelium  and in T  cells [71 ]. Smad4 
deletion was achieved in a broad range o f  epithelia by use o f Cre 
under the contro l o f  either the m urine mammary tum or virus 
prom oter (M m tv )-C re ) or the transthyretin promoter 
(T tr-C re ). A lthough loss o f  Smad4 was confirm ed in both sys­
tems, neither showed evidence o f  epithelial tumorigenesis in  the 
course o f  the study. However, in dramatic contrast to this, T-cell- 
specific deletion o f  Smad4 (mediated by Lck-C re  or C D 4-C re ) 
resulted in a number o f abnormalities in G I epithelia. In the 
small and large intestine, a phenotype high ly reminiscent o f  that 
seen by Haramis and colleagues and Batts and colleagues was 
seen, w ith  epithelial cells growing in to  the stroma and the pres­
ence o f  numerous cystic structures. Tumors were found to 
progress to invasive carcinomas, which also gave rise to distant 
metastases, again described as consistent w ith  phenotypes 
observed in human hereditary JPS. The findings o f  this study 
therefore im p ly  that although Smad4 appears to be redundant 
w ith in  epithelial cells, normal B M P  signaling w ith in  T  cells is 
required for suppression o f  G I epithelial tumors.
Other pathways
Numerous other signaling pathways have been im plicated in 
hum an colorectal tumorigenesis. T h is  has prom pted the inves­
tiga tion o f  a num ber o f  pathways that are no t classically consid­
ered a vita l fo r normal intestinal homeostasis, bu t clearly play a 
role in tum or suppression w ith in  the intestine.
The phosphoinositide 3-kinase (P I3 K )-A k t pathway has pre­
viously been proposed as a mediator between the W n t and BM P 
pathways in  the intestine [66]. Indeed, a recent paper has exam­
ined the consequences o f  increased P I3K—A k t signaling on intes­
tinal homeostasis through deletion o f  the pathway antagonist
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and tum or suppressor PTEN (Phosphatase and Tensin hom olog 
mutated on chromosome 10). He and colleagues deleted P T E N  
specifically in the epithelial and stromal cells o f the adult intes­
tine through use of conditional P T E N  alleles and M x l—Cre 7 2 ]. 
M ice were found to qu ickly develop m ultip le  polyps w ith in  the 
small intestine fo llow ing induction o f PTE N  loss. Further analy­
sis went on to suggest a role for PTEN, through m odu la tion  o f 
the P I3 K -A k t pathway, in regulating activation o f  W n t signaling 
in the intestinal stem cell, and therefore m odulating the replica­
tive capacity' o f  the intestinal stem cell. Thus, P T E N  loss was 
shown to result in an excess o f proliferative intestinal stem cells 
w ith in  the crypt.
However, recent findings in our own laboratory have in d i­
cated that P T E N  deletion specifically w ith in  the epithelia l cell 
popu lation of the intestine does not result in an overt phenotype 
m a r s h  M  Al.. s l'R .M irn  n;. This is in contrast to the phenotype 
observed in this study, which arises follow ing P T E N  deletion in 
both the stromal and epithelial compartments. These observa­
tions raise the tantalizing hypothesis that the tumor-suppressor 
function  o f  P TE N  w ith in  the intestine is cell-tvpe specific and 
also emphasize the importance o f  stromal-epithelial interactions 
in m a in ta in ing  homeostasis.
The Ras pathway, which also plays a role in m odulation o f  
the P I3 K -A k t signaling cascade, is implicated in colorectal 
tumorigenesis, w ith  up to 50% o f  human colorectal cancers 
showing oncogenic activation o f kirsten-Ras (k-Ras) 731. O ver­
expression of an activated m utant o f  k-Ras specifically w ith in  
the intestine under the contro l o f  the V il lin  prom oter has previ­
ously been shown to lead to rapid form ation o f neoplastic intes­
tina l lesions 7 1 : However, it has been argued that this is no t an 
accurate model o f  human tumorigenesis, ow ing to the fact that 
human tum ors rarely show overexpression o f k-Ras bu t more 
often display normal expression levels o f  m utant proteins. T h is  
has led to studies in which m utant k-Ras is expressed under the 
contro l o f its endogenous promoter. Tuveson and colleagues 
have generated mice harboring a floxed-STOP form  o f  m utant 
k-Ras, w h ich  is conditiona lly expressed from its endogenous 
prom oter fo llow ing  Cre-mediated excision o f  the STOP 
cassette :~v. W hen crossed w ith  cytom egalovirus-Cre, w h ich  is 
mosaically expressed throughout development, mice were not 
viable, ind ica ting  that activated k-Ras is not tolerated du rin g  
developm ent. Expression o f  the activated k-Ras allele was also 
induced specifically in the developing and adult G I tract 
through use o f  the Fabp-Cre construct. Th is was shown to 
lead to intestinal hyperplasia in all m utant mice analyzed, w ith  
a marked increase in pro life ra tion in hyperplastic and dysplas- 
tic  areas. In contrast to this, another study has shown that acti­
vation o f  k-Ras w ith in  the adult ep ithe lium  specifically does 
not result in d isrup tion  o f  normal intestinal homeostasis 7 6 ]. 
However, when com bined w ith  Ape m utation, this study shows 
that active k-Ras significantly accelerates in testina l tum origen ­
esis and drives progression to adenocarcinoma. These data 
therefore suggest that k-Ras is im portan t both fo r the develop­
ing intestinal ep ithe lium  and in intestinal tum ors, bu t is 
perhaps redundant in the fu lly  developed adult ep ithe lium .
Since the development o f  the first transgenic strains o f  mice, 
there has been a revolution in our capacity to manipulate the 
genome o f  the mouse and so begin to understand the true in vivo 
consequences o f gene function. Approaches based upon addition 
transgenics and constitutive knockouts have proven extremely 
valuable in reaching these goals but are lim ited  in certain 
respects, for example, ow ing to embryonic lethality. The develop­
m ent o f  conditional strategies has given researchers the ab ility  to 
delete genes in a more controlled manner, both spatially and 
temporally. In  this review, we have summarized the m ajor strate­
gies currently in use in the intestine and have illustrated their use 
w ith  respect to several major pathways. These approaches have 
given startling new insights into both normal and disease physi­
ology and have established the intestine as a paradigm system for 
the analysis o f  genotype-phenotype relationships.
Expert commentary
Recent technical advances have now made it  possible to genet­
ica lly  m an ipula te the intestine. First, there is an ever increasing 
batte ry o f  conventional transgenics that over- or misexpress a 
given gene. A lthough this now represents a fa irly  unsophisti­
cated approach, w ith  no true contro l over the level o f  transgene 
expression, such models are s till capable o f  revealing im portan t 
insights, fo r example in establishing the role o f  ind iv idua l 
genes in cryp t development. The more refined use o f  knockout 
m ice has greatly extended our analytical power, allow ing 
in vivo analysis o f  loss o f  function . A lthough  knockou t tech­
no logy is cu rren tly  dom inan t w ith in  the fie ld, i t  s till suffers 
from  a num ber o f  caveats that have precluded the study o f 
many genes w ith in  the intestine. The more recent advent o f 
con d itiona l strategies has given the fie ld  new impetus, extend­
ing bo th the genes that can be analyzed and the range o f  ques­
tions tha t can now  be addressed. Taken together, these strate­
gies are b u ild in g  a comprehensive genetic understanding o f  the 
in testine, one that is p rinc ipa lly  focused upon the c ryp t-v illu s  
axis o f  the small intestine.
Five-year view
T h is  review h igh ligh ts a range o f  techniques used to m od ify  
the mouse genome in  a spatially and/or tem porally contro lled 
manner. T h is  means that we are now theoretically capable o f  
in tro d u c in g  any m u ta tion  o f  choice in to  any cell o f  choice at 
any desired tim e. However, the theoretical capacity to achieve 
th  is does no t yet equate to the practical s ituation. To gain such 
fine  con tro l over gene expression in vivo remains remarkably 
technica lly challenging, and indeed the current state o f  the art 
remains lim ite d  to  a num ber o f  systems w ith in  the intestine. 
However, these have proved remarkably powerfu l in revealing 
true phenotype-genotype relationships and disease mecha­
nisms, as well as iden tify ing  novel therapeutic targets. The way 
forw ard has to be through increased refinem ent o f  these sys­
tems to generate increasingly accurate models o f  norm al and 
diseased physiology. For example, we now need to develop 
models in  w h ich  the genetics o f  adjacent cells can be inde­
pendently contro lled and so allow  a determ ination o f  the
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im portance o f  ce ll-ce ll interactions. We also need to develop 
the capacity to specifically target gene m an ip u la tion  to  tum ors 
in order to model therapeutic treatm ent. Finally, models need 
to be generated in w h ich we con tro l no t o n ly  the genome, bu t
where we begin to contro l the k inom e, m ethylom e, proteome 
and glycome. Such m odeling w ill be challenging to achieve, 
bu t remains the on ly true way o f  understanding both normal 
and diseased physiology.
/  Key issues
•  M o d e in g  in the  m ouse using c o n s titu tiv e  ove rexpress ion  and kn o cko u t approaches has proven very p o w e rfu l, b u t can be lim ited  
due  to  lack o f spa tia l and tem pora l c o n tro l ove r gene expression .
•  The deve jo p m e n t o f co n d itio n a l s tra teg ies , based up on  causes re c o m b in a tio n - lo c u s  o f crossover (C re-Lox), Flp—Frt and use o f 
te tra c y c lin e - and es troge n -de pen den t system s, has la rg e ly  ob v ia ted  these d ifficu lt ie s .
•  C on d itio n a  stra teg ies  have been used to  sho w  th a t a c tiv a tio n  o f  th e  W n t pa th w a y  th roug h  loss o f Ape con fers  a d ra m a tic  
pheno type  upon the  in testine, revealing th e  key c e llu la r consequences o f W n t ac tiva tion .
•  C o nd itiona l d e le tion  o f the W n t p a thw ay  co m p o n e n ts  [ i-c a te n in  and c -M y c  shows them  to  play key roles in bo th  tum orige nes is  
and no rm a l in te s tin a l hom eostasis.
•  D iffe re n t exp e rim e n ta l approaches can ho w ever y ie ld  s lig h t ly  d if fe re n t results, fo r example, fo llo w in g  c -M yc  defic iency.
•  C o nd itiona l d e re g u la tio n  o f the N otch p a th w a y  changes cell fa te  in the  sm all in tes tine , spec ifica lly  in re la tion  to  secre ta ry cells.
•  C on d itio n a l a c tiv a tio n  o f the Ras pa thw ay  th ro u g h  m u ta tio n  o f  k irs ten -R as accelerates in tes tina l tum origenesis, a lth o u g h  again 
d iffe re n t exp e rim e n ta l system s show  s o m e w h a t d if fe re n t e ffe c ts .
•  C o nd itiona l a c tiv a tio n  o f the p h ospho m os itid e  3 -k in a s e -A k t p a th w a y  also predisposes to  in te s tina l neoplasia, b u t again d iffe re n t 
experim enta l approaches are id e n tify in g  s u b tle tie s  in th is  assoc ia tion .
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